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 Abstract 
Cell proliferation, migration and invasion are the important features of tumour metastasis. 
Interestingly, during embryonic development, trophoblast cells show similar attributes like 
tumour cells to establish foeto-maternal communications and support normal pregnancy. 
The invasive nature of tumour as well as trophoblast cells (especially during the first 
trimester) are believed to be enhanced by a collection of “stem-like cells” (SLCs) called 
‘‘spheroid bodies’’. This sub-population of SLCs within tumour or trophoblast cells can 
proliferate to form a heterogeneous cell groups with different functional attributes. However, 
tumour SLCs proliferate during invasion; while trophoblast cells proliferate and then invade. 
Although several previous studies have produced SLCs from tumour cell lines in vitro, 
limited attempts were made to produce SLCs from trophoblast cells. Therefore, this study 
firstly aimed to produce and characterise SLCs from transformed first trimester trophoblast 
cell lines (HTR8sv/neo and TEV-1) and choriocarcinoma (trophoblast tumour cell lines 
JEG-3 and BeWo) in relation to a non-placental tumour cell line MCF-7. Secondly, to date, 
the factors that are responsible for there uncontrolled versus controlled invasion are not fully 
understood. On the other hand, it is worth noting that in pre-eclampsia (PE), the invasion of 
first trimester trophoblast cells is found to be reduced. Therefore, it was hypothesised that it 
would be possible to identify the important molecules that may be involved in the controlled 
trophoblast invasion by comparing the status of different factors that are identified with 
altered expression in tumour cells between (a) normotensive (NT) and PE placentae, and (b) 
in the SLCs produced in vitro from trophoblast cells. 
SLCs from transformed trophoblast and choriocarcinoma cells were produced by growing 
in non-attachable or ultra-low attachment flasks with or without doxorubicin (DOX) to 
produce DOX-resistant and non-resistant spheroids. The “stemness” feature of these 
spheroids was characterised by comparing the expressions of stem cell markers. The 
migration and invasive capacities of DOX-resistant and non-resistant spheroids were 
compared with their parental cells by wound-healing and 2-D/3-D invasion assays. The 
status and expression of novel factors that may be involved in cell proliferation and invasion 
was checked by quantitative real-time PCR and western blotting. Also a comparative 
proteomic (SWATH-MS) analysis was carried out to identify and compare the global 
changes of the peptide expression during SLCs transformation. In addition the RNA and 
protein expression of factors that are involved in trophoblast invasion were compared in 13 
NT and 12 PE placentae. 
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Abstract 
 
Both the transformed trophoblastic cell lines (HTR8/Sv-neo and TEV-1,) and gestational 
choriocarcinoma cell lines (JEG-3 and BeWo) were able to produce non- spheroidal cells 
(non-resistant and drug resistant) under 3-D conditions. These spheroids showed increased 
protein expression of stem cells markers, such as OCT4, SOX2 and NANOG. On the other 
hand, both trophoblast CDX2 and the cell fate determining transcription factor, NOTCH1, 
were reduced in spheroidal cells confirming the “stem-like” transformation.  Moreover, the 
2-D invasion assay showed a statistically significant increase in the invasive potential 
(number invaded cells) of spheroids. This significance was found to be higher in untreated 
spheroids from transformed trophoblast cells; P<0.0005 (for both HTR8svneo and TEV-1) 
and in one of the choriocarcinoma cells JEG-3; whilst the significance between untreated 
spheroids of BeWo and their parental cells was slightly less (P<0.05). 
The 3-D invasion assays have shown a significant time dependent increase in the invasions 
of non-resistant spheroidal cells in comparison with DOX-resistant counterpart, especially 
the non-resistant spheroidal cells produced from HTR8/Svneo (p<0.0005) at 48 hours. 
Spheriodal cell invasion of non-resistant TEV-1 and choricarcinoma cells was significantly 
higher than DOX-resistant cells (p<0.005). Therefore this study has produced spheroidal 
cells from (a) transformed first trimester trophoblast (HTR8/Svneo and TEV-1) and (b) 
choriocarcinoma (JEG-3 and BeWo) cells.  Since these cell lines are of trophoblast origin, it 
is possible to use these spheroids as comparative models to study the effects of 
chemotherapeutic agents on (a) physiologically rapidly dividing cells (HTR8/Svneo and 
TEV-1) and (b) tumour models (JEG-3 and BeWo) of similar origins. 
Comparisons of mRNA and protein expression between NT and PE placentae have shown a 
statistically significant increase in the expressions of ALDH3A1, AURK-A, PDGFRα, and 
TWIST1 in PE placentae (p<0.05); whilst AURK-C and JAG-1 expression was down-
regulated. SWATH-MS analysis has also highlighted up-regulation of novel proteins that 
are associated with proliferation, invasion and cell cycle control in the spheroids produced 
from these cell lines. These proteins include plasminogen, vitronectin and ALDH1A3. 
However, the function of most of these factors have not been fully investigated in placenta. 
In summary the study has generated and characterised “stem-like” spheroids from 
transformed trophoblast and choriocarcinoma cells. These spheroidal cells may be useful as 
in vitro toxicological models to study the in vivo cellular effects on rapidly dividing cells. 
 
v 
 
 List of Figures 
Figure 1.1: The interface between mother and foetus in placenta. ..................................................... 2 
Figure 1.2: Illustration the both sides of the human placental. A) Represents the foetal side; B) 
Represents the maternal side. ......................................................................................... 3 
Figure 1.3: Illustration of the early stages of human placental development. .................................... 5 
Figure 1.4: Schematic representation of different layers of developing trophoblast .......................... 6 
Figure 1.5: Schematic representation of adhesion of blastocyst. ........................................................ 7 
Figure 1.6: Trophoblast differentiation via different cell lineages...................................................... 9 
Figure 1.7: The different stages involved in spiral artery remodelling. ............................................ 11 
Figure 1.8: Different types of trophoblast cells during invasion. ..................................................... 12 
Figure 1.9: Schematic representation of normal spiral artery remodelling. ...................................... 13 
Figure 1.10: Spiral artery remodelling between NT and PE placentation. ....................................... 18 
Figure 1.11: Hallmarks of Cancer. .................................................................................................... 20 
Figure 1.12: The metastasis process during tumour invasion. .......................................................... 23 
Figure 1.13: Micro-environments of placental and tumour invasion. ............................................... 27 
Figure 1.14: Similarities in cell proliferation between trophoblast and tumour cell. ........................ 28 
Figure 1.15: Similarities and differences between trophoblast and tumour invasions. ..................... 30 
Figure 1.16: Summary of the interaction between AURK-A and p53. ............................................. 32 
Figure 1.17: The origins of specialisation of stem cells. ................................................................... 36 
Figure 1.18: The similarity of the spheroid like structure in tumour and blastocyst. ....................... 39 
Figure 1.19: Comparison between in vivo solid tumour and spheroid model. .................................. 40 
Figure 2.1: Schematic representation of protocol used to generate non-resistant (normal) spheroids.
 ...................................................................................................................................... 53 
Figure 2.2: Schematic representation of protocol used to generate resistant spheroids. ................... 53 
Figure 2.3: Summary flow chart of IHC protocol. ............................ Error! Bookmark not defined. 
Figure 2.4: Summary of invasion assay steps.……………………………………….. ……………61 
Figure 3.1: Relative mRNA expression analysis of tumour associated factors between NT and PE 
placentae ....................................................................................................................... 68 
Figure 3.2: The expression of ALDH3A1  protein in  NT and PE placentae……………………...71 
Figure 3.3: ALDH3A1 localisation determined by immunohistochemistry…………………………..……72 
Figure 3.4: AURK-A protein expression in NT and PE placentae……………………………………………….73 
Figure 3.5: AURK-A localisation determined by immunohistochemistry………………….....…..74 
Figure 3.6: AURK-C protein expression in NT and PE placentae…………………………………75 
Figure 3.7: AURK-C localisation determined by immunohistochemistry…………………………76 
Figure 3.8: PDGFRα protein expression in NT and PE placentae……………………….………...77 
Figure 3.9: PDGFRα localisation determined by immunohistochemistry…..…..…………………78 
Figure 3.10: TWIST1 protein expression in NT and PE placentae. .................................................. 78 
Figure 3.11: TWIST1 localisation determined by immunohistochemistry…………..…………….80 
Figure 3.12: JAG1 protein expression in NT and PE placentae. ...................................................... 80 
Figure 3.13: JAG1 localisation determined by immunohistochemistry. ........................................... 81 
Figure 4.1: Chemical structure of Doxorubicin. (Adopted from Suzuki et al., 2005) ...................... 94 
Figure 4.2: The effect of doxorubicin on mitochondrial activity (MTT) and toxicity (LDH) of 
transformed trophoblast cell lines. ............................................................................... 97 
Figure 4.3: The effect of doxorubicin on mitochondrial activity (MTT) and toxicity (LDH) of 
placental choriocarcinoma cells. .................................................................................. 97 
Figure 4.4: The effect of doxorubicin on mitochondrial activity (MTT) and toxicity (LDH) of MCF-
7 cells. ........................................................................................................................... 99 
Figure 4.5: Generation of normal spheroids. .................................................................................. 100 
Figure 4.6: Generation of resistant spheroids from transformed trophoblast cell line (HTR8/SVneo).
 .................................................................................................................................... 100 
Figure 4.7: Generation of resistant spheroids from transformed trophoblast cell line (TEV-1). .... 101 
Figure 4.8: Generation of resistant spheroids from choriocarcinoma cell line (JEG-3). ................ 102 
Figure 4.9: Generation of resistant spheroids from choriocarcinoma cell line (BeWo). ................ 103 
vi 
 
 Figure 4.10: Generation of resistant spheroids from human breast adenocarcinoma cell line (MCF-
7). ................................................................................................................................ 104 
Figure 4.11: Immunofluorescence staining of OCT4 and SOX2 in transformed trophoblast cells.
 .................................................................................................................................... 106 
Figure 4.12: Immunofluorescence staining of OCT4 and SOX2 in choriocarcinoma cells............ 107 
Figure 4.13: Immunofluorescence staining of OCT4 and SOX2 in MCF-7 cells. .......................... 108 
Figure 4.14: Immunofluorescence staining of OCT4 and NANOG in transformed trophoblast cells.
 .................................................................................................................................... 110 
Figure 4.15: Immunofluorescence staining of OCT4 and NANOG in choriocarcinoma cell lines.
 .................................................................................................................................... 111 
Figure 4.16: Immunofluorescence staining of OCT4 and NANOG in MCF-7 cells. ..................... 112 
Figure 4.17: Immunofluorescence staining of CDX2 and NOTCH1 in transformed trophoblast cells.
 .................................................................................................................................... 114 
Figure 4.18: Immunofluorescence staining of CDX2 and NOTCH1 in choriocarcinoma cell lines.
 .................................................................................................................................... 115 
Figure 4.19: Immunofluorescence staining of CDX2 and NOTCH1 in MCF-7 cells. ................... 116 
Figure 4.20: Relative mRNA expression of OCT4 in trophoblast and tumour cells. ..................... 119 
Figure 4.21: Relative mRNA expression of SOX2 in trophoblast and tumour cells. ..................... 121 
Figure 4.22: Relative mRNA expression of NANOG in trophoblast and tumour cells. ................. 123 
Figure 4.23: Relative mRNA expression of CDX2 in trophoblast and tumour cells. ..................... 125 
Figure 4.24: Relative mRNA expression of NOTCH1   in trophoblast and tumour cells. ............. 127 
Figure 4.25: The expression of OCT4 protein in trophoblast and tumour cells. ............................. 129 
Figure 4.26: The expression of SOX2 protein in trophoblast and tumour cells.............................. 131 
Figure 4.27: The expression of NANOG protein in trophoblast and tumour cells. ........................ 133 
Figure 4.28: The expression of CDX2 protein in trophoblast and tumour cells. ............................ 135 
Figure 4.29: The expression of NOTCH1 protein in trophoblast and tumour cells. ....................... 137 
Figure 5.1: Migration of the HTR8/SVneo cell line. ...................................................................... 150 
Figure 5.2: Migration of the TEV-1 cell line. ................................................................................. 152 
Figure 5.3: Migration of the JEG-3 cell line. .................................................................................. 154 
Figure 5.4: Migration of the BeWo cell line. .................................................................................. 156 
Figure 5.5: Migration of the MCF-7cell line .................................................................................. 158 
Figure 5.6: HTR8/SVneo invasion.................................................................................................. 160 
Figure 5.7: TEV-1 invasion. ........................................................................................................... 161 
Figure 5.8: JEG-3 invasion. ............................................................................................................ 162 
Figure 5.9: BeWo invasion. ............................................................................................................ 163 
Figure 5.10: MCF-7 invasion. ......................................................................................................... 164 
Figure 5.11: Invasion potential of untreated and DOX-treated spheroids of HTR8/SVneo. .......... 165 
Figure 5.12: Invasion potential of untreated and DOX-treated spheroids of TEV-1. ..................... 166 
Figure 5.13: Invasion potential of untreated and DOX-treated spheroids of JEG-3. ...................... 167 
Figure 5.14: Invasion potential of spheroids untreated and DOX-treated of BeWo. ...................... 168 
Figure 5.15: Invasion potential of untreated and DOX-treated spheroids of MCF-7. .................... 169 
Figure 6.1: Relative mRNA expression of ALDH3A1. .................................................................. 182 
Figure 6.2: Relative mRNA expression of AURK-A. .................................................................... 184 
Figure 6.3: Relative mRNA expression of AURK-C...................................................................... 186 
Figure 6.4: Relative mRNA expression of PDGFRα. ..................................................................... 188 
Figure 6.5: Relative mRNA expression of TWIST1. ...................................................................... 190 
Figure 6.6: Relative mRNA expression of JAG1............................................................................ 192 
Figure 6.7: The expression of ALDH3A1 protein. ......................................................................... 194 
Figure 6.8: The expression of AURK-A protein. ............................................................................ 196 
Figure 6.9: The expression of AURK-C protein. ............................................................................ 198 
Figure 6.10: The expression of PDGFRα protein. .......................................................................... 200 
Figure 6.11: The expression of TWIST1 protein. ........................................................................... 202 
Figure 6.12: The expression of JAG1 protein. ................................................................................ 204 
 
vii 
 
  
Figure A 1 The purity of extracted RNA from NT and PE placental tissues. ................................. 232 
Figure A 2: Confirmation of PCR products in agarose gel. ............................................................ 233 
Figure A 3 : The DNA sequencing data for AURK-A PCR product. ............................................. 234 
Figure A 4: Example of BLAST matching data for AURK-A sequence obtained from sequencing.
 .................................................................................................................................... 234 
Figure A 5: The purity of extracted RNA from trophoblast cell lines in parental conditions. ........ 237 
Figure A 6: Example of PCR products confirmation in Agarose gel.............................................. 237 
 
List of Tables 
Table 1.1: Summary of factors involved in trophoblast invasion. .................................................... 15 
Table 1.2: Activators and inhibitors of angiogenesis. ....................................................................... 22 
Table 2.1: Buffers and solutions ....................................................................................................... 43 
Table 2.2: Details of primary antibodies with concentrations for IHC, WB and IF. ........................ 44 
Table 2.3: Details of secondary antibodies with concentrations for IHC, WB and IF. ..................... 45 
Table 2.4: Details of the cell lines used in this study. ....................................................................... 49 
Table 2.5: IRS system for Visualisation and semi-quantification. .................................................... 57 
Table 3.1: Demographic details of the normotensive and pre-eclamptic subjects. ........................... 65 
Table 3.2: The primers for the specific gene and their annealing temperatures (Ta) ........................ 66 
Table 3.3: Immuno-reactivity score (IRS) of all factors of interesting ............................................. 69 
Table 3.4: Overall correlation between mRNA, protein expression and IRS in PE in comparison to 
NT placentae. .................................................................................................................. 83 
Table 4.1: The origins and features of the different cell lines used in this study. ............................. 92 
Table 4.2: The primers for specific markers and their annealing temperature (Ta). ....................... 117 
Table 6.1: Identification of up-regulated proteins/peptide in HTR8/SVneo cells. ......................... 206 
Table 6.2: Identification of up-regulated proteins/peptide in TEV-1 cells. .................................... 209 
Table 6.3: Protein changes that are common to HTR/SVneo and TEV-1 cells. ............................. 211 
 
Table A 1: Clinical Data ................................................................................................................. 231 
Table A 2: NCBI accession numbers for factors. ........................................................................... 233 
Table A 3: NCBI accession numbers for markers. ......................................................................... 238 
 
  
 
 
 
 
 
 
 
 
 
viii 
 
 Abbreviations 
ALDH3  Aldehyde dehydrogenase 3 
ALDH3A1  Aldehyde Dehydrogenase 3 Family, Member A1 
APM    Antigen Presentation Machinery 
AURK   Aurora kinases 
AURK-A   Aurora kinase A 
AURK-C   Aurora kinase C 
BCA   Bicinchoninic acid 
bFGF    basic Fibroblast Growth Factor 
bHLH    basic Helix-Loop-Helix 
BME                           Basement Membrane Extract  
BSA   Bovine Serum Albumin 
cDNA                          Complementary DNA  
CDS    Coding Sequences 
CDX2                         Caudal Type Homeobox 2 
CRIP2  Cysteine-Rich Protein 2 
CSC   Cancer Stem Cell 
CSF    Colony Stimulating Factor 
CTB    Cytotrophoblasts 
CTLs    Cytotoxic T Cells 
DAB    3,3'-Diaminobenzidine 
DCs    Dendritic Cells 
DNA                          Deoxyribonucleic acid 
DOX             Doxorubicin hydrochloride 
DPBS                         Dulbecco's Phosphate-Buffered Saline 
DTT                                   Dithiothreitol 
ECM   Extra-Cellular Matrix 
ECs    Endothelial Cells 
egEVT   endoglandular Extravillous Trophoblast, endoglandular trophoblast 
EGF    Epidermal Growth Factor 
EMT    Epithelial-Mesenchymal Transition  
enEVT   endovascular Extravillous Trophoblast, endovascular trophoblast 
ES, ESC  Embryonic Stem Cells 
EVT   Extravillous Trophoblast 
ix 
 
Abbreviations 
 
FBS   Foetal Bovine Serum 
FGR                             Foetal Growth Restriction 
FSCs      Foetal Stem Cells  
GAPDH                      Glyceraldehyde 3-phosphate dehydrogenase 
hAEC    Human Amniotic Epithelial Cells 
HB-EGF   Heparin-Binding Epidermal Growth Factor 
hCG    human Chorionic Gonadotropin  
HGF    Hepatocyte Growth Factor 
HIAR    Heat Induced Antigen Retrieval 
HLA-G   Human Leukocyte Antigen-G 
HOX    Homeobox 
hPL    human Placental Lactogen 
HPRT1                       Hypoxanthine-guanine phosphoribosyltransferase 
HSCs    Hematopoietic Stem Cells 
IAA                              Iodoacetamide 
ICM    Inner Cell Mass 
iEVT    interstitial Extravillous Trophoblast  
IFN-γ   Interferon gamma 
IGF-1   Insulin like Growth Factor 1 
IHC    Immunohistochemistry 
IL-10   Interleukin 10 
IUGR    Intra-Uterine Growth Restriction 
JAG-1   Jagged-1 
LDH   Lactate Dehydrogenase 
LIF    Leukaemia Inhibitory Factor 
MAPK   Mitogen Activated Protein Kinases 
MET    Mesenchymal-Epithelial Transition  
MHC    Major Histocompatibility Complex 
MMP-9  Matrix Metalloproteinase 9 
MMPs   Matrix Metalloproteinase 
mRNA   messenger RNA 
MSCs    Mesenchymal Stem Cells 
MTT   3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide 
 NAD    Nicotinamide adenine dinucleotide  
NADH               Reduced form of NAD     
x 
 
Abbreviations 
 
NANOG                       Homeobox Transcription Factor Nanog  
NCBI    National Centre for Biotechnology Information 
NK    Natural Killer Cells 
NOTCH1                      Notch Homolog Translocation-Associated 
NT   Normotensive, Normal placenta 
OCT4                          Octamer-binding transcription factor 4 
PBS                              Phosphate-buffered saline  
PBST                          PBS with Tween 20 
PCR                            polymerase chain reaction 
PDGF    Plated-Delivered Endothelial Growth Factor 
PDGFRα   Platelet-Derived Growth Factor Receptor Alpha 
PE   Pre-Eclamptic, Pre-Eclampsia 
PGF    Placental Growth Factor 
PI3K    Phosphoinositide 3-Kinase 
PIGF    Placenta-Like Growth Factor 
POU                             Pit-Oct-Unc   
qRT-PCR  Quantitative Real-Time PCR 
RNA    Ribonucleic acid 
RNS    Reactive Nitrogen Species 
ROS    Reactive Oxygen Species 
SCs    Stem Cells 
SEM   Standard Error Mean 
SFM   Serum-Free Media 
SOX2    Sex-determining region Y (SRY)-Box 2 
STB    Syncytiotrophoblasts 
Ta    Annealing temperatures 
TAEB                     Triethyl ammonium bicarbonate buffer 
TBS                     Tris-buffered saline 
TCR    T-Cell Receptor 
TGF-β   Transforming Growth Factor beta 
TICs    Tumour-Initiating Cells 
TIMP-1   Tissue Inhibitors of Metalloproteinase 1 
TIMPs   Tissue Inhibitors of Metalloproteinases 
TNF-α   Tumour Necrosis Factor alpha 
tPA   tissue-type Plasminogen Activator 
xi 
 
Abbreviations 
 
TSC    Trophoblast Stem Cells 
TSP-1   Thrombospondin 1 
UCB    Umbilical Cord Blood Stem Cells  
uPA   urokinase-type Plasminogen Activator 
vCTBs   villous Cytotrophoblast 
VEGF    Vascular Endothelial Growth Factor Family 
WB    Western Blotting 
WHO    World Health Organisation  
xii 
 
 Table of Contents 
Copyright statement ..........................................................................................................................i 
Communications resulting from this study ................................................................................... ii 
Acknowledgements ......................................................................................................................... iii 
Abstract  ...............................................................................................................................iv 
List of Figures  ...............................................................................................................................vi 
List of Table  ............................................................................................................................ viii 
Abbreviations  ...............................................................................................................................ix 
Table of Contents .......................................................................................................................... xiii 
Chapter 1  Introduction ...................................................................................................... 1 
1.0  Introduction ....................................................................................................................... 2 
1.1   Human Placenta ................................................................................................................ 2 
1.1.1  Structure of mature human placenta .................................................................. 3 
1.1.2  Functions of the placenta ..................................................................................... 4 
1.1.3  Early development of the placenta ...................................................................... 4 
1.1.3.1  Pre-implantation .................................................................................... 4 
1.1.3.2  Implantation .......................................................................................... 5 
1.1.3.3  Detailed structure and functions of trophoblast ................................. 8 
1.1.3.4  Pathways of human trophoblast cell differentiation .......................... 8 
1.1.3.5  Spiral artery remodelling in detail ..................................................... 13 
1.1.3.6  Regulation of trophoblast differentiation and invasion ................... 14 
1.1.4  Placental complications ...................................................................................... 16 
1.1.4.1  Pre-eclampsia (PE) .............................................................................. 16 
1.1.4.2  Pathophysiology of Pre-eclampsia ..................................................... 17 
1.2  Tumour  ............................................................................................................................ 19 
1.2.1  Hallmarks of cancer ........................................................................................... 19 
1.3  Similarities between placentation and tumourigenesis ................................................ 26 
1.3.1  Invasion ................................................................................................................ 27 
1.3.2  Proliferation ........................................................................................................ 28 
1.3.3  Vasculogenic mimicry and immune escape ...................................................... 29 
1.4  Differences between trophoblast and tumour invasion ................................................ 29 
1.5  Potential factors of interest common to tumours and placenta ................................... 30 
1.5.1  Human aldehyde dehydrogenase 3 family, member A1 (ALDH3A1) ............ 30 
1.5.2  Aurora kinases (AURK) ..................................................................................... 31 
1.5.3  Platelet-derived growth factor receptor alpha (PDGFRα) ............................. 33 
1.5.4  Basic helix loop helix protein (TWIST1) .......................................................... 33 
34T1.5.5 34T 34TJAG1 (Jagged-1)34T ................................................................................................. 34 
1.6  Importance of “stem-like” cells in invasion .................................................................. 34 
xiii 
 
 1.6.1  Stem Cells ............................................................................................................ 35 
1.6.2  Classification of Stem Cells ................................................................................ 35 
1.6.3  Stem cell markers ............................................................................................... 36 
1.6.4  The ability of trophoblast to produce stem-like cells ....................................... 38 
1.7  Spheroid (3-D) cell culture .............................................................................................. 39 
1.8  Aims and hypothesis ........................................................................................................ 41 
Chapter 2      Materials and Methods ................................................................................ 42 
2.1  Buffers and solutions ....................................................................................................... 43 
2.3  Placental tissue collection ................................................................................................ 45 
2.4  Total RNA extraction ...................................................................................................... 45 
2.5  cDNA template preparation by Reverse Transcription ............................................... 46 
2.6  Gene expression study ..................................................................................................... 46 
2.6.1  Primer designing and optimising .......................................................................... 46 
2.6.2  Gene amplification using conventional PCR and gradient PCR .................... 47 
2.6.3  Agarose gel electrophoresis ................................................................................... 48 
2.6.4  PCR product confirmation by DNA sequencing .............................................. 48 
2.6.5  Relative expression of factors of interest by quantitative Real-Time PCR 
(qRT-PCR) ........................................................................................................ 48 
2.7  In vitro cell culture ........................................................................................................... 49 
2.7.1  Cell revival and subculture ................................................................................ 49 
2.7.2  Cryopreservation of cells ................................................................................... 50 
2.8  In vitro cytotoxicity assays .............................................................................................. 50 
2.8.1  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay
 ............................................................................................................................ 50 
2.8.2  CytoTox 96® Non-Radioactive Cytotoxicity/ Lactate dehydrogenase assay 
(LDH assay) ...................................................................................................... 51 
2.9  Generation of non-resistant (normal) and drug resistant spheroids .......................... 51 
2.9.1  Generation of non-resistant (normal) spheroids .............................................. 52 
2.9.2  Generation of Doxorubicin (DOX) resistant spheroids:.................................. 53 
2.9.3  RNA extraction from normal cells and spheroidal cells .................................. 54 
2.10  Protein expression studies ............................................................................................... 54 
2.10.1 Tissue lysate preparation for protein analysis ................................................. 54 
2.10.2  Cell lysate preparation for protein analysis ..................................................... 54 
2.10.3  Estimation of protein concentration by Bicinchoninic acid (BCA) assay ...... 54 
2.10.4  Protein separation by SDS-PAGE ..................................................................... 55 
2.10.5  Protein analysis by Immunoblotting ................................................................. 55 
2.11  Staining protocol .............................................................................................................. 55 
2.11.1  Immunohistochemistry (IHC) ........................................................................... 55 
2.11.2  Immunofluorescence staining ............................................................................ 58 
xiv 
 
 2.12  Scratch /Wound healing assay ........................................................................................ 59 
2.13  Invasion assay .................................................................................................................. 60 
2.14 Cultrex® 96 well 3-D spheroid Basement Membrane Extract (BME) cell invasion 
assay  ............................................................................................................................ 61 
Chapter 3     Comparative expression analysis of tumour associated factors in 
Normotensive (NT) and Pre-eclamptic (PE) placentae ................... 63 
3.1 Introduction ..................................................................................................................... 64 
3.2 Results  ............................................................................................................................ 65 
3.2.1 Human placental samples ....................................................................................... 65 
3.2.2 Gene expression studies .......................................................................................... 66 
3.2.2.1 Relative mRNA expression of factors of interest in NT and PE ..... 67 
3.2.3  Protein expression and Cellular localisation of factors of interest in NT and 
PE....................................................................................................................... 69 
3.3  Discussion ......................................................................................................................... 82 
3.3.1  Comparative expression analysis between NT and PE placentae .................. 83 
3.4  Conclusions ...................................................................................................................... 88 
Chapter 4  Establishment and characterisation of stem like cells from 
trophoblast and tumour cell lines .......................................................... 89 
4.1  Introduction ..................................................................................................................... 90 
4.1.1 Establishing stem like cells from human trophoblast and tumour cell lines ..... 93 
4.1.2  Using DOX to select drug resistant spheroids .................................................. 94 
4.2  Results  ............................................................................................................................ 95 
4.2.1  Determination of cell seeding density for different cell lines .......................... 95 
4.2.2  Use of Doxorubicin to select spheroids ............................................................. 95 
4.2.2.1  Effect of Doxorubicin on cell viability and toxicity .......................... 95 
4.2.3  Generation of spheroids from trophoblast and tumour cells.......................... 98 
4.2.3.1  Generation of non-resistant (normal) spheroids .............................. 98 
4.2.3.2  Generation of drug resistant spheroids ............................................. 99 
4.2.4  Immunofluorescence staining of stem cell markers ....................................... 104 
4.2.4.1  Expression of OCT4 and SOX2 markers for trophoblast and tumour 
cell lines .............................................................................................. 104 
4.2.4.2  Expression of OCT4 and NANOG1 markers for trophoblast and 
tumour cell lines ................................................................................ 108 
4.2.4.3  Expression of CDX2 and NOTCH1 markers in trophoblast and 
tumour cell lines ................................................................................ 112 
4.2.5  Gene expression studies of stem cell markers ................................................ 116 
34T .2.5.1 34T 34TRelative mRNA expression of stem cells markers in trophoblast and 
tumour cell lines34T ................................................................................ 117 
4.2.6  Protein expression of stem cell markers ......................................................... 128 
4.2.6.1  Protein expression of OCT4 ............................................................. 128 
xv 
 
 4.2.6.2  Protein expression of SOX2 .............................................................. 130 
4.2.6.3  Protein expression of NANOG ......................................................... 132 
4.2.6.4  Protein expression of CDX2 ............................................................. 134 
4.2.6.5  Protein expression of NOTCH1 ....................................................... 136 
4.3  Discussion ....................................................................................................................... 138 
4.3.1  Effect of Doxorubicin on cell viability and toxicity ....................................... 138 
4.3.2  Generation of non-resistant (normal) spheroids ............................................ 139 
4.3.3  Generation of resistant spheroids from trophoblast and tumour cell lines . 139 
4.3.4  Characterization of stem cell markers by Immunofluorescence .................. 140 
4.3.5  Relative mRNA/protein expressions of stem cell markers ............................ 142 
4.4  Conclusions .................................................................................................................... 145 
Chapter 5      Understanding the cellular behaviour of spheroidal cells derived 
from trophoblast and tumour cell lines ............................................. 146 
5.1  Introduction ................................................................................................................... 147 
5.2  Results  .......................................................................................................................... 149 
34T5.2.1 34T 34TIn vitro cell migration by scratch/wound healing assay34T ................................. 149 
5.2.2.1  Migration of transformed trophoblast cell lines ............................. 149 
5.2.2.2  Migration of choriocarcinoma cell lines .......................................... 153 
5.2.2.3  Migration of MCF-7 tumour cells .................................................... 157 
5.2.2  Cell invasion Assay ........................................................................................... 159 
5.2.2.1  The invasion of transformed trophoblast cell lines ........................ 159 
5.2.2.2  The invasion of choriocarcinoma cell lines ..................................... 161 
5.2.2.3  The invasion of MCF-7 cell line ....................................................... 163 
5.2.3  3-D Spheroid BME cell invasion assay ........................................................... 164 
5.2.3.1  3-D invasion by spheroids produced from transformed trophoblast 
cell lines .............................................................................................. 164 
5.2.3.2  3-D invasion by spheroids from choriocarcinoma cell lines .......... 166 
5.2.3.3  3-D invasion by spheroids produced from adenocarcinoma breast 
cancer cell line. ................................................................................... 168 
5.3  Discussion ....................................................................................................................... 170 
5.3.1  In vitro cell migration analysis using scratch /wound healing assay ............ 170 
5.3.1.1 Migration of transformed trophoblast cell lines ............................. 170 
5.3.1.2  Migration of choriocarcinoma cell lines .......................................... 171 
5.3.1.3  Migration of MCF-7tumour cell line. .............................................. 172 
5.3.2 Cell invasion Assay................................................................................................ 172 
5.3.2.2  2-D Invasion by choriocarcinoma cell lines .................................... 173 
5.3.2.3  2-D Invasion the MCF-7 cell line ..................................................... 174 
5.3.3  3-D Spheroid BME cell invasion assay ........................................................... 175 
xvi 
 
 5.3.3.1  3-D invasion of spheroids produced from transformed trophoblast 
cell lines .............................................................................................. 175 
5.3.3.2  3-D invasion of spheroids produced from choriocarcinoma cell lines 
  ............................................................................................................ 175 
5.3.3.3  3-D invasion of spheroids produced from the MCF-7 cell line ..... 176 
5.4  Conclusions .................................................................................................................... 177 
Chapter 6 Comparative expression analysis of tumour associated factors in 
trophoblast cell lines under different conditions………………….178 
6.1  Introduction ................................................................................................................... 179 
6.2  Results  .......................................................................................................................... 181 
6.2.1 Relative mRNA expression ................................................................................... 181 
6.2.1.1 Relative mRNA expression of ALDH3A1 ........................................... 181 
6.2.1.2  Relative mRNA expression of Aurora kinase A (AURK-A) ......... 183 
6.2.1.3  Relative mRNA expression of Aurora kinase C (AURK-C) .......... 185 
6.2.1.4  Relative mRNA expression of PDGFRα .......................................... 187 
6.2.1.5 Relative mRNA expression of TWIST1 ........................................... 189 
6.2.1.6  Relative mRNA expression of JAG1 (Jagged 1) ............................. 191 
6.2.2  Protein expression analysis .............................................................................. 193 
6.2.2.1  Protein expression of ALDH3A1 ..................................................... 193 
6.2.2.2 Protein expression of AURK-A ........................................................ 195 
6.2.2.3  Protein expression of AURK-C ........................................................ 197 
6.2.2.4 Protein expression of PDGFRα ........................................................ 199 
6.2.2.5     Protein expression of TWIST1 ........................................................ 201 
6.2.2.6    Protein expression of JAG1 .............................................................. 203 
6.2.3  Proteomic analysis of global protein/peptide expressions ................................ 205 
6.2.3.1 Identification of altered proteins in HTR8/SVneo cells ................. 205 
6.2.3.2  Identification of altered proteins in TEV-1 cells ............................ 208 
6.3  Discussion ....................................................................................................................... 212 
6.3.1  Relative mRNA/protein expressions of factors of interest ............................ 213 
6.3.2   Proteomics on   global expressions of protein in transformed trophoblast cell 
lines .................................................................................................................. 216 
6.4  Conclusion ...................................................................................................................... 218 
Chapter 7  General Discussion ..................................................................................... 219 
7.0  Discussion ....................................................................................................................... 220 
7.1  Expression analysis of factors interest in NT and PE ................................................ 220 
7.2  Generation of spheroids from trophoblast and tumour cell lines ............................. 223 
7.3  Migration capacities of spheroidal from trophoblast cell lines ................................. 224 
7.4 Invasion capacities of spheroidal cells from trophoblast cell lines ............................ 225 
7.5  Global expressions of protein in transformed trophoblast cell line .......................... 227 
xvii 
 
 7.6  Conclusion ...................................................................................................................... 227 
7.8  Future work ................................................................................................................... 229 
Appendix  ............................................................................................................................ 231 
A.1 Clinical data of patients .................................................................................................... 231 
A.2 The extraction of RNA from NT (Panel A) and PE (panel B) placental tissues. ......... 232 
A.3. Temperatures optimisation for factors of interest ........................................................ 233 
A.4. Accession numbers for target factors used for primer designing ................................ 233 
A.5 Example of sequencing ..................................................................................................... 234 
A.6 Western blot whole blots .................................................................................................. 235 
A.7 The extraction of RNA from trophoblast cell lines ........................................................ 237 
A.8 Temperatures optimisation for markers of interest ...................................................... 237 
A.9 Accession numbers for target factors used for primer designing ................................. 238 
References  ............................................................................................................................ 239 
 
 
 
 
 
xviii 
 
 1.  
 
 
 
 
 
 
 
 
Chapter 1 
Introduction 
  
1 
 
Chapter 1: Introduction 
 
1.0  Introduction 
The process of embryo development is somewhat similar to tumourigenesis in terms of 
biological behaviour such as proliferation, migration, invasion, gene expression, and the 
mechanism of immune escape (Ferretti et al., 2007). This makes the placenta an interesting 
physiological model to study and compare the process of proliferation and invasion with that 
seen in tumour development (Ma et al.,  2010). This study might help to understand the 
behavioural similarities and differences between tumour and placenta.  
1.1   Human Placenta 
The birth of a healthy infant depends on the development of a highly specialised organ called 
the placenta (Guttmacher et al., 2014). The placenta is a temporary organ which plays a 
significant role in maintaining pregnancy and supporting the normal growth and 
development of the foetus. The world placenta comes from two terms, the first from a Latin 
word “placenta”, meaning a flat cake (Enders and Blankenship, 1999), and the second from 
Greek “plakoenta” meaning flat (wwwP1P). During pregnancy the normal growth of the foetus 
depends on the crosstalk between foetal membranes and amniotic fluid (Gude et al., 2004). 
Human placenta is categorised as a haemochorial villous organ. Despite the fact the maternal 
and foetal circulation do not directly mix, an intimate contact is established between 
maternal blood circulation and placental trophoblast cells in order to support an adequate 
supply of nutrients to the foetus (Gude et al., 2004). Figure 1.1 shows the materno-foetal 
interface with a detailed of the placenta. 
 
Figure1.1: The interface between mother and foetus in placenta. 
This figure shows the localisation of the placenta in the uterus and the cross-section of 
placenta displaying circulation of the blood. [Figure adapted from www2] 
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1.1.1  Structure of mature human placenta 
In humans, the placenta is discoidal in shape. A mature full-term placenta is around 22 cm 
in diameter with a central thickness of 2.5 cm. The placenta weighs around 470 g (Huppertz, 
2008) . These measurements differ from one placenta to other and also depends on the mode 
of delivery (since measurements are made on the post-delivery placenta). However, the 
weight of the placenta is related to that of the foetus. There are two surfaces of a placenta: 
(a) foetal surface and (b) maternal surface (Huppertz, 2008) (www3). 
• Foetal surface 
The foetal surface is known as the chorionic plate and has the umbilical cord associated to 
its centre (See Figure 1.2 A). It is covered by the amnion and a single layered epithelium 
(Huppertz, 2008). The umbilical cord is a continuation of the chorionic vessels that arise 
from the chorionic mesenchyme. The chorionic arteries arise from two umbilical arteries 
which supply the villous trees.  Furthermore, the villous trees continue to the chorionic veins 
and finally forms a single umbilical vein (Huppertz 2008).  
• Maternal surface 
The attachment site of the placenta onto the uterus is called the maternal surface (or decidua 
basalis or basal plate) (Huppertz, 2008). The surface is covered with grooves and clefts as 
seen in Figure 1.2 B. Furthermore, it consists of a mixture of trophoblast and maternal cells 
from uterine decidua, including decidual stroma cells, natural killer cells (NK) and 
macrophages (Gude et al., 2004) 
 
Figure1.1: Illustration of both human placental sides. A) Represents the foetal side; B) 
Represents the maternal side. [Figure adapted from Kay et al., 2011] 
3 
 
Chapter 1: Introduction 
 
1.1.2  Functions of the placenta  
The placenta provides a suitable environment which enables the foetus to exchange gases, 
such as oxygen from maternal blood to foetus and carbon dioxide from foetus to maternal 
blood (Gude et al., 2004). Moreover, it also facilitates the exchange of nutrients and 
electrolytes from mother to foetus, such as carbohydrates (glucose) which is considered to 
be the source of energy for the foetus (Gude et al., 2004). Other examples include lipids 
(fatty acid, glycolipids, vitamins, and cholesterol) and amino acids which are essential for 
the synthesis of proteins in the foetus (Ji et al., 2013). Likewise, the placenta also serves as 
an endocrine and metabolic organ by producing hormones, growth factors, antibodies, and 
other nutrients required to support the growth of the foetus; while also removing waste 
products. It acts as a barrier which separates the foetal and maternal blood, which plays an 
essential role in protecting the foetus from the maternal immune attack during pregnancy (Ji 
et al., 2013).  It also helps to protect the foetus from diseases and infection of maternal origin 
and from xenobiotic molecules (Donnelly and Campling, 2014). 
1.1.3  Early development of the placenta 
The early development of the placenta starts with interactions between the invading 
blastocyst and the uterine wall (Forbes and Westwood, 2010). This process is dependent on 
several factors, such as receptivity of the uterus, blastocyst apposition/adhesion to the 
endometrial epithelium, and invasion into endometrial stroma. The type of implantation 
which occurs in humans is termed as interstitial implantation, where the embryo is 
completely embedded within endometrium (Forbes and Westwood, 2010). The steps after 
fertilisation are discussed below (see sections 1.1.3.1. to 1.1.3.4). 
1.1.3.1  Pre-implantation 
Fertilisation usually occurs in the fallopian tube at 24 to 48 hours after ovulation when the 
mature oocytes are fertilised by a sperm to form a diploid zygote and this is counted as (Day 
0) of placental development (Hamilton and Boyd, 1960). Pre-implantation events in relation 
to their appropriate position in the female reproductive tract are summarised in Figure 1.3. 
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Figure1.3: Illustration of the early stages of human placental development. Figure 
revised from (www4) 
 
The fertilised egg (zygote) moves along the fallopian tube into the uterus and undergoes 
several stages of cleavage and differentiation. During the first mitotic division, the zygote 
divides to become the two cell stage (Day 1). This is followed by the four cells stage (Day 
2), and eight cell stage (Day 3), Divisions continue until the zygote reaches a round mass of 
cells (blastomere or morula) which is formed with 12-16 cells (Day 4) (Norwitz, 2001). The 
morula then enters the uterine cavity; during which a fluid-filled cavity appears in the inner 
side of the morula and further cell divisions occur, resulting in development of the morula 
to a blastocyst (Norwitz, 2001). The cells on the outer side of the morula thicken and flatten 
out while the cells inside become more compact and adhere to one another forming a cavity. 
This gives rise to an outer layer of trophoblast cells and an inner cell mass of embryo proper.  
The blastocyst “hatches” from the zona pellucida by constant contraction and expansion. 
The free blastocyst then aligns along the uterine wall. The inner cell mass give rise to the 
foetus while the outer trophoblast layer gives rise to extra embryonic structures, and leads to 
the implantation of the blastocyst into the uterus to form the placenta (Red-horse et al., 2004; 
Foulk, 2012).  
1.1.3.2  Implantation  
Implantation is a complex process and can only take place in a limited period of time, named 
the "window of receptivity" (Lunghi et al., 2007). During days 6-7, the blastocyst implants 
into the endometrium of the uterus and around Day 10 the blastocyst is fully embedded in 
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the stromal tissue of the uterine wall (Lunghi et al., 2007).  The implantation process includes 
three stages: apposition, adhesion and invasion – see below (James et al., 2012). To support 
implantation, and receive the blastocyst, the endometrium is changed extensively in its 
morphology, biochemical composition and the ability to secrete hormones such as oestrogen 
and progesterone.  This step is known as decidualisation, an essential step to establish the 
pregnancy resulting in modification of endometrial stromal cells, vessels, and uterine glands 
(Lunghi et al., 2007; van Mourik et al., 2009).  
• Apposition of blastocyst on the uterine mucosa: 
As mentioned in section 1.1.3.1, at the end of the pre-implantation stage the free blastocyst 
aligns along the uterine wall. Meanwhile, the outer layer of blastocyst starts the cellular 
differentiation process which results in formation of trophectoderm and the remaining part 
is the embryoblast which later becomes the embryo body (www5). Establishment of 
cytotrophoblasts (CTBs) at the embryonic pole is the result of mitotic division of a diploid 
layer of trophoectoderm. Later the cytotrophoblast cells produce a non-mitotic layer of 
syncytial cells called syncytiotrophoblasts (STBs) (www5).  
Soon after the embryo is released from the zona pellucida, STBs place in proximity to the 
uterine wall where the outer compact zone of the endometrium interacts with these 
trophoblast cells (www5). The elevation of progesterone and oestrogen during this period 
plays a major role in flattening the uterine cavity in order to minimise the chance of the 
blastocyst being flushed out and also being pressed against the uterine epithelium (www5). 
The apposition process is summarised in Figure 1.4. 
 
Figure1.4: Schematic representation of different layers of developing trophoblast  
The blastocyst hatches out of the partially dissolved zona pellucida. (1) Zona pellucuida, (2) 
Trophoblast (outer cell layer), (3) Hypoblast (part of the inner cell mass), (4) Blastocyst 
cavity, (5) Epiblast (part of inner cell mass or embryo proper). Figure revised from (www5). 
 
• Adhesion of the blastocyst to the endometrium 
Soon after the apposition of the blastocyst, its adhesion onto the maternal endometrium 
begins. During this time the cytoskeleton of endometrial epithelial lining undergoes 
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structural modulation to facilitate the formation of pinopodes (Carlson and Mosby, 1994). 
This structural change can enhance the adhesion of STBs with endometrial epithelial lining 
(See Figure 1.5). At this stage, the microvilli present on the outer surface of STBs interact 
with the epithelial cell membrane of the endometrium which reduces the chance of being 
flushed out of the blastocyst (Carlson and Mosby, 1994). The presence of cytokines, such as 
leukaemia inhibitory factor (LIF) in uterine fluid, is believed to support successful 
implantation of the blastocyst. Up-regulated LIF along with heparin-binding epidermal 
growth factor (HB-EGF) stimulates the hatching of the blastocyst and trophoblast growth 
(Carlson and Mosby, 1994).  
 
Figure1.5: Schematic representation of adhesion of blastocyst. Figure revised from 
(www5). 
 
• Invasion 
After adhesion of the blastocyst to the maternal endometrium, intra/inter-cellular signalling 
mechanisms initiate changes in polarisation of the endometrial epithelial cells. These cells 
are involved in redistribution of apical cells, basolateral membrane domains, and 
remodelling of tight and adhering junctions of endometrium tissues (Gude et al., 2004). The 
invasion of the blastocyst is accomplished by the inter-link between STBs and the lateral 
border of the endometrial epithelial cells. The invasion is facilitated by decidual cells, which 
contribute to the breakdown of basal lamina as well as other materials of basement 
membrane including laminin, collagen IV etc.  In order to facilitate this implantation process 
maternal endometrium undergoes several physiological preparations supported by many 
hormones. These hormones in turn regulate other growth factors, cytokines and adhesion 
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molecules to enhance implantation (Gude et al., 2004). The rapid proliferation of 
mononuclear trophoblast cells followed by invasion is not very different from that seen in 
aggressive tumours.  
1.1.3.3  Detailed structure and functions of trophoblast  
Trophoblast, the specialized cell type in a placenta, plays an important role in implantation 
and formation of the materno-foetal interface (Huppertz, 2008). In the invasion process, 
trophoblast cells undergo differentiation to form a multinucleated syncytiotrophoblast (STB) 
(Huppertz, 2008). This STB penetrates the uterine epithelium crossing the basal lamina and 
embeds the embryo into the stroma. The mononucleated cytotrophoblast cells (CTBs) form 
the second layer and do not come into contact with the maternal interface. They act as stem 
cells for the STB, which upon rapid division and fusion finally lead to the expansion of the 
placenta (Aplin, 1991). The main event during placental development is trophoblast invasion 
into maternal spiral arteries to remodel the arterial walls to enhance blood supply, which is 
an important process for successful development of the placenta and pregnancy (Aplin, 
1991).  Trophoblast invasion begins early in pregnancy and continues until the 20th week of 
gestation. This invasion (and migration) of trophoblast is controlled by several factors 
secreted by endometrial glands, such as epidermal growth factor (EGF), vascular endothelial 
growth factor (VEGF), cytokines, transcription factors, extracellular matrix degradation 
enzymes, and human leukocyte antigen-G (HLA-G). The molecular steps involved in 
trophoblast differentiation are poorly understood (Goldman-Wohl and Yagel, 2002; Knöfler 
and Pollheimer, 2012). However, trophoblast invasion has been found to be increased or 
decreased under different oxygen concentrations (Anin et al., 2004). Shallow or poor 
trophoblast invasion is associated with pregnancy complications such as miscarriage, pre-
eclampsia (PE) and intrauterine growth restriction (IUGR). Likewise, the excessive invasion 
of trophoblast leads to placenta accreta (Harris, 2010). 
 
1.1.3.4  Pathways of human trophoblast cell differentiation 
The human trophoblast cells have a heterogeneous group of immature cell populations which 
include stem cells (trophoblast stem cells, TSC) and progenitor cells (Gude et al., 2004). 
The differentiation of these mononuclear cytotrophoblast progenitor cells is categorised into 
two main pathways: 1) the invasive extra-villous trophoblast pathway which is found to be 
active during first trimester, and 2) the non-invasive villous trophoblast pathway which 
appears later in pregnancy. This suggests that the differentiation process of trophoblast cells 
is a dynamic procedure that continues until the end of pregnancy (Gude et al., 2004;  Ji et 
al., 2013). The two pathways are summarised in Figure 1.6. 
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Figure1.6:Trophoblast differentiation via different cell lineages. 
[Figure adapted from Gude et al., 2004] 
 
(1) Invasive Pathway 
During the invasive extravillous pathway, CTB stem cells, at the basement membrane of the 
anchoring villi, invade into the uterine tissue, where they first proliferate and then migrate 
into the decidua and the myometrium (Guibourdenche et al., 2009). EVT are primarily 
mononuclear cells that are found in the smooth chorion, chorionic plate and basal plate. The 
functions of EVT include transformation of the maternal spiral arteries, toleration to 
hypoxia, adhesion to ECM, stimulating the CTB proliferation/differentiation, interaction 
with the maternal immune system and enhancing apoptosis (Guibourdenche et al., 2009). 
The EVT cells divide into three subtypes, namely (a) interstitial trophoblast (iEVT), (b) the 
endovascular trophoblast (enEVT) and (c) endoglandular trophoblast (egEVT) (Hammer, 
2011). Several studies have confirmed that the reduction in numbers of both interstitial and 
endovascular trophoblast and failure in re-modelling are associated with PE and IUGR 
(Guibourdenche et al., 2009). 
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• Interstitial extravillous trophoblast (iEVT)  
These non-proliferative cells are dispersed in the decidua and express three different 
phenotypes: (1) the large polygonal iEVTs (not invasive) (2) small spindle-shapes iEVTs 
(invasive) and (3) placental bed giant cells (Ferreti et al., 2007). The large polygonal iEVTs 
stay in the transition phase between placenta and decidua, maintaining firm attachment to 
the uterus throughout the pregnancy (Ferreti et al., 2007). They also secrete trophoblastic 
glue to enhance adhesion. On the other hand, the small spindle shaped iEVT cells invade to 
the inner layer of myometrium during the second trimester of the pregnancy (Ji et al.,  2013). 
They move deeper into the decidua and start to differentiate into multinucleated round cells 
called placental bed giant cells. These cells restrict the EVT invasion outside myometrium 
and therefore limit the invasion (Ji et al., 2013). They have the ability to secrete human 
chorionic gonadotropin (hCG) and human placental lactogen (hPL) which supplies energy 
to the embryo (Ferreti et al., 2007). It has been suggested, that these cells play a role in the 
maintenance of pregnancy and secretion of protease inhibitors which are responsible for 
controlling the EVTs invasion past myometrium (Hammer, 2011). The placental invasion 
fragments beyond the uterus and long-term establishment in the mother (Kinder et al., 2015).  
Physiologically, invasion of the endometrium by the trophoblast is limited to the decidua 
basalis. Placenta accreta is present when there is excessive invasion during placentation 
extending beyond the decidua basalis. While placenta increta presents if there is extend 
invasion into the uterine myometrium. Moreover, if the placental villa penetrate the 
myometrium and reach the uterine serosa or even invade neighboring organs such as the 
bladder and intestines this is known as placenta percreta (Findeklee and Costa, 2015). 
• Endovascular trophoblast (enEVT) 
The enEVT cells play a significant role in the re-modelling of the uterine spiral arteries   
(Lyall, 2006). After 11-14 weeks of pregnancy EVTs start to invade the uterine spiral 
arteries, and by replacing the maternal endothelial lining they induce: (a) the loss of elastic 
tissue and (b) reduction of the number of the smooth muscle cells (Ashton et al., 2005). This 
mechanism is known as "pseudo-vasculogenesis" or vascular mimicry (Ashton et al., 2005). 
The permeation process of enEVT to the spiral arteries causes the blockage of the vessels by 
forming plugs which aids vascular remodelling of spiral arteries at the end of first trimester. 
As mentioned above, this leads to changes in the structure of arteries, extends the vessels, 
and creates a low resistance against blood flow resulting in high flow utero-placental 
circulation (Ji et al., 2013) (See Section 1.1.3.5 for a detailed explanation).  
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The five stages that occur during remodelling include: 
i. Decidual activity associated with early vascular remodelling, 
ii. iEVT involved in vascular remodelling, 
iii. enEVT migration, 
iv. The insertion of enEVTs into the vessel wall, and 
v. The re-endothelisation and sub-intimal thickening (Staff et al., 2010) (See Figure 
1.7). 
 
 
Figure1.7: The different stages involved in spiral artery remodelling. 
Starting with non-pregnancy conditions, Stage I shows the earliest stage in vascular 
remodelling which consists of compact endothelia. Stage II is associated with 
disorganisation of the vascular smooth muscles. Stage III is initiated by the start of plug 
formation by enEVT. In Stage IV enEVT is embedded and replaces the original smooth 
muscle cells. The re-endothelialisation occurs at last stage V. [Figure adapted from 
Pijneborg et al.,  2006] 
 
As the maternal blood circulates through the intervillous space, this helps the developing 
foetus to establish its haemotrophic nutrition (Moser et al., 2010). As stated above, the 
invasion of trophoblast cells is important for establishing foeto-maternal circulation.  
• Endoglandular trophoblast (egEVT)  
A study by Huppertz et al. (2008) have suggested the presence of an additional sub-
population of EVTs named as endoglandular extravillous trophoblast cells (egEVT) (see 
Figure 1.8).  The first evidence of egEVTs existence was produced in an in vitro study in the 
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first trimester decidua and placenta explant co-culture, where indication of glandular 
remodelling was observed with a similar mechanism to enEVT spiral artery remodelling 
(Moser et al., 2010). The glandular cell replacement by the egEVT may provide a 
mechanism which supports both (a) opening of the uterine glands to the intervillous space 
and (b) provides histiotrophic nutrition to the embryo ahead of the development of good 
perfusion of the placenta (Ji et al., 2013). 
 
 
Figure1.8: Different types of trophoblast cells during invasion. 
iEVT invade and embed into myometrial smooth muscle to make a firm attachment. enEVT 
invades the spiral arteries to remodel them. enEVT are involved in the remodelling of uterine 
endometrial glands. [Figure adopted from Moser et al., 2010] 
 
(2)  Non-invasive Villous pathway  
The non-invasive villous pathway is also known as the syncytial pathway and includes the 
CTB cells which differentiate by fusion to form the multinucleated STBs that covers the 
entire surface of the villi (Guibourdenche et al., 2009). Therefore, the villous cytotrophoblast 
(vCTBs - the inner layer) consists of both the STBs and CTBs (Hammer, 2011).  These villi 
are in direct contact with maternal blood within the intervillous space and are involved in 
gas, nutrient and waste exchange (Ferretti et al., 2007). Moreover, the syncytial layer plays 
a major role in the maintenance of the pregnancy by releasing important hormones into the 
maternal circulation such as hCG and hPL (Ferretti et al., 2007). As explained in section 
1.1.3.2, STBs protect the foetus by inhibiting the maternal immune response. The STB layer 
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is maintained by the continual proliferation, differentiation, and fusion of CTBs (Forbes and 
Westwood, 2010; Ji et al., 2013). 
1.1.3.5  Spiral artery remodelling in detail 
As explained in Section 1.1.3.4, uterine spiral arteries in non-pregnant women have a 
compact vascular smooth muscle cells which helps them to maintain a steady blood flow 
(See Figure 1.7).  However, during pregnancy this blood supply must be increased to match 
the demands of the developing foetus and is usually carried out by invasive endovascular 
(enEVT) trophoblast cells (Chandan et al., 2002). The first step starts with the vacuolation 
of endothelial cells within the spiral arteries, followed by the migration of iEVTs which will 
invade the uterine tissue. They have the ability to penetrate one-third of the adjacent 
myometrium (Chandan et al., 2002). The enEVTs migrate towards uterine arteries and 
replace all the endothelial cell lining in the arteries. They also degrade the muscular layer 
which is essentially required to maintain blood vessel integrity (Chandan et al., 2002). This 
is called re-endothelisation which helps in the lowering of vascular resistance to allow 
increased flow during pregnancy (Aplin, 2006). This remodelling of spiral arteries 
transforms the endometrial blood flow from “high resistant, low flow” to “low resistant, high 
flow” circulation (See Figure1.9). This is essential for the maintenance of pregnancy as it 
prevent any hypoxia induced oxidative stress (Knöfler and Pollheimer, 2012).  
 
 
Figure1.9: Schematic representation of normal spiral artery remodelling. 
The remodelling process involves replacement of endothelial cells by enEVTs and 
destruction of smooth muscles by iEVTs.  [Figure Adapted from www6] 
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1.1.3.6  Regulation of trophoblast differentiation and invasion 
The trophoblast invasion is tightly controlled by several factors including hormones, 
cytokines, proteases like matrix metalloproteinase (MMPs) and their inhibitors [tissue 
inhibitors of metalloproteases (TIMP)], major histocompatibility complex (MHC) and 
surface integrins (Ferretti et al., 2007). Differentiation and development of trophoblast cells 
is influenced by many other factors which exert their effects in a paracrine or autocrine 
manner (Staun-Ram and Shalev, 2005). The vascular endothelial growth factor family 
includes five members namely VEGF-A, -B, -C, -D and placenta-like growth factor (PIGF) 
which are considered essential for differentiation (Ferretti et al., 2007). Furthermore, the 
Placental Growth Factor (PGF) is found in spiral artery remodelling. Trophoblast cells also 
express several other factors such as human leukocyte antigens (HLA), including HLA-E, 
polymorphic HLA-C, and HLA-G, which interact with decidual NK cells (Holtan et al., 
2009).  All these factors are secreted not only by the trophoblast cells and villous 
mesenchymal cells, but also secreted from the uterine stromal, glandular, endothelial cells, 
and many other immune cells present at the maternal-foetal interface. Some of these factors 
and their functions are summarised in Table 1.1 
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Table 1.1: Summary of factors involved in trophoblast invasion [Table adapted from Staun-Ram and Shalev, 2005]. 
Factors Source Differentiation Proliferation Migration Invasion Functions 
VEGF family CTBs, STBs, EVTs, and decidua cells.     
Regulate trophoblast invasion by activating different 
signalling cascades as PI3K/Akt pathway. 
Vasodilation, syncytialisation, angiogenesis  
EGF Decidua, CTBs, EVTs,     STBs differentiation, placental endocrine function modulation, embryo implantation  
PIGF Trophoblast cells     Angiogenesis  
IGF-1 Trophoblast cells     Both foetal and placental  development  
TGF-β Decidua, trophoblast,  uNK 
cells     Inhibit early  trophoblast  differentiation and induces syncytialisation, down regulate invading of CBTs  
HGF CTBs, decidua, trophoblast villous STBs     Rapid trophoblast cell proliferation  
CSF Placenta, decidua   N/A  Stimulate growth invasive trophoblast cells  
Angiopoietin 
 
Decidua, endothelial cells, 
STBs, CTBs  N/A N/A N/A Angiogenesis  
Adhesion molecules Tips of anchoring villi, CTBs N/A N/A   Placental anchorage 
hCG Produced by trophoblast  N/A   Control regulation of invasion process  
Progesterone Produced by placenta N/A N/A N/A  Maintain placenta,  and control CTBs invasion  
 
EGF = Epidermal growth factor; IGF-1 = Insulin like growth factor; TGF-β = Transforming growth factor beta; HGF = Hepatocyte growth factor; CSF 
= Colony stimulating factor; hCG = human chorionic gonadotrophin.  = Increased;  = decreased; N/A = data not available 
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1.1.4  Placental complications 
There are diverse clinical conditions and complications associated with pregnancy (www7). 
Complications resulting from abnormal placentation of embryo at second-trimester may lead 
to foetal death, and at the early stage may lead to severe diseases such as: pre-eclampsia 
(PE), intra-uterine growth restriction (IUGR) and abruption of placenta (Chaddha et al., 
2004). PE is most common disease that occurs in near-term pregnancies and causes death or 
early delivery of the foetus (www7). A detailed description of this syndrome is given below. 
 
1.1.4.1  Pre-eclampsia (PE) 
PE affects around 3-8% of pregnancies in the world and is one of the leading causes of 
perinatal maternal morbidity and mortality.  Pre-eclampsia is derived from the Greek word 
‘eklampsis’, meaning sudden flash or growth (Red-Horse et al., 2004). It is a pregnancy-
specific condition which develops after 20 weeks of pregnancy and is characterized by 
hypertension (≥140/90 mm Hg), proteinuria (concentration ≥30 mg/24 hours) and other 
systemic disorders such as organ damage and convulsions (Redman and Sargent, 2005). For 
mothers, it may cause other cardiovascular diseases such as chronic hypertension, ischemic 
stroke and heart disease (Goldman-Wohl and Yagel, 2002). Also, the babies who are born 
from pre-eclamptic pregnancies, are at risk of coronary heart disease, metabolic syndromes 
(such as diabetes) or stroke in their adult life (Roberts and Cooper, 2001;  Uzan et al.,  2011). 
The risk factors for PE include pre-natal obesity, a family history of PE, multiple 
pregnancies, and chronic medical disorders such as long-term hypertension or diabetes 
(Redman and Sargent, 2005). Moreover, Immune and paternal factors may also affect 
women's risk for preeclampsia. It has been suggested that the risk for preeclampsia is 
increase with a change in paternity, limited sperm exposure with the same partner, or 
increased duration of time between pregnancies. These findings has noted that an immune 
tolerance mechanism contributes to the pathogenesis of preeclampsia (Saftlas et al., 2003). 
Shallow trophoblast invasion during spiral artery remodelling can lead to PE, and IUGR 
(Kaufman and Disis, 2004; Pijenborg et al., 2006).  
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1.1.4.2  Pathophysiology of Pre-eclampsia 
Maternal PE is a condition that occurs in the last stage of pregnancy. This conditions starts 
with maternal responses like hypertension. In most of the cases, it is influenced either by 
environmental factors or maternal nutritional factors (Redman and Sargent, 2005). The 
maternal disease (or symptoms) occurs after 20 weeks and shows as full blown PE before 
34 weeks of pregnancy.  In contrast, placental PE is a condition where the placenta is 
becoming defective under hypoxia and oxidative stress (See Figure 1.10). Although the 
mechanism which leads to PE remains unclear, the pathophysiology may have two distinct 
stages: two distinct stages depending on the placental interaction: (1) placental PE and (2) 
maternal PE (Redman and Sargent, 2005). 
Stage 1:This is called “poor placentation” and is characterized by shallow trophoblast 
invasion that results in placental ischemia (Sankaralingam et al., 2006). The failure of 
trophoblasts to convert the spiral arteries results in poor remodelling, therefore restricting 
the utero-placental flow before 20 weeks of pregnancy, i.e. well before any clinical signs of 
PE (Goldman-Wohl and Yagel, 2002; Redman and Sargent, 2005). 
Stage 2: This is characterized by a maternal inflammatory responses to defective placental 
circulation and a resultant hypoxia, by releasing factors which activate (or cause) the 
maternal endothelial dysfunction (Sankaralingam et al., 2006). The recruitment of dendritic 
cells, macrophages and NK cells towards decidua is coupled with maternal symptoms such 
as hypertension and proteinuria, blood clotting and liver dysfunction (Redman and Sargent, 
2005). In rare cases, the foetus may suffer from respiratory insufficiency, decreased 
nutritional supply and asphyxia leading to death (Redman and Sargent, 2005). 
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Figure1.10: Spiral artery remodelling between NT and PE placentation. 
[A] Normal placentation associated with maternal decidua by anchoring villi. The 
cytotrophoblasts (blue) cross the placental maternal bridges and invade the maternal decidua 
next to the spiral arteries. The maternal endothelium (yellow) is encouraging remodelling of 
the arterial wall that results in smooth muscle replacement and arterial dilatation. In a normal 
pregnancy the activity of immune cells such as NK cells (red) and macrophages (purple) 
are down regulated to help the cytotrophoblasts invasion into the myometrial segments.  [B] 
Pre-eclampsia is characterised by an impaired arterial remodelling and shallow 
cytotrophoblast invasion. [C] and [D] illustrate the two stages of PE. [Figure adopted from 
Redman and Sargent, 2005] 
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1.2  Tumour  
Cancer is one of the major health problems which leads to a large number of deaths 
worldwide (www8). According to the World Health Organisation (WHO) it is second among 
deadly diseases, following cardiovascular diseases (www8). It is a highly heterogeneous 
disease that includes more than 100 different types of human cancer (Grizzi et al., 2006). 
Tumourigenesis is a complex multi-development process consisting of transformation, 
proliferation, growth, invasion and metastasis which leads to cancer (Grizzi et al., 2006). 
There are several contributing factors to the development of cancer, these include 
bacterial/viral infection, carcinogenic chemicals, organic and inorganic fibers and physical 
aberrations including ionising radiation and ultraviolet rays, somatic mutations etc. About 
50% of all cancers are linked to lifestyle, such as diet, exposure to industrial toxins, tobacco 
and alcohol consumption (Devi, 2004; Abel and Di Giovanni, 2008). The tumour can be 
benign, if its growth is local (i.e. without invasion). It can also be malignant, if growth is 
uncontrolled, invades the neighbouring tissues and results in metastasis  
1.2.1  Hallmarks of cancer 
Hanahan and Weinberg (2000), initially identified six fundamental hallmarks of tumour 
growth and metastasis, which are shared by most of the tumour cells: (1) Sustaining 
proliferative signalling, (2) evading growth suppression, (3) resistance to cell death program, 
(4) enabling replicative immortality, (5) inducing angiogenesis, (6) activation of invasion 
and the metastasis process. In 2011, they added four more additional hallmarks namely (7) 
deregulating cellular energetics, (8) avoiding immune destruction, (9) genomic instability 
and mutation, and (10) tumour promoting inflammation (See Figure 1.11). All these 
hallmarks are described below. 
 
19 
 
Chapter 1: Introduction 
  
 
Figure1.11: Hallmarks of Cancer. 
The figure represents the 10 characteristic changes taking place in cancer cells for tumour 
growth and transformation. [Adapted from Hanahan and Weinberg, 2011] 
 
(1) Sustaining proliferative signalling 
In normal tissues, cells are controlled by the production and release of growth-promoting 
signals (Hanahan and Weinberg, 2011). These signals enhance cell growth and division 
cycle, and lead to normal tissue functions. In order for normal cells to convert from inactive 
to a proliferative state, they need mitogenic growth signals (or growth factors) and in the 
absence of these growth signals, normal cells die (Hanahan and Weinberg, 2011). On the 
other hand, cancer cells may produce growth factors themselves (Lemmon and Schlessinger, 
2010).  Moreover, they gain the ability to enhance these mitogenic signals and alter growth 
receptors (Kroll et al., 2010).  
(2) Evading growth suppressors  
In normal cells, the proliferation process is regulated by growth suppressors which drive the 
healthy cells into quiescent stage (G0). According to Hanahan and Weinberg (2011), the 
developing tumour cells must evade anti-proliferative signals in order to drive them to 
malignant growth. Moreover, inactivation of tumour suppressor genes (that stop cell growth 
and proliferation) has been reported in many human cancers (Hanahan and Weinberg, 2011)  
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(3) Resisting cell death 
A stable ratio between cell proliferation and cell death helps to maintain the growth of 
normal tissues (Elmore, 2007).  Apoptosis (or programmed cell death) is an important 
cellular process which occurs in both physiological and pathological conditions. However, 
cancer cells lose the balance between cell division and cell death (Elmore, 2007).  Almost 
all tumour cells develop an ability to evade apoptosis by down regulating pro-apoptotic 
factors (such as Bax, Bim, and Puma), and increasing the expression of anti-apoptotic 
regulators (Bcl-2, Bcl-xL) or that of survival signals (Igf1/2) (Hanahan and Weinberg, 2011; 
Wong 2011). 
(4) Enabling replicative immortality 
One of the interesting features of normal cells is their potential to lose the ability of 
replication at some point leading to senescence (Hanahan and Weinberg, 2011). It has been 
reported that the tumour cells evade senescence by the inactivation of the tumour suppressor 
genes (e.g. p53 and pRb) resulting in uncontrolled proliferation and growth of the tumour 
(Herzig and Christofori, 2002). Cell death is mainly caused due to progressive shortening of 
the telomeres which occurs after each cell cycle.  Yet this phenomenon is also surmounted 
by the over-expression of telomerase activity which ultimately results in indefinite cell 
proliferation (Kim et al., 1994). 
(5) Inducing angiogenesis  
Tumour cells require oxygen, nutrients and the removal of waste products during rapid 
growth and invasion (Folkman, 1971).  In order to do this they need to vascularize which is 
achieved by a complex process called angiogenesis and in its absence a tumour may become 
necrotic or apoptotic (Holmgren et al., 1995).  Therefore, angiogenesis is an important step 
for successful invasion, metastasis and growth of the tumour. Physiological angiogenesis is 
a complex process that normally occurs during embryonic development and in wound 
healing (Oklu et al., 2010). However, pathological angiogenesis is critical for cancer cells.  
Angiogenesis is regulated by a balance between angiogenic activators and angiogenic 
inhibitors. The expression levels of angiogenic factors reflect the aggressiveness of the 
tumour cells (Nishida et al., 2006). Tumour endothelial, stromal, and circulating host cells 
(endothelial progenitor cells, platelets, and macrophages) are capable of stimulating 
angiogenesis by producing several angiogenic factors, such as VEGF, EGF, bFGF, TGF-β 
and TNF-α (Nishida et al., 2006) (See Table 1.2). VEGF has two primary roles: Firstly it 
induce a proliferative effect on the endothelial cells thereby enhances their growth by 
increasing their survival and lowering the rate of the apoptosis in them, and secondly, it is 
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known to increase vascular permeability (Nishida et al., 2006). These aid the invasion by 
creating a way for extravasation and migration for the tumour from/into the circulation 
(Dimova et al., 2014). Apart from this, there are a number of cellular stress factors important 
to stimulate angiogenesis signalling such as hypoxia, low pH, and lack of nutrients.  In fact, 
angiogenesis in tumour tissue is a multistep development, mediated by endothelial cells 
(ECs) (Dimova et al., 2014). 
 
Table 1. 1: Activators and inhibitors of angiogenesis. 
Angiogenesis  Activators Angiogenesis  Inhibitors 
 
Vascular endothelial growth factor family (VEGF) 
 
basic fibroblast growth factor (bFGF) 
 
Acidic fibroblast growth factor (aFGF) 
 
Transforming growth factor (TGF-β) 
 
Tumour necrosis factor (TNF-α) 
 
Platelet-derived  growth factor (PDGF) 
 
Hepatocyte growth factor (HGF) 
 
Epidermal growth factor (EGF) 
 
Placental growth factor (PGF) 
 
Colony stimulating factor (CSF) 
 
Matrix metalloproteinase (MMPs) 
 
 
Interleukin  IL4 
 
Interleukin  IL10  
 
Interleukin  IL12 
 
Endostatin 
 
Interferon  IFN- α 
 
Tissue inhibitors of 
metalloproteinase (TIMPs) 
 
Angiopoietin-2 
 
Angiotensin 
 
Thrombospondin 1 (TSP-1) 
 
p53 
[Table adapted from Nishida et al., 2006] 
 
To summarise a small tumour is formed when a cell has acquired genetic modifications that 
allow unlimited growth and escape from apoptosis. Once a tumour has reached the size of 
about 1 to 2 mm3, the oxygen and nutrient supply become insufficient (Thijssen et al., 2009).  
This results in production and release of different growth factors into the nearby tissue. The 
secreted growth factors bind to receptors on ECs in nearby vessels. The ECs are then 
activated and start producing proteases and other digestive enzymes, such as MMPs, to 
degrade the basal membrane and the extracellular matrix (Oklu et al., 2010). This 
extracellular matrix dissolution allows the release of pro-angiogenic factors. Finally, the ECs 
start to divide, and migrate into the surrounding tissues to form new vascular structures. This 
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helps tumour cells to grow, and undergo metastasis (see below) (Thijssen et al., 2009 ; Oklu 
et al., 2010). 
(6) Activating invasion and metastasis  
Metastasis is a complex multistep process, responsible for around 90% of all cancer 
mortalities (Djamgoz et al., 2014). During metastasis cell separation from the primary 
tumour occurs first when cells gain the ability to survive without adherence (Weinberg, 
2008). They then detach from the primary tumour mass and invade the neighbouring tissues 
and basement membranes ((Nguyen, 2008). Following this, they enter the blood vessels and 
lymphatic circulation (intravasation), being transported by these circulations to new organ 
or tissue sites in the body (extravasation) (Nguyen, 2008; Weinberg, 2008; Bravo-Cordero 
et al., 2012). These steps for metastasis are summarized in Figure 1.12.   
 
 
Figure1.12: The metastasis process during tumour invasion. 
[Adapted from Geho et al., 2005] 
 
During cancer development, tumour cells change their plasticity by morphological and 
phenotypical conversions from epithelial to mesenchymal transition (EMT) (Kong et al., 
2011). However, it is worth noting EMT is also shown in normal cells. It is a normal 
physiological process recognized as a feature of embryogenesis, especially during 
morphogenesis and is characterized by the epithelial cells losing adhesion and detachment 
from tight junctions. They change cell shape, and become more migrant and invasive (Kong 
et al., 2011). Apart from embryogenesis, EMT plays an important role during wound 
healing, chronic inflammation and fibrosis. EMT has a critical role in tumour metastasis, 
which is induced by factors associated with tumour aggressiveness, such as FGF, VEGF, 
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PDGF and integrins (Kong et al., 2011; Van Zijl et al., 2011).  Cells with EMT phenotype 
are rich sources for cancer stem-like cells. In the case EMT is associated with a loss of 
epithelial factors such as E-cadherin (Das et al., 2014). In most tumour types, down-
regulation in the expression of E-cadherin has been illustrated and correlated with the 
increased invasion and metastatic process (Devi, 2004). Another important transformation 
during metastasis is the opposite of EMT that is from mesenchymal-epithelial transition cells 
(MET), especially at secondary sites (Kong et al., 2011). This reverse mesenchymal-
epithelial transition generates secondary epithelia (Samatov et al., 2013). This process 
allows mesenchymal cells to regain the epithelial cell-to-cell junctions for colonisation at 
secondary sites (Van Zijl et al., 2011). Thus, EMT and MET play essential roles in both 
normal development and cancer metastasis (Heerboth et al., 2015).  
(7) Deregulating cellular energetics 
During normal cellular respiration, glucose through glycolysis gets converted to pyruvate, 
which is further converted to carbon dioxide in mitochondria resulting in ATP production. 
However, during anaerobic metabolism, only the glycolysis takes place, to reduce the usage 
of oxygen and leads to the accumulation of lactic acid (Warburg mechanism). This latter 
mechanism is also observed in tumour cells even during the presence of oxygen. This results 
in an 18-fold reduction in ATP production. This deficit in synthesis of ATP is compensated  
by the up-regulation of glucose transporter proteins in the cell membrane, leading to 
increased transport of glucose molecules inside the cells (DeBerardinis et al., 2008; Hsu and 
Sabatini, 2008; Jones and Thompson, 2009). Therefore, cancer cells can conserve energy to 
entrap glucose which is needed for rapid proliferation by artificially producing an anaerobic 
metabolism. 
(8) Avoiding immune destruction 
Tumour cells create a microenvironment to escape from the immune response. Immune 
surveillance is essential to prevent the development and progression of tumour cells 
(Kaufman and Disis, 2004). In this process, the innate and the adaptive immune systems 
cooperate in functioning, and T cells play an essential role in detecting and eliminating the 
tumour cells. T cells are activated by the T-cell receptor (TCR) that binds with antigen 
peptides presented on major histocompatibility complex molecules (MHCs). The 
recognition of peptides presented by MHC class I molecules results in the activation of 
CD8+ cytotoxic T cells (CTLs). Additionally, another subset of T cells, the CD4+ T cells, 
recognises peptides presented by MHC class II molecules and improve the ability of 
dendritic cell (DCs) to induce CTLs (Bennaceur et al., 2009). CD4+ T cell activation 
24 
 
Chapter 1: Introduction 
  
significantly increases innate immunity, such as activation of macrophages and NK cells, by 
enhanced IFN-γ secretion (Töpfer et al., 2011)). IFN-γ levels improve the recognition 
capacity of T cells through induction of higher expression levels of MHC class I molecules 
on the target cell (Töpfer et al., 2011). Apart from them, neutrophils are also involved in 
innate immunity. They bring about rejection of tumours by directly killing the tumour cells 
through various mechanisms such as destruction of tumour vessels and inhibition of 
angiogenesis (Igney and Krammer, 2002). Moreover, tumours can display tumour antigens 
and can stimulate other immune cells. 
Interestingly, tumour cells escape CTL recognition by producing abnormalities in the 
antigen presentation machinery (APM). This includes down regulation or complete loss of 
MHC class I molecules as observed in many types of carcinoma. (Töpfer et al., 2011). There 
are several mechanisms by which the tumour can escape from the immune cells. For 
example, the down-regulation of adhesion molecules present in malignant tissue may inhibit 
the immune system. The tumour stroma also plays a critical role in inhibiting immunity, 
which serves as a physical barrier between the tumour and immune cells. The down-
regulated expression of the tumour antigen results in enhanced tumour incidence and 
metastasis. Furthermore, the downregulation expression of HLA-A and-B on the cell surface 
of tumour cells will normally prevent recognition CD8+ cytotoxic T cells, class II HLA 
downregulation expression prevents recognition by CD4+ T cells but expression of HLA-C 
and HLA-G non-classical MHC class I leads to inhibtions of NK cell cytotoxicity function 
(Töpfer et al., 2011). Tumour stroma also expresses immunosuppressive factors and these 
factors may be expressed by the malignant cells themselves or by non-cancerous (such as 
epithelial or stromal) cells that are present at the tumour site (Ochsenbein et al., 2001).  There 
are several immunosuppressive factors, such as TGF-β, that play an essential role in 
proliferation, activation, and differentiation of cells of innate and adaptive immunity 
(Gabrilovich et al., 1996). Other immunosuppressive factors expressed by malignant cells 
are prostaglandins, interleukin (IL-10), macrophage and CSF (Igney and Krammer, 2002; 
Kroll et al.,2010). 
(9) Genomic instability and mutation 
Tumour progression is a multistep process and is believed to be acquired by successive 
clonal expansions resulting in a mutant genotype (Hanahan and Weinberg, 2011). In each 
cell, there exists a DNA repair mechanism that detects and resolves various defects in the 
DNA after every replication, ensuring a minimal rate of spontaneous mutations. In cancers, 
there is an increase in this rate of mutation due to its sensitivity to mutagenic agents or failure 
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of DNA repair mechanism which ultimately results in tumour formation (Negrini et al., 
2010; Salk et al., 2010). 
 
(10)  Tumour promoting inflammation 
Inflammation is a helpful response that is activated to repair tissue injury. However, if 
inflammation is unregulated, it can become chronic, inducing malignant cell transformation 
in the surrounding tissue (Landskron et al., 2014). The inflammatory response shares several 
molecular targets and signalling pathways with the tumourigenic process (Landskron et al., 
2014). The inflammatory system can act as activator or inhibitor in tumour growth (Welch, 
2008). The hypoxic environment and severe metabolic stress activates inflammatory 
infiltrates, such as cytokines (Whiteside, 2008). Depending on the tumour 
microenvironment, cytokines can modulate an anti-tumoural response but during chronic 
inflammation they can also induce cell transformation and malignancy. Inflammation also 
induces generation of reactive oxygen species (ROS) and reactive nitrogen species (RNS) at 
the site of inflammation. These species trigger DNA damage and mutations on the genes of 
differentiating and proliferating cells (Landskron et al., 2014). In fact, most cells responsible 
for inflammation may contribute to some of the hallmarks of cancer by supplying growth 
factors, matrix-metalloproteinases, pro-angiogenic factors and survival factors (Karnoub and 
Weinberg, 2007;  DeNardo et al, 2010). 
 
1.3  Similarities between placentation and tumourigenesis  
In both placentation and tumourigenesis the invasion phenotype is acquired by up/down 
regulation of many cell specific adhesion molecules, extended activity of matrix-digested 
enzymes (along with other expressed enzymes such as telomerase) and/or expression of 
proto-oncogenes (Soundararajan and Rao, 2004). Trophoblast and tumour cells both have 
the capability of escaping the host’s immune system and can also establish an abundant 
blood supply (Soundararajan and Rao, 2004) (See Figure 1.13). The regulatory components 
for tumour cell migration and invasion are also shared by the human trophoblast cells. In 
fact, due to the migratory and invasive capacities, the trophoblast cells are often considered 
as ‘pseudo-malignant tissue’ which show ‘physiological metastasis’ (Soundararajan and 
Rao, 2004). As seen in Figure 1.13, different adhesion molecules, proteases MMPs and 
plasminogen are involved in both the processes. Apart from these molecules, EGF can up 
regulate the enzymatic signal transduction in order to activate mitogen activated protein 
kinases (MAPK) (Ferretti et al., 2007). Also, PDGFR which is expressed by EVT as well as 
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tumour cells can trigger c-Myc function to stimulate cell proliferation (Soundararajan and 
Rao, 2004). Both processes are compared in detail as follows. 
 
Figure 1.13: Micro-environments of placental and tumour invasion. 
Both placenta and tumour interfaces are supported by similar molecules as shown in the 
figure. [Adapted and modified from Holtan et al., 2009] 
 
1.3.1  Invasion 
Both establishment of a successful pregnancy and tumourigenesis are dependent on 
maintaining adequate blood and nutrient supply (Holtan et al., 2009). However, the cellular 
events of trophoblast cells are much more organised as they follow a specific pattern of 
“differentiation during proliferating” followed by “invasion without distance metastasis” 
(Holtan et al., 2009). As explained in Section 1.1.3.2, EVT cells differentiate into an invasive 
phenotype. These cells then migrate into the maternal decidua through the CTB cell columns 
(Holtan et al., 2009). Several molecular factors are involved during the ‘physiological 
metastisation’ (Ferretti et al., 2006). In contrast, the cancer cells show “proliferation during 
invasion” followed by “distant metastasis”.  Tumour cells follow a three-step process 
(known as the three-step hypothesis) to complete the invasion process within host tissue 
(Liotta, 1984). The first step is the attachment or adhesion of tumour cells with host tissue 
and is similar to blastocyst adhesion after hatching from the zona-pellucida. The second step 
is degradation of the extra cellular matrix (ECM) by aggressive cancerous cells with the help 
of secreted hydrolysis enzymes (Liotta, 1984). This is also seen in EVT cell migration in 
placental development. The third step is motility or locomotion of the invading tumour cells 
within modified ECM (similar to the events in spiral artery remodelling). However, the 
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aggressive invasion of tumour cells is brought about by the cyclic repetition of these steps 
(Plantefaber and Hynes, 1989; Albelda et al., 1990; Behrens et al., 1993; Oka et al., 1993).  
1.3.2  Proliferation  
The capacity for extensive proliferation is identical in trophoblast and tumour cells. At the 
early stage of adhesion, cytotrophoblast stem cells trigger rapid proliferation (Ferretti et al., 
2006). Studies have shown that there is a close resemblance between the behaviour of highly 
proliferative vCTBs and evCTBs which show a tumorigenic phenotype after neoplastic 
transformation (Ferretti et al., 2006). However, CTB proliferation is highly controlled 
(Pollheimer and Knofler, 2005). In both cases, the ability to oscillate cell expansion is not 
only determined by proliferation rate, but also by the rate of evasion of apoptosis. Activation 
of many cell surface receptors can induce the escape mechanism for apoptosis in non-
malignant trophoblast and malignant cells (Ferretti et al., 2006). For example, trophoblast 
and cancer cells both express common ligand/receptor pairs including insulin growth 
factor1/2 (IGF1/2) ligand for the receptor IGF-1R to achieve survival signal stimuli (Butt et 
al., 1999). Phosphorylation of these receptors can activate the phosphoinositide 3-kinase 
(PI3K) pathway to minimize apoptosis rates in both tumour and trophoblast cells (Butt et 
al., 1999).  
 
Figure1.14: Similarities in cell proliferation between trophoblast and tumour cell. 
During trophoblast cell proliferation, rapid cell expansion leads to formation of STBs (A) 
and a similar attribute in tumour cells also helps in cell multiplication (B). [Adapted and 
modified from Mathew et al., 2007] 
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1.3.3  Vasculogenic mimicry and immune escape  
During vasculogenic mimicry, invading trophoblast cells within maternal spiral arteries 
further differentiate into a vascular phenotype and similar attributes are also present in 
tumour cells (Zhou et al., 1997). Elementary key genes and cell signalling pathways for 
vasculogenic mimicry are shared by both malignant and non-malignant trophoblast cells 
(Zhou et al., 1997). Angiopoietins, the chief controllers of vascular remodelling are up-
regulated during early placentation and also in tumour angiogenesis.  Also, PGF which is a 
member of the VEGF family is highly expressed by trophoblast cells and tumour cells (Cao 
and Leu, 2007).  Despite the fact that trophoblasts express paternal antigens, the maternal 
immune monitoring system is unable to reject the embryo (Ferretti et al., 2006). This is 
mainly due to the down-regulation of major histocompatibility complex (MHC) class I or 
class II molecules. Due to this, invading trophoblast cells still manage to evade the maternal 
immune system (Weetman, 1999). This down-regulation is also shown in tumour cells 
enabling them to elude T-cell-mediated immune responses (Bubenik, 2003).  In addition, 
evCTBs highly express the non-classic MHC gene which encodes HLA-G in order to 
inactivate NK cell function. By sharing similar cellular mechanism, the tumour cells also 
inactive NK cells (Sinkovics and Horvath, 2005).  
 
1.4  Differences between trophoblast and tumour invasion 
Although there are several similarities between early embryo and tumour development, there 
are also differences between them (See Figure 1.15).  As mentioned (in Section 1.3), the 
main difference between trophoblast and tumour invasion is that during trophoblast 
development, the molecular mechanisms such as proliferation, invasion and migration are 
well regulated (Ferretti et al., 2007). The invasion of trophoblastic cells is spatial, in that the 
invasion mechanism is stopped after the development of placenta (Ferretti et al., 2007). 
Instead of continuing invasion, trophoblast cells start apoptosis after establishing a definitive 
placenta (Kliman et al., 1990). Specifically, trophoblast invasion declines rapidly 20 weeks 
after establishing materno-foetal communication, this demonstrates that trophoblast 
differentiation occurs under tightly controlled circumstances (Fitzgerald et al., 2005). Thus, 
the regulated migration and invasion of trophoblast cells is also known as a “controlled 
programme of terminal differentiation” (Soundararajan and Rao, 2004). 
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Figure1.15: Similarities and differences between trophoblast and tumour invasions. 
 
In contrast, tumour invasion happens randomly, without any control in the cells transferring 
to distant organs. In tumour cells, there is a loss of regulation of cell cycle proteins which 
causes abnormal proliferation of cells and uncontrolled cell division (Cross et al., 2003). 
However, trophoblast cells do not show any deviation from the normal cell cycle, which is 
achieved by placenta-specific genes, cytokines and endocrine factors through either 
inhibition or promotion of the invasion processes (Cross et al., 2003). As trophoblast cells 
divide, differentiate and then invade, the lifespan of a single trophoblast cell (and also the 
invasive depth) is limited (Richard, 2011).  In contrast, tumour cells divide and invade at the 
same time. As mentioned before, trophoblast invasion is controlled during implantation in 
both space (endometrium) and time in the first trimester (12 weeks post conception) (Cohen 
and Bischof, 2007).  
 
1.5  Potential factors of interest common to tumours and placenta  
Interestingly, several different factors are believed to play important roles in placental and 
tumour invasion. However, the functional status of many of these factors has not been fully 
established. Some of these factors are listed below. 
1.5.1  Human aldehyde dehydrogenase 3 family, member A1 (ALDH3A1) 
Aldehyde dehydrogenase 3 (ALDH3) belongs to the mammalian aldehyde dehydrogenase 
family that is involved in the metabolism of endogenous/exogenous aldehydes, and 
neurotransmitters (Vasiliou and Nebert, 2005). Depending on their physiochemical 
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properties, 12 ALDH genes are present in humans which are located on different 
chromosomes, and distributed in various tissues including brain, liver, stomach, kidney and 
testis.  Although, each member of the ALDH family have a different function, collectively 
their activities include enhancing cell proliferation, differentiation, drug resistance, and cell 
response to oxidative stress. Interestingly, ALDH also activates other compounds that are 
beneficial to the cells (Canuto et al., 2001). For example, ALDH3A1 converts an aldehyde 
precursor to an acid thereby preventing DNA damage (Ho et al., 2008).   This indicates that 
ALDH3 is capable of providing cellular protection.  The activity of ALDH has been used to 
identify, and select stem-like cell lineage amongst endothelial progenitor, mesenchymal, 
epithelial and hematopoietic stem cells. For example, van den Hoogen et al. (2010) used 
ALDH3A1 to compare and isolate populations of primary human prostate cancer cells. 
Likewise, the expression and activity of ALDH3A1 was found to be a marker for cancer 
stem cells in many solid tumours, such as breast, ovarian and colon cancer (Ma and Allan, 
2011). It has an important effect in tumour progression during metastatic initiation but the 
mechanism that controls the constitutive expression of ALDH3A1 remains unclear 
(Reisdorph and Lindahl, 2001). Most importantly the mechanism of ALDH3A1 at the 
trophoblast invasion stage is yet to be clearly understood (Jelski and Szmitkowski, 2008).  
1.5.2  Aurora kinases (AURK)  
Aurora kinase (AURK) genes are a group of serine-threonine kinases which are commonly 
known as mitotic kinases which were first isolated from Drosophila (Bhat et al., 1996). They 
play an important role in regulation of cell division in G2 to M phase, and the deregulation 
of AURK activity leads to defects in the functions of centrosome, maturation, and spindle 
formation (Dar et al., 2010). Moreover, the signalling of Aurora kinase associated with 
mitotic errors is closely connected to chromosomal aneuploidy in cancer cells  (Dar et al., 
2010; Banno, 2013). The two subtypes of AURK which are of interest in this study are 
explained below. 
 Aurora kinase A (AURK-A)  
Aurora kinase A (AURK-A) is also named as STK15/BTAK, BTAK (Breast Tumour 
Activated Kinase) (Berdnik and Knoblich, 2002). It plays a major role in cell cycle 
regulation of meiosis, mitosis cytokinesis, chromosome maturation and centrosome 
separation (Ma et al., 2003).  Interestingly, centrosome maturation happens in the G2 phase 
where many proteins that accumulate at the centrosomes lead to tumourigenesis. AURK-A 
is over-expressed in several human cancers including gastric cancer, breast cancer and 
neuroblastoma (Ma et al., 2003). Furthermore, many oncogenic functions including the 
activation of growth signalling pathways, reduction in the functions of p53, p73, and 
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phosphatidylinositide 3-kinase/AKT are caused due to the abnormal expression of AURK-
A. P53 is a tumour suppressor protein that plays an important role in preventing the 
development of cancer cells at several regulatory points during the cell cycle (Ryan et al., 
2001). P73 regulates the cell cycle and induces apoptosis in cells under stress (Zawacka-
Pankau et al., 2010). A strong correlation between AURK-A over-expression, p53 function 
and tumourigenesis has been reported (Vader and Lens, 2008). By phosphorylating p53, 
AURK-A decreases the transcriptional activity of p53 mRNA (Vader and Lens, 2008). 
However, p53 inhibits AURK-A activity by binding to the catalytic domain of AURK-A.   
In addition, p53 induces a protein called DNA-damage-inducible protein (GADD45a) that 
also participates in inhibiting AURK-A function (Vader and Lens, 2008).  This indicates that 
the effect of AURK-A over-expression on centrosome regulation is dependent on p53 status 
(See Figure 1.16).  
 
 
Figure1.16: Summary of the interaction between AURK-A and p53. 
The function of P53 is related to the over-expression of AURK-A in tumourigenesis, where 
p53 stability is decreased by phosphorylation of AURK-A. In contrast, p53 inhibits AURK-
A function by inducing GADD45a. [Figure adopted from Vader and Lens, 2008] 
 
The role of AURK-A in tumour and trophoblast cells is still not fully understood. It is 
suggested that over-expression of AURK-A potentially affects cell proliferation and VEGF-
mediated angiogenesis. Moreover, on the placental side, it has been suggested that spindle 
and chromatin dynamics is regulated by AURK-A during early and late stages of mammalian 
oocyte maturation (Shuda et al., 2009).  
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 Aurora kinase C (AURK-C)  
AURK-C is another member of the AURK protein family that is over expressed in many 
types of cancer, such as breast, liver and prostate, which suggests that AURK-C may have 
the potential to induce proliferative capacity in tumour cells (Dieterich et al., 2007).  
Remarkably, it has been found that the mRNA and protein of AURK-C is also over expressed 
in normal rapidly dividing tissues such as testis. The exact role and function of AURK C in 
carcinogenesis and placental development is not clearly known (Dar et al., 2010;  Kollareddy 
et al., 2008; Banno, 2013). It has been found that AURK-C plays an important role during 
pre-implantation of embryo (Zeng et al., 2004; Macaulay et al., 2011).  
1.5.3  Platelet-derived growth factor receptor alpha (PDGFRα) 
 PDGF is a family of growth factors that play a major role in several physiological functions, 
including embryogenesis and angiogenesis. PDGF also plays an important role in cellular 
differentiation and development, regulation of growth such as proliferation (Looman et al., 
2007).  It was characterised as a mitogen for fibroblasts and cells of mesenchymal-origins, 
such as smooth muscle cells (Looman et al., 2007). PDGF exists in three isoforms PDGF-α, 
PDGF-β and PDGF-αβ which can function as hetero- or homodimers (Majumdar et al., 
2009).  Expression of PDGF and its receptors became an area of interest because they are 
thought to promote human cancer development and progression.  PDGF encodes a protein 
responsible for cell transformation, indicating an autocrine mechanism in tumourigenesis 
(Raica and Cimpean, 2010). Furthermore, the co-expression of PDGF-α and PDGF-β, and 
their receptors have been identified in the cellular signalling seen in malignant gliomas 
(Alvarez et al., 2006). The status and functions of PDGFRα in trophoblast cells are not fully 
understood. 
 
1.5.4  Basic helix loop helix protein (TWIST1) 
TWIST1 is a member of the basic helix-loop-helix (bHLH) family of proteins (Murre et al. 
1989). The bHLH structure was recognised in the DNA binding proteins E12 and E47, and 
was first identified in Drosophila (O’Rourke and Tam, 2002). It plays an essential role in 
promoting tumour metastasis from epithelial to mesenchymal transition by promoting the 
formation of invadopodia, specialized membrane protrusions for ECM degradation (Eckert 
et al.,  2011). It is over-expressed in a variety of tumours, e.g. prostate, lung, breast, uterus, 
and liver cancer. TWIST1 also plays a vital role during embryonic growth of tissues such as 
muscle and bone (Cabrera Je, 2013).  In mouse and rat, the mRNA expression of TWIST-1 
was present in the mesoderm of the gastrulating embryo and was also found in the limb bud 
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mesenchyme during the organogenesis phase (Maestro et al., 1999). Both TWIST-1 and 
TWIST-2, can inhibit the p53 that is essential for cell death. Interestingly, they can interfere 
with the p53 tumour suppressor pathway by modification of the action of ARF/MDM2/p53 
action ( Maestro et al.,  1999; O’Rourke and Tam, 2002 ). 
1.5.5  JAG1 (Jagged-1) 
   Jag-1 (or Jagged-1) is a protein encoded by the JAG1 gene, also known as CD339 (www9). 
It is considered as a ligand for multiple NOTCH receptors and acts as a mediator for NOTCH 
signalling. It interacts with NOTCH 2 and 3 receptors, but in the presence of calcium it can 
interact with NOTCH 1 receptors as well (Purrow et al., 2005). The NOTCH signalling may 
act either positively or negatively to influence cell processes such as proliferation, 
differentiation and apoptosis, depending on the cell type (Purrow et al., 2005). Therefore, 
JAG-1 can play a crucial role in tissue formation during the development of an embryo 
(Karanu et al., 2000).  Moreover, NOTCH was found to be present in the cytoplasm of the 
CTB, EVT and placental stroma in the first trimester of the pregnancy.  It was also present 
in the STB, endothelial cells and stroma of placental villi ( De Falco et al., 2007). Studies 
have shown that JAG1 is a potent pro-angiogenic factor in mice embryos (Benedito et al., 
2009). It has been proposed as a promoter of metastasis in both breast and bone cancer by 
engaging NOTCH signalling, however, the mechanism behind this remains unknown (Sethi 
et al., 2011).  
 
1.6  Importance of “stem-like” cells in invasion 
Another distinctive character shown by both tumour and trophoblast cells is presence of stem 
cell populations. In the case of tumours, the cancer stem cells (CSCs) show a high 
tumourigenic capacity of replenish self-renewal and differentiate into other cell types (Yoo 
et al., 2013). On the other hand, trophoblast stem cells are involved in promoting self-
renewal only (Red-Horse et al., 2015). Surprisingly some interesting data has demonstrated 
that during the development of tumour, ‘‘sphere forming cells’’ or ‘‘spheroids’’ can enhance 
tumourigenesis and increase the metastatic ability of malignant cells in vivo (Burleson et al., 
2006). Likewise, spheroid like structure formation has also been reported in the case of non-
malignant trophoblast cells (Sivasubramaniam, Unpublished data). A detailed discussion of 
spheroidal attributes of these two cellular types is given in (Chapter 4). A general description 
of different types of stem cells is given below. 
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1.6.1  Stem Cells 
Cells with the ability to renew themselves and to generate mature cells through the process 
of differentiation within a particular tissue are known as stem cells (Reya et al., 2001; Gao, 
2007). Three significant properties differentiate these cells from normal cells, which are: (a) 
an ability to renew independently which maintains the stem cell pool within the host; (b) an 
ability to regulate the number of cells produced, and (c) an ability to differentiate to develop 
all the functional elements of the tissue (Al -Hajj et al., 2004). Even though stem cells differ 
in their developmental potential, they must maintain a balance between self-renewal and 
differentiation. Consequently, the concept of regulation of self-renewal is important in 
cancer since it is considered to be a disease of unregulated self-renewal (Reya et al., 2001; 
Tuch, 2006). 
1.6.2  Classification of Stem Cells 
Depending on their ability to differentiate, stem cells are classified as totipotent, pluripotent, 
or multipotent.  Totipotent stem cells have the ability to become any kind of cell in the body 
and usually develop from the fertilized egg.  Pluripotent stem cells develop from the three 
embryonic tissue layers, i.e. ectoderm, endoderm and mesoderm (Gao et al., 2008: Kaur et 
al., 2009). They can be obtained from the inner cell mass (ICM) of the blastocyst. 
Multipotent stem cells can differentiate into more than one type of specialised cell in tissue 
or organ, and are isolated from many tissues of the body   (Mousa, et al., 2006). These cells 
can self-renew to repair any damaged tissue like the haematopoetic stem cells in bone 
marrow, blood, neuronal stem cells of brain and hepatic stem cells of liver (See Figure1.16). 
Multipotent stem cells are further differentiated into three types depending on their ability 
to renew; Long term self-renewing cells, Short term self-renewing and Progenitor multi-
potent cells incapable of self-renewal (Gao et al., 2008: Kaur et al., 2009). Division of stem 
cells generates daughter cells possessing the properties of their parent cells. Different types 
of stem cells that are produced from trophoblast are summarised in Figure1.17. 
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Figure1.17: The origins of specialisation of stem cells. 
The single cell begins to divide and multiply at a rate much faster than somatic cells after a 
sperm fertilizes an egg. The totipotent stem cells (SCs) rising in the inner mass of the 
blastocyst are known as embryonic stem cells (ES). ES can differentiate into various tissue 
types of the human body. [Figure adopted from Chaudry, 2004] 
 
1.6.3  Stem cell markers 
There are many molecular markers used to isolate and characterize various stem cell 
populations, some of which include OCT4, SOX2, NANOG, NOTCH1 and CDX2. 
Although the marker profiles of stem cell populations often change depending on their site 
of origin or species, these molecular markers provide a systematic approach to characterize 
a healthy stem cell population (www10). 
 OCT4 
 OCT4 is a transcription factor belonging to the POU (Pit-Oct-Unc) transcription factor 
family and is also known as OCT-3, OCT3/4 and POU5F1 (Schöler et al., 1990).  It plays 
a crucial role in the embryonic development, acts as a regulator of self-renewal and 
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differentiation, maintains and re-establishes pluripotency of embryonic stem (ES) cells in 
both human and mouse (Shi and Jin, 2010). It is usually expressed in the early cleavage stage 
of the inner cell mass. Studies indicate that mRNA and protein expression of OCT4 are found 
in several human tissue specific adult stem cells and different types of cancer stem cells 
(Atlasi et al., 2007).  
 SOX2 
SOX2 (Sex-determining region Y (SRY)-Box 2) is a member of the SOX family of 
transcription factors (www11). It plays a vital role in maintenance and differentiation of stem 
cells. It is required for trophoblast formation and progression of several human malignancies 
Laga et al. (2010) findings suggest that SOX2 is a novel biomarker used for subpopulations 
of stem cell niches related to melanocyte ontogeny and tumorigenesis and a growing number 
of studies illustrate the relationship between SOX2 and cancer. In breast cancer cells, SOX2 
promotes cell proliferation and tumourigenesis (Xiang et al., 2011). Both SOX2 and OCT4 
have essential roles during embryogenesis. They generate pluripotent stem cells  from human 
cord blood cells and work together to regulate genes necessary for the self-renewal  
(Herreros-Villanueva et al., 2013; Rizzino, 2013). 
 NANOG 
NANOG is a homeodomain-containing transcription factor which is expressed in the inner 
cell mass and embryonic stem cells (ES).  It has important roles in maintaining self-renewal 
amongst undifferentiated pluripotent stem cells during early embryonic development. 
NANOG and OCT4 work together to support stem cell potency and self-renewal in several 
germ cell and tumours (Siu et al., 2012; Wang et al., 2013)). It is associated with tumour 
aggressiveness, metastasis and chemo-sensitivity. The knockdown of NANOG has been 
reported to inhibit ovarian cancer cell proliferation and invasion. Therefore, several studies 
suggest that NANOG can be used as a target for molecular therapeutics and as a potential 
marker to target ovarian cancer (Siu et al., 2012; Wang et al., 2013). OCT4, NANOG and 
SOX2 are all identified to be co-up-regulated in many human tumours, including prostate 
and breast cancer and tumours may be controlled by restricting the expression of these three 
genes. Likewise, they can be used as  tumourigenesis markers, which can act as molecular 
switches that control the CSC cell fate during cancer development (Liu et al., 2013). 
 NOTCH1 
NOTCH1 is a transmembrane receptor which was first identified in Drosophila. There are 
two pathways involved in NOTCH signalling: canonical signalling and non-canonical 
signalling. Canonical NOTCH signalling is achieved by cell–cell interaction, but non-
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canonical signalling is not completely understood (De Falco et al., 2007; Cuman et al., 
2014). Studies in the past, demonstrated that the NOTCH signalling pathway was necessary 
for the development of the placenta (Zhao and Lin, 2012).  It is believed NOTCH1 signalling 
controls uterine decidualisation and plays an essential role in implantation. Moreover, 
members of the NOTCH signalling pathway have been identified in placental growth and 
reported to play an important role during placentation (Zhao and Lin, 2012). This involves 
endometrial trophoectoderm interactions during the initiation of attachment, and regulation 
of EVT invasion (Zhao and Lin, 2012).  It is also essential for spiral artery remodelling in 
the decidua, angiogenesis progression and vascular homeostasis in the adults. On the other 
hand, the irregular signalling of NOTCH is found in PE and IUGR (Cuman et al., 2014). 
Interestingly, NOTCH also plays an essential role in tumour development and can act as an 
oncogene (Bolós et al., 2007). 
 CDX2 
CDX2 is a nuclear homeobox transcription factor that belongs to the caudal-related family 
of CDX homeobox (HOX) genes (www13). The gene encodes CDX2 plays an essential role 
during embryonic development. It is expressed in the embryonic trophoectoderm and in the 
spongiotrophoblast component of the placenta at later stages of development (Murthi et al., 
2011). HOX genes can be used as markers and targets for some diseases, such as cancer, 
diabetic wound healing, and Alzheimer’s disease. It is also expressed in the intestinal 
epithelium, where it plays roles in establishment and maintenance of intestinal epithelial 
cells (Saad et al., 2011). Previous studies have suggested that the expression of CDX2 is 
down-regulated during colorectal carcinogenesis (Bai et al., 2003). They proposed that 
CDX2 acts as a tumour suppressor by promoting cellular differentiation and inhibiting 
proliferation. The absence of CDX2 results in an aggressive tumour with enhanced 
metastasis of colorectal cancer (Bai et al., 2003).   
1.6.4  The ability for trophoblasts to produce stem-like cells  
As mentioned before in Section 1.1.3.4, the placenta is a pseudo-malignant organ which 
shows ‘physiological metastasis’ (Ferretti et al., 2007). Both the process of tumorigenesis 
and placentation begin with a highly invasive form of cells (See Figure 1.18). One of the 
unique characteristics of the trophoblast cells is the ability to produce stem cell populations 
that are involved in the promotion of self-renewal (Red-Horse et al., 2014). Trophoblast cells 
also demonstrated the ability to produce stem-like cells during invasion (John et al., 1993). 
Likewise, spheroid like structure formation has also been reported in malignant cancers 
including ovarian cancer (Burleson et al., 2004). Also, in vitro studies have shown that the 
embryonic stem cells (ESCs) can grow into three-dimensional spheres called embryonic 
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bodies (EBs) in culture media (Sivasubramaiyan et al., 2009).  Comparative photoelectron 
micrographs of tumour spheroidal cells and blastocyst are given in Figure 1.18.  
 
 
Figure1.18: The similarity of the spheroid like structure in tumour and blastocyst. 
 
1.7  Spheroid (3-D) cell culture 
Three-dimensional (3-D) cell culture in vitro models have been used in research as an 
intermediate between in vitro cultures and in vivo tumour (Fennema et al., 2013). Cells  that 
are cultured in 3-D grow as aggregates have many different names such as mammosphere, 
micro-mass and spheroid (Fennema et al., 2013). This system mimics various properties of 
solid tumours such as cell heterogeneity and production of  similar proliferating, quiescent 
regions with a necrotic core (Weiswald et al., 2015). Moreover, tumour cells cultured as 
spheroids exhibit more resistance to therapy than those cultured as a monolayer. In fact 3-D 
culture provides “multicellular resistance,” enhanced by cell-cell contacts, cell-matrix 
contacts, and the 3-D shape (similar to the in vivo situation) (Phung et al., 2011). Thus, it 
provides a microenvironment similar to a solid tumour (See Figure 1.19). These features 
limit the delivery of anti-cancer drugs to core cancer cells that are located far from blood 
vessels (Phung et al., 2011).  
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Figure1.19: Comparison between in vivo solid tumour and spheroid model. 
The 3-D culture creates an oxygen gradient similar to in vivo solid tumours. This feature limits the 
delivery of anticancer drugs to the core of the spheroids. [Adopted from Phung et al., 2011] 
 
 
As explained in in several parts of the introduction, there are similarities and differences 
between tumour and trophoblast cells. The pseudo-tumourigenic properties of trophoblast 
cells can be used not only to compare the status of common factors between these two 
processes; but also can be exploited to study the toxicological effects of chemotherapeutic 
agents in physiologically rapid dividing cells. In order to achieve the former; trophoblasts of 
placental disorders with low trophoblast invasion (such as PE) can be compared. Likewise, 
it is also essential to establish in vitro 3-D spheroid cultures of “stem-like cells” from 
trophoblast derived cells to study the latter.  
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1.8  Aims and hypothesis  
A literature review indicated differential gene expression patterns in normotensive and PE 
placentae. The factors of interest (ALDH3A1, AURK-A and C, PDGFRα, TWIST1, and 
JAG1) have also been demonstrated to be involved in proliferation, migration and invasion 
of various cells. Furthermore it has been shown that due to resemblance of trophoblast cells 
to tumour cells, it may be possible to produce spheroids from both the cell types. Therefore, 
it was hypothesised: 
• The expression of factors that are involved in trophoblast invasion would be altered in 
pre-eclamptic placentae. 
• These expression patterns may also be different in non-resistant and drug-resistant 
spheroids from those of the original parental cells. 
• The invasive capacities of non-resistant and drug-resistant spheroids would be different 
from the original parental cells.  
• Compared to parental cells, the global protein expression profiles would be altered in 
non-resistant and drug-resistant spheroidal cells. 
Aims: 
• To compare the expression patterns of common factors related to invasion, such as 
ALDH3A1, AURK-A and C, PDGFRα, TWIST1, and JAG1 involved in normotensive 
(NT) and pre-eclamptic (PE) placentae. 
• To generate spheroids from transformed trophoblast (HTR8/SVneo, TEV-1) and 
choriocarcinoma (JEG-3, BeWo) cell lines and to check the effects of the 
chemotherapeutic agent Doxorubicin in producing drug resistant spheroids from 
trophoblast cell lines. 
• To characterise the “stemness” feature by studying the expressions of stem cell markers 
such as OCT4, SOX-2, NANOG, CDX2 and NOTCH1. 
• To compare the migration and invasion potentials amongst non-resistant, drug-resistant 
spheroids and their parental cells. 
• To investigate the expression patterns of common factors such as ALDH3A1, AURK- (A 
and C), PDGFRα, TWIST1, and JAG1 in parental cells and spheroidal cells (untreated and 
DOX-treated) originated from four trophoblast cell lines. 
• To investigate the changes in the global protein (peptide) expression profiles in parental and 
spheroidal cells (untreated and DOX-treated) which are produced from transformed 
trophoblast cell lines (HTR8/SVneo and TEV-1) by using SWATH-MS technique. 
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2.1  Buffers and solutions 
All buffers and solutions were prepared in sterile glass bottles and maintained at 
recommended temperature when not in use with some solutions prepared fresh 
immediately before to use. 
Table 2.1: Buffers and solutions 
Reagent Recipe 
TAE Buffer 50X 242 g Tris Base, 57.1 ml Acetic Acid, 100 ml 0.5M EDTA, 1 litre ddH2O, pH 8.5 
1X TAE buffer (pH 8.0) 50X TAE buffer 20ml, ddH2O 980ml 
1% Agarose used for RNA Agarose 0.4, 1X TAE 40ml, Ethidium bromide (Sigma) 2μl 
1.5% Agarose used for DNA Agarose 0.6, 1X TAE 40ml, Ethidium bromide (Sigma) 2μl 
PBS-Tween20 (PBS-T) 1 litre 1X PBS, 5ml Tween 20 
TBS-Tween20 (TBS-T) 1 litre 1X TBS, 5ml Tween20 
TBS 10X 24.23g Trizma HCl, 80.06g NaCl, 1 litre ddH2O, pH 7.6 
PBS 1X 10 Phosphate Buffered-Saline tablets (Fisher Scientific) in 1 litre ddH2O 
Running Buffer 5X 15 g Tris Base, 72 g Glycine, 5.0 g SDS, 1 litre ddH2O, pH 8.3. 
Transfer Buffer 10X 60.4 g Tris Base, 288 g Glycine, 1.8 litres ddH2O. Methanol added to 1X transfer buffer before use. 
Laemmli Buffer 4X 
200mM Tris-HCl pH 6.8, 400mM DTT, 0.8% w/v SDS, 
0.4%  w/v Bromophenol blue, 40% v/v glycerol, 5% v/v β-
mercaptoethanol 
Antibody Buffer 3% BSA, TBS-T, 0.02% Sodium Azide 
50mM  (Triethyl ammonium 
bicarbonate) TEAB buffer 
 
Diluting 1M stock solution 20 times (i.e. 500 μl of 1M stock 
solution +9.5 ml of nanopure grade water) 
0.5 M dithiothreitol (DTT; MW 
154.25) Dissolve 0.077 g of DTT in 1ml of nanopure water 
 
0.55 M iodoacetamide (IAA; MW 
184.96) 
 
Dissolve 0.0407 g of IAA in 400 μl of 50mM TEAB buffer 
0.1% formic acid  50 ml of nanopure water in and remove 50 μl of nanopure water and add 50 μl of  neat formic acid  
5% Acetonitrile in 0.1% formic 
acid 
10 ml of 0.1% formic acid in 15 ml red-top tube remove 500 
μl of 1% formic acid and add 500 μl of 100% acetone 
acetonitrile. 
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2.2 Antibodies 
All antibodies were prepared and stored according to manufacturer’s guidelines and used 
before the expiry date. The concentration of each antibody (primary or secondary) for 
Immunohistochemistry (IHC), Immunofluorescence (IF) and Western blotting (WB), are 
summarised in Tables 2.2 and 2.3. 
Table 2.2: Details of primary antibodies with concentrations for IHC, WB and IF. 
Primary antibodies             Supplier Antibody dilutions 
Rabbit Anti-ALDH3A1 Abcam IHC (1:200); WB (1:500) 
Rabbit Anti-Aurora A Abcam IHC (1:20); WB (1:500) 
Rabbit Anti- Aurora C Abcam IHC (1:200); WB (1:500) 
Rabbit Anti- Jagged1 Abcam IHC(1:500); WB (1:10000) 
Rabbit Anti-PDGFR Abcam IHC (1:500); WB (1:500) 
Rabbit Anti-TWIST1 Abcam IHC (1:200); WB (1:500) 
Mouse Anti-OCT4 Abcam IF (1:200); WB (1:500) 
Rabbit Anti-SOX2 Abcam IF (1:500); WB (1:500) 
Rabbit Anti-NANOG Abcam IF (1:50); WB (1:1000) 
Rabbit Anti-CDX2 Abcam WB (1:500) 
Mouse Anti-CDX2 Abcam IF (1:50) 
Rabbit Anti-NOTCH1 Abcam IF (1:150); WB (1:1000) 
Controls 
Mouse Anti-Vimentin 
(positive control for IHC) 
 
NCL-L-VIM- Leica IHC (1:400) 
Active PDGF protein 
 
Abcam 
 
WB (1:500) 
 
  
44 
 
Chapter 2: Materials and Methods 
  
Table 2.3: Details of secondary antibodies with concentrations for IHC, WB and IF. 
Secondary Antibodies Supplier Antibody dilutions 
Donkey Anti-Rabbit Human IgG H+L (HRP) 
conjugated Abcam WB (1:3000) 
FluoresceinAnti-Rabbit IgG (H+L)       
             Vector Laboratories, Inc WB (1:1000) 
Biotinylated Anti-Mouse/Rabbit IgG provided 
with VECTASTAIN Elite ABC Kit 
PK-6200 
Vector Laboratories, Inc IHC (1:1000) 
Goat anti-Mouse IgG (H+L), Alexa Fluor®  
 life technologies  IF (1:1000) 
Goat anti-Rabbit IgG (H+L), Alexa Fluor® 
  life technologies   IF (1:1000) 
 
 
2.3  Placental tissue collection 
Human placental tissue samples were obtained from the Nottingham City Hospital following 
informed consent from donors under NHS ethical approval [NREC Ref: 12/NE/0112]. This 
ethical approval was extended to suit this study by the Health Research Authority-NRES 
Committee North East. The demographic details of the placentae are given in Section 3.2.1. 
These samples were collected and stored appropriately at -80°C until further use. Some of 
the samples were further preserved by paraformaldehyde fixation and embedded in paraffin 
for immunostaining protocol.  
 
2.4  Total RNA extraction 
RNeasy® Plus Mini-kit (Qiagen) was used to perform the total RNA isolation and 
purification from placental tissues according to the manufacturers (Qiagen, Inc) instructions. 
Homogenisation of placental samples was carried out by crushing the samples with liquid 
nitrogen and transferred into pre-cooled centrifuge tubes after which 600µl of RLT buffer 
with 6µl β-mercaptoethanol (Sigma Aldrich) was added to the samples. This homogenized 
lysate was transferred into a QIAshredder® (Qiagen) and centrifuged at 15,000 x g for 2 
minutes in a microcentrifuge (Microcentaur Sanyo).  The supernatant was transferred into a 
gDNA eliminator spin column. The column was centrifuged again at 10,000 x g for 30 
seconds to remove any genomic DNA. The supernatant was mixed with 600µl 70% ethanol 
(Fisher Scientific). This mixture was transferred to an RNeasy spin column placed in a 
collection tube. Centrifugation was repeated at 10,000 x g for 15 seconds. The RNeasy spin 
column was retained and 700µl Buffer RW1 was added and centrifuged again at 10,000 x g 
for 15 seconds. This was followed by 2x 500µl RPE Buffer washes. Lastly the column was 
treated with 30-50µl RNase-free Millipore water and centrifuged at 10,000 x g for 1 minute. 
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The supernatant was transferred to a new eppendorf tube and stored at -80°C. The purity and 
quantity of RNA were measured by using Nanodrop® spectrophotometer. The extracted 
RNA samples were electrophoresed in 1% agarose gel (BIOzym group) to fractionate the 
two RNA subunits, 28S and 18S. 1kb ladder (New England, BioLabs® Inc) was used to 
identify the two subunits. 
 
2.5  cDNA template preparation by Reverse Transcription 
SuperScript™ II Reverse Transcriptase kit (Invitrogen™) was used to convert RNA into 
cDNA. Depending on the total RNA concentration of 10pg-5µg, a 20µl reaction volume was 
prepared. The reaction mixture was created in an eppendorf tube with 15 µl of nuclease free 
water, with 1µl of extracted RNA samples,1 µl Oligo (dT) 15 Primer (Promega), 1µl dNTP 
mix (10mM each) (Promega) and 1µl RNAsin (Promega). This mixture was gently vortexed 
then heated to 65°C for 5 minutes followed by chilling quickly on ice. 4µl of 5X First-Strand 
Buffer and 2µl of 0.1M DTT was added to the reaction and mixed well. The sample was 
incubated at 42°C for 2 minutes. After this incubation, 1µl of SuperScript™ II was added and 
allowed to incubate at 42°C for 50 minutes. The sample of cDNA was stored at -20°C. 
 
2.6  Gene expression study 
2.6.1  Primer designing and optimising  
PCR primers were designed by using Coding DNA sequences (CDS) for the factors of 
interest from National Centre for Biotechnology Information (NCBI) website (www14). CDS 
was used to design the primers using Primer 3 Input version 4 (www15) and Integrated DNA 
Tool (www16) was used to check the properties of primers such as annealing temperature, 
hairpin loops, GC content etc.  ClustalW2 software was used to find the common nucleotide 
regions between all the variants (if the factors has more than one variant) (www17).  BLAST 
software (www18) was used to check specificity of the primer sequences and the specific 
primers were finalised. The criteria used for primer design are given below: 
1) Sequence: 
a) The following were avoided (i) 3 or more runs of G or C at 3´ end, (ii) a T at the 3´ 
end, (iii) mismatches at the 3´ end and complementary sequences. 
b) 3´ end should end in G or C or CG or GC. This will increase efficiency of priming. 
2) The length of primer was kept between 18-22 nucleotides.  
3) The GC content was between 40-60%. 
4) Melting temperature (Tm) was kept between 55-80 °C. 
5) Product size was less than 200 bps. 
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6) Primer Concentration: 0.1-0.5µM. 
 
The primer sequences with their annealing temperatures are given in Table3.2. The 
annealing temperatures for the primers were first calculated using the following equations: 
𝑻𝑻𝒎𝒎 = 4 ( 𝐺𝐺 + 𝐶𝐶) + 2 (𝐴𝐴 + 𝑇𝑇) 
𝑻𝑻𝒂𝒂 = 𝑇𝑇𝑚𝑚  𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹𝐹 + 𝑇𝑇𝑚𝑚 𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝑅𝐹𝐹𝑅𝑅𝑅𝑅2 − 5℃  
Where Tm is melting temperature for the primers, Ta is the annealing temperature for the 
gene of interest. 
2.6.2  Gene amplification using conventional PCR and gradient PCR 
Factors of interest were amplified using the primers designed in Section 2.6.1 by 
conventional TECHNE Thermocycler TC3000 (Bibby Scientific Ltd.). The PCR Master 
Mix (Promega) was used for the reaction mixture. The reaction mixture was prepared 
according to the company guidelines. 
 Reaction Mixture for 25µl: 
Components  Volume Final concentration 
PCR Master Mix, 2X 12.5µl 1X 
upstream primer, 10µM 0.5µl 0.1–1.0µM 
downstream primer, 10µM 0. 5µl 0.1–1.0µM 
DNA template 1µl <250ng 
Nuclease-Free water  10.5µl N.A. 
 General program setting for PCR amplification was as follows: 
• Initial denaturation at 95°C for 2 minutes 
o Denaturation at 95°C for 30 seconds 
o Annealing at X°C for 30 seconds                 x 40 cycles                  
o Extension at 72°C for 30 seconds  
• Final Extension at 72°C for 2 minutes 
Note: Where X°C is the Ta calculated in Section 2.6.1  
TECHNE 3Prime temperature gradient PCR (Geneflow Ltd.) was also used to amplify 
genes for which calculated Ta showed low/no dimer products. The PCR product size was 
analysed by using 1.5% agarose gel using a 100bp ladder (New England Biolabs® Inc). 
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2.6.3  Agarose gel electrophoresis 
Agarose gel electrophoresis was carried out to check the size and integrity of the product 
whether from a DNA or RNA sample. The desired percentage of agarose gel was prepared 
in fresh 1X TAE buffer; 1.5% agarose gel was used to analyse PCR products and 1% agarose 
gel to detect the integrity of the RNA samples. Ethidium bromide (Sigma) was used as a 
detection dye in the gel. The gel was electrophoresed at 50 Volts for 15 minutes followed by 
80 volts for 30 minutes. The gels were then imaged on Gel Doc (InGenius, Syngene) under 
UV light.   
2.6.4  PCR product confirmation by DNA sequencing 
The PCR products were cleaned by using a Wizard® Genomic DNA purification kit 
(Promega) according to the manufacturer’s guidelines. An equal volume of membrane 
binding solution was mixed with the PCR products. The mixture was transferred to a 
Minicolumn assembly and incubated at room temperature for 1 minute. The Minicolumn 
was then centrifuged at 16,000 x g for 1 minute. Following this the column was washed 
twice with membrane wash solution and centrifuged at 16,000 x g for 1 minute. Purified 
DNA was eluted out from the column using nuclease-free water. The purified samples were 
sent for sequencing at the Functional Genomics, Proteomics and Metabolomics Facility, 
University of Birmingham, for DNA sequencing. The sequences were analysed using 
Chromas lite 2.1.1 software for accuracy. 
2.6.5  Relative expression of factors of interest by quantitative Real-Time PCR 
(qRT-PCR) 
Factors of interest were amplified by using a Corbett quantitative PCR (qRT-PCR) thermo 
cycler (Corbett Lifesciences). The reaction mixture of qRT-PCR was prepared at a final 
volume of 12.5µl. Millipore water 4.25µl; SYBR Green 6.75µl (Biorad Laboratories, Inc.); 
forward and reverse primers 0.5µl 10 pM/µL; and cDNA samples 0.5µl were used. 
Nuclease-free water was used as negative control. The program started with an initial 
denaturation for 5 minutes at 95°C. The number of cycles for amplification was 40 with a 
denaturation at 95°C for 30 seconds. Depending on the primer of interest, the annealing 
temperature was set for 30 seconds and the extension at 72°C for 10 seconds. The annealing 
temperatures for each gene are given in Table 3.2. The melting curve for the factors was 
analysed after the reaction using Rotor Gene-6000 Series 1.7 software and the delta Ct values 
(2-ΔΔCt )  were calculated. 2-ΔΔCt   is a method to calculate relative quantitative expression by 
comparing Ct values (Livak and Schmittgen, 2001). The mRNA expression of target factors 
are normalised to an endogenous reference gene (house-keeping gene) and relative to 
calibrator (positive control). The house-keeping genes used in this study are GAPDH, 
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HPRT1and TBP1. The calibrator for factors expression was MCF-7 a tumour cell line of 
non-placental origin. 
 
2.7  In vitro cell culture 
2.7.1  Cell revival and subculture 
The cells were revived from liquid nitrogen storage by thawing the vials quickly in warm 
water. Thawed cells were added with 10 ml of growth media to remove the cytotoxic effects 
of freeze media and centrifuged at 1,000 x g for 5 minutes. The supernatant was discarded 
and 1ml of growth media was added to the pellet. Cells were then transferred into T25 flasks 
(Sarstedt). All cell lines specifications and culture media are summarized in Table 2.4. The 
growth media were supplemented by 10% FBS (foetal bovine serum) (Lonza), 2mM L-
Glutamine (Lonza) and 25U/ml penicillin/streptomycin (Lonza). Cells were grown in T25 
flasks incubating at 37˚C in a humidified atmosphere of 95% (v/v) air/5% (v/v) carbon 
dioxide. A daily check was performed and the cell lines were sub-cultured when they reached 
70-95% confluence. 
Table 2.1: Details of the cell lines used in this study. 
Cell line Cell type  Medium Provider 
HTR-8/SVneo Human First-trimester villous trophoblast  RPMI-1640 
Dr Charles Graham University 
of Kingston, Canada 
TEV-1 Human First-trimester extravillous trophoblast RPMI-1640 
Dr  Mei Choi Choey University 
of Hong Kong, China 
JEG-3 Human placenta choriocarcinoma EMEM ECACC* 
BeWo Human placenta choriocarcinoma Ham’s F12 ECACC* 
MCF-7 Human breast adenocarcinoma cell line 
DMEM ATCC# 
 
   *European Collection of Cell Cultures; #American Type Culture Collection 
After the cells attained 70-95% confluency sub-culture was carried out by discarding the 
media and washing the flasks three times with 1X PBS (Lonza). Trypsin 1X (Sigma) was 
added to the flask to detach the cells and incubated for 2 minutes at 37°C. The duration of 
trypsinisation differed according to the cell types. An inverted light microscope (Motic 
AE2000, Scientific Laboratory Supplies Ltd.) was used to check detachment of the cells. 
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 Afterwards, respective growth media for each cell line was added to stop the action of 
trypsin. The cells were collected into Sterilin tubes (Sarstedt) and were centrifuged for 5 
minutes at 1,000 x g in Harrier 15/80 centrifuge (Sanyo).  
The supernatant was discarded and 1ml of growth media was added to the pellet and mixed 
well to achieve a suspension of single cells. Viable cells were counted by using 0.4% (v/v) 
trypan blue (Sigma Aldrich). 100µl of cell suspension was mixed with 300µl trypan blue. A 
small volume (10µl) of this mix was used to count in a haemocytometer. The cell numbers 
in four large grids were counted to estimate the total cell count using following calculation. 
𝐂𝐂𝐂𝐂𝐂𝐂𝐂𝐂 𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐍𝐂𝐂𝐍𝐍𝐍𝐍/𝐍𝐍𝐂𝐂  = Average cell number × 104 × 4 (dilution factor) 
       
These cells were both bulked up and transferred into T75/T175 flasks (Sarstedt) and used 
for further experiments or frozen down as below.           
  
2.7.2  Cryopreservation of cells 
For a continuous supply of cell lines, cells were cryopreserved in liquid nitrogen. The cell 
pellet after centrifugation was re-suspended in freeze media (Media 6.4ml, 
Penicillin/Streptomycin 0.1ml, FBS 2.5ml, and DMSO 1.0ml). The cells with freeze media 
were then transferred to cryovials placed on ice and immediately transferred to a -80˚C 
freezer. The following day the cells were moved into liquid nitrogen for long storage.  
 
2.8  In vitro cytotoxicity assays 
2.8.1  MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) assay 
Doxorubicin hydrochloride (10 mg) was obtained from Sigma Aldrich. This was 
reconstituted by diluting in 10ml of filtered distilled water to achieve the final concentration 
of 1mg/ml. and stored as aliquots at 4 °C covered with foil.  The MTT assay was carried out 
with an appropriate number of cells (5 x104) which were transferred into 96 well plates 
grown along with different concentration  of Doxorubicin hydrochloride (250, 500, 1000, 
2000 and 4000 ng/ml) being incubated for 24 and 48 hours at 37°C. After incubation the 
media were removed from the wells and 50µl of 5mg/ml MTT solution (Sigma Aldrich) was 
added to each well. The plates were wrapped in aluminium foil and incubated for an hour at 
37°C. After incubation 500µl DMSO (Sigma Aldrich) was added to each well and 
thoroughly mixed. The plates were gently agitated in a plate shaker to dissolve the crystals. 
A small volume of this solution 200 µl was transferred into a 96 well plate and the 
absorbance read at 570 nm. MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
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bromide) is a yellow soluble tetrazolium salt.  The MTT assay is a colorimetric assay based 
on reduction of MTT to insoluble purple formazan crystals by both mitochondrial and extra- 
mitochondrial dehydrogenases (Fotakis and Timbrell, 2006). The viable and proliferating 
cells contain higher NADH or NADPH ratios which act as mediators in the reduction of 
MTT. Likewise, succinate and NADH-linked mitochondrial substrates such as malate, 
pyruvate or glutamate support MTT reduction (Liu et al.,  1997). Therefore, the viability is 
directly proportional to the amount of crystals formed. All five cell lines which were used in 
this study are adherent cells. Therefore, a trypsinisation step is required before the cells are 
prepared for seeding. This causes stress to the cells and reduces their metabolic activity.  
Most of the cells require 24 hours of recovery from trypsin stress and function again as viable 
cells. Therefore, the effect of DOX on viable cells with different concentrations was 
investigated after 24 hours of the cells seeding. 
2.8.2  CytoTox 96® Non-Radioactive Cytotoxicity/ Lactate dehydrogenase assay 
(LDH assay) 
An appropriate number of cells (5 x104) was plated and treated exactly as in Section 2.8.1. 
An additional set of wells was plated for maximum lactate dehydrogenase (LDH) release 
and used as positive Control. The assay was carried out according to the manufacturers’ 
guidelines. After DOX treatment, Lysis Solution (10X) was added to the maximum LDH 
release control wells. After 45 minutes, the plates were centrifuged at 250 x g for 5 minutes.  
After centrifugation 50µl of the supernatant from each well was mixed with 50µl of Substrate 
Mix and incubated for 30 minutes on a shaker protected from light. After 30 minutes of 
incubation the reaction was stopped by adding 50 µl of Stop solution.  The absorbance was 
read at 490 nm. The CytoTox 96® non-radioactive cytotoxicity assay measures the release 
of LDH from the damaged cell membrane of non-viable cells into the cell culture media. 
LDH converts lactate to pyruvate with reduction of NAD+ to NADH/H+. The H+ from 
NADH/H+ is transferred to the tetrazolium salt INT (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-
phenyltetrazolium chloride) which reduces it to a red formazan dye (Cobb, 2013). The 
amount of red formazan dye is proportional to the amount of LDH released into the media. 
Hence, CytoTox 96® non-radioactive cytotoxicity assays indirectly measure cell death. 
  
2.9  Generation of non-resistant (normal) and drug resistant spheroids  
Previous studies within this laboratory by Dr Selman Ali have shown that spheroids can be 
generated from tumour cell lines by two different methods either by (1) growing the cells in 
ultra-low attachment flasks to produce normal spheroid, and (2) treating the cells with a 
chemotherapeutic agent (Doxorubicin) to select drug resistant spheroids. The same protocol 
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was used in this study to generate respective spheroids from trophoblast cell lines. 
2.9.1  Generation of non-resistant (normal) spheroids 
This assay was carried out to check the ability of trophoblast cells to produce spheroids. The 
procedure involves four stages as explained below. 
• Stage 1 (Bulking up of parental cells)  
Cell lines (usually 5 x106 cells/ml) were grown in a T75 flask under normal conditions in 
their respective media for 72 hours. Once the cells reached to 80-90% confluence, they were 
harvested and sub-cultured for stage 2. 
• Stage 2 (Spheroid formation)  
The cells harvested from stage 1 were trypsinised and counted to determine 5 x106 cells/ml. 
They were then sub-cultured in non-adherent (Ultra-Low Attachment) (Sigma-Aldrich) T75 
flasks in 20ml of serum-free media. This media contained (1% w/v L-glutamine and 1% v/v 
penicillin/streptomycin) supplemented with growth factors: 5μg/ml each of bFGF (Sigma-
Aldrich), EGF (Sigma-Aldrich) plus 5μg/ml of insulin (Sigma-Aldrich), and 0.4% BSA 
(Sigma-Aldrich). Cells were incubated for 3-5 days. Spheroid formation was monitored 
under the microscope every 24 hours.  
• Stage 3 (Cell sorting by gravity separation)  
The spheroids were separated from single cells by gravity separation. The cell mixture 
containing both spheroids and single cells was transferred into Sterilin tubes (Sarstedt) and 
kept at room temperature for 10 minutes to separate the spheroids from the single cells. The 
spheroid cells settled at the bottom of the tube.  The single cells from the upper layer of the 
media were carefully removed without disturbing the pellet of spheroids. Afterwards, the 
spheroids were then centrifuged for 5 minutes at 1,000 x g. 
• Stage 4 (The ability of normal spheroid cells to grow under normal conditions) 
Spheroids were grown in normal adherent flasks for 72 hours under normal growth media 
conditions to observe their growth rate (See Figure 2.1). 
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Figure 2.1: Schematic representation of protocol used to generate non-resistant 
(normal) spheroids. 
 
2.9.2  Generation of Doxorubicin (DOX) resistant spheroids 
This assay was carried out to select the spheroids that are resistant to doxorubicin. The 
procedure involves four stages as shown in Figure 2.2. The protocol was exactly the same 
as generating non-resistant (normal) spheroids except for the additional drug treatment with 
different concentrations of doxorubicin for 48 hours at stage one. 
 
 
Figure 2.2: Schematic representation of protocol used to generate resistant spheroids. 
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2.9.3  RNA extraction from normal cells and spheroidal cells 
RNA extraction and cDNA template preparation were carried out as explained in sections 
2.4 and 2.5 for parental and spheroids cells (untreated and DOX-treated). 
 
2.10  Protein expression studies 
2.10.1 Tissue lysate preparation for protein analysis 
The placental samples NT and PE were homogenized in liquid nitrogen to avoid protease 
degradation of proteins and transferred to centrifuge tubes. RIPA (Radio-
Immunoprecipitation Assay) buffer 10ml (Sigma Aldrich) and protease inhibitor cocktail 
(Roche) 0.2 % (v/v) and 1 mM Na3VO4 (Sigma Aldrich) were added to the samples. Then 
samples were vortexed for 30 minutes followed by 5 minutes incubation on ice. The tubes 
were incubated on ice for 1 hour then were centrifuged at 27,000 x g for 15 minutes at 4°C 
(Harrier 15/80 refrigerated centrifuge, Sanyo). The supernatant (i.e. the native form of the 
tissue lysate) was collected and stored at -80°C. 
2.10.2  Cell lysate preparation for protein analysis 
Cells were lysed directly in lysis buffer to collect whole cell extracts. Cells were washed 
twice with 1X PBS then transferred into 20 ml universal tubes and centrifuged at 27,000 x g 
for 15 minutes at 4°C. The supernatant was discarded and the pellet re-suspended in 1X PBS 
to remove the remaining growth media and centrifuged once again. The supernatant was 
removed and RIPA buffer 300μl (Sigma Aldrich) with protease inhibitor cocktail (Roche) 
0.2 %( v/v) and 1 mM Na3VO4 (Sigma Aldrich) were added to the cell pellet. Cells were 
then incubated on ice for 1 hour. The samples were centrifuged at 27,000 x g for 10 minutes 
at 4°C (Harrier 15/80 refrigerated centrifuge, Sanyo).  Finally the cell lysate supernatant was 
collected and stored at -80°C. 
2.10.3  Estimation of protein concentration by Bicinchoninic acid (BCA) assay 
All protein concentrations were determined using BCA (Sigma Aldrich) according to the 
manufacturer’s instructions to estimate the protein concentrations in the tissue and cells 
lysates prepared as mentioned earlier in Sections 2.10.1 and 2.10.2. The BCA working 
reagent was prepared by mixing 50 parts of reagent A (BCA) with 1 part of reagent B (4% 
w/v Copper (II) sulphate solution, Sigma Aldrich). The different concentrations of BSA 
(Bovine Serum Albumin) (Fisher Scientific) at 0.2, 0.4, 0.6, 0.8 and 1mg/ml were used to 
establish a standard curve. The placental tissue or cell lysates, together with BSA standards 
and blank (RIPA buffer) were added to a 96 well plate and mixed with 8 parts of BCA 
working reagent. The plate was incubated for 30 minutes at 37°C. The absorbance was 
measured at a wavelength of 570 nm by using a microplate reader (Biochrom Asys 
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UVM340). The protein concentrations of samples were derived from calculations based on 
the standard curve. 
2.10.4  Protein separation by SDS-PAGE 
Protein lysate samples were denatured for SDS-PAGE separation by using Laemmli buffer 
4X at 70-80˚C for 10 minutes on a heating block.  Equal concentrations of the protein 
samples were loaded into 10% or 12.5% w/v SDS-PAGE along with molecular weight 
markers (Biorad Laboratories, Inc.). ProtoGel® 30% w/v, ProtoGel® 4X Resolving and 
ProtoGel® stacking buffers were used to prepare SDS-PAGE gels according to the 
manufacturers’ guidelines (National Diagnostics). The SDS-PAGE was run at 50 volts for 
30 minutes followed by 90 volts for 1 hour. Finally the results were visualised by staining 
with Coomassie Brilliant Blue (BioRad Laboratories, Inc.). 
2.10.5  Protein analysis by Immunoblotting 
Immunoblotting was carried out after protein separation from SDS-PAGE on to 0.2µm 
nitrocellulose membrane (Sigma Aldrich) by wet-transfer over-night in a cold room. The 
nitrocellulose membrane was incubated in blocking solution (3% w/v BSA in 1X TBS-
Tween20) for 1 hour. After incubation, the membrane was washed three times with Millipore 
water followed by a 1X TBS-Tween20 wash. The membrane was then incubated in primary 
antibody overnight on a shaker at 4oC. Following incubation the membrane was washed and 
incubated in secondary antibody for 1-2 hours. After this the membrane was washed by 1X 
TBS-Tween20, three times for 5 minutes each to remove excess secondary antibody, and 
developed by using UV light (US Chemiluminescent Substrate Interchim). Image capture 
was carried out by using a Gel Doc, InGenius (Syngene).  New GeneSys Image analyser 
software was used for blots captured by InGenius and AIDA Image analyser software 
version 5.2 was used to quantify the bands. The expression levels of the proteins of interest 
were normalised against the house keeping proteins (β-actin).  
 
2.11  Staining protocol 
2.11.1  Immunohistochemistry (IHC) 
IHC was performed to investigate the cellular localisation of the proteins of interest in the 
tissue sections. The placental samples were embedded in paraffin, sectioned at 5µm 
thickness and placed onto poly-L-lysine coated slides (Thermo Scientific) for 1 hour at 60ºC. 
The protocol was divided into the following steps: 
a. Pre-staining:  
Paraffin wax was removed from the slides using xylene (Fisher Scientific) twice for 
5 minutes. 
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b. Hydration:  
Slides were hydrated through an alcohol gradient as follows: 
• 2x in Absolute alcohol for 2 minutes 
• 2x in 95%  v/v ethanol for 2 minutes 
• 1x in 75%  v/v ethanol for 2 minutes 
• 1x ddH2O for 2 minutes 
c. Heat induced antigen retrieval (HIAR): 
HIAR was used to break the methylene bridge formed during PF-fixation. The 
slides were heated for 20 minutes in a microwave at high temperature with retrieval 
buffer (10mM Tris-1mM EDTA buffer, pH 9 or 10mM Citrate buffer, pH 6). This 
was followed by washing with 1XPBS.  
d. Blocking endogenous peroxide : 
To block the slides from the endogenous peroxidase activity 3% v/v hydrogen 
peroxide (H2O2) (Fisher Scientific) in methanol was used for 30 minutes. This was 
followed by washing with distilled water. 
e. Primary antibody and Secondary antibody: 
The sections were blocked for unspecific binding with horse serum for 30 minutes 
or longer. The slides were then incubated with 100µl primary antibodies over-night 
at 4ºC at appropriate dilutions for each antibody. Then the slides were carefully 
rinsed with 1X PBS 3 times for 5 minutes to remove weakly bound to non-specific 
sites and to allow a proper binding between primary and secondary antibodies. For 
the negative controls, no primary antibodies were used in the incubation. After this, 
the slides were incubated with the biotinylated-conjugated secondary antibody in 
an ABC kit for 1 hour at room temperature.  
f. DAB (3,3'-diaminobenzidine) DAB:  
      After several 1X PBS washes, DAB substrate (Vectastain®) was prepared according 
to the manufacturers’ guidelines and was used to develop the detection of the 
chromogenic product. In the presence of antibody conjugated to peroxidase enzyme 
and peroxide, the DAB is oxidised to give a brown colour.   
g. Morphological histochemical staining:  
The slides were dipped for 20 seconds in Gills Haematoxylin. This stained the cell 
nucleus with blue.  This stain is used to demonstrate general tissue structures. 
Therefore, NT and PE placentae were counter-stained with haematoxylin for 
morphology comparison as well as for the demonstration of tissue antigens. 
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h. Dehydration and Mounting 
The slides were dehydrated in an alcohol gradient as follows: 
• 1x in 75% v/v ethanol for 2 minutes.  . 
• 2x in 95% v/v ethanol for 2 minutes  
• 2x in Absolute alcohol for 2 minutes 
Absolute alcohol treatment was followed by soaking in xylene for 10 minutes. Then 
the slides were mounted using Entellen® and covered with coverslips. Finally the 
slides were viewed and photographed at 20X magnification by using an Olympus 
camera DP73. The steps of the IHC protocol are summarised in Figure 2.3. 
i. Visualisation and semi-quantification of IHC 
A semi-quantitative scoring system was used to evaluate the status and expression 
of each factor. The images captured were taken approximately at the same locations 
in comparative slides. The staining in the images was then semi-quantified using a 
point scale immuno-reactivity scoring (IRS) system (as shown in Table 2.5). These 
scorings were carried out compared to the positive staining for vimentin IRS (scored 
as 3) and negative stain (secondary antibody only; 0) in the same sample. Multiple 
images of the slides were scored independently by three observers. Their individual 
scores were then compared and tallied for final scores. The most frequently repeated 
score between the three scorers (the mode) was taken as the final score for the 
factors of interest in an overall pool of samples (NT and PE). A weighted kappa 
statistical analysis was also performed with the scores provided individually by the 
three scorers to analyse the inter-observer error. The values for the kappa were 
interpreted as mentioned by Viera and Garrett (2005). If the values were: < 0, there 
was less chances of agreement; 0.01–0.20, indicated slight agreement; 0.21– 0.40, 
fair agreement; 0.41–0.60, moderate agreement; 0.61–0.80, substantial agreement 
and 0.81–0.99, practically perfect agreement  
 
               Table 2.2: IRS system for Visualisation and semi-quantification. 
Immunoreactivity score system (IRS)    Staining Intensity  
0 No staining or Very low staining 
1 Low staining  
2 Medium staining  
3 High staining  
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Figure 2.3: Summary flow chart of IHC protocol. 
 
2.11.2  Immunofluorescence staining 
The general protocol followed for immunofluorescence staining is given below: 
• Cell culture:  The different types of cells were grown on sterile glass cover slips 
GG-18-PLL (neuVitro), poly-l-lysine coated coverslips under the respective growth 
conditions. The coverslips were then rinsed with 1X DPBS  
• Cell fixing:  The media was removed from the culture plate and the coverslips were 
rinsed with 1X PBS.  Cells were then fixed with 4% w/v formaldehyde in 1X PBS 
for 30 minutes. Next, the cover slip was washed gently by 1X PBS 3 times for 5 
minutes.  
• Permeabilisation: For staining intracellular proteins the cells fixed with 
paraformaldehyde and methanol were permeabilised in 0.25% v/v Triton X-100 in 
PBS for 15 minutes. This was followed by three washes in 1X PBS for 5 mintues. 
The permeabilisation step was not required for acetone fixed cells and for detection 
of membrane proteins. 
• Blocking: The cover slips were then incubated in (1% w/v BSA in PBST) for 1 hour 
at room temperature. For paraformaldehyde-fixed coverslips, 0.3M Glycine was 
added to the blocking buffer. 
• Primary and secondary antibody incubation: The coverslips were then incubated 
in primary antibody diluted in 1% w/v BSA in 1X PBST for 1 hour at room 
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temperature or overnight at 4ºC in a humidified dark chamber. After incubation the 
coverslips were washed again in 1X PBS 3 times for 5 mintues. The coverslips were 
then incubated in secondary antibody diluted in 1% w/v BSA in 1X PBST for 1 hour 
at room temperature in the dark followed by five minutes washes with 1XPBS. 
• Counter staining: The coverslips, if required, were counter-stained with 
VECTASHIELD® HardSet™ mounting medium with DAPI. Once dried, the edges of 
the coverslips were sealed with colourless nail varnish to prevent them from moving 
while taking images. The images were captured using an Olympus camera with 
suitable filters at different magnifications (Objective magnification: 20X and 40X). 
This assay was carried out to stain the spheroidal cells. The protocol is exactly the 
same except for the first step when spheroidal cells (untreated and DOX-treated) 
were collected from a non-adherent flask and transferred into 15 ml universal tubes 
for centrifugation at 500 x g for 10 minutes. Finally spheroids were washed 3 times 
for 5 minutes and mounted on the slides with two drops of VECTASHIELD® 
HardSet™ mounting medium after securing the area boundaries by means of a 
hydrophobic image barrier pen (Vector Laboratories, Inc). 
 
2.12  Scratch /Wound healing assay 
A wound healing assay was carried out to evaluate cell migration. Cells were plated at 
optimum densities (5x104)  into 24 well plates (Falcon) until 90-95% confluence. In the case 
of spheroids they were trypsinised after harvestinig to break  them down to single cells and 
re-suspended in the respective growth media. Cells were then transferred to 24 well plates 
(Falcon) until 90-95% confluence. A straight scratch was made on the cell monolayer by 
using a 2 μl pipette tip at an angle of about 90 degrees. The cells were washed gently with 
1X PBS (Lonza) to remove the debris after the scratch. 1ml of serum free media (media with 
1% w/v L-glutamine and 1% v/v penicillin/streptomycin) with DOX and without DOX 250 
ng/ml (Sigma) was added to the cells according to the set experiments to check the effect of 
DOX on the migration property of  normal and spheroidal cells at 24 and 48 hours. The 
scratches were continuously imaged in real time using a Leica microscope at 30 minute 
intervals for 48 hours The images were analysed using WimscratchP P automated analysis by 
WimasisP Pquantitative image analysis (wwwP19P). This software identifies the edge of the 
scratch and measures the gap area.  
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2.13  Invasion assay  
The invasion assay was carried out using the BD Falcon™ BioCoat tumour invasion systems 
(BD Falcon) with fluoroBlock™ 96 well insert plate (8µm pore size) coated with BD matrigel 
matrix.  This was compared with migration of cells through uncoated BD Falcon™ 
FluoroBlok™ 96 well insert plates. The assay used was as follows: 
• Rehydration: A BD falcon BioCoat™ tumour invasion plate was removed from -20°C 
and kept for half an hour at room temperature. The apical chambers were filled with 75 
μl of warm media and allowed to rehydrate for 2 hours at 37˚C at 5% v/v COR2R. The 
uncoated BD falcon fluoroBlock P™ P 96 well insert plate that was used as a cell migration 
control does not required rehydration.  
• Pre-staining the cells:  The cells were grown to 70% confluency and collected after 
trypsinisation. Collected cells were incubated with 10µM CellTrace™ CFSE  red dye 
(Molecular Probes®) for 45 minutes. After incubation the cells were centrifuged and re-
suspended in warm media.  
• Cell suspension: Cell densities of 1.25x104 cells were prepared in SFM (media with1% 
w/v L-glutamine and 1% v/v penicillin/streptomycin).  
• Setting up assay: The media was removed from apical chambers after rehydration of BD 
falcon Bio Coat™ tumour invasion plate and replaced with 50μl of cell suspension. The 
50μl of cell suspension was also added to the apical chambers of the BD falcon 
fluoroBlock™ 96 well insert migration plate. The bottom of the chambers was filled with 
growth media containing 5% v/v FBC, which acts as a chemoattractant. In addition, the 
apical as well as the bottom chambers were treated with 250 ng of DOX in treatment 
condition. 
• Taking images:  After incubating the plates for 24 hours at 37°C and 5% CO2 the 
membranes were removed from the inserts with a special knife and mounted on slides. 
The fluorescence of invaded cells was then read at a wavelength of 494/517 nm (Ex/ Em) 
followed by image capture at the end of the assay using a fluorescent microscope 
(Olympus BX51) with an Olympus camera. The invasion assay steps are summarised in 
Figure 2.4 
• Calculation of cell invasion percentage: The number of cells invaded from the tumour 
invasion plate together with percentage invasion (see below for equation) was analysed 
using ImageJ software.  
 
𝐼𝐼𝐼𝐼𝑅𝑅𝐹𝐹𝑅𝑅𝐼𝐼𝐹𝐹𝐼𝐼 % = 𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑅𝑅𝐹𝐹 𝐹𝐹𝑜𝑜 𝑐𝑐𝑅𝑅𝑐𝑐𝑐𝑐𝑅𝑅 𝐼𝐼𝐼𝐼𝑅𝑅𝐹𝐹𝐹𝐹𝑅𝑅𝐹𝐹 
𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑁𝑅𝑅𝐹𝐹 𝐹𝐹𝑜𝑜 𝑐𝑐𝑅𝑅𝑐𝑐𝑐𝑐𝑅𝑅 𝑁𝑁𝐼𝐼𝑚𝑚𝐹𝐹𝐹𝐹𝑚𝑚𝑅𝑅𝐹𝐹 × 100  
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Figure 2.2: Summary of the Invasion assay steps. 
 
2.14 Cultrex® 96 well 3-D spheroid Basement Membrane Extract (BME) cell 
invasion assay 
This assay is standardized for a three-dimensional cell structure, where invasive cells can 
penetrate a barrier consisting of components resembling basement membranes in vitro in 
response to chemoattractant/invasion modulation compounds. The assay duration was 3 
days. At day1, 10X Spheroid Formation ECM was thawed on ice overnight at 4ᵒC in a 
refrigerator.  At day 2, cells were harvested (without and with DOX) and the optimal seeding 
density for each cell line was added usually 2x103 cells/ml per well for trophoblast cells; 
whereas MCF-7 was seeded with a density of 1.5x103 cells/ml. A single cell suspension was 
prepared in 1X spheroid formation ECM and 50µl of single suspension (in 1X ECM) was 
dispensed to each well. The plate was centrifuged at 300 x g for 5 mines to make all the cells 
acentric in position then incubated for 72 hours at 37°C with 5% CO2 supply. After 72 hours 
the plate was taken out and left on ice for 5 minuts to cool down. Invasion Matrix 50µl was 
added per well and centrifuged at 200 x g for 5mins to remove bubbles. The plate was 
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incubated again for 1 hour at 37 °C with 5% CO2 supply to promote gel formation. After 
this 100µl of warm culture media was added to each well. The plate was then placed under a 
confocal microscope for imaging at 4 hour intervals for 48 hours. Later, images were 
analysed using Image-J software and data were quantified using GraphPad Prism software. 
2.15  Cell lysate preparation for mass spectrometry 
A stepwise explanation of this protocol is given below.  
Initial Steps: 
a. Sample preparation: Cell lines (5x106 cells/ml) were harvested by trypsinisation in the 
case of parental (adherent) cells, while spheroids (suspension) cells were centrifuged at 
300 x g for 10 min, washed twice with 1X PBS and then centrifuged at 300 x g for 10 
min. The residual PBS was discarded. Then 15 μl of 8M urea and 1.5 μl of Protease 
MAX ™ (Sigma) was added to the cell suspension.  Afterwards, the cell lysates were 
mixed by vortexing. To the lysed solution 58.5μl of 50 mM TEAB (Sigma) was added 
and incubated on ice for 15 min. To enhance cell lysis a sonicator was used, incubated 
in a water bath for 5 min and repeated three times. After final sonication the solution was 
centrifuged at 14,000 x g for 15 min at 4ºC. The samples were transferred into a fresh 
labelled tube for the alkylation and reduction step. 
b. Reduction and Alkylation:  In this step, 1.0μl of 0.5 M DTT (Sigma) was added to 
samples incubated at 56°C for 20 minutes in a water bath. Following this 2.7μl of 0.55M 
IAA (Sigma) was added and the sample mixed well and incubated at room temperature 
in the dark for 15 minutes.  
c. Trypsinisation:   This step was carried out using freshly made trypsin by adding 20μl 
of 1 mM HCL (Sigma) to re-suspend all trypsin completely. From the cell lysate 50μg 
of protein together with 100μl of 50 mM TEAB (Sigma) solution was mixed with 2μg 
of trypsin, vortexed and incubated at 37°C overnight with gentle shaking. 
Final step: 
After trypsinisation, the samples were concentrated using a SpeedVac concentrator for 
30-40 minutes. Finally, 20μl of 5% Acetonitrile/0.1% (Sigma) formic acid solution 
(Sigma) was added to the samples and transferred into a new tube. The samples were then 
analysed using a TripleTOF® 6600 System SCIEX. A spectral library was constructed 
using the output from ProteinPilot 5 (SCIEX) combining 4 IDA runs per comparison and 
filtered and aligned to spiked in iRT peptides (Biognosys, Switzerland) using PeakView 
2.0 (SCIEX). SWATH data extraction, quantitation and fold change analysis were carried 
out using SCIEX OneOmics cloud processing software. 
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3.1 Introduction 
Tumour and placenta show several similarities as mentioned in previous chapter 1 in Section 
1.3). They both have capacity for proliferation, differentiation, and invasion through the 
surrounding tissues by degrading the extra-cellular matrix (ECM) (Ferretti et al., 2007). In 
addition, tumour and placenta also possess other novel characteristics, such as interacting 
with endothelial cells, evading the  immune response, escaping apoptosis, and establishing 
nutrient supply by angiogenesis (Ferretti et al., 2007). However, the invasion of placental 
trophoblast cells into the uterine wall, is a unique and controlled process, which is essential 
for foetal development. If the invasion is shallow, it results in a multisystem disease called 
pre-eclampsia (PE) which affects 5-7% of pregnant women (Louwen et al., 2012). It is 
considered as a major cause of maternal and foetal mortality worldwide. The complete 
pathophysiology of this syndrome is not well understood. However, many factors have been 
identified for pre-eclampsia which include: genetic predisposition, reduced/abnormal 
trophoblast invasion with impaired spiral artery remodelling (during placental development), 
immunologic intolerance, ethnicity and variations in inflammation (Sankaralingam et al., 
2006). Most of the research is focused on various gene expression and epidemiological 
factors that have been modified during pre-eclampsia (Sankaralingam et al., 2006). 
Microarray techniques and proteomic studies, have identified potential genes and proteins 
that are altered in PE when compared to normal placenta (Sankaralingam et al., 2006; 
Enquobahrie et al., 2008). Therefore, these genes and proteins might be used to understand 
the pathogenesis of PE and also for the development of new therapeutic targets (Yang and 
Kong, 2015).  
Interestingly, most of these altered genes and proteins have been reported to be closely 
involved in tumour development as well (Louwen et al., 2012). In fact, the NT, PE and 
tumour, can be considered as three scenarios; (a) normotensive pregnancy where there is a 
controlled but normal trophoblast invasion, (b) pre-eclampsia, the invasion is low, and (c) 
tumour where there is uncontrolled invasion. By comparing the status of factors between NT 
and PE placentae, it will be easy to understand their importance in the invasive process and 
can further be used to target tumours invasion.  Therefore, the primary aim of this chapter is 
to compare the status of the tumour associated factors, such as ALDH3A1, AURK- (A and 
C), PDGFRα, TWIST1, and JAG1, in NT and PE placentae. Interestingly, these factors are 
believed to play important roles in tumour invasion as mentioned in Section (1.5). These 
factors may also be expressed in human placenta invasion. However, the functional status of 
many of these factors has not been fully established. 
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3.2 Results 
The mRNA expressions of the above mentioned factors (See Section 3.1) were compared 
between 13 NT and 12 PE human placental tissue samples. To confirm that changes in 
mRNA expressions were also faithfully translated into protein changes, the identified 
proteins were qualitatively and semi-quantitatively compared by immunohistochemistry 
(IHC) and western blotting. The MCF-7 human breast adenocarcinoma cell line was used as 
a tumour cell line of non-placental origin for all of the experiments in this study. 
3.2.1 Human placental samples 
The demographic details of NT and PE samples are given in Table 3.1 (Ethical approval was 
obtained from NHS REC: 12/NE/0112). Individual patient data can be found in Appendix 
A.1 
 
Table 3.1: Demographic details of the normotensive and pre-eclamptic subjects. 
 
The details are expressed as mean ± SD, N/D= none detected, n=number of women in each 
group.  § Mann – Whitney U test. 
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3.2.2 Gene expression studies 
According to the protocol in Section 2.9.3, total RNA was extracted and reverse transcribed 
from 13 NT and 12 PE placental samples. The ratio of absorbance at 260/280 nm ranged 
from 1.9-2.3, showing that the RNA was pure and the integrity was well maintained. The 
extracted RNA was found to be pure from genomic DNA, when the RNA samples were 
subjected to  electrophoresis in a 1% w/v agarose gel and two bright clear bands were 
separated (28S and 18S) (See Appendix A.2).  Primers for all factors of interest were 
designed as mentioned in Section 2.6.1. The primer sequences for the factors and the house 
keeping genes, along with their optimised annealing temperatures (Ta) are summarised in 
Table 3.2. Single bands were obtained for all the PCR products at regions of approximately 
200 bp in a 1.5% agarose gel, without any presence of primer and/or product dimers (See 
Appendi A.3). The accession numbers for target factors are listed in Appendix A.4.  All PCR 
products were confirmed by DNA sequencing carried out by Source Bioscience 
(Birmingham, UK). Examples of DNA product confirmation gel and sequencing data can be 
found in Appendix A.5.  
Table 3.2: The primers for the specific gene and their annealing temperatures (Ta)  
Factors of interest Primer  sequence  (5' to 3') 
Primer 
Length 
(nucleotides) 
Annealing  
Temperature 
(Ta) °C 
ALDH3A1 
Forward GATCCAGCAGGAGCA 15  
58.2 Reverse GTCTTCACGGGCTCA 15 
 AURK- A 
Forward GAATTGGCAAATGCCCTG 18 
        53.7 Reverse AGGGGGCAGGTAGTCCAG 18 
 AURK-C 
Forward TTGGAGAGACTGCCCCTG 18 
        58.2 Reverse GCAGACAGGGCTCAGGAA 18 
 PDGFR-α 
Forward CGACAGCAGACAGGGCTTTA 20 
        59.5 Reverse AACAGCACAGGTGACCACAA 20 
  TWIST1 
Forward CAGTGATTCCCAGACGGA 18 
        58.2 Reverse TTCAGTGGCTGATTGGCA 18 
JAG1 
Forward TCAACGGGGGAACTTGTAGC 20 
53.2 Reverse TGACAGGGATCAGAGAGGCA 20 
Housekeeping genes 
GAPDH 
Forward ACCACCAACTGCTTAGCACC 20 
58 Reverse CCATCCACAGTCTTCTGGGT 20 
   HPRT1 
Forward TGACACTGGCAAAACAATGCA 21 
55 
Reverse GGTCCTTTTCACCAGCAAGCT 21 
    TBP1 
Forward TGCACAGGAGCCAAGAGTGAA 21 
56 Reverse CACATCACAGCTCCCCACCA 20 
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3.2.2.1 Relative mRNA expression of factors of interest in NT and PE  
Quantitative real–time PCR (qRT-PCR) was carried out to determine the mRNA expression 
level of the different factors of interest in NT and PE placental samples. The 2-ΔΔCt values 
were calculated as mention in Section 2.6.5.  Figure 3.1 shows a Scatter-plot displaying the 
different mRNA expression level for each factors in NT and PE samples as shown in Figure 
3.1. The expression patterns of individual factors are reported below: 
 The human aldehyde dehydrogenase 3A1 (ALDH3A1) 
Relative expression of ALDH3A1 is shown in Figure 3.1, Panel A. There was a significant 
up-regulation in the levels of ALDH3A1 mRNA expression in PE samples when compared 
to NT placentae samples (p<0.05). 
 Aurora kinase A (AURK-A) 
Interestingly, there was a statistically significant difference in the relative mRNA 
expressions of AURK-A in PE when compared to NT. The expression of AURK-A mRNA 
was up regulated in PE placentae (p<0.001; See Figure 3.1, Panel B). 
 Aurora kinase C (AURK-C)  
The relative mRNA expression level of AURK-C was significantly reduced in PE samples 
when compared to NT samples (p<0.05; See Figure 3.1, Panel C). 
 Platelet-derived growth factor (PDGFRα) 
The relative mRNA expression level of PDGFα was significantly reduced in NT when 
compared to PE (p<0.01; See Figure 3.1, Panel D).  
 Basic helix loop helix protein (TWIST1) 
As seen in Figure 3.1, Panel E, there was a significant up-regulation  in mRNA expression 
level of TWIST1 in PE placentae when compared to NT (p<0.01). 
 JAG1 (Jagged 1)  
In Figure 3.1, Panel F, there was a statistically significant down regulation in mRNA 
expression level in PE when compared to NT (p<0.01). 
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Figure 3. 1: Relative mRNA expression analysis of tumour associated factors between 
NT and PE placentae. 
The relative mRNA expressions of the following factors were found to be significantly up-
regulated in PE placenta; ALDH3A1 (panel A), AURK-A (panel B); PDGFα (panel D) and 
TWIST1 (panel E). In contrast, the mRNA expressions of AURK-C (panel C), and JAG1 
(panel F) are significantly down-regulated in PE placentae.  Statistical significance was 
determined using Mann-Whitney U test (n=13 NT and 12 PE 
respectively;*p<0.05;**p<0.01; ***p<0.001). Data represent the median of three individual 
experiments, each performed in triplicate. 
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3.2.3  Protein expression and cellular localisation of factors of interest in NT and PE 
The expression of all factors of interest were investigated in both NT and PE samples using 
western blot analysis, to check the alterations between mRNA and protein expressions; for 
methods see Section 2.10. Equal amount of placental samples (50µg) were loaded, as 
confirmed by β-actin on the same blots. Only (20µg) of the positive control were loaded to 
avoid over-saturation of the blot. The positive controls were suggested by the supplier 
(Abcam) and was different for each factor. The scatter-plots for protein expression of each 
factors of interest is shown in the following Figures: 3.2, 3.4, 3.6, 3.8. 3.10, and 3.12. The 
last lane in both NT and PE blots are the positive controls which are separated by dotted 
lines in the blot. The protein expression levels were normalised by using housekeeping β-
actin protein levels as internal control. Representative whole blots for each antibodies used 
against the factors are presented in Appendix A.6 
The status and cellular localisation of factors was studied by using Immunohistochemistry 
(IHC) methods. For IHC the positive and negative controls are required for validity of 
staining. The brown staining with 3,3′-Diaminobenzidine (DAB) substrate were used as a 
positive staining and scored according to the intensity of staining. The negative controls were 
treated only with secondary antibody, therefore no immuno-reactivity (brown staining) was 
observed. The scoring was carried out by three different individuals (at least one of them 
was a histologist) and the semi-quantified immune-reactivity scores (IRS) between NT and 
PE samples are shown in Tables 3.3. The Fleiss Kappa statistics was performed on this IRS 
data which provided a kappa value of 0.47, suggesting a moderate level of agreement 
between the scorers. 
 
        Table 3. 3: Immuno-reactivity score (IRS) of all factors of interesting  
Factors NT (n=5) PE  (n=5) P Value Significance 
ALDH3A1 2±0.4 2±0.3 > 0.9999 Ns 
AURK-A 1±0.2 3±0.2 0.0085 ** 
AURK-C 2±02 1±0.3 0.0133 * 
PDGFRα 2±0.2 2±0.3 > 0.9999 Ns 
TWIST1 1±0.2 2±0.3 0.0004 *** 
JAG1 1±0.3 1±0.2 > 0.9999 Ns 
 
The intensity of staining was represented by the mode ±SEM of the IRS from 5 individual 
samples in each group. Unpaired t-test was then performed on the IRS modes of NT and PE 
(ns= no significance) (*p<0.05;**p<0.01; ***p<0.001). 
69 
 
Chapter 3:  Expression analysis of tumour associated factors in NT and PE  
  
 Protein expression of ALDH3A1  
The predicated molecular weight of ALDH3A1 protein declared by the supplier (Abcam) 
was 50 kDa. The single band at 49kDa was observed in most of the placental (NT and PE) 
samples, as well as in MCF-7 cells, which was used as a positive control for ALDH3A1. 
ALDH3A1 expression could be observed in almost all PE samples. However, only 10/13 
samples of NT showed expression of ALDH3A1. Interestingly, the protein expression 
patterns agreed with quantitative mRNA analysis data showing a statistically significant 
increase of ALDH3A1 expression in PE samples (p<0.05) (Figure 3.2). 
 
Figure 3. 2: The expression of ALDH3A1 protein in NT and PE placentae. 
Scatter-plots are derived from 13 NT and 12 PE samples and relative expression was 
determined from three independent blots. Mann Whitney U test was performed (*p<0.05). 
Quantified data are expressed as the ratio of the ALDH3A1/ β-actin. The error bars (±SEM) 
are represented with brown lines. A representative western blots showing the single bands 
detected by both anti-ALDH3A1 and β-actin antibodies are also shown.  
 
 
 Cellular localisation of the ALDH3A1  
Moderate immuno-staining of ALDH3A1 was observed in both NT and PE samples (Figure 
3.3). The staining in the STB layers (red arrows) of the placental villi in PE tissues were 
slightly higher when compared with the STB layer in NT tissues. No staining differences 
were detected between NT and PE in both the mesenchymal cells (red star) and foetal blood 
vessels (black arrows). Therefore, the overall staining intensities for NT and PE showed no 
significant difference (Table 3.3). 
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Figure 3.3: ALDH3A1 localisation determined by immunohistochemistry. 
Five placental samples for each group (NT and PE) are represented here. The IRS for 
ALDH3A1 for each sample was scored in comparison to the IRS of positive (Vimentin) and 
negative controls (2nd Ab only) of the same sample. Magnification 20X; scale bar=100μm. 
STB layer (red arrows), the mesenchymal stromal cells (red star) and foetal blood vessels 
(black arrows). 
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 Protein expression of AURK-A 
Almost all of the PE samples showed expression of AURK-A protein (Figure 3.4). The 
single bands for AURK-A were detected at 48kDa for all (NT and PE) placental samples 
and the positive control (Hela cells) which was within the predicted range (between 46-48 
kDa). The expression levels were significantly higher in PE samples (p<0.001) when 
compared to NT samples. 
 
Figure 3.4: AURK-A protein expression in NT and PE placentae. 
Scatter-plots are derived from 13 NT and 12 PE samples and relative expression was 
determined from three independent blots. Mann Whitney U test was performed (***p<0.001). 
Quantified data are expressed as the ratio of the AURK-A / β-actin.  The error bars (±SEM) 
are represented with brown lines. Representative western blots showing the single bands 
detected by both anti-AURK-A and β-actin antibodies are also shown. 
  
 
 Cellular localisation of the AURK-A 
The IRS data of AURK-A suggested that the intensity of staining was more pronounced in 
PE samples, when compared with NT samples (See Table 3.3). The entire PE sections were 
completely stained; with higher staining intensities around the STB layer (red arrows).  
However, the weak staining intensity was found in the mesenchymal stromal cells (red star) 
and foetal blood vessels (black arrows). Overall, the staining intensity in PE tissues was 
higher when compared to low staining levels in NT tissues (Figure 3.5). 
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Figure 3.5: AURK-A localisation determined by immunohistochemistry. 
Five placental samples for each group (NT and PE) are represented here. The IRS for AURK-
A for each sample was scored in comparison to IRS of positive (Vimentin) and negative 
controls (2nd Ab only) of the same sample. Magnification 20X; scale bar=100μm. STB layer 
(red arrows), the mesenchymal stromal cells (red star) and foetal blood vessels (black 
arrows). 
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 Protein expression of AURK-C 
The anti-AURK-C antibody produced single bands in almost all of the NT samples and 
positive control (Hela cells). However, only some of the PE samples showed expression of 
AURK-C (Figure 3.6).  The detected bands were at 36 kDa which is within the predicted 
range (20-36). The expression levels of AURK-C in NT samples were significantly higher 
than in PE samples. 
 
 
Figure 3.6: AURK-C protein expression in NT and PE placentae. 
Scatter-plots are derived from 13 NT and 12 PE samples and relative expression was 
determined from three independent blots. Mann Whitney U test was performed (**p<0.01). 
Quantified data are expressed as the ratio of the AURK-C / β-actin. The error bars (±SEM) 
are represented with brown lines. Representative western blot showing the single bands 
detected by both anti-AURK-C and β-actin antibodies are also shown.  
 
 
 Cellular localisation of the AURK-C 
The staining intensity of AURK-C was less in PE samples when compared with NT samples, 
as seen in Figure 3.7.  In   NT, IRS for AURK-C was observed in the STB layers (red arrows). 
No staining difference was observed between NT and PE samples, in both the mesenchymal 
stromal cells (red star) and foetal blood vessels (black arrows). The IRS data, which showed 
statistically lower expression of AURK-C staining in PE compared to NT samples (p<0.05) 
(Table 3.3). 
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Figure 3.7: AURK-C localisation determined by immunohistochemistry. 
Five placental samples for each group (NT and PE) are represented here. The IRS for AURK-
C for each sample was scored in comparison to the IRS of positive (Vimentin) and negative 
controls (2nd Ab only) of the same sample. Magnification 20X; scale bar=100μm. STB layer 
(red arrows), the mesenchymal stromal cells (red star) and foetal blood vessels (black 
arrows). 
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 Protein expression of PDGFRα: 
The expression of PDGFRα protein showed a single band in both placental samples and 
positive control (PDGF protein). These bands were detected at 36 kDa whilst the expected 
molecular weight of the band was in the range of 14-20 kDa. Only a few NT samples showed 
expression of PDGFRα, when compared to the expression in all the PE samples and positive 
control (Figure 3.8). Thus, there was a significant difference in the expression levels between 
NT and PE placentae (p<0.01).   
 
 
 
Figure 3.3: PDGFRα protein expression in NT and PE placentae. 
Scatter-plots are derived from 13 NT and 12 PE samples and relative expression was 
determined from three independent blots. Mann Whitney U test was performed (**p<0.01). 
Quantified data are expressed as the ratio of the PDGFRα / β-actin. The error bars (±SEM) 
are represented with brown lines. Representative western blots showing the single bands 
detected by both anti- PDGFRα and β-actin antibodies are also shown.  
 
 Cellular localisation of the PDGFRα 
Both NT and PE tissues showed moderate immuno-reactivity for PDGFRα (See Figure 3.9). 
In general, the STB layer (red arrow) was clearly stained in both NT and PE tissues. 
Although, the STB layer in PE showed deeper staining than STB layer in NT. The IRS data 
showed equal intensities of staining in NT and PE tissues, without any significant difference 
(Table 3.3). 
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Figure 3.9: PDGFRα localisation determined by immunohistochemistry. 
Five placental samples for each group (NT and PE) are represented here. The IRS for 
PDGFRα for each sample was scored in comparison to IRS of positive (Vimentin) and 
negative control (2nd Ab only) of the same sample. Magnification 20X; scale bar=100μm. 
STB layer (red arrows), the mesenchymal stromal cells (red star) and foetal blood vessels 
(black arrows). 
 
 Protein expression of TWIST1 
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The predicated molecular weight of TWIST1 protein as declared by the antibody supplier 
(Abcam) was between 21- 36 kDa. However, a single band was observed for TWIST1 in 
both positive control (Hela cells) and placental samples at 49 kDa (Figure 3.10). The protein 
expression level of TWIST1 was significantly increased in PE samples when compared to 
NT placentae (p<0.05). 
 
 
Figure 3.10: TWIST1 protein expression in NT and PE placentae. 
Scatter-plots are derived from 13 NT and 12 PE samples and relative expression was 
determined from three independent blots. Mann Whitney U test was performed (*p<0.05). 
Quantified data are expressed as the ratio of the TWIST1 / β-actin. The error bars (±SEM) 
are represented with brown lines. Representative western blots showing the single bands 
detected by both anti- TWIST1 and β-actin antibodies are also shown.  
 
 Cellular localisation of the TWIST1 
As seen in Figure 3.11, the staining intensity of TWIST1 expression was more intense in PE 
when compared with the NT tissues, especially in the STB layer. Interestingly, these are also 
confirmed by the IRS data which showed statistical significance for differences in TWIST1 
expression in PE and NT samples (p<0.001) (Table 3.3). The staining was clearly observed 
in the STB layer in both NT and PE.  
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Figure 3.11: TWIST1 localisation determined by immunohistochemistry. 
Five placental samples for each group (NT and PE) are represented here. The IRS for 
TWIST1 for each sample was scored in comparison to IRS of positive (Vimentin) and 
negative control (2nd Ab only) of the same sample. Magnification 20X; scale bar=100μm. 
STB layer (red arrows), the mesenchymal stromal cells (red star) and foetal blood vessels 
(black arrows). 
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 Protein expression of JAG1   
The molecular weight of the JAG1 protein was predicted between 75-137 kDa according to 
the antibody supplier (Abcam). A single band of JAG1 expression were observed at 75 kDa 
in the positive control (Hela cells) and in placental samples. A significant reduction in the 
expression was observed in PE samples when compared to NT samples (p<0.01) (See Figure 
3.12). 
 
 
Figure 3.12: JAG1 protein expression in NT and PE placentae. 
 
Scatter-plots are derived from 13 NT and 12 PE samples and relative expression was 
determined from three independent blots. Mann Whitney U test was performed (**p<0.01). 
Quantified data are expressed as the ratio of the JAG1/ β-actin. The error bars (±SEM) are 
represented with brown lines. Representative western blots showing the single bands 
detected by both anti-JAG1 and β-actin antibodies are also shown.  
 
 
 Cellular localisation of the JAG1 
Both NT and PE samples showed lower immuno-reactivity to JAG1 (Figure 3.13). The STB 
located at the surface of placental villi (red arrow) layer showed intense staining in NT 
samples when compared with PE samples. On the other hand, the IRS data analysis did not 
show any statistically significant difference in staining between the two groups (See Table 
3.3). Some staining was also observed in the mesenchymal stromal cells (red star) in NT 
tissues.  
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Figure 3.13: JAG1 localisation determined by immunohistochemistry. 
Five placental samples for each group (NT and PE) are represented here. The IRS for JAG1 
for each sample was scored in comparison to IRS of positive (Vimentin) and negative control 
(2nd Ab only) of the same sample. Magnification 20X; scale bar=100μm. STB layer (red 
arrows), the mesenchymal stromal cells (red star) and foetal blood vessels (black arrows). 
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3.3  Discussion  
The Placenta has a central role in foetal and maternal physiology and development (Sood et 
al., 2006). The variation of placental gene expression patterns can be associated with several 
maternal or foetal abnormalities including PE (Kleinrouweler et al., 2013). Several studies, 
using RNA or DNA microarray techniques, have shown that some genes are common in 
placental and tumour development, therefore, it was essential to understand their molecular 
mechanisms during placental development (Sood et al., 2006; Louwen et al., 2012; 
Kleinrouweler et al., 2013). The expression of these genes can be used as novel biomarkers 
in diagnostics, especially for early detection of PE (Kleinrouweler et al.,2013). The prime 
aim of this chapter was to compare the level of mRNA and protein expression (in NT and 
PE placentae) of some factors of interest that were identified from microarray technology 
(Ali, 2011). Although, there were several investigations about PE in past few years, the 
mechanisms of PE development still remains unknown (Vanwijk et al.,  2000). However, it 
is generally accepted that the pathogenesis of PE begins during the first and early second 
trimester of pregnancy, where there is impaired trophoblast invasion and remodelling of the 
spiral arteries (Goldman-Wohl and Yagel, 2009).  Moreover, several factors that have been 
suggested to be involved in PE, but several others still remain to be investigated or 
discovered. 
The factors which are considered in this chapter include ALDH3A1, AURK-A, AURK-C, 
PDGFRα, TWIST1 and JAG1, which were identified by microarray as common molecules 
involved in tumour invasion (Ali, 2011) and could be involved in trophoblast invasion due 
to the resemblance of placental invasion to tumour. They mostly fall under the categories of 
enzymes (ALDH3A1, AURK-A, AURK-C), transcription factor (TWIST1), growth factor 
receptors (PDGFRα) and signalling proteins (JAG1) The status of these factors in PE 
placentae have not been investigated earlier. Furthermore, since these factors have been 
suggested to play roles in tumour invasion (Ali, 2011), studying the status of these factors in 
PE (where the invasion is low) would help it to better understand their functions. 
ALDH3A1 is an enzyme which plays a role in normal and cancer stem cell biology, and 
hence used as a marker for the identification and isolation of cancer cells (Januchowski et 
al.,2013). Aurora kinases (AURK-A and C) both are overexpressed in several human cancers 
and normal tissues. Their overexpression could help to provide a new target for the treatment 
and understanding of cancer mechanisms (Xu et al.,  2014). PDGFRα is a growth factor that 
plays a major role in several physiologic functions, including embryogenesis and 
angiogenesis (Majumdar et al., 2009). The transcription factor, such as TWIST1, which 
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plays a vital role during embryonic growth, is also associated with cancer development and 
overexpressed in a variety of tumours e.g., prostate, lung, and breast (Cabrera Je, 2013).  
JAG1 or Jagged-1 is a protein encoded by JAG1 gene and plays a crucial role in tissue 
formation during the development of embryo (Karanu et al., 2000). The mRNA and protein 
expression level of JAG1 are used as biomarkers for  breast cancer (Dickson et al.,  2007). 
Therefore, understanding these factors that may be affected in reduced trophoblast invasion 
(as in PE) could shed some light on their importance in tumour invasion as well. The results 
of this chapter are summarised in Table 3.4.  
Table 3.4: Overall correlation between mRNA, protein expression and IRS in PE in 
comparison to NT placentae. 
PE 
 Factors 
interesting 
mRNA by qRT-PCR 
(compared to NT) 
Protein by WB 
(compared to NT) 
 IHC 
IRS       Cell type 
ALDH3A1 (+)* (+)* ns STB 
AURK-A (+)*** (+)*** (+)** 
STB, mesenchymal 
stromal cells and 
foetal blood vessels 
AURK-C (-)* (-)** (-)* STB 
PDGFRα (+)** (+)** ns STB 
TWIST1 (+)** (+)* (+)*** STB 
JAG1 (-)** (-)** ns 
STB, mesenchymal 
stromal cells 
 
The results of AURK-A, AURK-C and TWIST1, showed correlation between mRNA, protein 
expression and IRS. (-) down regulated; (+) up regulated; ns= no significance; *p<0.05;**p<0.01; 
***p<0.001. 
 
 
3.3.1  Comparative expression analysis between NT and PE placentae  
 
 ALDH3A1 
ALDH3A1 is a member of the ALDH3 family; others include ALDH3A2, ALDH3B1, and 
ALDH3B2). The ALDH3 family plays important role in cell proliferation, differentiation 
and survival, especially during the cellular responses to oxidative stress (Marchitti et al., 
2010).  Its expression has also been reported in mouse embryonic cells. Although ALDH3A1 
proteins are believed to play a role in tumourigenesis, their exact functions are not 
completely understood, apart from the fact that they are up-regulated in tumour cells (Muzio 
83 
 
Chapter 3:  Expression analysis of tumour associated factors in NT and PE  
  
et al., 2012). It has been suggested to play a role in maintaining tumour cell growth, motility, 
and gene expression and are therefore used as a functional markers for cancer (Muzio et al., 
2012). 
Over the last few years, ALDH3A1 has been studied in placental tissues, but then its role in 
placenta remains unclear (Marchitti et al., 2010). The data from this study suggest that both 
mRNA and protein levels of ALDH3A1 are significantly increased in PE placentae when 
compared to NT (p<0.05). However, no significant difference could be observed from the 
IHC data, apart from visible strong staining in the STB layers of PE tissues compared to NT 
tissues. IHC is a qualitative tool to confirm the presence or absence, and localization of a 
protein in or on cells/tissue by using antibody (Torlakovic et al.,  2015). However, it has 
some limitations for quantitation, for example, the brown colour of DAB reaction product is 
not a true absorber of light, but rather it scatters light (Rudbeck, 2015).  The more protein 
there is in the tissue, the more DAB will precipitate, but the colour does not follow a linear 
relationship between the amounts of DAB and how dark it shows (Rudbeck, 
2015). Moreover, thick sections of tissue tend to give stronger staining intensity than thin 
sections because there is more tissue with more antigen into which the DAB product may 
precipitate  (van der Loos, 2008).  Although, the sections used in this study were all 5 µm in 
thickness to minimise these limitations there were still no correlation to mRNA and protein 
by western blotting. Furthermore, Western blotting was carried out in this study which is a 
relatively accurate method for protein quantitation. Machitti et al. in 2010, used western blot 
analyses to show that ALDH3A1 was expressed in different mouse tissues including 
placentae. In placental tissues, its expression plays a helpful and physiological role against 
oxidative stress, i.e. it protects the trophoblasts from damage, prevents pregnancy loss at 
early stages and placental toxicity, and can be considered as a foetal antioxidant (Marchitti 
et al., 2010). Therefore, the overall high expression of ALDH3A1 in PE tissues could act to 
overcome the oxidative stress caused by the abnormal re-modelling of the spiral arteries. 
 AURK-A 
The involvement of Aurora-A during cell division makes it a potential drug target for cancer 
therapy (Staff et al., 2009). To the best of the author’s knowledge, this is the first study on 
the expression of AURK-A in NT and PE placentae, and there were no previous data to be 
found on AURK-A expression in placenta. Interestingly, the data from this study showed 
that AURK-A was overexpressed in PE placental samples.  
 
84 
 
Chapter 3:  Expression analysis of tumour associated factors in NT and PE  
  
Yoon et al. in 2012 have indicated that Aurora A is essential for post-implantation embryo 
growth and survival. Moreover, their data show that the effects of ablation of Aurora A at 
post-implantation stages can impact the embryo differently depending on the tissues affected 
by the mutation, such as in epiblast.  Interestingly, in this present study, results showed an 
overall positive correlation between mRNA and protein expression levels, and were up-
regulated in PE samples. This present study thus provides evidence for the expression of 
AURK-A in both NT and PE placentae.  
Results from IHC illustrated that AURK-A also showed higher staining for PE than NT 
placentae.  Thus, there was a high significant correlation between, mRNA, WB and IHC for 
AURK-A. Its over-expression in PE tissues shows that it might play a role in placental 
abnormalities and other pathological characteristics of PE. Moreover, the overexpression of 
AURK-A in both PE and cancerous tissues suggest that it could be a potential therapeutic 
target for these diseases.  
 AURK-C 
AURK-C is overexpressed in many cancer cell lines and it is believed to increase the cellular 
proliferation and migration of tumours (Dieterich et al., 2007).  Khan et al. (2012), found 
that AURK-C can stimulate formation of multinuclear cells from mononuclear cells 
condition by amplifying the centrosome. Furthermore, AURK-C is also linked to male 
infertility (Fellmeth et al.,  2015). Schindler et al. (2012) reported the involvement of 
AURK-C in the cytokinesis process during normal oocyte maturation and in pre-
implantation of embryos. Although, it is highly expressed in normal tissues (e.g. testis), its 
function is not yet clear (Harrington et al., 2004). Interestingly, there was a correlation 
between the intensity of IHC staining, mRNA and protein expression levels of AURK-C. 
Both mRNA and protein expression levels of AURK-C were decreased in PE. AURK-C 
expression was localised in the STB layers of both NT and PE samples.  According to semi-
quantitative analysis of IHC for AURK-C, it is evident that AURK-C IRS is significantly 
higher in NT placentae in comparison with PE placentae. Thus, from this study it can be 
predicted that AURK-C might be expressed during first trimester trophoblast cells to 
enhance, proliferation and invasion of EVT cells, which are important for successful 
pregnancy. Additionally, there may be possible involvement of AURK-C during the 
formation of STB from mononuclear CTB. During formation of STB from CTB in normal 
placenta, some of the trophoblast cells undergo apoptosis in order to maintain the cell 
numbers (Crocker at al., 2003). However, in PE placenta this cell death number is 
dramatically increased resulting in placental dysfunction (Ishihara et al., 2002). The down-
regulation of AURK-C in PE placenta when compared with NT placentae reported in this 
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study, could be due to disturbed trophoblast fusion during syncytial layer formation during 
this condition. 
 PDGFRα 
PDGFRα belongs to the tyrosine kinase receptor family which has 2 subtypes: PDGFRα and 
PDGFRβ. Although the underlying mechanisms remain largely unknown, PDGFRα are 
predicted to be involved in cellular proliferation, differentiation, growth development and 
pro-angiogenesis (Andrae et al., 2008). During embryonic development, PDGFRα regulates 
cell growth and differentiation (Majumdar et al., 2009). PDGFR signalling has important 
functions during embryogenesis, and its overexpression is associated with several 
pathological conditions such as cancer (Betsholtz et al., 2001).  It has been found to be 
expressed in mouse pre-embryos and in human placental cells (Osterlund et al.,1996). 
PDGFR α signalling is essential for the normal blood vessel formation and for the proper 
cellular organization of several organs such as brain, kidney and placenta (Looman et al., 
2007). Hence, they are one of the important mediators of mammalian development. While 
the importance of the β-isoform of PDGFR in trophoblast proliferation during pregnancy 
have been demonstrated (Holmgren et al., 1995). Conversely the function of α-isoform has 
not been fully established in placental development.  
In addition, a study by Kita et al. (2003) has shown that both PDGFRα and β in human 
placenta are expressed in the syncytiotrophoblast and the villous cytotrophoblast. The 
present finding of this study also supports these previous studies, where STB layers express 
PDGFRα in both NT and PE. However, the STB layer in PE showed deeper staining than in 
NT. Although, the overall IRS data showed equal intensities of staining in NT and PE tissues 
without any significant differences. Interestingly, there was a correlation between the mRNA 
and protein expression levels of PDGFRα, which were increased significantly (p<0.01) in 
PE compared to NT. This confirms the findings of Jurcovicova et al. (1998) who presented 
that PDGF mRNA expression values for NT placenta are considerably lower when compared 
to PE placentae. In contrast a study by (Jarvenpaa et al., 2007), showed that PDGFRα was 
down-regulated in patients with PE associated with intrauterine growth restriction (IUGR), 
using microarray analysis. It is worth noting that the PE placentae samples used in current 
study did not have IUGR complications. 
In this present study, 13 NT and 12 PE placentae were used, whereas only 3 NT and 2 PE 
with (IUGR) were used by (Jarvenpaa et al., 2007). Furthermore, the PE placentae used in 
this study were only mild pre-eclamptic, not severe unlike the one used by (Jarvenpaa et al., 
2007). According to Morey et al (2006), qRT-PCR is the most common validation tool used 
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for confirming gene expression results obtained from microarray analysis and confirmed 
their results usually are in agreement. Yet, there is still a debate on which of the two 
techniques is most reliable. Therefore, in this study western blot was used to check the 
validity of the mRNA and IHC results. 
 TWIST1 
TWIST1, is a transcription factor that belongs to the basic helix-loop-helix (bHLH) family. 
It plays a major role in regulatory functions during embryogenesis. It regulates cell 
proliferation, migration and differentiation in embryonic development (Ansieau et al.,  
2008). Moreover, it also plays multiple role in cancer initiation, progression and metastasis 
process (Qin et al., 2012). It can override oncogene-induced cell senescence and apoptosis 
(Maestro et al., 1999). In addition, TWIST1 increases cancer cell resistance to chemotherapy 
and enhances cancer stem cell (CSC) population (Mani et al., 2008). It plays a role in 
inducing epithelial–mesenchymal transition (EMT) and it allows the acquisition of a 
mesenchymal phenotype that permit the invasion and release of cells from the primary 
tumour (Ansieau et al., 2010). In addition, it regulates many proteins associated with EMT 
such as E-cadherin, which is essential for epithelial cell-cell adhesion (Ansieau et al., 2010). 
Therefore, TWIST1, can be considered as an important tumour biomarker. The expression 
of TWIST1 during embryonic development of mouse has been studied previously (Qin et 
al., 2012) However, information relating to the TWIST1 expression profile during human 
embryogenesis is lacking. A strong mRNA expression of TWIST1 was observed in placenta, 
especially in the foetal side of the placenta during a study conducted by Wang et al. (1997) 
using human tissues and cells originating from different human tissues to observe TWIST1 
expression. Furthermore, it is highly expressed in the mesoderm-derived embryonic 
mesenchyme and the adult stem cells of the mesenchyme (Qin et al., 2012).  
In the present study, a statistically significant increase was observed in both mRNA (p<0.01) 
and protein expression levels (p<0.05) of TWIST1 in PE. Interestingly, when these results 
were also validated with IHC, intense staining for TWIST1 was detected in the STB layer of 
PE placentae rather than NT placentae. A study by Sitras et al. (2009) also reported up-
regulation of the second member of the bHLH family (BHLHB2) in PE placentae. Therefore, 
it could be suggested that TWIST1 over-expression in placental tissues might play a role in 
placental abnormalities and the pathological characteristics of PE.  
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 JAG1 
JAG1 belongs to the group of NOTCH signalling proteins which are responsible for 
vasculogenesis and angiogenesis in embryonic development during gestation (Funahashi et 
al., 2011). Therefore, most researchers investigated previously the expression pattern of 
NOTCH receptors and their ligands during pregnancy in order to study the vasculogenesis   
and angiogenesis process in human placenta. NOTCH signalling might represent a key 
regulatory pathway that controls trophoblast proliferation, motility, and differentiation 
(Haider et al., 2014).  Furthermore, the published studies demonstrate that NOTCH 
signalling and their ligands pathway have a crucial role in the development of the placenta. 
The normal function of JAG1 is to stimulate vasculogenesis and angiogenesis, but its 
mechanism in metastasis remains to be elucidated (Purow et al., 2013: Sethi et al., 2011). 
 In this study, both mRNA and protein expression levels of JAG1 were decreased (p<0.01) 
in PE compared to NT placentae. The STB layer along with some mesenchymal stromal 
cells showed intense staining in NT when compared to PE. These results agreed with the 
investigations of Herr and colleagues (2011), Jarvenpaa et al. (2007) and De Falco et al.  
(2007), where down-regulation of JAG1 were also reported in PE placentae followed by up-
regulation in STB and placental stromal layer of NT placenta.  
The functional details of these factors will be discussed in chapter 7.  
 
3.4  Conclusions 
The collective data from mRNA, protein expression and IHC studies, suggest that the 
expression patterns of ALDH3A1, AURK-A, PDGFRα, and TWIST1 are increased in PE 
placentae. Since placental invasion resembles tumorigenesis, and the fact that expression of 
the presumed tumour markers is altered in PE (that has low invasiveness), they may be an 
interesting avenue to explore. In contrast, the data from this chapter suggest the expression 
patterns of AURK-C and JAG1 are down-regulated in PE samples. This could be associated 
with the signaling pathways in development of placenta and in various invasion mechanisms. 
The investigation of the protein expression of these factors (ALDH3A1, AURK-A and-C, 
PDGFRα, TWIST1 and JAG1) may provide valuable insights into placental function and 
help to identify molecular mechanism of both NT and PE. To further investigate the 
molecular mechanisms of these factors, in vitro study by using different placental origin cell 
lines to investigate the protein expression of these factors were conducted (See Chapter 6). 
Therefore, it is important to study and investigate the functions of these factors during 
placental development by using primary cultures (See Section 7.8: Future Studies).  
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4.1  Introduction 
As previously mentioned in Chapter 1, placenta is an extra-embryonic temporary organ and 
yet it encompasses innumerable functions for development and survival of the foetus (Sood 
et al., 2006).  Due to ethical constraints, it is impossible to carry out in vivo studies; equally 
development of ex vivo models remains to be challenging. The human placenta is made up 
of a heterogeneous groups of cells which include trophoblast, mesenchymal and stromal 
fibroblasts with neighbouring connective tissues (Novakovic et al., 2011). These cell types 
exhibit differences in morphology, function and gene expression. Therefore, in vitro research 
using cell lines remains the important model systems in which to study placental 
development. Previous in vitro studies have used all these different cell types to understand 
the physiological and pathological functions of placenta (Ji et al.,  2013).  
There are two ways for in vitro studies; (1) primary cells developed from term and /or first 
trimester aborted pregnancies, such as  CTBs, ST and EVTs and (2) placental derived cell 
lines from placental extravillous trophoblast and tumour cells (such as choriocarcinoma) 
(Novakovic et al., 2011). Bilban and colleagues (2009 and 2010) by using microarray and 
bioinformatics analysis compared the gene expression profile of  three choriocarcinoma cell 
lines (JEG-3, BeWo and ACH-3P), two EVT-derived cell lines (HTR8/SVneo and SGHPL-
5) and primary trophoblasts (EVTs and CTBs). They reported that the three types of cells 
were found to be significantly different with respect to their gene expression profiles. 
Although, primary trophoblast cultures are highly useful in studying the differentiation and 
functions of trophoblasts, these cells remain suitable only for short term studies, but not for 
longer culture to study early development phases (Ji et al.,  2013).  
On the other hand, a number of trophoblast cell lines are available for in vitro analysis of 
placental function (King et al., 2000). These cell lines are important research tools used as a 
replacement for primary trophoblast cells (Burleigh et al., 2007). Placental derived cell lines 
have similar characteristics and behave similarly to cells they were isolated from (Novakovic 
et al., 2011). An example of a placental derived cell line is BeWo, which was established in 
1968 by Patillo and Gey.  Following this, several other placenta derived cell lines were 
established (Fogh et al., 1977; Graham et al., 1993; Feng et al., 2005).  These cell lines are 
immortalised by several techniques and they are regarded as powerful tools for long term 
examination. However, during immortalization the physiological function of these cells may 
be altered. Therefore, it is strongly suggested to use more than one cell line during any in 
vitro investigation to determine the functional compatibility of these cell lines and to obtain 
meaningful data.  
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In this study, four different placental cell lines were used. Two of which were transformed 
(non-tumour) placental cell lines (HTR8/SVneo and TEV-1), produced by individual 
immortalisation of first trimester EVT using  SV-40 large T antigen (Novakovic et al.,  2011) 
and retroviral vector respectively (Feng et al., 2005).  The other two cell lines (JEG-3 and 
BeWo), were derived from gestational choriocarcinoma. Both the EVT and choriocarcinoma 
cells show capacity to invade, however, the EVT cells invade only after proliferation while 
choriocarcinoma cells can proliferate and invade at the same time (Farnk et al., 1999). 
Therefore, it was evident that there are differences in mechanisms, gene expressions and 
functions between the two groups. Thus, two different groups of cell lines were used in this 
study. MCF-7, breast adenocarcinoma cell line has unique biological properties (Osborne et 
al., 1987). In this study MCF-7 was used as a tumour cell line of non-placental origin. The 
information relating to all cell lines used are summarized in Table 4.1.  
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      Table 4.1: The origins and features of the different cell lines used in this study (Table adapted from Novakovic et al., 2011). 
92 
 
Chapter 4: Generation spheroidal from trophoblast cells   
 
4.1.1 Establishing stem like cells from human trophoblast and tumour cell lines 
Stem cell research has offered solutions for several clinical problems and opened new 
windows in drug testing, placental development studies, cancer and gene therapy  (Mousa et 
al., 2006).  They are the undifferentiated primary cells of all multicellular organisms, that 
have the capacity for self-renewal, proliferation and differentiation into specialized cell types  
(Mousa et al.,  2006). Stem cells can be isolated from various types of tissues and/or organs. 
For example, adult stem cells can be obtained from bone marrow, skeletal muscle and skin; 
while embryonic stem cells are derived from embryos (www20). The placenta can be used as 
a main source to isolate different types of stem cells such as hematopoietic stem cells 
(HSCs), human amniotic epithelial cells (hAEC), embryonic stem cells (ES), mesenchymal 
stem cells (MSCs), trophoblast stem cells (also known as trophoendodermal stem cells), 
umbilical cord blood stem cells (UCB) and foetal stem cells (FSCs) (Mousa et al., 2006 ; 
Avasthi et al.,  2008).  These stem cells can form aggregated clusters called spheroids with 
stem cell features able to grow in suspension culture (Manuel Iglesias et al., 2013). There 
are many molecular markers have been used to characterize various stem cell populations 
such as surface marker (CD133, CD90, CD29 and CD44) and transcription factors (OCT4, 
SOX2, and NANOG) (Zhao et al., 2012). These spheroids were selected from 3-D culture. 
In cancer research, 3-D cell culture is used as a tool to produce spheroids to investigate the 
growth formation and behaviour of tumours as they behave like solid tumour (Mehta et al., 
2013).  Besides spheroids culture is a useful method in vitro to understand the physiological 
and biological processes involved in organogenesis in the embryo (Oudar 2000). This study 
focused on embryonic stem cell markers such as transcription factors (OCT4, SOX2, and 
NANOG), trophoblast transcription factor (CDX2) and a receptor involved in cell fate 
determination (NOTCH1). Most of these factors are expressed not only in embryonic stem 
cells but also in a number of tumour cells (James et al., 2012). The transcription factors 
(OCT4, SOX2, and NANOG) play crucial roles in embryonic development, acting as a 
regulator of self-renewal/differentiation, maintaining and re-establishing pluripotency of 
embryonic stem cells (ESCs) (Miyazawa et al., 2014). CDX2 has an essential role in the 
differentiation process of the trophectoderm (the outer epithelial layer of the blastocysts) 
(James et al., 2012). Likewise, the over-expression of NOTCH1 protein was associated with 
several aggressive tumours (Hendrix et al., 2003). Moreover, this chapter deals with the 
generation of spheroids from four trophoblast cell lines (HTR8/SVneo, TEV-1, JEG-3 and 
BeWo) and MCF-7 cell line.  
As explained in chapter 1, human trophoblast cells exhibits some similarities with malignant 
cells, including rapid proliferation and the ability to invade the surrounding tissue; whereas 
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they do not have the ability to metastasise or exhibit unlimited growth (Fennema et al., 
2013). Hence, the aim of this chapter was to generate and select non-resistant (normal) and 
drug resistant spheroids from transformed trophoblast (HTR8/SVneo, TEV-1) and 
choriocarcinoma (JEG-3, BeWo) cell lines and to check for “stemness” feature by studying 
the expressions of stem cell markers such as OCT4, SOX2, NANOG, CDX2 and NOTCH1. 
 
4.1.2  Using DOX to select drug resistant spheroids 
Doxorubicin (DOX)/Adriamycin, is an anthracycline antibiotic isolated from Streptomyces 
peucetius var. caesius and has been widely used as a chemotherapeutic agent for the 
treatment cancers (Suzuki et al., 2005). The chemical name of DOX is (8S-cis)-10-[(3-
amino-2,3,6-trideoxy-α-L-lyxohexopyranosyl)-oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-
8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione) (Suzuki et al., 2005). Its structure is 
given in (Figure 4.1)  
 There are two mechanisms by which DOX acts on the cancer cells: (1) it has an ability to 
interact with plasma membranes, intercalate with DNA, and disrupt topoisomerase-II, (2) 
generation of the free radicals and their damage to cellular membranes, DNA and proteins 
(Gewirtz, 1999). DOX is oxidized to semi-quinone, an unstable metabolite, which is 
converted back to doxorubicin .This process releases reactive oxygen species (ROS) that can 
lead to lipid peroxidation and membrane/DNA damage, oxidative stress, and activates 
apoptotic pathways (Doroshow, 1986). 
 
 
Figure 4.1: Chemical structure of Doxorubicin. (Adopted from Suzuki et al., 2005) 
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4.2  Results 
4.2.1  Determination of cell seeding density for different cell lines 
It was essential to determine the appropriate cell seeding densities for each cell line before 
performing any of the assays. A previous study within this laboratory (by Dr Anushuya 
Tamang) has determined the accurate cell density by using an MTT assay. Based on these 
findings, (5x 10P4 P/ml) cells were selected as optimal seeding density for all placental cell 
lines.   
4.2.2  Use of Doxorubicin to select resistant spheroids 
To determine the optimal concentration of DOX to select resistant spheroids, the cells were 
treated with different concentration of Doxorubicin (250, 500, 1000, 2000 and 4000 ng/ml) 
coupled with MTT and LDH assays. 
4.2.2.1  Effect of Doxorubicin on cell viability and toxicity  
In HTR8/SVneo, there were no significant changes in the mitochondrial activity (cell 
viability) when they were treated with 250 ng/ml of DOX compared to control (no 
treatment). There was a slight reduction in the mitochondrial activity (cell viability) when 
cells were treated with 500 ng/ml treatment but was not significant when compared with the 
untreated control. With the concentrations of 1000 ng/ml and above, a significant reductions 
in the mitochondrial activity (cell viability) were observed (See Figure 4.2, Panel A). Figure 
4.2 Panel B shows the status of LDH released into the media by HTR8/SVneo cell line. A 
significant reduction in the level of LDH release was observed with the cells treated with 
both 250 ng/ml and 500ng/ml of DOX at 24 and 48 hours compared to control (100% lysis 
buffer). The reduction was significant only at 48 hours for 1000ng/ml treatment but not at 
24 hours for the same treatment. Interestingly, a significant increase in the level of LDH 
release was observed with 4000ng/ml of DOX only at 48 hours of treatment (p<0.01) when 
compared to control (100% lysis buffer). 
In the MTT assay, the TEV-1 cell line showed no significant change of viability when they 
were treated with 250 ng/ml of DOX at 24 hours; but a significant increase in the 
mitochondrial activity (cell viability) was observed for the same treatment at 48 hours. There 
was a significant reduction of mitochondrial activity (cell viability) with 500 ng/ml treatment 
(p < 0.001). Concentrations of 1000 ng/ml and above, showed a significant reduction in the 
mitochondrial activity (cell viability) (p< 0.0001) (See Figure 4.2, Panel C). In the case of 
LDH assay, the status of LDH released into the media by TEV-1 cell line is shown in Figure. 
4.2, Panel D. A significant reduction in the level of LDH release was observed with cells 
treated with 250 ng/ml, 500 ng/ml and 1000 ng/ml of DOX at both 24 and 48 hours, 
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compared to control (100% lysis buffer).  No significant change in the level of LDH release 
was observed with 2000 ng/ml and 4000 ng/ml treatment. 
 
Figure 4.2: The effect of doxorubicin on mitochondrial activity (MTT) and toxicity 
(LDH) of transformed trophoblast cell lines. 
 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The data are a representation as the percentage of control cells (= 100%) 
and represent the mean ± SEM of three independent experiments each performed in 
triplicate. (**p < 0.01, ***p < 0.001, and ****p < 0.0001); MTT assay was carried out in 
comparison with no treatment as control (depicted as “a” in the figures), while LDH assay 
was in comparison with 100% lysis control (depicted as “b” in the figures). 
 
The effect of DOX on placental choriocarcinoma cell lines showed slightly different results 
when compared with the transformed cell lines. In the MTT assay, there was a significant 
increase in the mitochondrial activity (cell viability) in both the JEG-3 (p<0.001) and the 
BeWo (p<0.01) cell lines with 48 hours of 250 ng/ml DOX treatment when compared to 
control.  In addition, a significant reduction in mitochondrial activity was noted at 24 hours 
of treatment for the BeWo cell line alone (p<0.01). However, when cells were treated with 
concentration at 500 ng/ml and above, there was a significant reduction in mitochondrial 
activity (p<0.0001) (See Figure 4.3, Panel A and C). There was a significant reduction 
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(p<0.0001) in levels of LDH release from these cells lines treated with 250 mg/ml and 500 
ng/ml DOX when compared to control (100% lysis buffer) (See Figure 4.3, Panel B and D). 
Significant reduction of LDH levels were also noted at 1000 ng/ml in JEG-3 (p<0.0001) and 
BeWo (p<0.01) cell lines.  There was no significant change in the levels of LDH at 2000 
ng/ml and 4000 ng/ml DOX treatment in both the cell lines.  
 
 
Figure 4.3: The effect of doxorubicin on mitochondrial activity (MTT) and toxicity 
(LDH) of placental choriocarcinoma cells. 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The data are a representation as the percentage of control cells (= 100%) 
and represent the mean ± SEM of three independent experiments each performed in 
triplicate. (**p < 0.01, ***p < 0.001, and ****p < 0.0001); MTT assay was carried out in 
comparison with no treatment as control (depicted as “a” in the figures), while LDH assay 
was in comparison with 100% lysis control (depicted as “b” in the figures). 
 
In the  case of MCF-7, as seen in Figure 4.4, Panel A, treatment with 250ng/ml of DOX 
resulted in increase in mitochondrial activity (p<0.01) at 48 hours, whereas no significant 
change was observed at 24 hours of treatment. There was a significant reduction in the 
mitochondrial activity at the concentration of 500 ng/ml (p<0.001) and above (p<0.0001) 
compared to the control. Panel B in Figure 4.4 shows the levels of LDH release with a 
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significant reduction in the LDH release at 250 ng/ml, 500 ng/ml and 1000 ng/ml DOX 
treatment; while no significant change was observed at 2000 ng/ml and 4000 ng/ml treatment 
compared to control (100% lysis buffer). 
Overall, all concentrations of DOX above 1000 ng/ml were found to be toxic to placental as 
well as tumour cells. In summary, the 250 ng/ml and 500 ng/ml treatments were optimal 
concentrations of DOX for further investigations. 
 
Figure 4.4: The effect of doxorubicin on mitochondrial activity (MTT) and toxicity 
(LDH) of MCF-7 cells. 
Statistical analysis was carried out using two-way ANOVA (Dunnett’s multiple comparison 
test against control). The data are a representation as the percentage of control cells (= 100%) 
and represent the mean ± SEM of three independent experiments each performed in 
triplicate. (**p < 0.01, ***p < 0.001, and ****p < 0.0001); MTT assay was carried out in 
comparison with no treatment as control (depicted as “a” in the figures), while LDH assay 
was in comparison with 100% lysis control (depicted as “b” in the figures). 
 
4.2.3  Generation of spheroids from trophoblast and tumour cells 
As mentioned in Section (2.9), two methods were carried out to generate spheroids, namely: 
(a) non-resistant (normal) spheroid generation and (b) drug resistant spheroid generation. 
4.2.3.1  Generation of non-resistant (normal) spheroids  
The placental derived cell lines were checked for ability to form 3-D spheroids on non-
adherent flask without treating them with DOX. All the cell lines showed the ability to 
produce spheroids. As seen in Figure 4.5, Panel A and B (row 2), both the transformed 
trophoblast cell lines (HTR8/SVneo and TEV-1) were capable of producing spheroid bodies 
in non-adherent flasks. Also, they were able to revert back to normal grow (after detachment 
and in growth media) in the adherent flask [See Figure 4.5, Panel A and Panel B (row 3)]. 
98 
 
Chapter 4: Generation spheroidal from trophoblast cells   
 
The two choriocarcinoma cells (JEG-3 and BeWo) also showed a similar trend in forming 
spheroid bodies [See Figure 4.5, Panel C and Panel D (row 2 and 3)]. A larger sized spheroid 
was observed for MCF-7 cells when compared to the spheroids produced from other 
trophoblast cell lines. MCF-7 spheroids also had the ability to grow under normal adherent 
conditions [See Figure 4.5, Panel E (row 2 and 3)]. 
 
 
Figure 4.5: Generation of normal spheroids. 
The ability of transformed trophoblast (HTR8/SVneo and TEV-1) and choriocarcinoma 
(BeWo and JEG-3) cell lines to generate non-resistant spheroids are shown in Panels A to 
D. Likewise, the MCF-7 is shown in Panel E. Row 1 = Parental cells without treatment; Row 
2 = Spheroidal cells produced from non-adherent 3-D culture; Row 3 = the ability of 
spheroidal cells to re-grow onto normal adherent 2-D culture. Scale bar= 100μm.  
 
4.2.3.2  Generation of drug resistant spheroids  
DOX was used to produce an environment for physiological stress, which can develop drug-
resistant spheroids. This was achieved by treating cells with chemotherapeutic drugs such as 
DOX.    HTR8/SVneo and TEV-1 cell lines, which were exposed to  all concentrations above 
1000 ng/ml of DOX in normal condition for 48 hours, were found to be dead and appeared 
floating rather than clustering together to form spheroids in the non-adherent flask [See 
Figure 4.6 and 4.7, Panels A and B].  However, cells with both 250 ng/ml and 500 ng/ml 
DOX treatments, cultured in non-adherent flasks with serum free media, supplemented with 
growth factors produced viable spheroids. The cells which were treated with 500ng/ml, 
found to form spheroids of smaller sizes when compared to spheroids produced from cells 
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treated with 250 ng/ml. Interestingly, for most of the spheroids produced by treating with 
250 ng/ml, the cells retained the ability to attach and re-grow in the adherent flask under 
normal conditions after they were manually disseminated. Also, some of these cells had 
similar morphology to the parental cells, which indicates these cells have the ability to self-
renew and differentiate to form cells that are similar to that of the parental cells [See Figure 
4.6 and 4.7, Panel D]. Therefore, 250 ng/ml was used as the optimal concentration of DOX 
for selecting spheroids from both transformed trophoblast cell lines. Similar results were 
obtained from both choriocarcinoma cell lines (JEG-3 and BeWo) treated with 250 ng/ml of 
DOX [See Figure 4.8 and 4.9, Panels B, C and D]. MCF-7 showed similar results to the 
placental derived cell lines with both DOX concentrations (250 and 500 ng/ml); however, 
the spheroids formed by MCF-7 were bigger in size compared to placental cell lines [See 
Figure 4.10, Panels B, C and D]. In addition, MCF-7 cells treated with 1000 ng/ml of DOX 
were able to produce small spheroids compared to trophoblast cells lines (which did not form 
any spheroids at 1000 ng/ml). 
 
Figure 4.6: Generation of resistant spheroids from transformed trophoblast cell line 
(HTR8/SVneo). 
Panel A shows HTR8/SVneo normal parental cells; Panel B shows parental cells after 
treatment with different concentrations of DOX. Panel C shows the ability of the cells to 
produce spheroid bodies from each concentration of DOX; Panel D shows the re-growth of 
the cells dispersed from spheroids onto adherent flasks under normal conditions. This was 
only observed in 250 ng/ml concentration of DOX. Scale bar= 100μm.  
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Figure 4. 2: Generation of resistant spheroids from transformed trophoblast cell line 
(TEV-1). 
Panel A shows TEV-1 normal (parental cells); Panel B shows parental cells after treatment 
with different concentration of DOX. Panel C shows the ability of the cells to produce 
spheroid bodies from each concentration of DOX; Panel D shows the re-growth of the cells 
dispersed from spheroids onto adherent flasks under normal conditions. This was only 
observed in 250 ng/ml concentration of DOX. Scale bar= 100μm.  
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Figure 4. 3: Generation of resistant spheroids from choriocarcinoma cell line (JEG-
3). 
Panel A shows JEG-3 normal (parental cells); Panel B shows parental cells after treatment 
with different concentration of DOX. Panel C shows the ability of the cells to produce 
spheroid bodies from each concentration of DOX; Panel D shows the re-growth of the cells 
dispersed from spheroids onto adherent flasks under normal conditions. This was only 
observed in 250 ng/ml concentration of DOX. Scale bar= 100μm.  
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Figure 4. 4: Generation of resistant spheroids from choriocarcinoma cell line (BeWo). 
Panel A shows BeWo normal (parental cells); Panel B shows parental cells after treatment 
with different concentration of DOX. Panel C shows the ability of the cells to produce 
spheroid bodies from each concentration of DOX; Panel D shows the re-growth of the cells 
dispersed from spheroids onto adherent flasks under normal conditions. This was only 
observed in 250 ng/ml concentration of DOX. Scale bar= 100μm.  
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Figure 4.10: Generation of resistant spheroids from human breast adenocarcinoma 
cell line (MCF-7). 
Panel A shows MCF-7 normal (parental cells); Panel B shows parental cells after treatment 
with different concentration of DOX. Panel C shows the ability of the cells to produce 
spheroid bodies from each concentration of DOX; Panel D shows spheroid bodies produced 
by treating with 250, 500 and 1000 ng/ml of DOX re-growing in an adherent flask under 
normal conditions while others cannot. Scale bar= 100μm. 
 
4.2.4  Immunofluorescence staining of stem cell markers  
As mentioned in Section 2.11.2, co-immunofluorescence staining was carried out in parental 
cells (with and without DOX treatment) and spheroids (non-resistant and DOX-resistant).  
The stem cell markers which were studied include: transcription factors (OCT4, SOX2 and 
NANOG), trophoblast transcription factor (CDX2), and NOTCH1 which is a receptor 
involved in regulating cell fate determination associated with both cancer stem cells and 
human embryonic stem cells. 
4.2.4.1  Expression of OCT4 and SOX2 markers  
As shown in Figure 4.11, Panel I (row A), HTR8/SVneo parental cells (both untreated and 
DOX-treated) showed positive green staining of OCT4. The perinuclear and cytoplasmic 
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localization was clear on closer observation. Since spheroidal cells (untreated and DOX-
treated) appear as aggregated cells, intracellular localisation was not distinctly visible. Figure 
4.11, Panel II (row A), there was no staining of OCT4 in TEV-1 parental cells compared to 
spheroid (untreated and DOX-treated). However, TEV-1 parental and spheroidal cells 
showed positive red staining of SOX2 (Panel II; row B).  
As for choriocarcinoma cells, there was no staining of OCT4 observed in parental cells in 
JEG-3 cell line [See Figure 4.12, Panel I (row A)], while BeWo parental cells showed a 
positive staining [See Figure 4.12, Panel II (row A)]. On the other hand, the staining for 
SOX2 was consistent in parental cells (both DOX-treated and un-treated) of JEG-3 and 
BeWo. The spheroids of both cell lines were positive to OCT4 and SOX2. However, the 
intracellular localization of these factors in spheroidal cells is not clear.  
MCF-7 cells showed a similar results to the TEV-1 cell, there was no staining of OCT4 
observed in the parental cells (untreated and DOX-treated).  However, spheroidal (untreated 
and DOX-treated) cells of the same cell line showed clear staining of OCT4 [See Figure 
4.13, Panel I (row A)]. Panel II (row B) from the same figure showed positive red staining 
for SOX2 of perinuclear and cytoplasm regions, which was clearly visible in parental cells 
compared to spheroidal cells. 
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Figure 4.11: Immunofluorescence staining of OCT4 and SOX2 in transformed 
trophoblast cells. 
Panel I and II shows immunofluorescence staining images for HTR8/SVneo and TEV-1 
cells. Rows A, B and C show staining for OCT4, SOX2 and nuclear staining with DAPI 
respectively, in parental and spheroidal cells.  Rows D show the three combined staining 
(OCT4+SOX2+DAPI) in parental cells and spheroidal cells. [Objective magnification=40X; 
Scale bar =50 µm]. 
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Figure 4.12: Immunofluorescence staining of OCT4 and SOX2 in choriocarcinoma 
cells. 
Panel I and II shows immunofluorescence staining images for JEG-3 and BeWo cells. Rows 
A, B and C show staining for OCT4, SOX2 and nuclear staining with DAPI respectively, in 
parental and spheroidal cells. Rows D show the three combined staining 
(OCT4+SOX2+DAPI) in parental cells and spheroidal cells. [Objective magnification=40X; 
Scale bar =50 µm]. 
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Figure 4.13: Immunofluorescence staining of OCT4 and SOX2 in MCF-7 cells. 
Row A shows immunofluorescence staining images of OCT4 in MCF-7 cell. Row B shows 
immunofluorescence staining images of SOX2. Row C shows nuclear staining with DAPI 
and Row D shows two combined staining (SOX2+DAPI) in parental cells and three 
combined staining (OCT4+SOX2+DAPI) in spheroidal cells. [Objective 
magnification=40X; Scale bar =50 µm]. 
 
 
4.2.4.2  Expression of OCT4 and NANOG1 markers  
The HTR8/SVneo parental cells (both untreated and DOX-treated) showed positive green 
staining of OCT4 in the perinuclear and cytoplasmic region. This intracellular localization 
was more distinct in parental cells when compared to spheroid cells due to cell aggregates 
[See Figure 4.14, Panel I (row A)]. On the other hand, Figure 4.14, Panel II (row A), showed 
that there was no staining of OCT4 observed in TEV-1 parental cells (untreated and DOX-
treated), while clear staining of OCT4 was observed in the spheroid cells (untreated and 
DOX-treated). Moreover, Figure 4.14, Rows B in Panels I and II, showed positive red 
staining of NANOG in the perinuclear and cytoplasmic regions. This localization was clear 
in parental cells compared to spheroid cells from both HTR8/SVneo and TEV-1 cell lines.  
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There was no staining of OCT4 observed in JEG-3 parental cells (untreated and DOX-
treated). However, spheroid cells (untreated and DOX-treated) of the same cell line showed 
clear staining of OCT4 [See Figure 4.15, Panel I (row A)]. In the case of BeWo cells, 
parental (both untreated and DOX-treated) cells showed positive green staining of OCT4 in 
the perinuclear and cytoplasmic regions. This intracellular localization was distinct in 
parental cells than in spheroidal cells. Figure 4.15, Panels I and II (row B) showed positive 
red staining of NANOG in the perinuclear and cytoplasmic regions which was clearly 
apparent in parental cells compared to spheroid cells from both JEG-3 and BeWo cell lines.  
From Figure 4.16, Panel I (row A), there was no staining of OCT4 observed in MCF-7 
parental cells (untreated and DOX-treated). However, spheroid (untreated and DOX-treated) 
of the same cell line showed clear staining of OCT4.  Row B from the same figure showed 
positive red staining of NANOG in  perinuclear and cytoplasmic regions which was clearly 
apparent in parental cells compared to spheroid (untreated and DOX-treated) cells.  
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Figure 4.14: Immunofluorescence staining of OCT4 and NANOG in transformed 
trophoblast cells. 
Panel I and II shows immunofluorescence staining images for HTR8/SVneo and TEV-1 
cells. Rows A, B and C show staining for OCT4, NANOG and nuclear staining with DAPI 
respectively, in parental and spheroidal cells.  Rows D show the three combined staining 
(OCT4+NANOG+DAPI) in parental cells and spheroidal cells. [Objective 
magnification=40X; Scale bar =50 µm]. 
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Figure 4.15: Immunofluorescence staining of OCT4 and NANOG in choriocarcinoma 
cell lines. 
Panel I and II shows immunofluorescence staining images for JEG-3 and BeWo cells. Rows 
A, B and C show staining for OCT4, NANOG and nuclear staining with DAPI respectively, 
in parental and spheroidal cells. Rows D show the three combined staining 
(OCT4+NANOG+DAPI) in parental cells and spheroidal cells. [Objective 
magnification=40X; Scale bar =50 µm]. 
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Figure 4.16: Immunofluorescence staining of OCT4 and NANOG in MCF-7 cells. 
Row A shows immunofluorescence staining images of OCT4 in MCF-7 cell. Row B shows 
immunofluorescence staining images of NANOG. Row C shows nuclear staining with DAPI 
and Row D shows two combined staining (NANOG+DAPI) in parental cells and three 
combined staining (OCT4+NANOG+DAPI) in spheroidal cells. [Objective magnification= 
40X; Scale bar =50 µm]. 
 
4.2.4.3  Expression of CDX2 and NOTCH1 markers  
The transformed trophoblast parental cells, HTR8/SVneo and TEV-1, untreated and DOX-
treated showed positive green staining of CDX2 within perinuclear and cytoplasmic regions. 
This intracellular localisation was distinct only in parental cells. On the other hand, there 
was no staining of CDX2 observed in spheroid untreated and DOX-treated from both 
HTR8/SVneo and TEV-1 cell lines [See Figure 4.17, Panels I and II (row A)].  From Panels 
I and II (row B) of Figure 4.17, clear red staining of NOTCH1 in perinuclear and 
cytoplasmic regions in parental cells than in spheroidal cells. 
Both parental cells (untreated and DOX-treated) and spheroid (untreated and DOX-treated), 
from both placental choriocarcinoma cell lines (JEG-3 and BeWo) showed negative staining 
for CDX2 [See Figure 4.18, Panels I and II (row A)]. In contrast, Panels I and II (row B) in 
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Figure 4.18, showed there was a clear red staining of NOTCH1 in perinuclear and 
cytoplasmic regions. This was more apparent in parental cells than in spheroidal cells. 
Both parental cells (untreated and DOX-treated) and spheroid (untreated and DOX-treated) 
derived from MCF-7, showed similar results as both trophoblast choriocarcinoma cells 
(JEG-3 and BeWo). There was no significant staining of CDX2 in all cell conditions [See 
Figure 4.19, Panel I (row A)]. On the other hand, (row B) from the same figure showed a 
clear red staining of NOTCH1 in perinuclear and cytoplasmic regions in parental cells. 
However, the localisation of NOTCH1 in spheroidal cells was not distinguishable.  
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Figure 4.17: Immunofluorescence staining of CDX2 and NOTCH1 in transformed 
trophoblast cells. 
Panel I and II shows immunofluorescence staining images for HTR8/SVneo and TEV-1 
cells. Rows A, B and C show staining for CDX2, NOTCH1 and nuclear staining with DAPI 
respectively, in parental and spheroidal cells.  Rows D show the three combined staining 
(CDX2+NOTCH1+DAPI) in parental cells and spheroidal cells. [Objective 
magnification=40X; Scale bar =50 µm]. 
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Figure 4.18: Immunofluorescence staining of CDX2 and NOTCH1 in 
choriocarcinoma cell lines. 
Panel I and II shows immunofluorescence staining images for JEG-3 and BeWo cells. Rows 
A, B and C show staining for CDX2, NOTCH1 and nuclear staining with DAPI respectively, 
in parental and spheroidal cells.  Rows D show the three combined staining 
(CDX2+NOTCH1+DAPI) in parental cells and spheroidal cells. [Objective 
magnification=40X; Scale bar =50 µm]. 
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Figure 4.19: Immunofluorescence staining of CDX2 and NOTCH1 in MCF-7 cells. 
Row A shows immunofluorescence staining images of CDX2 in MCF-7 cell. Row B shows 
immunofluorescence staining images of NOTCH1. Row C shows nuclear staining with 
DAPI and Row D shows two combined staining (NOTCH1+DAPI) in parental cells and 
spheroidal cells. [Objective magnification: 40X (scale bar =50 µm)]. 
 
4.2.5  Gene expression studies of stem cell markers 
As explained in Section 2.9.3, the total RNA was extracted from HTR8/SVneo, TEV-1, JEG-
3, BeWo and MCF-7 cell lines, and reverse transcribed to produce cDNA templates. The 
purity and integrity of RNA samples was high without any genomic DNA contamination, as 
indicated by the ratio of 260/280 nm which ranged in between 1.9-2.3. When the total RNA 
samples were subjected to electrophoresis in a 1% agarose gel two bright and clear bands 
were observed corresponding to 28S and 18S as shown in Appendix A.7. 
Primers for all markers of interest were designed as mentioned in Section 2.6.1. The 
sequence details of each primer and the optimised annealing temperatures (Ta) are 
summarised in Table 4.2. The purity and the final product sizes of all PCR products were 
checked by agarose gel electrophoresis Appendix A.8. The accession numbers of stem cell 
markers used to design the primers are listed in Appendix A.9. 
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Table 4.1: The primers for specific markers and their annealing temperature (Ta). 
 
 
4.2.5.1  Relative mRNA expression of stem cells markers in trophoblast and tumour 
cell lines 
Following the qualitative immunofluorescence study, the relative expressions of stemness 
and trophoblast markers were checked by comparing the mRNA (qRT-PCR) and protein 
(western blotting) expression in different conditions. The mRNA expression was compared 
between: (a) untreated parental versus DOX-treated parental, (b) untreated parental versus 
untreated spheroid, (c) untreated spheroids versus DOX-treated spheroids and (d) DOX-
treated parental versus DOX-treated spheroids. Statistical significant was determined by a 
one-way ANOVA followed by Tukey's test for multiple comparisons between these different 
conditions.  
 
 
Markers of Interest  Primers  sequence  (5' to 3') 
Primer 
Length 
(nucleotides) 
Annealing  
Temperature 
Ta (°C) 
OCT4 
Forward AATTTGTTCCTGCAGTGCCC 20  
       55 Reverse CTCTCGTTGTGCATAGTCGC 20 
 
SOX2 
Forward CGGAAAACCAAGACGCTCAT 20  
55 Reverse TTCATGTGCGCGTAACTGTC 20 
 
NANOG 
Forward CCATCCTGCAAATGTCTTCTG 21 
     60.9 
Reverse CTTTGGGACTGGTGGAAGAAT 21 
 
CDX2 
Forward GGGAGGACTGGAATGGCTAC 20  
59.9 Reverse CCCAGAAGCGCAGGAAGG 18 
 
NOTCH1 
Forward GGCGGTGCACACCTATTCTG 19 
     58.2 
Reverse CAGGCGAGGAGTAGCTGTG 19 
Housekeeping genes  
 
GAPDH 
Forward ACCACCAACTGCTTAGCACC 20  
      58 Reverse CCATCCACAGTCTTCTGGGT 20 
 
HPRT1 
Forward TGACACTGGCAAAACAATGCA 21 
55 
Reverse GGTCCTTTTCACCAGCAAGCT 21 
 
 TBP1 
 
Forward TGCACAGGAGCCAAGAGTGAA 21 
56 
Reverse CACATCACAGCTCCCCACCA 20 
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 OCT4 
HTR8/SVneo showed a significant up-regulation of OCT4 mRNA expression level in both 
sets of comparison (a) untreated parental versus DOX-treated parental, and (b) untreated 
parental versus untreated spheroids. TEV-1 cells lines showed similar results to 
HTR8/SVneo (See Figure 4.20, Panels A and B).  On the other hand, the mRNA expression 
of OCT4 in the first choriocarcinoma cells (JEG-3) was significantly down-regulated in 
untreated  parental cells in comparison with spheroidal cell (p<0.001). Likewise, DOX-
treated parental showed down-regulation in OCT4 expression in comparison with respective 
spheroidal cells (p<0.01) (See Figure 4.20, Panel C). In the second choriocarcinoma cell line 
(BeWo), the mRNA expression of OCT4 was significantly up-regulated in DOX-treated 
spheroidal cells compared to both untreated spheroids (p<0.05) and DOX- treated parental 
cells (p<0.01) (See Figure 4.20, Panel D). The untreated spheroids of MCF-7 have shown a 
significant up-regulation relative to all other cell populations (p<0.0001) (See Figure 4.20, 
Panels E).  
  
118 
 
Chapter 4: Generation spheroidal from trophoblast cells   
 
 
Figure 4.20: Relative mRNA expression of OCT4 in trophoblast and tumour cells. 
The relative mRNA expression of OCT4 was compared between different conditions. The 
data from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
data for JEG-3 and BeWo cells are presented in panels C and D respectively. Panel E shows 
the data from MCF-7 cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01; *p<0.05). 
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 SOX2  
As can be observed from Figure 4.21, Panel A, there was no statistically significant 
difference in the relative expressions of SOX2 between all comparisons in HTR8/SVneo 
cells.  However, a significant up-regulation of SOX2 mRNA expression was seen in TEV-1 
between untreated spheroids and DOX-treated spheroids (p<0.01) (See Figure 4.21, Panel 
B).  From Figure 4.21, panel C, JEG-3 cells showed significant up-regulation of SOX2 
mRNA expression level of DOX-treated spheroids, in comparison with DOX-treated 
parental cells and untreated spheroids (p<0.0001).  It was also observed that SOX2 mRNA 
expression in BeWo cells was significantly higher in untreated spheroidal cells, in 
comparison to  both untreated parental cells and DOX-treated spheroids (p<0.0001) (See 
Figure 4.21, Panel E).  As for MCF-7 cells, the mRNA expression level of SOX2 in untreated 
spheroidal cells was significantly higher than the untreated parental cells (p<0.001) (See 
Figure 4.21, Panel F).  
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Figure 4.21: Relative mRNA expression of SOX2 in trophoblast and tumour cells. 
The relative mRNA expression of SOX2 was compared between different conditions. The 
data from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
the data for JEG-3 and BeWo cells are presented in panels C and D respectively. Panel E 
shows the data from MCF-7 cells. Statistical significance was determined using a one-way 
ANOVA followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM 
of three individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01). 
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 NANOG 
As seen in Figure 4.22, Panel A, DOX-treated parental HTR8/SVneo cells showed a 
significantly lower level of NANOG compared to untreated parental cells (p<0.001) and 
DOX-treated spheroidal cells (p<0.0001). Interestingly, in TEV-1 cells both DOX-treated 
parental and spheroids cells have shown a significant down-regulation in the NANOG 
mRNA expressions compared to their respective untreated cells (See Figure 4.22, Panel B). 
In contrast, JEG-3 showed a significant up-regulation of NANOG mRNA in untreated 
parental cells compared to DOX-treated parental cells (p<0.001) and spheroids (p<0.05).  In 
the case of BeWo cells, the untreated parental cells showed a significant down-regulation of 
NANOG mRNA expression compared to (a) DOX-treated parental cells (p<0.01) and (b) 
spheroidal cells (p<0.01) (See Figure 4.22, Panels C and D). 
 In the MCF-7 cells, the overall mRNA expression levels of NANOG in untreated spheroids 
cells was found to be up-regulated in comparison with all other  conditions types of this cells 
(p<0.0001) (See Figure 4.22, Panels E). 
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Figure 4.22: Relative mRNA expression of NANOG in trophoblast and tumour cells. 
The relative in mRNA expression of NANOG was compared between different conditions. 
The data from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. 
Likewise, the data for JEG-3 and BeWo cells are presented in panels C and D respectively. 
Panel E shows the data from MCF-7 cells. Statistical significance was determined using a 
one-way ANOVA followed by Tukey's test for multiple comparisons. Data represent the 
mean ±SEM of three individual experiments, each performed in triplicate (****p<0.0001; 
***p<0.001; **p<0.01; *p<0.05). 
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 CDX2 
The first transformed trophoblast cell line, HTR8/SVneo, showed a significantly higher level 
of CDX2 mRNA expression in untreated parental compared to (a) DOX-treated parental 
(p<0.01); and (b) spheroidal cells (p<0.001). There was also a significant difference in DOX-
treated spheroids compared to untreated spheroids (p<0.001) (See Figure 4.23, Panel A). 
The second transformed trophoblast cell line, TEV-1, showed a significantly higher level of 
CDX2 mRNA expressions in untreated parental compared to (a) DOX- treated parental 
(p<0.001); and (b) spheroidal cells (p<0.01). There was also a significant difference in 
untreated spheroids compared to DOX-treated spheroids (*p<0.05) (See Figure 4.23, Panel 
B).  
Interestingly, both choriocarcinoma cell lines showed similar results to transformed 
trophoblast cell lines in untreated parental compared to (a) DOX-treated parental; and (b) 
spheroidal cells (p<0.001) (See Figure 4.23, Panel C and D). 
Likewise, in MCF-7 cells there was a significant up-regulation of CDX2 mRNA expressions 
in untreated parental cells compared to untreated spheroids (p<0.001); and in DOX-treated 
parental cells in comparison to DOX-treated spheroids (p<0.01) (See Figure 4.23, Panel E). 
Overall, there is a significant down-regulation of the mRNA expression of CDX2 in spheroid 
cells condition when compared with the parental cells conditions in four trophoblast and 
tumour cell lines. 
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Figure 4.23: Relative mRNA expression of CDX2 in trophoblast and tumour cells. 
The relative mRNA expression of CDX2 was compared between different conditions. The 
data from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
the data for JEG-3 and BeWo cells are presented in panels C and D respectively. Panel E 
shows the data from MCF-7 cell. Statistical significance was determined using a one-way 
ANOVA followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM 
of three individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01; *p<0.05). 
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 NOTCH1 
HTR8/SVneo showed the mRNA expression of NOTCH1 was statistically increased in 
untreated parental cells compared to (a) DOX-treated parental (p<0.001) and (b) spheroidal 
cells (p<0.0001) (See Figure 4.24, Panel A). TEV-1 cells showed a significantly higher level 
of NOTCH1 mRNA expression in DOX-treated parental cells compared to (a) untreated 
parental cells (p<0.05) and (b) DOX-treated spheroids cells (p<0.0001).  A significant 
difference in NOTCH1 expression was also observed between untreated parental cells when 
compared to untreated spheroids (p<0.05) (See Figure 4.24, Panel B). 
In JEG-3 cells, no statistically significant difference in the relative expression of NOTCH1 
was observed in any comparisons (See Figure 4.24, Panel C). However, the mRNA 
expression of NOTCH1 level in BeWo cells was significantly higher in (a) untreated parental 
cells when compared to spheroidal cells, and (b) DOX-treated parental cells compared to 
DOX-treated spheroidal cells (p<0.0001) (See Figure 4.24, Panel D). As seen from Figure 
4.24, panel E, the relative mRNA expression level of NOTCH1 in MCF-7 was higher in 
untreated parental cells compared to DOX-treated parental cells and untreated spheroids 
(p<0.0001) (see Figure 4.24, Panel E). 
In general, there was a significant down-regulation of the mRNA expression of NOTCH1 in 
HTR8/SVneo, TEV-1, BeWo and MCF-7 cells under untreated and DOX-treated spheroidal 
cell conditions when compared with the parental cell conditions.  
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Figure 4.24: Relative mRNA expression of NOTCH1 in trophoblast and tumour cells. 
The relative mRNA expression of NOTCH1 was compared between different conditions. 
The data from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. 
Likewise, the data for JEG-3 and BeWo cells are presented in panels C and D respectively. 
Panel E shows the data from MCF-7cell. Statistical significance was determined using a one-
way ANOVA followed by Tukey's test for multiple comparisons. Data represent the mean 
±SEM of three individual experiments, each performed in triplicate (****p<0.0001; 
***p<0.001; *p<0.05). 
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4.2.6  Protein expression of stem cell markers 
The relative protein expression was compared between: (a) untreated parental versus DOX-
treated parental, (b) untreated parental versus untreated spheroid, (c) untreated spheroids 
versus DOX-treated spheroids, and (d) DOX-treated parental versus DOX-treated spheroids. 
The data were analysed using a one-way ANOVA followed by Tukey's post-hoc test for 
multiple comparisons. The equal amount of protein samples (30µg) from trophoblast and 
tumour cells were loaded onto the gel, as confirmed by the internal controls β-actin on the 
same blots. Specific positive controls were used for each factor as suggested by the antibody 
providers. Caco2 cells were used as a positive control for OCT4, NANOG and CDX2. While 
MCF-7 cell lines were used as positive control for NOTCH1 and SOX2. A lower level of 
the positive control (20µg) was loaded to avoid over-saturation of the blot. Protein 
expression levels were normalised using the housekeeping protein β-actin levels as an 
internal control.   
4.2.6.1  Protein expression of OCT4 
The OCT4 antibody produced a single band in spheroidal and parental (DOX-treated and 
untreated) samples in trophoblast cell lines, MCF-7 and the recommended positive control 
(Caco2 cell line). The detected bands were at 45 kDa which was within the predicted range 
for the protein (See Figure 4.25, Panel A). In contrast to mRNA expression, a significant 
increase in protein expression of OCT4 was observed in both HTR8/SVneo and TEV-1 
spheroidal cells (untreated and DOX-treated) compared to their parental cell counterparts 
(see Figure 4.25, Panel B and C).  In JEG-3 cells, both DOX-treated parental and untreated 
spheroids, showed a significant increase in OCT4 expression compared to untreated parental 
cells (p<0.01) (Figure 4.25, Panel D). However, the mRNA and protein expression were in 
agreement only in parental cells compared to untreated spheroids. From Figure 4.25, Panel 
E, a significant increase in protein expression of OCT4 was observed in BeWo cells between 
untreated parental with DOX-treated parental cells (p<0.05), and DOX-treated spheroids 
with DOX-treated parental cells (p<0.001). Interestingly, these differences in expression 
were also observed in mRNA expression (See Figure 4.20, Panel D).  In  MCF-7 cells (Figure 
4.25, Panel F) the OCT4 protein expression was significantly different in untreated parental 
cells compared to (a) DOX-treated parental cells (p<0.01) and (b) untreated spheroids 
(p<0.05). Likewise, only the OCT4 protein expression in DOX-treated spheroids was 
significantly higher than that of DOX-treated parental cells (p<0.01). In summary, the 
expression of OCT4 protein in four trophoblast cell lines and MCF-7 tumour cell was 
significantly increased in untreated and DOX-treated spheroids cells compared to parental 
cells conditions. 
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Figure 4.25: The expression of OCT4 protein in trophoblast and tumour cells. 
Panel A represents a western blot showing the single bands detected by anti-OCT4 for 
trophoblast cell lines (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and the breast cancer cell 
line MCF-7 under different conditions. Caco2 cell line used as the positive control and is 
separated with red dotted lines. Equal loading of protein was confirmed by β-actin 
expression. Panels B, C, D, E and F represents the ratio of OCT4 to β-actin densitometry 
readings for HTR8/SVneo, TEV-1, JEG-3, BeWo, and MCF-7 cells respectively.  A one-
way ANOVA followed by Tukey's test for multiple comparisons was carried out. Data 
represent the mean ±SEM of three individual experiments, each performed in triplicate 
(**p<0.01; *p<0.05). 
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4.2.6.2  Protein expression of SOX2 
As seen from Figure 4.26, the SOX2 antibody produced a single band in almost all the 
protein samples from trophoblast cell lines and MCF-7 cells. These bands were detected at 
37kDa, where the expected molecular weight of the band was in the range of 35-43 kDa. 
Interestingly, the overall protein expression of SOX2 was increased in the case of both 
untreated and DOX-treated spheroids (See Figure 4.26, Panel A). 
In HTR8/SVneo cells, the protein expression was significantly higher in untreated parental 
cells compared to DOX-treated parental cells (p<0.01) (See Figure 4.26, Panel B). Likewise, 
higher expression was observed in untreated spheroidal cells compared to untreated parental 
cells (p<0.05). Moreover, the protein expression of DOX-treated spheroids was significantly 
higher than that of DOX-treated parental cells (p<0.01). 
In contrast to mRNA expression, a significant increase in protein expression of SOX2 in 
TEV-1 spheroids (both DOX-treated and untreated) was observed when compared to their 
parental cell counterparts (p<0.01) (See Figure 4.26, Panel C). 
Also in contrast to mRNA expression data, a significant increase in protein expression of 
SOX2  was observed in both  JEG-3 and BeWo cells  between (a) untreated spheroids cells 
compared to untreated parental cells (p<0.05) and (b) DOX-treated spheroids compared to 
DOX-treated parental cell (p<0.01) (See Figure 4.26, Panel D and E). 
There was a significant increase in protein expression of SOX2 observed in MCF-7 
spheroids (both DOX-treated and untreated) compared to their parental cell counterparts 
(See Figure 4.26, Panel F). There was a correlation btween mRNA and protein expression 
in untreated parental compared to untreated spheroids (See Figure 4.21, Panel F).  
Overall, the protein expression of SOX2 in four trophoblast cell lines and MCF-7 was 
significantly increased in spheroids compared to parental conditions. 
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Figure 4.26: The expression of SOX2 protein in trophoblast and tumour cells. 
Panel A represents a western blot showing the single bands detected by anti-SOX2 for 
trophoblast cell lines (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and the breast cancer cell 
MCF-7 under different conditions. MCF-7 cell line used as the positive control and is 
separated with red dotted lines. Equal loading of protein was confirmed by β-actin 
expression. Panels B, C, D, E and F represents the ratio of SOX2 to β-actin densitometry 
readings for HTR8/SVneo, TEV-1, JEG-3, BeWo, and MCF-7 cells respectively. A one-way 
ANOVA followed by Tukey's test for multiple comparisons was carried out. Data represent 
the mean ±SEM of three individual experiments, each performed in triplicate (***p<0.001; 
**p<0.01; *p<0.05). 
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4.2.6.3  Protein expression of NANOG 
The NANOG antibody produced a single band in almost all trophoblast cell lines, MCF-
7cells and positive control (Caco2 cells). The expected molecular weight of the band was in 
the range of 36-55 kDa. Interestingly, the overall protein expression of NANOG was up- 
regulated in the case of spheroids (DOX-treated and untreated) in all cell lines. These bands 
were detected at 36 kDa (see Figure 4.27, Panel A).  
In contrast to mRNA expression, a significant increase in protein expression of NANOG in 
both HTR8/SVneo and TEV-1 spheroidal cells (both DOX-treated and untreated) was 
observed, when compared to their parental cell counterparts (See Figure 4.27, Panel B and 
C).  In the case of HTR8/SVneo DOX-treated parental cells compared to DOX-treated 
spheroids. There was a correlation in mRNA and protein expressions. 
Similar results were observed in JEG-3 and BeWo cell lines. There was a significant increase 
in protein expression of NANOG in spheroidal cells (both DOX-treated and untreated) 
compared to their parental cell counterparts (See Figure 4.27, Panel D and E).  Interestingly, 
the BeWo choriocarcinoma cell line showed there is correlation between mRNA and protein 
expressions in untreated spheroids versus untreated parental cells (See Figure 4.22, Panels 
C and D). 
There was a significant increase in protein expression of NANOG observed in MCF-7 
spheroidal cells (both DOX-treated and untreated) compared to their parental cell 
counterparts (p<0.01) (See Figure 4.27, Panel F). The difference observed in protein 
expression of NANOG between untreated parental versus untreated spheroids was also 
observed at the level of mRNA expressions (See Figure 4.22, Panel E). 
Generally, all four trophoblast and MCF-7 cell lines showed a significant increase of 
NANOG protein expression in spheroid cells compared to parental conditions. 
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Figure 4.27: The expression of NANOG protein in trophoblast and tumour cells. 
Panel A represents a western blot showing the single bands detected by anti-NANOG for 
trophoblast (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and the breast cancer cell MCF-7 
under different conditions. Caco2 cell line used as the positive control and is separated with 
red dotted lines. Equal loading of protein was confirmed by β-actin expression. Panels B, C, 
D, E and F represents the ratio of NANOG to β-actin densitometry readings for 
HTR8/SVneo, TEV-1, JEG-3, BeWo, and MCF-7 cells respectively. A one-way ANOVA 
followed by Tukey's test for multiple comparisons was carried out. Data represent the mean 
±SEM of three individual experiments, each performed in triplicate (**p<0.01; *p<0.05). 
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4.2.6.4  Protein expression of CDX2 
The CDX2 antibody produced a single band in most cell lines including positive control 
(Caco2 cells). The detected bands were at 42 kDa which is within the predicted range (30-
42). The expression of CDX2 was minimal in parental DOX-treated and untreated 
trophoblast cells (see Figure 4.28, Panel A).  
There were no significant changes observed in protein expression in  both choriocarcinoma 
cell lines, However, CDX2 expression was increased in HTR8/SVneo DOX-treated 
spheroids compared to untreated spheroids (p<0.05) (See Figure 4.28, Panel B). This 
difference in expression was also observed at the level of mRNA.  Likewise, in TEV-1 cells 
the expression was found to be elevated in parental DOX-treated compared to untreated cells 
(p<0.05) (Figure 4.28, Panel C). On the other hand, in MCF-7 cells a significant increase in 
the expressions of CDX2 was observed in untreated parental cells compared to (a) DOX-
treated parental and (b) untreated spheroids (p<0.001) (See Figure 4.28, Panel F). This 
difference in the expression was also observed at the level of mRNA. Furthermore, there 
was significant increase in protein expression between versus DOX-treated spheroids 
untreated spheroids (p<0.01). 
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Figure 4.28: The expression of CDX2 protein in trophoblast and tumour cells. 
Panel A represents a western blot showing the single bands detected by anti-CDX2 for 
trophoblast cell lines (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and the breast cancer cell 
MCF-7 under different conditions. Caco2 cell line used as the positive control and is 
separated with red dotted lines. Equal loading of protein concentration was confirmed by β-
actin expression. Panels B, C, D, E and F represents the ratio of CDX2 to β-actin 
densitometry readings for HTR8/SVneo, TEV-1, JEG-3, BeWo, and MCF-7 cells 
respectively. A one-way ANOVA followed by Tukey's test for multiple comparisons was 
carried out. Data represent the mean ±SEM of three individual experiments, each performed 
in triplicate (***p<0.001; **p<0.01; *p<0.05). 
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4.2.6.5  Protein expression of NOTCH1 
The NOTCH1 antibody produced a single band in some trophoblast cell lines and MCF-7 
(See Figure 4.29, Panel A). The predicated molecular weight of NOTCH1 protein as 
declared by the supplier (Abcam), was 125 kDa. However, a single band was observed at 
100 kDa for NOTCH1 in all samples as well as in positive control (MCF-7 cells). 
There was correlation between the mRNA and protein expression of NOTCH1 in 
HTR8/SVneo cells. It showed a significant increas in untreated parental compared to DOX-
treated parental cells (p<0.05), and also between untreated parental versus untreated 
spheroids (p<0.05) (See Figure 4.29, Panel B). However, in TEV-1 cells there was no 
significant increase in the expression of NOTCH1 between all conditions. 
In JEG-3 cells, a significant increase in protein expression of NOTCH1 was seen in parental 
untreated compared to DOX-treated parental cells and untreated spheroidal cells (See Figure 
4.29, Panel D). This change was not apparent in mRNA expression. In BeWo cells the 
expression of NOTCH1 was reduced in untreated spheroids compared to respective parental 
cells (p<0.05). This change was also observed in mRNA expression. 
In MCF-7 cells , there was a significant change in protein expression level of NOTCH1 
especially in untreated parental cells compared to (a) DOX-treated parental cells (p<0.001) 
and (b) untreated spheroids (p<0.01). Moreover, in spheroid untreated compared to DOX-
treated spheroids NOTCH1 protein level only were lower (p<0.05). 
Overall, the protein expression of NOTCH1 in trophoblast cells was down-regulated in 
spheroids (both DOX-treated and untreated) compared to parental cell conditions. 
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Figure 4.29: The expression of NOTCH1 protein in trophoblast and tumour cells. 
Panel A represents a western blot showing the single bands detected by anti-NOTCH1 for 
trophoblast cell lines (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and the breast cancer cell 
MCF-7 under different conditions. MCF-7 cell line used as the positive control and is 
separated with red dotted lines. Equal loading of protein was confirmed by β-actin 
expression. Panels B, C, D, E and F represents the ratio of NOTCH1 to β-actin densitometry 
readings for HTR8/SVneo, TEV-1, JEG-3, BeWo, and MCF-7 cells respectively.A one-way 
ANOVA followed by Tukey's test for multiple comparisons was carried out. Data represent 
the mean ±SEM of three individual experiments, each performed in triplicate 
(****p<0.0001; ***p<0.001; **p<0.01; *p<0.05). 
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4.3  Discussion 
Methodical investigation of the status of any placental proteins, biomarkers and factors in 
situ has always been challenging due to ethical constraints. Moreover, the morphology of 
the placenta is clearly different from one individual to another even during normotensive 
pregnancies (Orendi et al., 2011). To avoid these problems, placental explants and many 
different types of placental cells have been isolated and immortalised to be used as in vitro 
models (Orendi et al., 2011). For this study, four placental cell lines were studied: 
HTR8/SVneo and TEV-1 (representing early first trimester trophoblast cells) together with 
JEG-3 and BeWo (choriocarcinoma cell lines) and MCF-7 (human breast adenocarcinoma 
cell line), which represents a tumour cell line of non-placental origins.  
The trophoblast stem cells derived either from normal or choriocarcinoma placental cell lines 
are another powerful tool that can be used to understand the trophoblast cell immunology, 
biology, and placental development (King et al.,  2000). In addition, trophoblast spheroid 
generation is a useful method that can mimic and can be used to investigate the trophoblast 
during early differentiation stages, as these investigations are challenging in humans. 
Therefore, trophoblast cells have been cultured with other cell types in either two 
dimensional (2-D) or three dimensional (3-D) culture systems, where they are able to more 
to closely mimic the specialized features of trophoblast cells inside the uterus during 
pregnancy (Ji et al.,  2013).   
The aims of this chapter were to generate and select spheroids from four trophoblast cell 
lines (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and also from MCF-7 cells. To check the 
effects of chemotherapeutic agent (Doxorubicin) in producing drug resistant spheroids from 
all four trophoblast cell lines and MCF-7.  After selection of spheroids from trophoblast cell 
lines, the expression of various stem cell markers was studied to determine the capacity for 
‘stemness’ ability of these cell lines. 
4.3.1  Effect of Doxorubicin on cell viability and toxicity 
The first choice of assays to check cell viability and cytotoxicity were MTT and LDH assays, 
due to their quick and straight forward protocols, cost effectiveness and reliability. The data 
suggest that the lower concentrations of DOX do not affect mitochondrial activity; while at 
higher concentrations, DOX becomes cytotoxic to the cells used. The LDH assay showed 
minimum LDH release in cells treated with 250 and 500 ng/ml DOX concentrations 
compared to control. 
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There are two mechanisms by which DOX acts on cell cytotoxicity: (1) it has an ability to 
interact with plasma membranes, intercalate with DNA, and disrupt topoisomerase-II, (2) 
generation of the free radicals and their damage to cellular membranes, DNA and proteins 
(Gewirtz, 1999).   
4.3.2  Generation of non-resistant (normal) spheroids 
As explained in Section 4.2.3.1, both the first trimester transformed trophoblast and 
choriocarcinoma cells have shown the ability to form spheroids. From literature searches, it 
is clear that this is the first successful attempt to produce spheroid bodies in the transformed 
first trimester trophoblast cell line TEV-1. In fact, there is only one recent study, which has 
managed to produce spheroids from other placental cell lines (Webber et al., 2013). They 
illustrated that HTR8/SVneo cells have a high ability to form spheroid bodies and was in 
agreement with the present study. However, they reported that JEG-3 cells have only a 
limited ability to form spheroid bodies, while in this study, JEG-3 cells were found to have 
produced spheroids. The difference between the two studies may depend on the methodology 
used to produce spheroids. The previous study used hanging drops, which is a simple and 
inexpensive method to produce spheroid. However, it is difficult to change media, add drugs 
and track the spheroid behaviour during formation (Achilli et al., 2012; Mehta et al., 2013). 
In contrast, this study as explained before in (Section 2.9) used non-adherent flasks with a 
cocktail of growth factors to induce spheroid formation. Furthermore, Grummer et al. 1994 
reported the formation and properties of spheroids produced from the BeWo and JEG-3 cell 
lines. The present study also prove the formation of spheroids from BeWo cells. 3-D culture 
can be a useful model to studying the differentiation, attachment and invasion potential of 
trophoblast.  
Overall, the findings of this study indicate that, all four trophoblast cell lines are capable of 
producing spheroids under non-adherent conditions and re-grow again under normal 
conditions (See Section 4.2.3.1). 
4.3.3  Generation of resistant spheroids from trophoblast and tumour cell lines 
Spheroids were aggregated as clusters of cells, formed by self-assembly with the help of 
growth factors and non-adherent culture flasks. Compared to 2-D cell monolayer cultures, 
spheroidal 3-D models can closely replicate essential physiological conditions and in 
vivo cellular responses to external motivations (Mehta et al., 2013). 3-D cultures offer many 
physiological advantages for testing of drug delivery and toxicity, by allowing the study 
about their in vivo metabolism in vitro. In addition, the cellular heterogeneity of spheroid 
produced from 3-D culture can closely mimic the cell morphology in vivo as well as their 
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functions such as proliferation, differentiation, gene expression, etc. However, 3-D cell 
culture can be expensive for large-scale production and time consuming (Mehta et al., 2013). 
Furthermore, the 3-D systems still lack the complex vascular systems which support tissues 
in vivo for nutrients, oxygenation, and removal of waste (Edmondson et al., 2014). Cells 
grown in this system perform these functions only by diffusion processes.  
The drug-resistant spheroid bodies were generated using DOX. All concentrations above 
1000 ng/ml of DOX showed reduced cell viability in all four trophoblast cell lines 
(HTR8/SVneo, TEV-1, JEG-3 and BeWo). In addition, the small cells resulting from DOX 
treatment did not revert back to a monolayer morphology, when cultured back into adherent 
cell culture flasks. However, the spheroids produced from 250 and 500 ng/ml DOX were 
larger in size and also reverted back into a monolayer upon growing in adherent cell culture 
flasks. Similar results could be observed in the MCF-7 cell line.  Nevertheless, the spheroids 
produced by MCF-7 cells were bigger in size compared to the trophoblast cell lines. 
Additionally, the DOX resistant spheroids generated from all four trophoblast cell lines were 
smaller when compared with the non-treated spheroids. However, the DOX treatment did 
not affect the ability of MCF-7 cell line to produce larger spheroids.   
These preliminary results indicate that the trophoblast cells lines exhibit “stemness”   
features in spheroid bodies, such as self-renewal, as they possessed the ability to re-grow 
again under normal conditions.  Although the MCF-7 cells treated with 1000 ng/ml of DOX 
were able to produce small spheroids, considering a uniform selection criteria, 250 ng/ml 
DOX treatment was selected as the optimum dose to generate drug resistant spheroids in all 
five cell lines.   
4.3.4  Characterization of stem cell markers by Immunofluorescence 
The expression of transcription factors (such as SOX2, NANOG) that are associated with 
“stemness” were clearly observed in all the cell lines used (under all conditions). In the case 
of OCT4, there was no staining in parental (both DOX-treated and untreated) TEV-1, JEG-
3 and MCF-7 cells. On the other hand, both parental cells of HTR8/SVneo and BeWo have 
shown immunofluorescence for OCT4. This shows OCT4 expression was cell lines 
dependent for parental cells type. However, the presence of OCT4 in the spheroidal cells 
generated from all trophoblast cells and MCF-7 suggests that these cell lines have 
transformed into stem-like cells upon spheroid formation.  
OCT4, SOX2 and NANOG form a core regulatory network that coordinates to determine 
the self-renewal and differentiation of embryonic stem cells (ESCs) which can contribute to 
tumorigenesis (Chang et al., 2008). Interestingly, the expression of OCT4, SOX2 and 
NANOG in MCF-7 have already been reported by Ling et al. (2012) using 
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immunohistochemistry. Likewise, Webber et al. (2013) have confirmed the expression of 
SOX2, NANOG, and NOTCH1 in HTR8/SVneo spheroid cells. Although these findings 
support the present finding partially, the data from Webber et al. (2013) have not shown the 
expression of OCT4 in HTR8/SVneo spheroid cells and expressions in JEG-3 were not 
reported. These differences may be attributed to the use of different antibodies, and 
differences in the experimental procedure for producing spheroids.  
However, the staining for the trophoblast transcription marker CDX2, was absent in the 
spheroidal cells generated from all cell lines. Interestingly, staining for CDX2 was detected 
in the parental cells of HTR8/SVneo and TEV-1. Since CDX2 is a specific trophoblast 
transcription factor. This finding suggests that CDX2 is a sign of trophoblast lineage 
derivation instead of a trophoblast stem cell differentiation. Jia et al. (2014) have shown 
CDX2 overexpression in HTR-8/SVneo cells enhanced the cell invasion by promoting 
MMP-9 expression and inhibiting TIMP-1 expression. The fact that the expression of CDX2 
was lost in spheroidal cells was contradictory with Webber et al. (2013) investigation, where 
they showed HTR8/SVneo and JEG-3 spheroid bodies expressed CDX2. These differences 
may be attributed to the use of different antibodies. Additional, differences in the 
experimental methods to produce spheroids such as hanging drop was used by Webber et al. 
(2013). 
NOTCH1 was detected in all four trophoblast cell lines (HTR8/SVneo, TEV-1, JEG-3 and 
BeWo) and MCF-7 in both parental and spheroidal cells (DOX-treated and untreated). 
NOTCH1 have been reported to be expressed in trophoblast stem cells and in differentiated 
trophoblast cells, and has been associated with “stemness” properties such as stem cell self-
renewal (Sarikaya and Jerome‑Majewska, 2011; Bolós et al., 2013). NOTCH1 activity was 
also associated positively with cancer growth or initiation of pro-tumorigenic activities in 
breast cancer cell lines such as MCF-7 (Bolós et al., 2013). Although the 
expression/localisation of these factors are not clear in spheroidal cells (due to the spheroidal 
nature), the parental cells show a clear cytoplasmic staining. Other studies using gastric 
cancer cell lines have also shown the cytoplasmic and perinuclear distribution of these 
factors  (Liu et al., 2013). 
Overall, both un-treated and DOX-treated spheroids showed positive staining for most of 
these factors except CDX2. Since spheroidal cells are associated as clusters, they might have 
complemented signals to each other, whilst monolayer cell cultures of parental cells may not 
have these signals (Liu et al., 2013). Moreover, the culture medium used for spheroids 
contained growth factors which may also contribute to the increased intensity of staining. It 
should be noted that in immunofluorescence studies, the intensity of staining is not 
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proportional to the expression levels. Especially in spheroidal cells, the staining intensity 
was affected by the clustering nature of the cells. 
4.3.5  Relative mRNA/protein expressions of stem cell markers  
The relative mRNA and protein expression level of each marker (OCT4, SOX2, NANOG, 
CDX2 and NOTCH1) was compared between the different conditions used in this study. 
Some comparisons showed a correlation between relative mRNA expression and protein 
level (especially in MCF-7 cells), whereas others results did not show this correlation. The 
reason for the mismatch correlation between mRNA and protein levels was not entirely 
explainable. It may be that expression of mRNAs are reciprocally reduced as a result of the 
high levels of protein expression. Another potential reason is that the half-life of some 
mRNA transcripts is extremely short due to RNA degradation. For data showing relatively 
high levels of mRNA compared to their protein counterpart; it can be argued that some 
transcripts have an extremely long half-life (Wang et al., 2002; Yang et al., 2003)  Either 
way it is suggested that the correlation between transcript and protein level can be as little 
as 40% for factors that have regulatory functions. This was also ascertained by 
Schwanhausser et al. (2013) who argued that there is poor genome-wide correlations 
between some mRNA and proteins, mainly between those factors involved in the regulation 
of cell division and differentiation (Schwanhausser et al., 2013)  
 OCT4  
In this study, spheroids (DOX-treated and untreated) from four trophoblast cell lines 
(HTR8/SVneo, TEV-1, JEG-3 and BeWo) and MCF-7 cells have shown an increase in the 
protein expression of OCT4 compared with the parental cells conditions of these cell lines. 
Similar results were observed in mRNA expression of OCT4 under spheroid (treated and 
untreated) when compared with the parental condition only in the JEG-3, BeWo and MCF-
7 cells. Li et al. (2012) recognized that SOX2 and OCT4 are associated with “stemness” 
characteristics in cancer cells, therefore, they could lead to cells immortality, as well as self-
renewable and invasive properties of cancer cells. Different studies have confirmed that 
OCT4 is responsible for the stemness properties and it is regulator expression and protects 
embryonic stem cells in an undifferentiated state (Boyer et al., 2005; Shi and Jin, 
2010; Zhang et al., 2015). Therefore, the high expression of OCT4 in the spheroids in this 
study suggests the “stemness” characteristic of these cells. 
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 SOX2  
SOX2 is an important transcription factor which is involved in many physiological processes 
including normal and pathological development such as maintenance the pluripotency of 
human ESC, and cancer  (Liu et al., 2013: Wu et al., 2013).  
In addition, it may have an essential role in trophoblast development. However, the role of 
SOX2 in human ESCs is not fully understood (Adachi et al.,  2010). SOX2 protein has been 
implicated in many processes of cancer including proliferation, growth, cellular migration 
and invasion, maintenance of the stemness of CSCs or TICs (tumour-initiating cells), and 
chemo-resistance (Liu et al., 2013). It has been reported that the placenta contain a 
population of multipotent stem cells which show expression of embryonic stem cells 
markers, such OCT4 and SOX2 (Miki and Strom, 2006). This supports the present findings 
which showed an increased protein expression of SOX2 in spheroids (DOX-treated and 
untreated) in almost all trophoblast cell lines used. The increased expression of SOX2 in 
spheroids also indicated its stem-like features. In addition, SOX2 expression in cancer cells 
has been found to correlate with the invasiveness of several types of solid tumours, such as 
breast cancer (Wu et al., 2013). It has been demonstrated that SOX2 was expressed in most 
of the human breast cancer cell lines such as MCF-7, T-47D and MDA-MB-231 cell lines 
(Chen et al., 2008). This agreed with current findings with SOX2 expressions in case of 
MCF-7 cells.  
 NANOG 
The transcription factors such as OCT4, SOX2 and NANOG have critical molecular 
switches regulating ESC fate, which might also operate in renewing cancer stem cells. They 
play a role in determining the self-renewal and differentiation of ESCs (Ling et al., 2012).  
The current study shows NANOG protein expression was up-regulated in spheroids (DOX-
treated and untreated) in all cell lines indicating that they have self-renewal properties. The 
mechanism of NANOG on stem cell pluripotency are still unknown (Miyazawa et al., 2014).  
Previous findings by Siu et al. (2008) reported that the knock down of the NANOG genes 
decreased mobility and invasion potential of trophoblast cells; suggesting NANOG may be 
involved in the malignant progression of trophoblast especially in the choriocarcinoma cell 
line JEG-3. The current study has shown that up-regulation of NANOG is common during 
the spheroidal transformation of all trophoblast cell lines suggesting NANOG expression 
may be linked to invasive properties (see Chapter 5). 
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 CDX2 
CDX2 plays an essential role during embryonic development and is involved in the processes 
of intestinal cell proliferation, differentiation, adhesion, and apoptosis (Bai et al., 2003). It 
is also a transcriptional regulator essential for the trophoblast lineage (Tolkunova et al., 
2006). However, the specific role of CDX2 in trophoblast invasion is still unclear; although 
it has been shown that aberrant expression of CDX2 is associated with intestinal 
inflammation and tumorigenesis (Coskun et al., 2011). The data from the current study have 
shown that there was no significant difference in the protein expression levels of CDX2 
during spheroidal transformation in all cell lines. This could be because the CDX2 
expression is repressed and regulated by the high expression of pluripotent OCT4 and 
NANOG transcription factors. The correlation of NANOG and OCT4 expressions to CDX2 
expression level during specialisation of the pluripotent trophoblast stem cell TSC have also 
been reported (Marchand et al., 2011).  Interestingly there was a decrease in the protein 
expression level of CDX2 under untreated spheroids compared to the parental cells in MCF-
7 cells. This may be due to the tumour suppressive role of CDX2 by inhibiting cell 
proliferation (Saad et al., 2011).  
 NOTCH1  
NOTCH1 plays important roles in many cellular processes, such as regulating proliferation, 
cell fate determination, differentiation, cell death and cell type specification that is critical 
for organogenesis (Zhao and Lin, 2012).  It isassociated with “stemness” properties, as well 
as with the differentiation of cancer stem cells (Prasad et al., 2009; Webber et al., 2013). 
There was a clear IF staining of NOTCH1 observed in four trophoblast cell lines under 
different conditions. However, the protein expression of NOTCH1 was decreased in 
spheroidal cells (both DOX-treated and untreated) compared to parental cells in four 
trophoblast cell lines. A previous study has also reported NOTCH1 expression in both 
trophoblast stem cells and in differentiated trophoblast cells (Sarikaya et al., 2011). 
However, the result from this study in the case of spheroidal cells was not as expected. 
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4.4  Conclusions 
The data from this chapter showed the ability of four trophoblast cell lines (HTR8/SVneo, 
TEV-1, JEG-3 and BeWo) to produce spheroids under 3-D culture. Re-grown under normal 
conditions, they were able to produce monolayer of cells. Overall, the data in this study 
suggest that compared to parental cells there was an increased protein expression of stem 
cell markers (such as OCT4, SOX2 and NANOG) in spheroidal cells (DOX-treated and 
untreated); as they are  required to maintain the stemness properties. Moreover, the positive 
staining for these factors could provide evidence that the spheroids generated from four 
trophoblast cell lines possess “stem-like cells” characteristics. The data suggests that these 
cells could be used as an in vitro model representing physiologically rapidly dividing cells.
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5.1  Introduction 
Uncontrolled cell proliferation along with cell invasion is important for aggressive tumour 
metastasis (Curran and Murray, 2000). Interestingly, during development of the human 
placenta, the trophoblast cells share some properties with tumour cells; for instance, 
differentiation, rapid proliferation, the ability to invade the surrounding tissue (including the 
basement membrane), migration and formation of new blood vessels (or angiogenesis) 
(Yagel et al., 1988). During the first trimester of pregnancy, extra-villous trophoblast cells 
invade into the maternal spiral arteries and into the uterine wall, which is essential for foetal 
development and normal pregnancy. Normally, the invasion of trophoblasts is controlled by 
several cellular interactions and/or molecular events such as extracellular matrix 
degradation, trophoblast differentiation and transcriptional regulation (Goldman-Wohl and 
Yagel, 2002). However, pre-eclampsia is characterized by shallow, insufficient trophoblast 
invasion, which leads to unmodified narrow spiral arteries and results in foetal hypoxia. This 
causes endothelial damage and finally leads to maternal symptoms such as  hypertension, 
oedema, and proteinuria (Goldman-Wohl and Yagel, 2002). Interestingly, in the early 18th 
Century, John Beard (1911) developed the idea that the trophoblast can be used as an ideal 
model for cancer, to study the regulation of cell growth and differentiation, as well as 
invasion. Therefore, a better understanding of all aspects of trophoblast invasion may result 
in the development of new therapies to treat diseases of pregnancy associated with over (such 
as choriocarcinoma) or under invasion (e.g. PE) (Graham and Lala, 1992). Furthermore, the 
understanding of trophoblast invasion may not only pave the way to unravel the molecular 
mechanisms involved in metastatic tumour cells, but also lead to identification of new 
therapeutic targets for inhibiting proliferation and invasion (Anin et al., 2004: Holtan et al.,  
2009).  
In order to understand tumour development, spheroid models have been used to understand 
the inter-relationship between tumour and endothelial cells (Oudar, 2000). These models 
have been used to study aspects such as wound healing, invasion, metastasis and 
angiogenesis. According to Oudar (2000), spheroid cells are powerful tools that reflect the 
degree of complexity and tumourigenicity in vivo when compared with monolayer cells. 
Grummer et al. 1994 reported the formation and properties of spheroids produced from the 
BeWo and JEG-3 cell lines. However, the invasive properties of these spheroids were not 
investigated.  
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To the best of the author’s knowledge, this is the first study which shows the invasive 
properties of spheroids formed from trophoblast cell lines.  
The present study aims to generate spheroids and characterise “stem-like cells” from 
transformed trophoblast cell lines (HTR8/SVneo, TEV-1) and trophoblast choriocarcinoma 
cells (JEG-3, BeWo) and MCF-7 cells. This comparative analysis of the migration and 
invasive potentials of parental and spheroidal cells was carried out to understand the 
behaviour of the spheroids produced from cells of trophoblast cells.  
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5.2  Results 
The wound healing (scratch) assay was carried out at first, followed by invasion assays using 
2-D matrigel and by 96 well 3-D spheroid BME. As mentioned in Section 2.12-2.14 assays 
were performed on both the parental cells from 2-D adherent flasks in DOX-treated and 
untreated conditions, along with the spheroids selected by using 3-D culture with or without 
DOX-treatment. The results are described below. 
5.2.1  In vitro cell migration by scratch/wound healing assay 
This assay was carried out to study the migration potential of transformed trophoblast cell 
lines (HTR8/SVneo and TEV-1), choriocarcinoma cell lines (JEG-3 and BeWo) and MCF-
7, amongst parental DOX-treated and untreated, spheroids DOX-treated and untreated, each 
at 24 and 48 hours. Spheroids were used after being harvested from non-adherent flasks and 
disrupted by trypsin for plating into adherent 24 well plates under normal growth conditions 
before migration (as described in Section 2.12). WimScratch/Wimasis software was used 
to analyse all confocal images, to calculate percentage wound closure. The experiment was 
repeated three times in quintuplicates. A two-way ANOVA followed by Tukey's post-hoc 
test was performed for multiple comparisons between: (a) parental untreated cells versus 
parental DOX-treated, (b) parental untreated cells versus spheroid untreated cells, (c) 
spheroid untreated versus spheroid DOX-treated cells and (d) parental DOX-treated cells 
versus spheroid DOX-treated cells. 
5.2.2.1  Migration of transformed trophoblast cell lines  
According to Figure 5.1, the HTR8/SVneo parental cells have covered 75% of the area at 24 
hours, and at 48 hours cells covered almost 95% of the scratch area. In the case of  the DOX-
treated parental cells, almost 98% of wound closure was observed at 24 hours and a gradual 
decrease to 80% was observed at 48 hours. Therefore, DOX showed an inhibitory effect on 
the cell migration only after 48 hours of HTR8/SVneo cells [Figure 5.1, Panel A (red arrow)]. 
In the case of untreated spheroids, wound closure of 45% was observed at 24 hours which 
was increased to 98% at 48 hours. In contrast, the DOX-treated spheroid covered 55% of the 
area in 24 hours and decreased to 49% of the area in 48 hours [Figure 5.1, Panel A (white 
arrow)]. 
 At 24 hours, there was a significant increase in wound closure in parental cells (both DOX-
treated and untreated) compared to their spheroidal cell counterparts (p<0.01). Likewise, a 
significant increase in wound closure was observed in untreated spheroids versus DOX-
treated spheroids at 48 hours (p<0.01) (Figure 5.1, Panel B). 
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Figure 5.1: Migration of the HTR8/SVneo cell line. 
Panel A: Represents the percent (%) wound closure at 0, 24 and 48 hours. The red arrow is 
pointing to the delayed effect of DOX on parental cells under treated conditions. The white 
arrow shows the effect of DOX on spheroidal cells. Panel B: Represents the quantitative 
analysis of wound closure using WimScratch/Wimasis at 24 and 48 hours. Statistical 
significance was determined using a two-way ANOVA followed by Tukey's test for multiple 
comparisons between each condition. Data represent the mean ±SEM of three individual 
experiments, each performed in quintuplicate (**p<0.01). 
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In the case of TEV-1 cells, untreated parental cells covered almost 100% of the scratch area 
within 48 hours. In contrast, when the parental cells were treated with DOX at 24 hours the 
closure was found to be 98%. Interestingly, the wound re-opened and showed only 86% 
healing at 48 hours [see Figure 5.2, Panel A (red arrow)].  
The migration of untreated spheroids was 90% at 24 hours and increased to 100% at 48 
hours. The migration of DOX-treated spheroids covered around 55% at 24 hours and the 
covered area was reduced to 40% at 48 hours, which shows limited migration even after 48 
hours [Figure 5.2, Panel A (white arrow)]. 
There was a significant increase in wound closure in the case of DOX-treated parental versus 
DOX-treated spheroids. Similarly, there was an increase in wound closure between untreated 
spheroids and DOX-treated spheroids at 24 and 48 hours (p<0.0001). At 48 hours, a 
significant increase in wound closure was observed between untreated parental and DOX-
treated parental (p<0.01) (Figure 5.2, Panel B). 
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Figure 5.2: Migration of the TEV-1 cell line. 
Panel A: Represents the percent (%) wound closure at 0, 24 and 48 hours. The red arrow is 
pointing to the delayed effect of DOX on parental cells under treated conditions. The white 
arrow shows the effect of DOX on spheroidal cells. Panel B: Represents the quantitative 
analysis of wound closure using WimScratch/Wimasis at 24 and 48 hours. Statistical 
significance was determined using a two-way ANOVA followed by Tukey's test for multiple 
comparisons between each condition. Data represent the mean ±SEM of three individual 
experiments, each performed in quintuplicate (****p<0.0001; **p<0.01). 
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5.2.2.2  Migration of choriocarcinoma cell lines  
Figure 5.3, Panel A, shows that the parental cells of JEG-3 covered 77% of the scratch wound 
area at 24 hours which was increased to 89% at 48 hours. A similar trend was observed for 
the DOX-treated parental cells, which covered almost 81% of the scratch area at 24 hours. 
However, the wound healed area was decreased to 61% at 48 hours [See Figure 5.3, Panel 
A (red arrow)]. In untreated spheroidal cells, the covered area remained 81% at 24 hours, 
but at 48 hours healing showed a slight increase to 85% in covered area. In the case of 
spheroidal cells under DOX treatment the covered area was 60% at 24 hours. Again like 
DOX-treated parental cells, at 48 hours, the cell covered area was reduced to 55% [See 
Figure 5.3, Panel A (white arrow)]. 
There was a significant reduction in the covered area of DOX-treated spheroids compared 
to both (a) DOX-treated parental (p<0.01) and (b) untreated spheroidal cells (p<0.01) at 24 
hours. Moreover, there was a significant increase in wound closure of untreated parental 
versus DOX-treated parental cells (p<0.01). Likewise, the wound closure in untreated 
spheroidal cells was higher than in DOX- treated spheroids cells (p<0.0001) at 48 hours (See 
Figure 5.3, Panel B).  
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Figure 5.3: Migration of the JEG-3 cell line. 
Panel A: Represents the percent (%) wound closure at 0, 24 and 48 hours. The red arrow is 
pointing to the delayed effect of DOX on parental cells under treated conditions. The white 
arrow shows the effect of DOX on spheroidal cells. Panel B: Represents the quantitative 
analysis of wound closure using WimScratch/Wimasis at 24 and 48 hours. Statistical 
significance was determined using a two-way ANOVA followed by Tukey's test for multiple 
comparisons between each condition. The data is a mean representative of three individual 
experiments each for two different passages performed in quintuplicate (n=3±SEM; 
****p<0.0001; **p<0.01). 
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In the case of BeWo cells, the untreated parental cells covered around 71% of the scratch 
area at 24 hours. At 48 hours it was increased to 80%. Whilst, DOX-treated parental cells 
covered 85% of the area at 24 hours, which was then decreased to 63% at 48 hours [see 
Figure 5.4, Panel A (red arrow)]. In the case of untreated spheroids, at 24 hours the cell 
covered area was 55% and this increased to 60% at 48 hours. On the other hand, in the DOX-
treated spheroidal cells, the covered area at 24 hours was 45% and this decreased to 36% at 
48 hours [see Figure 5.4, Panel A (white arrow)].   
Overall, the cell migration was reduced in DOX-treated spheroidal cells compared to DOX-
treated parental cells (p<0.001) at 24 hours. There was a significant increase in untreated 
parental cells compared to both DOX-treated parental cells and untreated spheroids 
(p<0.05). However, a significant reduction in cell migration was also observed in DOX-
treated spheroidal cells compared to both untreated spheroidal cells and DOX-treated 
parental cells (p<0.01). (See Figure 5.4, Panel B). 
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Figure 5.4: Migration of the BeWo cell line. 
Panel A: Represents the percent (%) wound closure at 0, 24 and 48 hours. The red arrow is 
pointing to the delayed effect of DOX on parental cells under treated conditions. The white 
arrow shows the effect of DOX on spheroidal cells. Panel B: Represents the quantitative 
analysis of wound closure using WimScratch/Wimasis at 24 and 48 hours. Statistical 
significance was determined using a two-way ANOVA followed by Tukey's test for multiple 
comparisons between each condition. Data represent the mean ±SEM of three individual 
experiments, each performed in quintuplicate (***p<0.001; **p<0.01;*p<0.05). 
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5.2.2.3  Migration of MCF-7 tumour cells 
In the case of MCF-7cells, the parental MCF-7 cells covered 63% of the wound at 24 hours, 
and at 48 hours this was slightly increased to 69%. In DOX-treated parental MCF-7, the cell 
covered area observed was 70% at 24 hours. A slight increase to 73% in wound closure was 
observed at 48 hours [Figure 5.5, Panel A (red arrow)].  
The wound closure observed in untreated spheroids cells at 24 and 48 hours, were 55% and 
58% respectively. In the case of DOX-treated spheroidal MCF-7 cells, the cells covered area 
was 58% at 24 hours and this was slight decreased to 50% at 48 hours [Figure 5.5, Panel A 
(white arrow)].  
There was a significant increase in wound closure in parental cells (both DOX-treated and 
untreated) compared to their spheroidal cell counterparts at 24 and 48 hours. Moreover, the 
wound closure in DOX-treated parental cells was faster than DOX-treated spheroids (See 
Figure 5.5, Panel B).  
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Figure 5.5: Migration of the MCF-7cell line  
Panel A: Represents the percent (%) wound closure at 0, 24 and 48 hours. The red arrow is 
pointing to the delayed effect of DOX on parental cells under treated conditions. The white 
arrow shows the effect of DOX on spheroidal cells. Panel B: Represents the quantitative 
analysis of wound closure using WimScratch/Wimasis at 24 and 48 hours. Statistical 
significance was determined using a two-way ANOVA followed by Tukey's test for multiple 
comparisons between each condition. Data represent the mean ±SEM of three individual 
experiments, each performed in quintuplicate (**p<0.01; *p<0.05). 
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5.2.2  Cell invasion Assay 
The cell migration assay was followed by an invasion assay using BD Falcon ™ BioCoat 
tumour invasion plates as explained in Section 2.13. This experiment was carried out to study 
the invading capacity of cells by comparing the number of cells invaded under different 
conditions. In this present study, spheroid cells which have a total diameter above 8.0 μm 
were involved. Therefore, the spheroids were disintegrated by using trypsin into single cells 
before performing the invasion assay. Image J software analysis was used to analyse the 
images taken using Olympus microscope of the bottom coated membrane. As in the 
migration assay, the invasion capacity of cells was compared between (a) untreated parental 
versus DOX-treated parental; (b) untreated parental versus untreated spheroidal cells; (c) 
untreated spheroidal versus DOX-treated spheroid and (d) DOX-treated parental versus 
DOX-treated spheroidal cells. This comparisons were performed by using a one-way 
ANOVA followed by Tukey's post-hoc test for multiple comparisons. Micrographs obtained 
from the cell invasion study, together with the quantitative analysis of number of cells 
invaded and percentage of cell invasion are given in Figures 5.6 to 5.10. The number of cells 
invaded and percentage of cells invasion were two different methods to calculate this 
property.  
5.2.2.1  The invasion of transformed trophoblast cell lines 
Both the transformed cell lines, HTR8/SVneo and TEV-1, were initially analysed for their 
invasive capacity. HTR8/SVneo cells showed a higher invasion capacity in untreated 
spheroids compared to other conditions of this cells.  Moreover, there was also a significant 
increase in the number of cells invaded by untreated parental compared to DOX-treated 
parental cells (p<0.05). There was a highly significant increase in the number of untreated 
spheroid cells invaded compared to all other cells/treatments (See Figure 5.6, Panel A and 
B). However, the percentage invaded of untreated spheroidal cells (that cell invasion in 
comparison to migration) was significantly lower than untreated parental and DOX-treated 
spheroidal cells (p<0.05) (See Figure 5.6, Panel C).  
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Figure 5.6: HTR8/SVneo invasion.  
Panel A: Represents the number of HTR8/SVneo cells invaded at 24 hours. Image was taken 
of the bottom coated membrane using an Olympus fluorescence microscope. Objective 
magnification 20X (Scale bar = 100 μm). Panel B: Represents the quantitative analysis of 
number of cells invaded using ImageJ and Graphpad software. Panel C: Represents the 
percentage of invasion calculated using the formula described in Section 2.13. The white 
bold arrow and glowing arrow are pointing towards parental invaded cells and invaded 
spheroids respectively. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in quintuplicate (****p<0.0001; *p<0.05). 
 
In the case of TEV-1 cells (see Figure 5.7, Panel A and B), there was a highly significant 
increase in the number of cells invaded by untreated spheroids compared to both untreated 
parental (p<0.0001) and DOX-treated spheroids (p<0.05). In addition, there was a significant 
reduction in the number of cells invaded by DOX-treated parental compared to DOX-treated 
spheroidal cells (p<0.05). However, there was no statistically significant increase in the 
percentage invasion under all conditions except in untreated parental versus DOX-treated 
parental cells (p<0.05) (Figure 5.7, Panel C).  
 
 
 
 
 
160 
 
                                                                                             Chapter 5: spheroidal behaviour study 
 
 
Figure 5.7: TEV-1 invasion. 
Panel A: Represents the number of TEV-1 cells invaded at 24 hours. Image was taken of the 
bottom coated membrane using an Olympus fluorescence microscope. Objective 
magnification 20X (Scale bar = 100 μm). Panel B: Represents the quantitative analysis of 
number of cells invaded using ImageJ and Graphpad software. Panel C: Represents the 
percentage of invasion calculated using the formula described in Section 2.13. The white 
bold arrow and glowing arrow are pointing towards parental invaded cells and invaded 
spheroids respectively. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in quintuplicate (****p<0.0001; *p<0.05). 
 
5.2.2.2  The invasion of choriocarcinoma cell lines 
Figure 5.8, Panels A and B, represent the invasion by JEG-3 cells. The data were similar to 
TEV-1 cells. There was a highly significant increase in the number of cells invaded by 
untreated spheroid compared to both untreated parental cells and DOX- treated spheroids 
(p<0.0001). Moreover, there was a significant reduction in the number of cells invaded by 
DOX-treated parental compared to DOX-treated spheroid cells (p<0.01) (See Figure 5.8, 
Panel A and B). There was no statistically significant increase in the percentage invasion 
under all conditions except in untreated parental verses DOX-treated parental cells (p<0.05) 
(See Figure 5.8, Panel C).   
In the BeWo cell line (see Figure 5.9, Panel A and B), there was only a significant increase 
in the number of cells invaded in untreated spheroids compared to untreated parental cells 
(p<0.05). The percentage of invasion followed the same pattern (See Figure 5.9, Panel C). 
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Figure 5.8: JEG-3 invasion. 
Panel A: Represents the number of JEG-3 cells invaded at 24 hours. Image was taken of the 
bottom coated membrane using an Olympus fluorescence microscope. Objective 
magnification 20X (Scale bar = 100 μm). Panel B: Represents the quantitative analysis of 
number of cells invaded using ImageJ and Graphpad software. Panel C: Represents the 
percentage of invasion calculated using the formula described in Section 2.13. The white 
bold arrow and glowing arrow are pointing towards the parental invaded cells and invaded 
spheroids respectively. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in quintuplicate (****p<0.0001; **p<0.01; 
*p<0.05). 
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Figure 5.9: BeWo invasion.  
Panel A: Represents the number of BeWo cells invaded at 24 hours. Image was taken of the 
bottom coated membrane using an Olympus fluorescence microscope. Objective 
magnification 20X (Scale bar = 100 μm). Panel B: Represents the quantitative analysis of 
number of cells invaded using ImageJ and Graphpad software. Panel C: Represents the 
percentage of invasion calculated using the formula described in Section 2.13. The white 
bold arrow and glowing arrow are pointing towards the parental invaded cells and invaded 
spheroids respectively. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in quintuplicate (n=; *p<0.05). 
 
 
5.2.2.3  The invasion of MCF-7 cell line 
In MCF-7 cells, there was a significantly higher number of cells invading in spheroids 
(untreated and DOX-treated) compared to parental cells (untreated and DOX-treated). 
Moreover, there was a significant reduction in the number of cells invaded by DOX-treated 
parental cells compared to DOX-treated spheroidal cells (p<0.0001) (See Figure 5.10, Panel 
A and B). The percentage of invasion showed a statistically significant increase between 
parental cells (both DOX-treated and untreated) compared to their spheroidal cell 
counterparts (p<0.01) (See Figure 5.10, Panel C). 
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Figure 5.10: MCF-7 invasion.  
Panel A: Represents the number of MCF-7 cells invaded at 24 hours. Image was taken of 
the bottom coated membrane using an Olympus fluorescence microscope. Objective 
magnification 20X (Scale bar = 100 μm). Panel B: Represents the quantitative analysis of 
number of cells invaded using ImageJ and Graphpad software. Panel C: Represents the 
percentage of invasion calculated using the formula described in Section 2.13. The white 
bold arrow and glowing arrow are pointing towards the parental invaded cells and invaded 
spheroids respectively. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean of three 
individual experiments, each performed in quintuplicate (n=3±SEM; ****p<0.0001; 
***p<0.001; **p<0.01). 
 
5.2.3  3-D Spheroid BME cell invasion assay  
3-D Spheroid BME cell invasion assays were carried out to compare the invasive potential 
of untreated and DOX-treated spheroidal cells. ImageJ software was used to analyse all 
confocal images, to measure changes in the invasion area at 12, 24 and 48 hours.  
5.2.3.1  3-D invasion by spheroids produced from transformed trophoblast cell lines 
In HTR8/SVneo cells, there was a significant increase in invasion potential observed for 
untreated spheroid compared to DOX-treated spheroids (see Figure 5.11). The significance 
was proportional with time. At 12 hours, there was no significant difference in the invasion 
capacity between untreated and DOX-treated spheroids. On the other hand, a significant 
increase was observed in invasion capacity of the cells at 24 and 48 hours.  
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This pattern of invasion was also noticed in the TEV-1 cell line. Untreated spheroids showed 
significant increases in invasion area compared to DOX-treated spheroids at 24 and 48 hours. 
In both transformed trophoblast cell lines (HTR8/SVneo and TEV-1), the size of the 
untreated spheroids were found to be larger than DOX-treated spheroids. Furthermore, a 
polygonal morphology with stretched protrusions was formed by the cells, which was clear 
in the untreated spheroid condition (See Figure 5.11 and 5.12, Panel A). In untreated 
spheroids invasion increased with time but these invasive characteristics were minimal (at 
24 and 48 hours) or absent (at 12 hours) in DOX-treated spheroids. See Figure 5.11 and 5.12, 
Panel B). 
 
Figure 5.11: Invasion potential of untreated and DOX-treated spheroids of 
HTR8/SVneo. 
Panel A: Represents images of invasion pattern of HTR8/SVneo untreated and DOX-treated 
spheroidal cells using confocal microscopy. Objective magnification=10X. Panel B: 
Represents the quantitative analysis of invasion area of untreated and DOX-treated 
spheroidal cells using ImageJ and Graphpad software. White bold arrow indicates active 
protrusions from spheroid untreated, which was clearer than in spheroid DOX-treated. 
Statistical significance was determined using two-way ANOVA followed by Sidak's 
multiple comparisons test performed to compare invasion area between untreated and DOX-
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treated spheroids at different times. Data represent the mean ±SEM of three individual 
experiments, each performed in quintuplicate (****p<0.0001; **p<0.01). 
 
Figure 5.12: Invasion potential of untreated and DOX-treated spheroids of TEV-1. 
Panel A: Represents images of invasion pattern of TEV-1 spheroids untreated and DOX-
treated cells using confocal microscopy. Objective magnification=10X. Panel B: Represents 
the quantitative analysis of invasion area of untreated and DOX-treated spheroid cells using 
ImageJ and Graphpad software. White bold arrow indicates active protrusions from spheroid 
untreated, which was clearer than in spheroid DOX-treated. Statistical significance was 
determined using two-way ANOVA followed by Sidak's multiple comparisons test 
performed to compare invasion area between untreated and DOX-treated spheroids at 
different times. Data represent the mean ±SEM of three individual experiments, each 
performed in quintuplicate (***p<0.001; **p<0.01). 
 
5.2.3.2  3-D invasion by spheroids produced from choriocarcinoma cell lines 
Both choriocarcinoma cell lines (JEG-3 and BeWo) were developed from trophoblast 
tumours. The size of the untreated spheroids were found to be larger than that of transformed 
trophoblast cells (See Figures 5.13 and 5.14, Panel A respectively). In the case of JEG-3 
cells, there was a significant increase in invasion potential observed in untreated spheroids 
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compared to DOX-treated  spheroids at 12, 24 and 48 hours. However, the DOX-treated 
spheroids from JEG-3 cells only produced a collection of spheroid like bodies without any 
invasive properties (see Figure 5.13, Panel B). Similarly, in BeWo cells, the untreated 
spheroids showed a higher invasion potential than DOX-treated spheroids at 12, 24 and 48 
hours (See Figure 5.14, Panel B). In contrast, the DOX-treated cells failed to produce any 
effective spheroids. In both choriocarcinoma cell lines (JEG-3 and BeWo), the size of the 
untreated spheroids were found to be larger than the DOX-treated spheroids. 
 
Figure 5.13: Invasion potential of untreated and DOX-treated spheroids of JEG-3. 
Panel A: Represents images of invasion pattern of JEG-3 spheroids untreated and DOX-
treated cells using confocal microscopy. Objective magnification=10X. Panel B: Represents 
the quantitative analysis of invasion area of spheroid untreated and DOX-treated cells using 
ImageJ and Graphpad software. White bold arrow indicates active protrusions from spheroid 
untreated, which was clearer than in spheroid treated. Statistical significance was determined 
using two-way ANOVA followed by Sidak's multiple comparisons test performed to 
compare invasion area between untreated and DOX-treated spheroids at different times. Data 
represent the mean ±SEM of three individual experiments, each performed in quintuplicate 
(***p<0.001). 
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Figure 5.14: Invasion potential of spheroids untreated and DOX-treated of BeWo. 
Panel A: Represents images of invasion pattern of BeWo spheroids untreated and DOX-
treated cells using confocal microscopy. Objective magnification=10X. Panel B: Represents 
the quantitative analysis of invasion area of spheroid untreated and DOX-treated cells using 
ImageJ and Graphpad software. White bold arrow indicates active protrusions from spheroid 
untreated, which was clearer than in spheroid DOX-treated. Statistical significance was 
determined using two-way ANOVA followed by Sidak's multiple comparisons test 
performed to compare invasion area between untreated DOX-treated spheroids at different 
times. Data represent the mean ±SEM of three individual experiments, each performed in 
quintuplicate (***p<0.001; **p<0.01). 
 
5.2.3.3  3-D invasion by spheroids produced from adenocarcinoma breast cancer cell 
line. 
In MCF-7 cells, untreated and DOX-treated spheroids remained as cell aggregates and did 
not invade into the surrounding invasion matrix. It has failed to produce effective spheroids 
in 3-D culture. The analysis showed no significant difference in invasion potential of 
untreated and DOX-treated spheroids. It was also evident in the micrographs that the 
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spheroids had failed to produce a polygonal morphology or an even network structure (See 
Figure 5.15, Panel A and B).  
 
Figure 5.15: Invasion potential of untreated and DOX-treated spheroids of MCF-7. 
Panel A: Represents images of invasion pattern of MCF-7 spheroids untreated and DOX-
treated cells using confocal microscopy. Objective magnification=10X. Panel B: Represents 
the quantitative analysis of invasion area of spheroid untreated and DOX-treated cells using 
ImageJ and Graphpad software. White bold arrow indicates active protrusions from spheroid 
untreated, which was not pronounced in DOX-treated spheroids). There was no statistically 
significant difference determined by using two-way ANOVA followed by Sidak's multiple 
comparisons test performed to compare invasion area between untreated and DOX-treated 
spheroids at different times. Data represent the mean ±SEM of three individual experiments, 
each performed in quintuplicate.  
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5.3  Discussion 
Successful placental implantation requires distinct cellular functions including attachment, 
migration and invasion of EVTs into the uterine endometrium (Norwitz et al., 2001). 
Reduced or aggressive invasion can cause gestational complications such as placental 
accreta (or choriocarcinoma) and PE or intrauterine growth restriction (IUGR) respectively 
(Graham and Lala, 1992). Spheroids produced from 3-D cultures are a useful method to 
investigate the physiological events such as wound healing, invasion and metastasis (Oudar, 
2000). Therefore, the aim of this chapter was to investigate and comparatively analyse the 
invasive potentials of parental and spheroidal cells from transformed trophoblast 
(HTR8/SVneo and TEV-1), choriocarcinoma cell lines (JEG-3 and BeWo) and MCF-7 cell 
line. 
5.3.1  In vitro cell migration analysis using scratch /wound healing assay 
Migration is a key property of living cells and plays a critical role in embryonic development, 
immune response, vascular morphogenesis and tissue repair (Kramer et al., 2011). Many 
pathological processes, such as cancer metastasis and inflammation, also involve cell 
migration (Kramer et al., 2011). Wound healing assays are suitable methods for studying the 
effects of cell–to-matrix and cell–to-cell interactions during migration (Liang et al., 2007). 
It is a simple, common and economical technique for studying cell migration in vitro. 
Therefore, it is an important and useful tool in biomedical research such as cancer biology 
and cell biology (Jain et al., 2012).  In fact, the comparative study of migratory behaviour of 
malignant cells and non-malignant trophoblast cells can shed light onto the prognosis of 
tumour metastasis (Kramer et al., 2011).  The present study, combines 3-D and 2-D cell 
culture techniques by producing spheroids to mimic the in vivo situation.  
5.3.1.1 Migration of transformed trophoblast cell lines  
HTR8/SVneo cell line has been previously used to study cell adhesion and migration 
(Hannan, 2010). The results explained herein showed that the migration of HTR8/SVneo 
parental cells was increased at 24 and 48 hours. As there was no treatment given to the 
parental cells, they may have proliferated and migrated at normal speed. In contrast, 
migration was greater in HTR8/SVneo DOX-treated parental than untreated parental cells at 
24 hours. However, the wound re-opened at 48 hours. This could be because 250 ng of DOX 
may have showed a delayed inhibitory effects on the cell migration. DOX has been reported 
to develop resistance in tumour cells, and toxicity in healthy tissues and cells (Gajewski, 
2007). Therefore, DOX maybe producing delayed anoikis in these cells by disrupting their 
contact with the ECM as explained by Gilmore (2005). Interestingly, the rate of migration in 
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untreated spheroids was higher at 48 hours. Spheroidal cells migrate faster than the parental 
cells. Since spheroids, act like solid tumours in vivo, the observed high migration by 
spheroidal cells may be due to their deregulated proliferation and an uncontrolled speed of 
migration (Ferretti et al., 2007). However, DOX-treated spheroidal cells showed a lower rate 
of migration than untreated spheroids at 48 hours. Furthermore, the monolayers produced by 
the spheroidal cells have the ability to re-grow under normal conditions, as clusters which 
are different from the normal cell monolayers [see section 4.2.3.2, Figures 4.6 to 4.10 Panel 
D (chapter 4)]. This might have affected the migration of spheroidal, especially DOX-treated 
cells. 
The migration of parental TEV-1 cells increased and covered almost 100% of the wound 
area within 24 and 48 hours. This could suggest a high proliferative and migratory capacity 
of these cells. In contrast, after treating with DOX, the wound initially healed well (95% by 
24 hours), but re-opened by 48 hours. This may suggest that DOX produces delayed anoikis 
in these cells by disrupting their contact with the ECM (Gilmore, 2005), and also affects the 
proliferation or migration of the cells (Denard et al., 2012). 
Data from this study showed that spheroids derived from TEV-1 show high migration and 
covered most of the scratch area at 24 and 48 hours. However, DOX-treated spheroid cells 
showed a lower rate of migration at 48 hours, perhaps because of DOX mediated effects on 
spheroidal migration speed, as these cells are plated as single cells and grow as monolayers. 
5.3.1.2  Migration of choriocarcinoma cell lines  
The migration of JEG-3 parental cells showed the wounds healed within 48 hours. However, 
after treating with DOX, the wound healing increased at 24 hours, interestingly, the wound 
re-opened at 48 hours. This reduction in wound covered area by the DOX indicates an effect 
of DOX on proliferation or migration of these cell. There was a slight increase in wound 
covered area in untreated spheroids. In contrast, the migration was slightly decreased in 
DOX-treated spheroids at 48 hours compared to 24 hours. In BeWo cells, the migration of 
parental cells was increased at 48 hours. This may be due to the slow growing nature of the 
BeWo cell line (Aplin et al., 1992). Since the cells are slow growing, the syncytial nature of 
the cell was unpredictable and as a result the scratch was not 100% covered. However, in 
parental DOX-treated cells the wound covered area was increased at 24 hours but decreased 
at 48 hours. This may be due to the slow effects of DOX. Untreated spheroids showed 
increased wound coverage at 48 hours. Overall, the wound healing of transformed 
trophoblast cells in both parental untreated and spheroids cells showed higher wound 
coverage than placental choriocarcinoma cell lines. This unexpectedly reduced rate of 
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wound healing in JEG-3 and BeWo cells may be due to the fact that these cell lines (despite 
having originated from choriocarcinoma), have a syncytial-like morphology. That is, they 
both grow in clusters of cells and migrate as sheets or clumps. Therefore, difference in cell 
motility cannot be observed as in transformed trophoblast cells. 
5.3.1.3  Migration of MCF-7 tumour cell line. 
The increase of cell covered area in the parental MCF-7 cell experiments was lower than for 
the trophoblast cell lines. The parental MCF-7 under DOX-treated condition, showed no 
significant change in cell covered area at 24 and 48 hours. This may be because the cells 
develop resistance to DOX over several sub-culture. Although the speed of migration of 
DOX-treated parental cells was low, the wound showed no signs of “re-opening” as in 
transformed trophoblast cells. Therefore, it is possible that the effects of DOX are somewhat 
resisted by the transformed trophoblast cells until 24 hours. However, long term exposure of 
DOX would have disrupted the cell-to-ECM contact. This phenomenon was not shown in 
MCF-7.   
DOX is an anthracycline antibiotic which can inhibit cell proliferation and induce apoptosis 
in tumour cells (Wang et al., 2004). Despite the fact that DOX is an active drug for breast 
cancer therapy and the best effect is only seen when used in combination of 
cyclophosphamide, Adriamycin, 5-Fluorouracil (CAF) (Czeczuga-Semeniuk et al., 2004). 
Ciftci and colleagues (2003), have demonstrated that DOX can inhibit cell proliferation up 
to 70-80% in 24 hours in the MCF-7 cell line regardless of concentration. There was no 
significant change observed in covered area by spheroids at 24 and 48 hours. DOX-treated 
spheroids of MCF-7 showed there was a slight increase in wound coverage at 48 hours 
compared to 24 hours, which may be due to the delayed effect of DOX. Studies by 
Bartholoma and colleagues, (2005) have demonstrated that spheroids of breast cancer cell 
lines (mainly MCF-7) can be used to study the cytotoxic effects of different drugs.  
5.3.2 Cell invasion Assay 
This assay is designed to monitor cell invasion by using the BD Falcon™ BioCoat tumour 
invasion system. This assay kit contains a FluoroBlok™ 96 well insert plate with a 
membrane (8.0 μm pore size). This membrane is coated with matrigel matrix that only allows 
single cells to pass. However, in this present study, spheroids which have a total size greater 
than 8.0 μm were involved. Therefore, the spheroids were dispersed using trypsin into single 
cells before performing the invasion assay. Also, in order to differentiate cell migration from 
invasion the experiment was duplicated in a control migration plate with a porous membrane. 
Hence, the migration plate will only measure the number of cells travelling through this 
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porous membrane. On the other hand, the cell invasion assay monitors the cell movement 
through the matrigel (Kramer et al.,  2013). The quantitation of this assay is achieved by pre-
labelling cells with a fluorescent dye as only labelled cells passing through the matrigel can 
be detected. 
5.3.2.1 2-D Invasion by trophoblast cell lines 
In this study, HTR8/SVneo cells showed a higher invasion capacity in untreated spheroids 
compared to other conditions. Previous studies have used HTR8/SVneo cell line as a model 
to investigate the proliferation and invasion of trophoblast cells (Zuo et al., 2014). While, 
TEV-1 cell line showed a highly significant difference in invasive capacity of untreated and 
DOX-treated spheroids compared to their respective parental counterparts. Previously, the 
TEV-1 cell line has been shown to have a higher invasive potential in response to TGFβ1 
treatment in vitro (Feng  et al.,  2005). TGFβ1 under in vivo conditions is reported to play a 
significant role in regulating extravillous trophoblast invasion, migration and proliferation 
(Graham and Lala, 1991; Peng, 2003).  Therefore, TEV-1 may be highly useful as a cell 
model to study the physiological and functional properties of human extravillous trophoblast 
invasion (Feng et al.,  2005). Interestingly, the invasion by DOX-treated spheroids was lower 
than the untreated spheroids in TEV-1. Therefore, it can be suggested that the treatment with 
DOX has reduced the invasion capacity of cells. However, the mechanism through which 
DOX inhibits invasion of cells is not completely understood (Denard et al., 2012). It is 
known that the trophoblast-derived proteinases (MMPs and the serine proteases) are 
essential for trophoblast invasion (Librach et al., 1991).  Also it has been previously shown 
that DOX treatment reduced the production of pro-MMP-2 and pro-MMP-9 at 24 hours of 
treatment, resulting in reduced cell proliferation along with reduced invasion. However, the 
status of MMPs in this study is yet to be investigated (Shen et al., 2009). 
5.3.2.2  2-D Invasion by choriocarcinoma cell lines 
JEG-3 cells showed similar result to TEV-1 cells, in that there was a highly significant 
increase in invasion capacity of untreated and DOX-treated spheroids compared to their 
respective parental cells. This confirms the findings by Buck and colleagues (2015), who 
have shown that the linear growth and invasion potential of spheroids from the hybridoma 
cell line, AC-1M88 (a fusion of primary EVT cells and the JEG-3 choriocarcinoma cell line), 
are much higher than differentially grown single cells. The invasion potential of untreated 
and DOX-treated spheroids was increased due to the spheroidal features, as they act as solid 
tumour. 
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In the case of BeWo, the only significant increase in invasion capacity was observed in 
untreated spheroids compared to untreated parental cells. The invasiveness of spheroids 
produced from JEG-3 and BeWo, as an in vitro model have been previously studied 
(Grummer et al., 1989). According to their experiment, differences in the adhesion and 
invasion processes were observed. JEG-3 cells showed the highest adhesion rate to 
endometrial epithelium and a fast/deep invasion into stroma. However, BeWo cells showed 
low adhesion rate to endometrial epithelium and shallow invasion into stroma. The data from 
this current study also confirmed the fact that the invasion potential of JEG-3 (both parental 
and spheroidal cells) was found to be higher than that of BeWo cells. 
5.3.2.3  2-D Invasion of the MCF-7 cell line 
Although, MCF-7 cells are derived from a non-invasive breast cancer compared to invasive 
cell line MDA-MB-231(Nagaraja et al., 2006), the MCF-7 cell line demonstrated similar 
results to TEV-1 and JEG-3 cells. There was a significantly high invasion capacity of 
untreated and DOX-treated spheroids compared to their respective parental cells. This could 
be that the MCF-7 spheroids after dispersion into monolayers exert invasive properties as 
they still have stem-like features. However, DOX-treated parental cells showed lower 
numbers of cells invading than untreated parental cells. Several studies have shown that 
DOX inhibits the growth of breast cancer cell lines in a dose and time dependant manner 
(Sharma et al., 2004). Therefore, the observed results were expected. It is known that DOX 
can reduce the invasion potential of MCF-7 cells by reducing the rate of proliferation (Pichot 
et al., 2009) and also reduce the invasion potential of spheroids produced by MCF-7 (Doillon 
et al., 2004). MCF-7 spheroids after dispersal showed higher number of cells invading the 
matrix when compared with the parental cells. This may be due to the nature of spheroids 
which act like solid tumours (Khanna et al., 2014).  
Overall, it is clear that the spheroids produced from both transformed trophoblast cell lines 
(HTR8/SVneo and TEV-1) and choriocarcinoma (JEG-3 and BeWo) cell lines were capable 
of invasion. The results of the present study are in general agreement with another study, 
which showed that there were potentially different invasive properties of HTR8/SVneo, 
JEG-3 and BeWo dependent on the cell type (Lash et al., 2007). However, monolayer cell 
invasion systems are commonly used to evaluate invasion of single cells. Therefore, this 
method is not competent enough to study the invasion potential of a spheroid. Although the 
spheroids were artificially separated into single cells to suit the 2-D invasion assay, it is not 
entirely appropriate to study the interactions between the invasive spheroid and the basement 
membranes. In order to compare the invasive behaviour of untreated and DOX-treated 
spheroids a further experiment 3-D invasion assay experiment is necessary. 
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5.3.3  3-D Spheroid BME cell invasion assay  
The 3-D spheroid BME cell invasion assay provides an easy, quick and quantitative process 
to compare morphological patterns as well as the speed of invasion. The study of parameters 
related to how cells can invade an artificial basement membrane acting as ECM in response 
to chemoattractants and/or inhibiting compounds, is important for embryonic development, 
immune response and tumour metastasis ( www21) . In this assay spheroids produced within 
each well can invade the surrounding matrix resulting in spindle-like formation, and the 
absence of this would indicate that there is less or no invasion (www21). This assay is 
commonly used in in vitro drug testing to compare the invasive patterns of aggressive 
tumours with and without drug intervention. The main advantage of this assay is that cell 
movement through a 3-D matrix closely mimics invasion in vivo (www21).  Interestingly, the 
invasion process occurs from cell clusters with well-established cell–cell interactions rather 
than from single cells, closely reflecting the in vivo situation in cancer. However, to the 
author’s knowledge this is the first study that has used this assay to compare the invasive 
potential of spheroids originating from transformed trophoblast and choriocarcinoma 
placental cells. 
5.3.3.1  3-D invasion of spheroids produced from transformed trophoblast cell lines 
In the case of HTR8/SVneo, the size of both untreated and DOX-treated spheroids were 
initially almost equal. However, with increasing time untreated spheroids invaded a large 
surface area with a more consistent growth trend than treated spheroids (viewed under time-
lapse images). However, DOX-treated spheroids showed minimal growth and invasion 
(Figure 5.11).  
It is also possible that the cells may have produced a mass to compensate for the effects of 
DOX, but that they retained some properties of invasion. For TEV-1 cells, the initial size of 
DOX-treated spheroids was smaller than that of untreated spheroids (Figure 5.12). However, 
untreated spheroid invasion increased with time. In contrast, compared to untreated 
spheroids, the invasion of DOX-treated spheroids was found to be low; yet they did show 
limited invasive potential in 3-D. Further investigations are needed to understand the 
survival mechanisms of these cell types after treatment.  
5.3.3.2  3-D invasion of spheroids produced from choriocarcinoma cell lines 
In the case of JEG-3 and BeWo cells, untreated spheroids showed a distinct increase in 
invading area with time (See Figure 5.13 and 5.14). These data suggest that spheroids 
derived from choriocarcinoma cell lines can potentially invade faster than those of 
transformed trophoblast cells. It is worth noting that a previous study has shown that BeWo 
cells can produce spheroids in vitro, (Grummer et al., 1994). In this present study, BeWo 
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cells were able to form spheroids (See Figure 5.14 Panel A). However, DOX-treated 
spheroids from both JEG-3 and BeWo cells have shown an unusual profile. The distorted 
shape of spheroids did not show any invasion in either cell line. This may be due to the 
persisting effect of the DOX treatment in these cell lines. 
5.3.3.3  3-D invasion of spheroids produced from the MCF-7 cell line 
According to the supplier’s (Amsbio) result (they used the same kit to test the morphology 
of 3-D invasion and to analyse the surface area of the MCF-7 cell line during 4 days), MCF-
7 cells remained as aggregates and did not invade into the surrounding invasion matrix. In 
contrast, invasive cells such as MDA-MB-231 did invade. The results in this study showed 
similar results and there was no significant difference in invasion capacity between MCF-7 
spheroids that were DOX-treated and untreated. Data from the current study also confirmed 
that both untreated and DOX-treated spheroids of MCF-7 cells did not show any ability to 
invade. They formed an irregular mass of cells which were incapable of invasion. Non-
invasive cancer cell lines stay as compact spheroids with a distinct border to the surrounding 
ECM and do not show any signs of invasion even after a long period of cultivation. However, 
invasive cell lines (such as the breast cancer line MDA-MB-231) start to invade into the 
surrounding matrix and show astral outgrowth from the spheroid (Kramer et al. 2013). 
Almost all of the cell lines used in this study were able to produce spheroids with DOX 
treatment with different morphologies. However, the DOX-treated spheroids are found to be 
small with lower invasion capacity. Therefore, it can be suggested that DOX-treatment, due 
to its toxicity, has produced an accumulation of cells (instead of true spheroidal cells), that 
are trying to survive in the stressed cellular microenvironment to avoid apoptosis. Further 
detailed study is necessary to understand the underlying mechanisms of invasion by 
spheroids produced from trophoblast (HTR-8/SVne, TEV-1, JEG-3 and BeWo) cell lines. 
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5.4  Conclusions 
The data obtained from this chapter suggest that the transformed trophoblast (HTR8/SVneo 
and TEV-1) and choriocarcinoma (JEG-3 and BeWo) cell lines are capable of producing 
spheroids with different invasive properties. There was no significant difference in invasion 
ability of both untreated and DOX-treated spheroidal cells generated from MCF-7. The 
wound healing of transformed trophoblast cells in both parental untreated and spheroids cells 
showed higher healing coverage than placental choriocarcinoma cells. Moreover these 
spheroids have shown the potential to invade under 2-D culture conditions, with different 
invasive properties. As for 3-D cell culture a time dependant increase in the invasion was 
observed especially in non-resistant spheroids confirming their “stem-like” attributes.  
Most of the previous studies focussed on JEG-3 and BeWo cells as a model of the invasive 
trophoblast. However, present study have shown HTR8/SVneo and TEV1 may also be used 
as additional models to represent physiologically rapidly dividing cells in the toxicological 
studies of chemotherapeutic agents. 
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6.1  Introduction 
Human placenta is a multifaceted and poorly understood organ, which has an essential role 
not only in the supply of nutrients to the foetus but also in the maintenance of pregnancy (Ji 
et al., 2013; www22). Primary human trophoblast cultures (CTBs and EVTs) may be ideal to 
study the molecular regulation of trophoblast invasion (Bilban et al., 2010). They provide 
critical insights into placental function in normal and abnormal development (Rosario et al., 
2012). Furthermore, EVT cells that are derived from early pregnancy are much more 
invasive than those from term placentae (Ji et al., 2013). Although, primary trophoblast 
cultures are useful tools to examine the differentiation and functions of the trophoblast, there 
are many major limitations to the use of these cells as in vitro models. Firstly, due to ethical 
constraints these cells are more difficult to obtain, and secondly, fresh primary cells have a 
very limited lifespan. Furthermore, they have limited ability to proliferate in culture, and 
hence, difficult to study the biochemical pathways and placental function (Ji et al., 2013). 
These limitations have hampered the use of these cells in standard molecular manipulation 
experiments, such as overexpression/silencing through plasmid DNA transfection etc.  
In addition, the gestational age of the placental tissue can influence the differentiation 
potential of CTBs and must be taken into account when primary cultured trophoblast cells 
are used as an in vitro model (Ji et al.,  2013).  In order to avoid these issues, several 
transformed model cell lines have been established over many years using different 
approaches. For example, trophoblast derived cell lines were used in an attempt to identify 
functional pathways differentially regulated by epigenetic modification (Novakovic et al., 
2011).   
Trophoblast cell lines can be used as an alternative to primary trophoblast cells to study 
placental function in vitro including, the processes of differentiation/invasion, 
hypoxia/oxidative stress responses, and foeto-maternal immunology (Burleigh et al., 2007). 
Since the cellular origins of transformed trophoblasts are likely to be diverse, it may be of 
value to increase the understanding of  the unique and shared phenotypes of these cells on a 
global scale (Burleigh et al., 2007).  
Most of the available cell lines can be separated into three main groups: (1) cell lines 
originating from normal tissue, such as HTR8/SVneo, SGHPL-4 and RSVT-2; (2) cell lines 
originating from malignant tissue, such as BeWo, JEG-3 and JAR; and (3) cell lines 
originating from embryonic carcinomas which have evidence of trophoblast differentiation, 
such as H9, NCR-G3 and NCCIT (King et al., 2000). 
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As explained in chapter 1, several tumour associated factors may also be expressed in human 
placenta. Cellular expression of these novel factors: ALDH3A1, AURK-A/C, PDGFRα, 
TWIST1, and JAG1 have been compared between NT and PE placentae in chapter 3. It 
would be interesting to study the changes in the expressions of these factors after spheroidal 
transformation. Apart from this it would be worth analysing the global changes in the 
protein/peptide expression between parental and spheroidal cells obtained in this study 
(Chapter 4). Recently, a new technique called SWATH-MS (Sequential Windowed 
Acquisition of All Theoretical Fragment Ion Mass Spectra), is being used for identification 
and quantification of a large number of proteins and proteomes from a complex mixture 
(Wang et al., 2015). SWATH is a suitable tool for identifying more differential ratios, being 
(a) more sensitive in the detection of small differential ratios, and (b) capable to cover a 
larger dynamic range (Bourassa et al., 2015). This could help to quantify dynamic changes 
in protein complex interaction level, for each different cell lines under different conditions.  
 
The first aim of this chapter was to compare the status of the tumour associated factors, such 
as ALDH3A1, AURK- A/C, PDGFRα, TWIST1, and JAG1, in parental and spheroidal cells 
(untreated and DOX-treated) produced from trophoblast cell lines (HTR8/SVneo, TEV-1, 
JEG-3 and BeWo) and MCF-7 cell line.  
The second aim was to investigate the changes in the global protein (peptide) expression 
profiles of non-resistant, and drug-resistant spheroids originated from transformed 
trophoblast cell lines (HTR8/SVneo and TEV-1) by using SWATH-MS. 
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6.2  Results  
6.2.1 Relative mRNA expression  
The relative expression of these factors were studied by comparing mRNA (qRT-PCR) 
expression under different conditions. Analysis was performed by using a one-way ANOVA 
followed by Tukey's Post-hoc test for multiple comparisons between (a) untreated parental 
versus DOX-treated parental, (b) untreated parental versus untreated spheroid, (c) untreated 
versus DOX-treated spheroids, and (d) DOX-treated parental versus DOX-treated spheroids.  
6.2.1.1 Relative mRNA expression of ALDH3A1 
HTR8/SVneo cells lines showed significant up-regulation of ALDH3A1 mRNA expression 
in untreated parental cells compared to (a) DOX-treated parental cells (p< 0.0001) and (b) 
untreated spheroids (p<0.001). Similarly, compared to DOX-treated spheroids, the untreated 
spheroidal cells showed an up-regulation of ALDH3A1 mRNA expression (p<0.001) (See 
Figure 6.1, Panel A). TEV-1 showed a significant in increase in mRNA expression of 
parental cells (both DOX-treated and untreated) compared to spheroidal cells counterparts. 
Moreover, there was a significant increase in mRNA expression in untreated spheroids of 
TEV-1 compared to DOX-treated spheroids (p<0.05) (See Figure 6.1, Panel B). On the other 
hand, the mRNA expression of ALDH3A1 in JEG-3 cells was significantly up-regulated in 
untreated spheroids compared to untreated parental cells (p<0.01) (See Figure 6.1, Panel C). 
BeWo cells showed a significantly higher level of ALDH3A1 mRNA expression in 
untreated parental compared to DOX-treated parental cells (p<0.05). Moreover, there was a 
significant up-regulation of ALDH3A1 mRNA expression level in DOX-treated BeWo 
spheroids compared to both DOX-treated parental and untreated spheroids (p<0.001) (See 
Figure 6.1, Panel D). As for MCF-7 cells, the mRNA expression levels in untreated 
spheroidal cells was significantly higher compared to its parental counterpart (p<0.001) and 
DOX-treated spheroids (p<0.0001) (See Figure 6.1, Panel E). There was also a significant 
difference in mRNA expression level in the same cell line between untreated parental and 
DOX-treated parental cells (p<0.01). 
.  
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Figure 6.1: Relative mRNA expression of ALDH3A1. 
The variance in mRNA expression was compared between different conditions. The data 
from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
JEG-3 and BeWo cells data are presented in panels C and D respectively. Panel E shows the 
data from MCF-7 cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01; *p<0.05). 
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6.2.1.2  Relative mRNA expression of Aurora kinase A (AURK-A) 
Figure 6.2 shows the relative mRNA expression of AURK-A in HTR8/SVneo, TEV-1, JEG-
3, BeWo and MCF-7 cells. As seen in Panel A, HTR8/SVneo showed significantly higher 
AURK-A mRNA expression in untreated parental compared to DOX-treated parental cells 
(p<0.01); and between untreated spheroids compared to DOX-treated spheroids (p<0.01). In 
TEV-1 cells, there was a significantly higher level of mRNA expression in untreated parental 
compared to both DOX-treated parental and untreated spheroids (p<0.0001). Also, there was 
a significant up-regulation in untreated spheroids compared to DOX-treated spheroids 
(p<0.01) (See Figure 6.2, Panel B). However, there was no a statistically significant 
difference in the relative expression of AURK-A between any comparison in both 
choriocarcinoma cell lines (BeWo and JEG-3) (See Figure 6.2, Panel C and D). In the MCF-
7 cell line, there was a significant up-regulation observed in untreated parental compared to 
both DOX-treated parental and untreated spheroids (p<0.0001). Also, there was a significant 
difference in mRNA expression in DOX-treated parental versus DOX-treated spheroids 
(p<0.0001) (See Figure 6.2, Panel E). 
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Figure 6.1: Relative mRNA expression of AURK-A. 
The variance in mRNA expression was compared between different conditions. The data 
from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
JEG-3 and BeWo cells data are presented in panels C and D respectively. Panel E shows the 
data from MCF-7cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; **p<0.01). 
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6.2.1.3  Relative mRNA expression of Aurora kinase C (AURK-C) 
Compared to other factors the mRNA expression of AURK-C was relatively low in all five 
cell lines. The HTR8/SVneo cell line showed a significantly higher level of AURK-C mRNA 
expression in untreated parental compared to DOX-treated parental cells (p<0.01). There 
was a significant down-regulation of mRNA expression in DOX-treated spheroids compared 
to both DOX-treated parental (p<0.05) and untreated spheroids (p<0.001) (See Figure 6.3, 
Panel A). TEV-1 cells showed a significant up-regulation of AURK-C mRNA expression 
level in untreated parental compared to both DOX-treated parental and untreated spheroidal 
cells(p<0.0001). Moreover, there was a significant down-regulation in DOX-treated 
spheroids compared to untreated spheroids (p<0.05) (See Figure 6.3, Panel B). Interestingly, 
the JEG-3 cell line showed similar result to the TEV-1cell line, while the BeWo cell line 
showed a similar result to HTR8/SVneo only in untreated parental compared to DOX-treated 
parental cells (See Figure 6.3, Panel C and D). From Panel E, the relative mRNA expression 
of AURK-C in MCF-7 was down-regulated in untreated parental cells compared to untreated 
spheroidal cells (p<0.0001) and DOX-treated parental compared to DOX-treated spheroidal 
cells (p<0.001). 
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Figure 6.3: Relative mRNA expression of AURK-C. 
The variance in mRNA expression was compared between different conditions. The data 
from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
JEG-3 and BeWo cells data are presented in panels C and D respectively. Panel E shows the 
data from MCF-7 cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01; *p<0.05). 
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6.2.1.4  Relative mRNA expression of PDGFRα 
There was a significant up-regulation of PDGFRα mRNA expression in HTR8/SVneo 
untreated parental cells compared to DOX-treated parental (p<0.0001) and in untreated 
spheroids compared with DOX-treated spheroidal cells (p<0.0001) (See Figure 6.4, Panel 
A). In TEV-1 there was a significant up-regulation in mRNA expression in untreated 
spheroids compared to both untreated parental and DOX-treated spheroids (p<0.0001) (See 
Figure 6.4, Panel B).  
For JEG-3 cells (Panel C), there was a significant up-regulation of PDGFRα mRNA 
expression level of DOX-treated parental cells in comparison to both (a) untreated parental 
cells (p<0.01), and (b) DOX-treated spheroids (p<0.001). Also, there was a significant 
down-regulation in untreated spheroids compared with untreated parental cells (p<0.0001). 
In BeWo cells, a significant down-regulation of mRNA expression was observed in DOX-
treated parental cells compared to (a) untreated parental cells (p<0.001) and (b) DOX-treated 
spheroids (p<0.05) (See Figure 6.4, Panel D).  
MCF-7 cells (Figure 6.4 Panel F), showed higher mRNA expression levels in (a) untreated 
parental cells in comparison to untreated spheroids (p<0.05) and also in DOX-treated 
parental compared with DOX-treated spheroids (p<0.01). However, a lower mRNA 
expression was observed in DOX-treated spheroids cells compared to untreated spheroids 
(p<0.01). 
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Figure 6.4: Relative mRNA expression of PDGFRα. 
The variance in mRNA expression was compared between different conditions. The data 
from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
JEG-3 and BeWo cells data are presented in panels C and D respectively. Panel E shows the 
data from MCF-7cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01; *p<0.05). 
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6.2.1.5 Relative mRNA expression of TWIST1 
From Figure 6.5, Panel A, the HTR8/SVneo cell line showed a significant down-regulation 
of TWIST1 mRNA expression in DOX-treated parental cells compared to untreated parental 
cells (p<0.01). Similar changes were observed in DOX-treated spheroids compared to 
untreated spheroids (p<0.01). It was also observed that TWIST1 mRNA expression in TEV-
1 cells was significantly higher in untreated parental cells in comparison to both (a) DOX-
treated parental, and (b) untreated spheroidal cells (p<0.001). Likewise in panel B, the 
mRNA expressions in untreated spheroids was found to be higher than that of DOX-treated 
spheroidal cells (p<0.01).   
Similar result to the HTR8/SVneo cell line was observed in the JEG-3 cell line. Additionally, 
BeWo cells showed similar results to TEV-1 cell line (See Figure 6.5, Panel C and D). In 
the MCF-7 cell line, a significant difference in mRNA expression of TWIST1 was observed 
in untreated parental compared to both (a) DOX-treated parental and (b) untreated spheroidal 
cells (p<0.0001). 
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Figure 6.2: Relative mRNA expression of TWIST1. 
The variance in mRNA expression was compared between different conditions. The data 
from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
JEG-3 and BeWo cells data are presented in panels C and D respectively. Panel E shows the 
data from MCF-7cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; ***p<0.001; 
**p<0.01; *p<0.05). 
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6.2.1.6  Relative mRNA expression of JAG1 (Jagged 1)  
There were no statistically significant differences observed in the relative expression of 
JAG1 between all comparisons in either HTR8/SVneo or BeWo cell lines (see Figure 6.6 
Panel A and D). However, in TEV-1, there was a significant up-regulation in untreated 
parental compared to both DOX-treated parental and untreated spheroidal cells (p<0.0001). 
Also, untreated spheroids expressed a higher level of JAG1 mRNA than DOX-treated 
spheroids (p<0.05) (Figure 6.6 Panel B).  A similar profile to that seen in TEV-1 cells was 
also observed in JEG3 cells, where untreated parental cells expressed significantly higher 
levels of JAG1 mRNA than either DOX-treated parental or untreated spheroidal cells 
(p<0.0001) (Figure 6.6 Panel C). Interestingly, MCF-7 cells showed a similar result to both 
trophoblast cell lines (HTR8/SVneo and BeWo) (Figure 6.6 Panel E). 
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Figure 6.3: Relative mRNA expression of JAG1. 
The variance in mRNA expression was compared between different conditions. The data 
from HTR8/SVneo and TEV-1 cells are given in panels A and B respectively. Likewise, 
JEG-3 and BeWo cells data are presented in panels C and D respectively. Panel E shows the 
data from MCF-7cells. Statistical significance was determined using a one-way ANOVA 
followed by Tukey's test for multiple comparisons. Data represent the mean ±SEM of three 
individual experiments, each performed in triplicate (****p<0.0001; *p<0.05). 
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6.2.2  Protein expression analysis 
Protein expression level were compared between different conditions as explained earlier in 
Section 6.2.1 Different positive controls, as suggested by the supplier (Abcam, UK), were 
used (separated by red dotted lines in the blot). The protein expression levels were 
normalised by using housekeeping protein β-actin levels as an internal control.   
6.2.2.1  Protein expression of ALDH3A1  
The predicated molecular weight of ALDH3A1 protein was 50 kDa. The single band was 
observed at 49kDa in untreated and DOX-treated parental and spheroidal cells. The 
ALDH3A1 antibody produced a single band in most samples from four trophoblast and 
tumour MCF-7) cell lines (see Figure 6.7). 
In HTR8/SVneo cells (Figure 6.7 Panel A), the ALDH3A1protein expression was 
significantly higher in DOX-treated parental cells compared to both (a) untreated parental 
cells; (b) DOX-treated spheroidal cells (p<0.001). Likewise, ALDH3A1 expression in 
untreated spheroids was found to be higher than untreated parental cells and DOX-treated 
spheroids (p<0.01). However, there were no statistically significant differences observed in 
the protein expression of ALDH3A1 between any conditions in TEV-1 cells (see Figure 6.7 
Panel B). In JEG-3 cells, there was a significant up-regulation in DOX-treated parental 
verses untreated parental cells and in DOX-treated spheroids versus untreated spheroids 
(p<0.01) (Figure 6.7 Panel C). In BeWo cells, there was a significant up-regulation in protein 
expression in DOX-treated parental cells versus DOX-treated spheroidal cells (p<0.05) 
(Figure 6.7 Panel D). 
The MCF-7 cells showed a significant up-regulation of protein expression in untreated 
spheroids compared to (a) untreated parental cells (p<0.001) and (b) DOX-treated spheroids 
(p<0.05). Interestingly, these differences in expression were also observed in mRNA 
expression.  Likewise, there was also a significant difference in DOX-treated spheroids 
versus DOX- treated parental cells (p<0.01). In general, the protein expression of ALDH3A1 
was significant higher in MCF-7 untreated spheroids compared to other conditions. 
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Figure 6.7: The expression of ALDH3A1 protein. 
The ratio of ALDH3A1 to β-actin densitometry readings are given for the HTR8/SVneo and 
TEV-1 cell lines in panels A and B respectively. Likewise Panel C and D represent JEG-3 
and BeWo cell lines; and Panel E shows the data for the MCF-7 cell line. MCF-7 cell line 
used as the positive control and is separated with red dotted lines. A one-way ANOVA 
followed by Tukey's test for multiple comparisons between different conditions was carried 
out. Data represent the mean ±SEM of three individual experiments, each performed in 
triplicate (***p<0.001; **p<0.01; *p<0.05). 
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6.2.2.2 Protein expression of AURK-A 
The AURK-A antibody produced single band at 48 kDa in most of the trophoblast cell lines, 
MCF-7 cells and positive control (Hela cells) (See Figure 6.8).  
There was correlation between mRNA and protein expression profile for AURK-A in 
HTR8/SVneo cells. There was a significant increase in untreated parental compared to DOX-
treated parental cells (p<0.05) and also between untreated spheroids and DOX-treated 
spheroids (p<0.001) (See Figure 6.8, Panel A). TEV-1 cells showed a significant up-
regulation in AURK-A protein level in DOX-treated spheroids compared to both (a) DOX-
treated parental cells (p<0.001) and (b) untreated spheroids cells (p<0.05) (Figure 6.8, Panel 
B). 
In JEG-3 cells, there were no significant changes in the expression of AURK-A between all 
conditions. On the other hand, a significant increase in protein expression was seen in BeWo 
DOX-treated parental cells compared to untreated parental cells (p<0.05) (See Figure 6.8, 
Panel C and D). This change was not seen in mRNA expression comparisons. The protein 
expression of AURK-A was increased in MCF-7 untreated spheroids compared to parental 
cells (p<0.05).  Also, there was a significant change in untreated spheroidal cells versus 
DOX-treated spheroidal cells (p<0.05) (See Figure 6.8, Panel E). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
195 
 
                       Chapter 6: expression analysis of tumour associated factors in trophoblast cells 
 
 
Figure 6.8: The expression of AURK-A protein. 
The ratio of AURK-A to β-actin densitometry readings are given for the HTR8/SVneo and 
TEV-1 cell lines in panels A and B respectively. Likewise Panel C and D represent JEG-3 
and BeWo cell lines; and Panel E shows the data for the MCF-7 cell line. Hela cell line used 
as the positive control and is separated with red dotted lines. A one-way ANOVA followed 
by Tukey's test for multiple comparisons between different conditions was carried out. Data 
represent the mean ±SEM of three individual experiments, each performed in triplicate 
(***p<0.001; **p<0.01; *p<0.05). 
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6.2.2.3  Protein expression of AURK-C 
The AURK-C antibody produced single bands at 36 kDa in almost all the four trophoblast 
cell lines, MCF-7 samples and positive control (Hela cells) (See Figure 6.9).   
There was a significant increase in protein expression of AURK-C observed in HTR8/SVneo 
DOX-treated parental cells compared with (a) their untreated counter parts (p<0.05), and (b) 
DOX-treated spheroidal cells (p<0.01). On the other hand, there was a significant reduction 
in protein expression in untreated spheroid compared to untreated parental cells (p<0.01) 
(See Figure 6.9, Panel A).  The TEV-1 cell line showed a significant increase in DOX-treated 
parental cells compared to untreated parental cells. (See Figure 6.9, Panel A).   
There was a correlation between mRNA and protein expression in JEG-3 untreated parental 
compared to untreated spheroidal cells (p<0.01). Difference in protein expression level were 
only observed in DOX-treated parental compared to DOX-treated spheroidal cells (p<0.01) 
(See Figure 6.9, Panel C).  The BeWo cells derived untreated spheroids showed a higher 
protein expression level of AURK-C than DOX-treated spheroids (p<0.01) (See Figure 6.9, 
Panel D).   
There was a significant increase in mRNA and protein expression of AURK-C observed in 
MCF-7 spheroidal cells (both DOX-treated and untreated) compared to their parental cell 
counterparts (p<0.01) (See Figure 6.9, Panel E). 
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Figure 6.9: The expression of AURK-C protein. 
The ratio of AURK-C to β-actin densitometry readings are given for the HTR8/SVneo and 
TEV-1 cell lines in panels A and B respectively. Likewise Panel C and D represent JEG-3 
and BeWo cell lines; and Panel E shows the data for the MCF-7 cell line. Hela cell line used 
as the positive control and is separated with red dotted lines. A one-way ANOVA followed 
by Tukey's test for multiple comparisons between different conditions was carried out. Data 
represent the mean ±SEM of three individual experiments, each performed in triplicate 
(***p<0.001; **p<0.01; *p<0.05). 
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6.2.2.4 Protein expression of PDGFRα 
The PDGFRα antibody produced a single band at 36kDa in all four trophoblast, MCF-7 
samples and positive control (PDGF protein), whilst the expected molecular weight of the 
band was in the range of 14-20kDa (Figure 6.10).   
In HTR8/SVneo cells (Figure 6.10, Panel A) the protein and mRNA expression of PDGFRα 
was significantly higher in untreated parental cells compared to DOX-treated parental cells 
(p<0.001). The protein expression in DOX-treated spheroids was significantly higher than 
that of DOX-treated parental cells (p<0.001). In TEV-1 cells, compared to parental cells 
spheroids showed a significant increase in protein expression of PDGFRα (p<0.01) (see 
Figure 6.10, Panel B). 
In JEG3 cells, a significant increase in protein expression of PDGFRα was seen in DOX-
treated parental cells compared to (a) untreated parental cells (p<0.001) and (b) DOX-treated 
spheroids (p<0.05) (Figure 6.10, Panel C). 
In BeWo cells, the expression of protein was reduced in DOX-treated parental cells 
compared to parental cells (p<0.001). Furthermore, a significant reduction was observed in 
untreated spheroids compared to parental cells (p<0.001) (Figure 6.10, Panel D). These 
changes were not observed in mRNA expression comparisons  
In MCF-7 cells (Figure 6.10, Panel E), the protein expression was higher in untreated 
parental cells compared to DOX-treated parental cells (p<0.001). Also, there was a 
significant difference between untreated parental and untreated spheroidal cells (p<0.001).  
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Figure 6.10: The expression of PDGFRα protein. 
The ratio of PDGFRα to β-actin densitometry readings are given for the HTR8/SVneo and 
TEV-1 cell lines in panels A and B respectively. Likewise Panel C and D represent JEG-3 
and BeWo cell lines; and Panel E shows the data for the MCF-7 cell line. PDGF (protein) 
used as the positive control and is separated with red dotted lines. A one-way ANOVA 
followed by Tukey's test for multiple comparisons between different conditions was carried 
out. Data represent the mean ±SEM of three individual experiments, each performed in 
triplicate (***p<0.001; **p<0.01; *p<0.05). 
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6.2.2.5     Protein expression of TWIST1 
The TWIST1 antibody produced single bands at 49kDa in all four trophoblast, MCF-7 
samples and positive control (Hela cells), whilst the expected molecular weight of the band 
was between 21- 36 kDa (Figure 6.11).   
Figure 6.11 Panel A shows that protein expression was lower in HTR8/SVneo DOX-treated 
parental cells compared (a) untreated parental and (b) DOX-treated spheroids (p<0.01). In 
TEV-1 cells (Figure 6.11, Panel B), the protein expression was significantly higher in DOX-
treated parental cells compared to untreated parental (p<0.05) and in DOX- treated parental 
cells versus untreated spheroids (p<0.01).  
The JEG-3 cells showed a significant change in protein expression in untreated parental cells 
compared to DOX-treated parental cells and untreated spheroidal cells (p<0.05) (Figure 
6.11, Panel C).  In the BeWo cells, a significant reduction in protein expression of TWIST1 
was observed in untreated spheroidal cells compared to (a) untreated parental cells and (b) 
DOX-treated spheroids (p<0.05) (Figure 6.11, Panel D).  
MCF-7 cells exhibited a high level of protein and mRNA expression of TWIST1 in DOX-
treated parental cells compared to DOX-treated spheroids (p<0.05) (Figure 6.11, Panel E). 
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Figure 6.14: The expression of TWIST1 protein. 
The ratio of TWIST1 to β-actin densitometry readings are given for the HTR8/SVneo and 
TEV-1 cell lines in panels A and B respectively. Likewise Panel C and D represent JEG-3 
and BeWo cell lines; and Panel E shows the data for the MCF-7 cell line. Hela cell line used 
as the positive control and is separated with red dotted lines. A one-way ANOVA followed 
by Tukey's test for multiple comparisons between different conditions was carried out. Data 
represent the mean ±SEM of three individual experiments, each performed in triplicate 
(**p<0.01; *p<0.05). 
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6.2.2.6    Protein expression of JAG1 
The JAG1 antibody produced single band at 75 kDa in all the four trophoblast cells, MCF-7 
and positive control (Hela cells) under different conditions (See Figure 6.12).  There were 
no significant changes observed in JAG1 protein expression level in HTR8/SVneo, TEV-1, 
BeWo and MCF-7 cell lines (See Figure 6.12, Panel A, B, D and E).  However, in JEG-3 
the protein expression of JAG1 was increased in DOX-treated parental cells compared to 
both (a) untreated parental, and (b) DOX-treated spheroids (p<0.01) (See Figure 6.12, Panel 
C). 
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Figure 6.12: The expression of JAG1 protein. 
The ratio of JAG1 to β-actin densitometry readings are given for the HTR8/SVneo and TEV-
1 cell lines in panels A and B respectively. Likewise Panel C and D represent JEG-3 and 
BeWo cell lines; and Panel E shows the data for the MCF-7 cell line. Hela cell line used as 
the positive control and is separated with red dotted lines. A one-way ANOVA followed by 
Tukey's test for multiple comparisons between different conditions was carried out. Data 
represent the mean ±SEM of three individual experiments, each performed in triplicate 
(**p<0.01). 
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6.2.3  Proteomic analysis of global protein/peptide expressions  
Sequential Windowed Acquisition of All Theoretical Fragment Ion Mass Spectra (SWATH-
MS) was carried out to identify novel proteins, whose expression is affected by spheroidal 
transformation. As the analyses have produced a very large data set, this chapter focuses 
only on the changes identified in the transformed trophoblast cell lines (HTR8/SVneo and 
TEV-1). SWATH-MS analysis is a recently developed technique, which enables 
quantification of mass spectrometry data (Wang et al., 2015). These proteins were selected 
from a long list of proteins identified according to their fold change only up-regulated 
proteins and functions related to cell division, proliferation and invasion. 
 
6.2.3.1 Identification of altered proteins in HTR8/SVneo cells   
A list of the most up-regulated proteins and their fold change in HTR8/SVneo cells are 
summarised in Table 6.1 [6.1A - untreated parental versus untreated spheroids; 6.1B 
untreated parental versus DOX-treated parental; 6.1C untreated spheroid versus DOX-
treated spheroids; and 6.1D. DOX-treated parental versus DOX-treated spheroids]. As can 
be seen in Table 6.1A, eight of the proteins with different fold changes were observed to be 
up-regulated in untreated spheroids compared to their parental counterparts. Interestingly, 
plasminogen, vitronectin, cysteine rich protein 2 and AL1A3 were all up-regulated in 
untreated spheroidal cells (6.1A). Many of these proteins are involved in cells differentiation 
and proliferation. In addition, the cell adhesion factor vitronectin and plasminogen were 
found to be up-regulated in both untreated and DOX-treated spheroidal cells. The details of 
fold changes with cells involved are summarised in table 6.1 (A) to (D). The most interesting 
proteins that have been identified in different cell populations of HTR8/Svneo and TEV-1 
by SWATH-MS are summarised in Table 6.3. 
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Table 6. 1: Identification of up-regulated proteins/peptide in HTR8/SVneo cells.   
HTR8/SVneo cells were collected from adherent and non-adherent flasks. The proteins were 
analysed by SWATH-MS using the following comparisons; untreated parental Vs untreated 
spheroids (6.1A); untreated parental Vs DOX-treated parental) (6.1B); untreated spheroids Vs DOX-
treated spheroidal cells (6.1C) and parental cells Vs DOX-treated spheroidal cells (6.1D).  
(A) Untreated parental versus untreated spheroids 
 
 
(B) Untreated parental versus DOX-treated parental cells  
 
The data were summarised after 4 individual experiments with different passage numbers (n=4) using SCIEX 
OneOmics with the following parameters: MLR weight >0.15, confidence >70%, algorithms. Both accession 
numbers and protein names are from the Uniprot database. The common proteins that were found among all 
the comparisons were encircled with red colour. 
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Table 6.1: Identification of up-regulated proteins/peptide in HTR8/SVneo cells. 
 (C) Untreated spheroids versus  DOX-treated spheroids  
 
 
 (D) DOX-treated parental versus DOX- treated spheroids 
 
 
 
 
The data were summarised after 4 individual experiments with different passage numbers (n=4) using SCIEX 
OneOmics with the following parameters: MLR weight >0.15, confidence >70%, algorithms. Both accession 
numbers and protein names are from the Uniprot database. The common proteins that were found among all 
the comparisons were encircled with red colour.   
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6.2.3.2  Identification of altered proteins in TEV-1 cells 
A list of the most up-regulated proteins and their fold changes are summarised in Table 6.2 
[6.2A untreated parental versus untreated spheroids; 6.2B untreated parental versus DOX-
treated parental; 6.2C untreated spheroids versus DOX-treated spheroids; and 6.2D  DOX-
treated parental versus DOX-treated spheroids. An overall two-fold up-regulation of AL1A3 
(Aldehyde dehydrogenase family 1 member A3) was observed in untreated parental versus 
spheroidal cells and in untreated parental versus DOX-treated parental cells [see tables 
6.2(A) and (B)]. Furthermore, there was a more than three fold up-regulation of proteolytic 
enzyme plasminogen in untreated spheroids in comparison with untreated parental cells 
[(Table 6.2(B)]. Interestingly, the three-fold up-regulation of plasminogen in untreated 
spheroids was also observed when compared to DOX-treated spheroids [Table 6.2(C)]. In 
contrast, the less than two-fold up-regulation of Galectin-1 (LEG1) was observed in 
untreated spheroids compared to DOX-treated spheroids [Table 6.2(C)] and in DOX-treated 
parental compared to DOX-treated spheroids [Table 6.2(D)]. The details of fold changes 
with cells involved are summarised in Table 6.2 (A) to (D). The most interesting proteins 
that have been identified in different cell populations of HTR8/SVneo and TEV-1 by 
SWATCH-MS are summarised in Table 6.3. 
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Table 6. 2: Identification of up-regulated proteins/peptide in TEV-1 cells.  
TEV-1 cells were pre-collected from adherent and non-adherent flask. The up-regulated 
proteins were analysed by SWATH-MS using following comparisons; untreated parental Vs 
untreated spheroids (6.2A); untreated parental Vs DOX-treated parental) (6.2B); untreated spheroids 
Vs DOX-treated spheroidal cells (6.2C) and parental cells Vs DOX-treated spheroidal cells (6.2D).  
(A) Untreated parental versus untreated spheroids 
 
(B) Untreated parental versus DOX-treated parental cells 
 
The data were summarised after 4 individual experiments with different passage numbers (n=4) using SCIEX 
OneOmics with the following parameters: MLR weight >0.15, confidence >70%, algorithms. Both accession 
numbers and protein names are from the Uniprot database. The common proteins that were found among all 
the comparisons were encircled with red colour.   
209 
 
                       Chapter 6: expression analysis of tumour associated factors in trophoblast cells 
 
Table 6.2: Identification of up-regulated proteins/peptide in TEV-1 cells. 
 (C) Untreated spheroids versus DOX-treated spheroids 
 
 
 (D) DOX-treated parental versus DOX- treated spheroids 
 
 
 
The data were summarised after 4 individual experimentations with different passage numbers (n=4) 
using SCIEX OneOmics with parameters MLR weight >0.15, confidence >70% algorithms used 
mentioned as detailed. Both accession numbers and protein names are from the Uniprot database. 
Any protein found in both conditions were encircled with red colour.  
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Table 6. 3: Protein changes that are common to HTR/SVneo and TEV-1 cells.  
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6.3  Discussion  
The aim of this chapter was to investigate and compare the status of the tumour associated 
factors ALDH3A1, AURK-A and C, PDGFRα, TWIST1, and JAG1 in four trophoblast cell 
lines (HTR8/SVneo, TEV-1, JEG-3 and BeWo) and MCF-7cells under different conditions. 
The expression of these factors have been investigated in placental tissues (NT and PE) in 
Chapter 3. In this chapter, the status of the same factors were analysed in different 
trophoblast cell lines and the spheroidal cells generated from them. Both mRNA and protein 
expression were compared by qRT-PCR and semi-quantitative western blotting respectively. 
To the best of author’s knowledge, this is the first study that has attempted to comparatively 
analyse the protein and mRNA expressions of these factors in (trophoblast) placental derived 
cells. Since some of the factors related to tumourigenesis have been shown to be changed 
with spheroidal transformation, it was also decided to compare the global protein expression 
(proteome) during spheroidal transformation. 
As mentioned in Section 6.1, there are many difficulties in using primary cell cultures. To 
elaborate further, the purity of primary trophoblasts are always questionable as these cultures 
readily become contaminated with other cell types such as fibroblasts, endothelial and 
mesenchymal cells  (Zuo et al., 2014). Furthermore, they cannot be maintained for long 
periods in culture. Therefore, several trophoblast cell lines have been established and 
characterised to investigate the proliferation and invasion of both placenta and placental 
tumours  (Zuo et al., 2014). These cells have different features and they share some 
molecular markers with their primary counterparts.  However, they are of limited value for 
studying the paracrine/autocrine interaction between sub-populations of trophoblast because 
all these cell lines differ from each other as they: a) do not comprise the sub-populations, b) 
have differing genetic backgrounds, and c) have been immortalised under different 
procedures or obtained after tumorigenic transformation strategies (Hiden et al.,  2007).   
Some of these cells have been used in this study, such as HTR8/SVneo, which is a human 
immortal first-trimester EVT cell line, originated from extravillous cytotrophoblast and 
exhibits similar in vitro invasive properties to the parental cells (Lala et al., 2002).The TEV-
1 cell line was established from a human first-trimester extravillous trophoblast cell line. It 
resembles EVTs in the expression of immunological antigens and phenotypic characteristics 
(Feng et al., 2005). JEG-3 is a choriocarcinoma cell line, used as a trophoblast cell model to 
study placental function and presents many of the biological and biochemical characteristics 
associated with syncytiotrophoblasts (Matsuo and Strauss, 1994). BeWo is another type of 
choriocarcinoma cell line, used in vitro as a model to mimic in vivo syncytialisation of 
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placental villous trophoblasts, to study villous trophoblast differentiation and fusion (Orendi 
et al., 2010).  
6.3.1  Relative mRNA/protein expressions of factors of interest 
The variance in mRNA and protein expression level of these factors (ALDH3A1, AURK- A 
and C, PDGFRα, TWIST1, and JAG1) were compared between different conditions. It is 
worth noting that data from different cell lines were found to be different to each other. This 
shows that the observations are cell line specific and might have been influenced by the way 
they were immortalised.  Also, compared to the house-keeping proteins, the expression of 
these factors are low, both at mRNA and protein levels. Some comparisons showed a 
correlation between relative mRNA expression and protein level (especially in MCF-7 cells), 
whereas other results did not show this correlation. As mentioned in Chapter4 (Section 
4.3.5), the reason for the mismatch correlation between mRNA and protein levels is not fully 
clear, but it may be possible that expression of mRNA is reciprocally reduced as a result of 
the high levels of protein expression. Moreover, it could be because of the half-life of some 
mRNA transcripts is extremely low due to RNA degradation.   
 ALDH3A1 
ALDH is also found in stem cells during early life and was demonstrated as an important 
marker for identification of SCs (Douville et al., 2009). Also ALDH1 can be a better marker 
of breast cancer SCs than CD44+/CD24- (Tanei et al., 2009). It has also been described as 
a stem cell marker in various solid tumours including lung cancer (Jiang et al., 2009), breast 
carcinoma (Ginestier et al., 2007), and colorectal cancer (Huang et al., 2009). ALDH1A3 
may influence cell activity and proliferation by controlling intracellular retinoid 
concentrations and play important roles in stem cell biology (Balber, 2011). It also plays an 
essential role in the cell proliferation, drug metabolism and regulation of growth and 
differentiation in both normal and cancer cells (Muzio et al., 2012). The mRNA of a specific 
isoform ALDH3 has been found to be expressed in placental tissue (Alnouti and Klaassen, 
2007). In this investigation, both HTR8/SVneo and BeWo cell lines showed a significant 
up-regulation in the protein expression of ALDH3A1 in DOX-treated parental compared to 
other conditions. In contrast to mRNA expressions, there was no significant difference in the 
protein expression level of ALDH3A1 in TEV-1 cells, in all conditions. Overall, the protein 
expression of ALDH3A1 was significantly higher in DOX-treated parental cells and 
untreated spheroid cells derived from JEG-3 cells.  This increased expression of ALDH3A1 
in both untreated and DOX-treated spheroids may indicate that spheroidal cells have 
increased their stem cell-like features. Interestingly, there was a significant up-regulation of 
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ALDH3A1 protein expression in MCF-7 spheroidal cells compared to parental 
conditions. This could be because MCF-7 is a breast cancer cell line as stated earlier (Tanei 
et al., 2009). 
 AURK-A  
As explained in Chapter 3, AURK-A shows a high expression in PE tissue samples. AURK-
A plays an important role in cell cycle progression, and has been implicated in tumour 
formation and progression (Fu et al., 2007). It is highly expressed in several tumour types 
such as breast, lung, colon, prostate and pancreas (Siggelkow et al., 2012). Furthermore, 
polymorphisms in the AURK-A gene are associated with increased primary breast cancer 
risk (Fletcher et al., 2006). Interestingly, the protein expression of AURK-A in MCF-7 cells 
was significantly higher in untreated spheroids compared with other conditions. A recent 
study showed that the protein expression of AURK-A was elevated in the MCF-7 cell line 
(Sun et al., 2014). According to the data presented in this chapter, the protein expression 
level of AURK-A was increased in HTR8/SVneo untreated spheroids compared to other 
conditions. A significant increase in protein expression of AURK-A in TEV-1 DOX-treated 
spheroidal cells was observed, compared to their spheroidal cell counterparts. This suggests 
that spheroids produced from the transformed trophoblast cell lines may have gained the 
ability to proliferate. On the other hand, despite their cancerous origins, there were no 
significant changes in the expressions of AURK-A in spheroids produced from JEG-3 and 
BeWo, as higher levels of expression were expected. 
 AURK-C 
The expression of AURK-C in trophoblast cells has not been reported yet. As explained in 
Chapter 3, there was a significant increase in the mRNA and protein expression of AURK-
C in NT placental tissues compared to PE. In the cell lines, a significant reduction in protein 
expression of AURK-C was observed in HTR8/SVneo, TEV-1 and JEG-3, in spheroidal 
cells (untreated and DOX-treated) compared to other conditions. However, in BeWo cells 
the protein expression was up-regulated in untreated spheroids compared to DOX-treated 
spheroids. Since AURK-C is overexpressed in cell transformation and tumour formation 
(Khan et al., 2011), in fact, this is the first study to show the expression of AURK-C in these 
cell lines and their spheroids. 
  
214 
 
                       Chapter 6: expression analysis of tumour associated factors in trophoblast cells 
 
 PDGFRα 
PDGFRα signalling has important functions during embryogenesis, and its overexpression 
is associated with several pathological conditions such cancer (Carvalho et al., 2005). The 
expression of PDGFR-α in trophoblast cell lines has not previously been investigated. The 
current data shows, a significant increase in protein expression of PDGFRα observed in 
DOX-treated spheroidal cells of HTR8/SVneo. In addition TEV-1 cells showed a significant 
increase in protein expression of PDGFRα in both spheroidal cells (untreated and DOX-
treated) compared to parental conditions. Increased expression of PDGFRα in untreated and 
DOX-treated spheroids in both transformed cell lines (HTR8/SVneo and TEV-1) may 
indicate that spheroidal cells have increased their stem-like cell features, [as PDGFRα was 
expressed by multipotent cardiovascular progenitors in mouse and human embryonic stem 
cell systems (Tallquist and Soriano, 2002)]. In contrast a significant reduction in protein 
expression was observed in spheroidal cells (untreated and DOX-treated) of BeWo cells 
compared to their parental cell counterparts. This was unexpected as PDGFR-α expression 
has been previously reported in various tumour types such as ovary, prostate, colon and lung 
(Bronzert et al., 1987). On the other hand, there was a significant difference in protein 
expression of PDGFRα between untreated spheroidal cells of MCF-7 confirming its 
expression being correlated with invasive breast carcinomas (Carvalho et al., 2005).  
 TWIST1 
TWIST1 plays many roles in promoting tumour metastasis (Kang and Massagué, 2004).  
Furthermore, studies showed TWIST1 plays a role in promoting trophoblast invasion in mice 
(Abell et al., 2009). However, the role of TWIST in human trophoblast invasion is still not 
clear. The current data shows that the protein expression of TWIST1 was significantly 
increased in the case of HTR8/SVneo spheroids (both DOX-treated and untreated) compared 
to their parental cells counterparts. This actually confirms the finding of Ng et al. (2012) that 
the mRNA and protein expressions of TWIST1 was substantially increased in HTR8/SVneo 
(more than both choriocarcinoma cell lines JEG-3 and BeWo). Regardless of the differences 
in the aims of the present study and the study by Ng et al. (2012), the findings of both studies 
agree that TWIST1 could play important role in spheroidal transformation and/or trophoblast 
invasion. 
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 JAG1 (Jagged1) 
Interestingly, the result from Chapter 3 showed that JAG1 mRNA and protein expression 
were high in human placental tissues. However, the result from this chapter showed that 
there was no significant change in the mRNA and protein expression levels of JAG1 
observed in trophoblast cells (HTR8/SVneo, TEV-1 and BeWo). On the other hand, the 
protein expression level was up-regulated in JEG3 DOX-treated parental cells compared to 
both (a) untreated parental, and (b) DOX-treated spheroidal cells. The MCF-7 cell line 
showed similar results to the trophoblast cell lines, (i.e. there was no significant change in 
mRNA and protein expression level of JAG1). According to Herr et al., (2011) NOTCH 
receptors 1-4 and their ligands JAG1, -2 are expressed in first and third trimester human 
placental tissue. Also many studies have identified NOTCH1 receptors in the endometrium, 
and blastocyst. Moreover, JAG1 was detected in placental endothelial cells (Zhao et al., 
2013).  It has also been demonstrated that NOTCH3 up-regulates its own ligand Jagged1 in 
human primary mammospheres (Zhang et al., 2010), and in human breast cancer cell lines, 
such as MCF-7 and MDA-MB-231 (Shao et al., 2015). NOTCH signalling plays important 
roles in implantation/placentation by the regulation of EVT invasion and spiral artery 
remodelling in the decidua and angiogenesis in the placenta (Cuman et al., 2013). However, 
the data obtained here did not show any changes with spheroidal transformation.  
6.3.2   Proteomics on global expressions of protein in transformed trophoblast cell lines 
Proteomics technology can provide valuable information on the dynamic changes of proteins 
(Yang et al., 2015). In this study, using SWATH-MS the up-regulated proteins between the 
following comparisons were identified: (a) untreated parental Vs. untreated spheroids; (b) 
untreated parental Vs. DOX-treated parental; (c) untreated spheroids Vs. DOX-treated 
spheroids; and (D) DOX treated parental Vs. DOX-treated spheroids. SWATH-MS analysis 
has identified up-/down-regulations of several proteins in different comparisons in 
transformed trophoblast (HTR8/SVneo and TEV-1) and choriocarcinoma (BeWo and JEG-
3) cell lines. However, due to the high volume of data only the proteins that have shown up-
regulation in fold changes in HTR8/SVneo and TEV-1 are discussed below. Interestingly, 
many of those proteins are found to be involved in cell proliferation, invasion, and 
differentiation. Others are involved in embryonic development and inflammation. These 
were up-regulated mainly in both un-/DOX-treated spheroids. As seen in Table 6.1 (A) and 
(C), in HTR8/SVneo both untreated and DOX-treated spheroids have shown up-regulation 
of many proteins.  These include plasminogen and vitronectin. On the other hand, in TEV-1 
cells only the untreated spheroids have shown up-regulation of these proteins.  
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Plasminogen is a precursor of plasmin during the blood clotting cascade (Stoppelli, 
2013).  Plasmin is one of the most important and reactive serine protease enzymes, present 
in blood that degrades many blood plasma proteins, including fibrin clots (Deryugina and 
Quigley, 2012). It plays a role in different physiological processes such as embryo 
development, wound healing (thrombolysis), and cancer development (Andreasen et al., 
2000).  The plasminogen system is composed of two types includes the urokinase-type (uPA) 
and the tissue-type (tPA) (Alfano et al., 2005) uPA is generally agreed to be the enzyme of 
most relevance to tumour biology, whereas tPA has a role in the generation of plasmin for 
fibrinolysis. As plasminogen activation plays an important role in vascular and tissue 
remodelling, tumour growth, and cancer progression (Andreasen et al., 2000) and the fact 
that  is up-regulated mainly in untreated spheroids (in TEV-1) and DOX-treated spheroids 
(in HTR8/SVneo cells) compared to parental cells indicate that these cells might have gained 
stemness features.  
In contrast, vitronectin (VNTC) showed up-regulation mainly in DOX-treated spheroidal 
cells followed by un-treated spheroids in HTR8/SVneo cells. On the other hand, TEV-1 cells 
showed the highest fold change only in un-treated spheroids. Vitronectin is an abundant 
adhesion glycoprotein in blood plasma associated with different extracellular matrix sites 
and tumour cells (Preissner and Reuning, 2011). Vitronectin is produced in the liver, 
however, its mRNA has been detected in various tissues, including the brain and heart, and 
this suggests its production by other cells (Seiffert et al., 1994). It plays an important role in 
cell migration, tissue repair and, tissue remodelling (Seiffert et al., 1994).  Moreover, it has 
many physiological functions such as cell adhesion, regulation of fibrinolysis, coagulation 
and immune defence, which could be key in the incidence and progression of severe PE, 
mainly in early-onset severe PE (Shen et al., 2012).  Different studies have reported that 
vitronectin protein expression has been found in breast cancer (Aaboe et al., 2003).  In 
addition, a significant increase in expression level of VTNC protein was found in the 
maternal-foetal interface of early-onset severe preeclampsia (Shen et al., 2012).  Here, the 
up-regulation of VNTC in spheroidal cells might be linked to their transformation and 
gaining invasiveness. 
The other protein that showed high fold changes in the up-regulation in spheroidal cells was 
cysteine-rich protein 2 (CRIP2). This protein was up-regulated in untreated spheroids and 
DOX-treated parental of HTR8/SVneo cells. It is also worth noting, ALDH1A3 was 
observed to be up-regulated in untreated spheroids in both HTR8/SVneo and TEV-1 cells as 
identified by SWATH-MS. However, the qRT-PCR (mRNA) and western blotting (protein) 
results of ALDH3A1 did not completely agree with this. This may be mainly due to 
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ALDH1A3 is a different gene to ALDH3A1, which there are from same grup (ALD), but 
under different family and member.  Overall the SWATH-MS data have identified several 
proteins that are up-regulated in untreated and DOX-treated spheroids. Some of the changes 
in proteins are consistent between HTR8/SVneo and TEV-1 cells (See Table 6.3). These 
proteins are linked with either cell proliferation, invasion or cell cycle control. For example, 
vitronectin has been identified as a component of serum which drives the differentiation of 
both breast and prostate CSCs (Hurt et al., 2010). It is also used as a substrate substitute in 
matrigel to study the maintenance and differentiation of human pluripotent stem cells 
(hPSCs) (Braam et al., 2008). This suggest the spheroidal cells expressing these proteins 
have gained “stem-like” behaviour; confirming the data obtained in Chapter 4. 
 
6.4  Conclusion 
According to the data from this study, the mRNA and protein expression of ALDH1A3, 
AURK-(A and C), PDGFRα, TWIST1, and JAG1 were differentially expressed in spheroidal 
and parental cells. Also, SWATH-MS analysis highlighted up-regulation of some proteins 
that are associated with proliferation, invasion and cell cycle control. This suggests that 
spheroidal (untreated and DOX-treated) generated from both transformed trophoblast cell 
lines, HTR8/SVneo and TEV-1, may have gained the “stemness” features.   
218 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
              Chapter 7 
7. General Discussion 
219 
 
                                                                                                           Chapter 7: General Discussion 
  
7.0  Discussion 
The aims of this study were firstly, to compare the expression patterns of common factors 
related to invasion, such as ALDH3A1, AURK-A and C, PDGFRα, TWIST1, and JAG1 
between normotensive (NT) and pre-eclamptic (PE) placentae. Secondly, to generate 
spheroidal cells from transformed trophoblast cells (HTR8/SVneo, TEV-1), and 
choriocarcinoma (JEG-3, BeWo) (using breast cancer cell line MCF-7 as non-placental 
tumour control). In addition, to check the effects of a chemotherapeutic agent (Doxorubicin) 
in producing drug resistant spheroids from all four trophoblast cell lines. This was followed 
by a characterisation of “stemness” feature by studying the expressions of stem cell markers, 
such as OCT4, SOX-2, NANOG, CDX2 and NOTCH1. Thirdly, to compare the migration 
and invasive potentials amongst non-resistant/drug-resistant spheroids and their original 
(parental) cells. Next linking with the first aim, the expression patterns of the common 
factors such as ALDH3A1, AURK- (A and C), PDGFRα, TWIST1, and JAG1 in spheroidal 
cells and their parental controls (both untreated and DOX-treated) were looked at. Finally, 
the study aimed to investigate the changes in the global protein (peptide) expression profiles 
in parental and spheroidal cells (untreated and DOX-treated) using SWATH-MS technique. 
  
7.1  Expression analysis factors of interest in NT and PE 
Differential gene expression techniques, such as microarray, have identified several 
candidate genes/factors involved in PE. As explained in chapter 3, these include growth 
factors, transcription factors, extracellular matrix proteins, and proteins involved in 
signalling pathways (Hansson et al., 2006;  Sood et al., 2006; Louwen et al., 2012). Using 
murine microarrays established by Dr Ali (Nottingham Trent University), some common 
molecules that might be hypothetically involved in trophoblast invasion were identified (eg.  
ALDH3A1, AURK-A, AURK-C, PDGFRα, TWIST1 and JAG1). To begin with, the mRNA 
and protein expression of these factors were compared in NT and PE placentae. 
Although, pathophysiology of PE is still unclear, it is associated with abnormal vascular 
remodelling of the spiral arterioles and shallow invasion (Goldman-Wohl and Yagel, 2002). 
The abnormal remodelling reduces the oxygen supply to the placenta and decidua, creating 
a hypoxic condition which leads to the production of reactive oxygen species (ROS) and 
ultimately to oxidative stress (www23). Oxidative stress plays an important role in the 
pathophysiology of PE (www23). The data explained in chapter 3 suggest that the expression 
of these factors are definitely altered in PE. Since many of these factors are involved in cell 
proliferation and/or invasion, their altered expressions in PE placentae confirms previous 
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findings/hypothesis of trophoblast dysfunctions being responsible for PE (Burton and 
Jauniaux, 2004; Pennington et al., 2012; Vaiman et al., 2013). The changes in the individual 
proteins are discussed below. 
 
Interestingly, the enzyme ALDH3 family has an important role during cell proliferation, 
differentiation, and also plays an important physiological role against cellular oxidative 
stress by detoxifying aldehydes derived from oxidative processes, such as ethanol 
metabolism (Marchitti et al., 2010). The present study showed that both mRNA and protein 
levels of ALDH3A1 are significantly increased in PE placentae compared to NT. ALDH3A1 
was recognized as an oxidative stress response protein as oxidative stress leads to increased 
ALDH3A1 expression (Moreb et al., 2008; Kim et al., 2014). ALDH3A1 is presumed to 
have a protective role against oxidative stress-induced apoptosis. This result is consistent 
with the hypothesis that oxidative stress is a significant factor in the pathogenesis of PE. 
Therefore, the higher levels of ALDH3A1 in PE could be a mechanism to overcome the 
oxidative stress induced apoptosis. 
 
Likewise, AURK-A plays an important role in the regulation of mitosis and cytokinesis 
(Kimura et al., 1999). Dysregulated Aurora-A expression leads to mitotic faults and results 
in pathological conditions (Mortlock et al., 2007). To date no studies on AURK-A 
expression in human placental tissues have been reported. A study carried out by Cho et al 
(2014), illustrated that oxidative DNA damage can be related to the expression of AURK-A 
protein. Significant up-regulation of mRNA and protein expression of AURK-A in PE was 
observed in present study. Interestingly, results from IHC illustrated that AURK-A also 
showed higher staining for PE than NT placentae. It can be assumed that the AURK-A 
expression increasing in PE due to the high oxidative stress. However, both mRNA and 
protein expression levels of AURK-C were increased in NT compared to PE. The data was 
also confirmed by IHC which illustrated higher staining for NT than PE. AURK-C has a role 
in the regulation of mitosis and cytokinesis (Kimura et al., 1999). It is expressed in many 
types of cancer, however the function of AURK-C in normal cellular processes is not fully 
understood (Quartuccio and Schindler, 2015). Therefore, it is difficult to predict the 
biological significance of this expression on the disease. Interestingly, it can be predicted 
that AURK-C might be expressed during first trimester trophoblast cells to enhance 
proliferation and invasion of EVT cells, which are important for successful pregnancy. 
Additionally, AURK-C could play a role during implantation by regulating cytokinesis 
(Mortlock et al., 2007).   The biological effects of PDGFs are exerted by activation of two 
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tyrosine kinases platelet-derived growth factor receptor PDGFRα and β. PDGFRα is 
instrumental during embryonic organogenesis and development by directing the cell 
proliferation, differentiation, migration, and function of specialised mesenchymal cells 
(Karlsson et al., 1999).   
The present study showed the mRNA and protein expression levels of PDGFRα are 
increased significantly in PE compared to NT. PDGFRα was studied only in early placenta 
but not near-term placental tissues. Therefore, a high expression in term PE samples could 
be an indication of malformation of the placenta.  
 
TWIST1 plays a role in cell proliferation, migration and differentiation in embryonic 
progenitor cell populations and transformed tumour cells (Ansieau et al., 2008). The current 
study shows a statistically significant increase of TWIST1 mRNA and protein expression in 
PE. Interestingly, these results were also validated with IHC and intense staining for 
TWIST1 was detected in the STB layer of PE placentae rather than NT placentae. Ng et al 
(2012) demonstrated that TWIST1 and N-cadherin are abundantly expressed in highly 
invasive EVT propagated from first-trimester human placenta. It could be suggested that 
TWIST1 over-expression in placental tissues might only has advantages in the early stage.  
A high expression of TWIST1 in PE placental samples could be a compensatory change to 
counteract the defective trophoblast invasion in PE.  
 
JAG1 is one of the five cell surface proteins (ligands) that interact with four receptors in the 
mammalian NOTCH signalling pathway (Zhao and Lin, 2012). Overall they play an 
important role in normal development of human placenta. Therefore, the defect of NOTCH 
signalling pathway could contribute to the pregnancy complications, such as PE (Zhao and 
Lin, 2012). Sahin et al. (2011), detected a significant decrease in the immunoreactivity of 
NOTCH proteins in PE compared to normal placentae. This was consistent with the present 
data where both mRNA and protein expression levels of JAG-1 were decreased in PE 
compared to NT placentae. A study by Hunkapiller et al. (2011) speculated that there was a 
correlation between reduced JAG-1 expression and failed vascular remodelling in PE. The 
low expression of JAG1 in PE in this study could be associated with incomplete remodelling 
of human spiral arterioles. 
 
These factors of interest were also investigated in trophoblast cell lines to confirm their 
expression patterns in these cells. The data showed that mRNA and protein expression of 
ALDH1A3, AURK-(A and C), PDGFRα, TWIST1, and JAG1 are expressed in these 
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trophoblast derived cell lines. However their expression levels in each trophoblast cell line 
were found to be different. The disparities in mRNA and protein expression could be due to 
their origins and differences in immortalization method used to develop these cells. In 
summary the factors that were identified from murine microarrays as potential markers for 
defective trophoblast invasion have all showed changes in PE placentae.  
 
7.2  Generation of spheroids from trophoblast and tumour cell lines 
In this study, both transformed trophoblast cells (HTR8/SVneo, TEV-1) and 
choriocarcinoma cells (JEG-3, BeWo) and also MCF-7 cells have shown the ability to 
produce non-resistant (normal) spheroids under non-adherent conditions. Moreover, they 
were able to revert back to normal growth under adherent conditions. Due to the nature of 
the MCF-7 cells, they produced a larger sized spheroid when compared to the spheroids 
produced from trophoblast cell lines. In 2013, Webber et al. illustrated that HTR8/SVneo 
cells have a high ability to form spheroidal bodies. Likewise multicellular spheroids were 
established from JEG-3 and BeWo in culture by Grummer et al. (1994).  In the case of MCF-
7 cells, several studies have shown that the cell line can be used as a model of 3-D cellular 
organization, which has ability to grow as multicellular spheroids (Villalobos et al., 1995; 
Guttilla et al., 2011).  Based on these findings the spheroid body-forming cells have several 
features, which include self-renewal, differentiation into specialized cell types and 
proliferation ( Cheng et al., 2012; Liu et al., 2013). The current findings suggest that all four 
investigated trophoblast cell lines have stem cell features; that is they are more than just 
aggregates of cells. Although previous studies have shown this spheroidal transformation 
abilities in HTR8/Svneo, JEG-3 and BoWo cell lines, to the best of the author’s knowledge, 
this was the first study to produce and characterise the spheroidal cells from TEV-1 cells. 
Since TEV-1 cells are also derived from first trimester trophoblast cells, this finding proves 
that most of the transformed EVT cells have the ability to produce spheroidal cells.  
Moreover, DOX was used in this study to select drug resistant spheroids generated from four 
trophoblast cell lines and also to check their aggressive profile.  
After producing spheroids, the expression of transcription factors (OCT4, SOX2 and 
NANOG), trophoblast transcription factor (CDX2), and NOTCH1 were checked. OCT4 
plays a key regulatory role in self-renewal and differentiation of pluripotency of mouse and 
human embryonic stem cells (Pan et al., 2002). Thus, the expression of OCT4 in trophoblast 
spheroids may be linked to “stem-like cells” properties, such as self-renewal, of these cells. 
From current data, compared to parental cells, the mRNA and protein expression of OCT4 
showed a significant increase in spheroidal cells (both DOX-treated and untreated) produced 
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from JEG-3, BeWo and MCF-7cell lines.  Likewise, SOX2 and NANOG play regulatory 
roles along with other transcriptional factors (OCT4 and NANOG) maintain pluripotancy 
and self-renewal features in human and mouse ESCs (Boyer et al., 2005). Interestingly, both, 
immunofluorescence staining and western blot, results suggested that SOX2 expression 
increased in spheroidal cells. In contrast, the mRNA expression of SOX2 was up-regulated 
only under untreated spheroid conditions compared to the parental conditions in TEV-1, 
JEG-3 and MCF-7 cells. The difference in expression patterns between mRNA and protein 
in this study, may be due to the half-life of mRNA, as protein cannot be translated from 
mRNA with very short or long half-life (Wang et al., 2002; Yang et al., 2003).  
The fact that the “stemness” markers OCT4, SOX2 and NANOG have increased especially 
in spheroidal cells from all four trophoblast cell lines suggests that these cells have 
transformed themselves into “stem-like” cells. According to Desoizet et al. (1998) the 
spheroids were used in oncology for studying the multi-drug resistant types of cancer. 
Moreover, it was also useful in studying the resistance to chemo- or radiotherapy. By using 
a spheroid model, it is possible to investigate cell to cell and extracellular matrix (ECM) to 
cell interactions in vitro (Nederman et al., 1984; Oudar, 2000; Mehta et al., 2013). The data 
explained in chapter 5 have clearly shown that DOX treated trophoblast cells produced 
spheroids that not only displaying “stemness” features, such as self-renewal by reverting 
back into a monolayer when re-grown under normal conditions, but also showed resistance 
against DOX treatment.  Therefore, these cells may be used as a model to study the 
toxicological effects of other chemotherapeutic effects on “physiologically rapidly dividing” 
cells.    
7.3  Migration capacities of spheroidal from trophoblast cell lines  
The ability for the cells to migrate is an important characteristics of all stem-like cells. 
However, as spheroidal cells grow in aggregate, they were transformed into the normal 
adherent flasks to study their capacities of migration. The current data showed that the 
migration rate of HTR8/SVneo and TEV-1 untreated spheroids was faster than the parental 
cells at 48 hours. This was expected since spheroids act like solid tumours in vivo with 
deregulated proliferation and an uncontrolled speed of migration (Ferretti et al., 2007). 
However, DOX-treated spheroidal cells showed low rate of migration at 48 hours. Spheroid 
monolayers are different from normal cell monolayers and they still have ‘stem like cells’ 
features and should show the ability to resist drug treatment. However the low rate of 
migration showed by the monolayers formed by the spheroidal cells may be due to the 
enhanced penetration by DOX. That is the penetration of DOX into the spheroidal cell 
clusters will be difficult; and therefore its effects will be limited in cells that are growing in 
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3-D culture. However, the DOX exposure would have been greater when these cells were 
re-transformed into monolayers. Thus, DOX could have been absorbed rapidly. In fact, the 
3-D structures provide a multicellular resistance model that mimics the chemotherapy 
resistance often found in solid tumours in vivo (Oudar, 2000). This might have affected the 
migration of spheroidal, especially DOX-treated cells. Unfortunately due to the growth 
patterns of choriocarcinoma cells (BeWO and JEG-3), it was impossible to carry out a wound 
healing assay even with parental cells. These cells do not produce cell monolayers and it was 
extremely difficult to produce a uniform wound (or scratch) as such attempts disrupted cell 
attachments.  
7.4 Invasion capacities of spheroidal cells from trophoblast cell lines  
The analysis of growth, proliferation and invasion of trophoblast cells in culture is essential, 
to understand the functions of the placenta by using different trophoblast cell lines (Zuo et 
al., 2014).  Moreover, study of trophoblast  cell invasion will lead to a better understanding 
of trophoblast invasion mechanisms and this will be essential for the treatment of 
pathological conditions which are involved in placental over-invasion (e.g., 
choriocarcinoma) or under-invasion (e.g., pre-eclampsia). Moreover, it is also important to 
develop therapies for cancer (Graham and Lala, 1992). However, comparing the invasion of 
parental and spheroidal cells is difficult. Therefore, two different approaches were made (a) 
A 2-D invasion assay to compare the invasive potentials between parental and spheroidal 
cells. For this the spheroidal cells were manually disrupted into single cells. This was 
essential as the BD Bio-coat invasion assay kit has a membrane that would only allow single 
cells with the optimum diameter of 8 µm. Also by breaking spheroids into single cells, it 
would be interesting to see whether they have gained true transformation into “stem-like 
cells” and (b) A 3-D invasion assay to see and compare the invasive potential of un-treated 
and DOX-treated spheroidal clusters that were made from trophoblast cells.  In fact 
monolyer spheroidal cells are not entirely appropriate to study the interactions between the 
invasive spheroid and the basement membranes. Thus, 3-D invasion was used to compare 
the invasive behaviour of spheroidal cells. 
The current data strongly suggest that in 2-D invasion assay all trophoblast cell lines 
(HTR8/SVneo, TEV-1, JEG-3, and BeWo) showed a higher invasion in untreated spheroids 
compared to other conditions with different capacity in each cell lines.  This shows that 
untreated spheroidal cells have truly transformed into “stem-like cells”. In addition the 3-D 
invasion assay using a BME-3D kit, have shown, with time the invasion of untreated 
spheroidal cells of all trophoblast cell lines (HTR8/Svneo, TEV-1, JEG-3 and BeWo) was 
higher than that of  DOX-treated spheroids. Moreover the data suggested that spheroids of 
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choriocarcinoma can potentially invade faster than that of transformed trophoblast cells. It 
may be due to the nature of these cells, as they are malignant trophoblastic tumour cells. 
However, DOX-treated spheroids in both JEG-3 and BeWo showed a strange behaviour, 
where the distorted shape of spheroid did not show any invasion in both cell lines. This may 
be due to the persisting effect of the DOX treatment in these small spheroids. According to 
Gong et al. (2015), the penetration capability of DOX can be influenced by spheroid size. 
Their study reported that stronger DOX penetration was observed within the smaller 
spheroids compared to larger spheroids which showed higher chemo-resistance. Likewise 
the study by Gong et al. (2015), suggested that 3-D spheroids drug sensitivity depended on 
the spheroids size. Unfortunately, both untreated and DOX-treated spheroid of non-
invasive cells (MCF-7) remained as cell aggregates and did not show any ability to invade 
into the surrounding invasion matrix in 3-D assay. That is despite the ability of MCF-7 
producing spheroids under non-adherent conditions with serum-free medium contained 
growth factors (See Chapter4), they did not show any invasion in 3-D cell invasion assay. 
This was not expected as MCF-7 was used as a non-placental tumour positive control to 
detect/compare invasions with trophoblast cell lines.  
According to studies supplementary growth factors, such as bFGF, FGF, EGF and insulin 
(IGF), are necessary to maintain and influence cell proliferation, motility, survival and 
morphogenesis (Rodrigues et al., 2010). However the effect of each growth factor is 
different. For example, bFGF has a role in forming tumour spheres and in maintaining the 
characteristics of sphere-forming cells (Min et al., 2015). FGF plays an important role in 
creating tumour spheroids and increasing the internal population (Kondo et al., 2004). It has 
been reported that EGF promoted sphere formation and enhanced the self-renewal capacities 
of human glioma-derived cancer stem cells CSCs (Soeda et al., 2008). Insulin has an 
essential role in proliferation of normal stem cell (Ziegler et al., 2014).  Arsenijevic et al. 
(2001) reported that in the absence of IGF, EGF or FGF embryonic cells were unable to 
stimulate sphere formation. Furthermore, study of Min et al. (2015) reported that the 
spheroids from MCF-7 cells maintained in media containing growth factors showed greater 
cell proliferation than spheroids in media with FBS. Therefore, it can be assumed that the 
growth factors might play a role in MCF-7 spheroid formation under 3-D culture.    
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7.5  Global expressions of protein in transformed trophoblast cell line  
Comparative SWATH-MS analysis amongst spheroid and parental cells (untreated and 
DOX-treated) have identified up-regulation of 14 novel proteins generated from 
HTR8/SVneo cell lines. Likewise 8 novel proteins have been identified to be up-regulated 
in TEV-1. Interestingly, most of these proteins were associated with cell adhesion, 
proliferation, differentiation, invasion and embryo implantation. The most interesting 
proteins that were found in both HTR8/SVneo and TEV-1 cell lines under different 
conditions are plasminogen, vitronectin and ALDH1A3.  Due to time restrictions it was not 
possible to further analyse the real time expression profiles of all the new/novel peptides that 
were identified by the SWATH-MS analysis as up-/down-regulated in different spheroid 
cells (See Section 7.7) 
 
7.6  Conclusion  
The data from this study suggest that 
• The mRNA and protein expression of ALDH1A3, AURK-(A and C), PDGFRα, 
TWIST1, and JAG1 were differentially expressed in NT, and PE placenta. 
Interestingly their expression was also found to be different in untreated and DOX-
treated spheroidal cells compared to their parental counterparts. 
• This study has successfully generated and characterised “stem-like” spheroidal cells 
from four different trophoblast cell lines (namely HTR8/SVneo, TEV1, JEG-3 and 
BeWo) using non-adherent 3-D culture.  
• These spheroids showed increased protein expression of stem cells markers, such as 
OCT4, SOX2 and NANOG. On the other hand, both trophoblast CDX2 and the cell 
fate determining transcription factor, NOTCH1, are reduced in spheroidal cells. 
• Spheroids generated from different trophoblast cell lines may also be used as an in 
vitro model to study the toxicological effects of chemotherapeutic agents on 
physiologically rapidly dividing cells. 
• SWATH-MS analysis highlighted up-regulation of novel proteins that are associated 
with proliferation, invasion and cell cycle control in both transformed trophoblast 
cell lines (See the synopsis of the PhD thesis).
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SYNOPSIS OF THE PhD THESIS 
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7.8  Future work 
Firstly the comparative expression analysis between NT and PE samples need to be extended 
to check the status of the molecules/proteins that were using SWATH-MS with a larger 
number of placental samples to identify the changes in global protein expression profiles in 
PE samples. The status of these identified proteins would then be checked in real time using 
qRT-PCR and immunoblots. Also by using primary culture, such as CTBs, and EVTs, the 
role of these newly identified factors during first trimester can be investigated using in vitro 
invasion studies. This will be shed some light on functional relationships of these proteins 
during placental invasion. The cellular expression of these proteins can also be identified 
using cellular fractionation techniques such as micro-dissection and coupled with 
mRNA/protein expression studies in particular cellular groups, such as CTB, STB and 
deciduas.  
 
Interestingly, this study has successfully showed the potentials of producing “stem-like” 
spheroid cells. Further studies may also be appropriate to check the status of other 
“stemness” markers such as CD44, CD34, CD90 and CD133 in spheroids produced from 
trophoblast cells lines, especially HTR8/Svneo and TEV-1 to confirm the stem-like 
transformation during 3-D culture. Upon confirmation, the effects of oxidative stress, a 
contributing factor for PE, on the invasion of spheroid cells can be compared with their 
respective parental cells. The results would show whether there are any differences in the 
responses to oxidative stress by spheroids.  
Furthermore exploration studies using these cells as in vitro models of physiologically 
rapidly dividing cells are essential. Using 3-D spheroids of transformed trophoblast cell lines 
HTR8/Svneo and TEV-1, the effects of current chemotherapeutic agents on physiologically 
rapidly dividing cells can be studied in relation to other non-trophoblast tumour cell lines. 
Depending on the results, it may be possible also to investigate the ability of primary 
trophoblast cells such as CTBs, ST and EVTs to produce spheroid under the same conditions.  
 
Also as explained in section 7.6 (and in chapter 5), the MCF-7 clone used in this study was 
found to be non-invasive; therefore it is essential to repeat the invasion assays with spheroids 
obtained from invasive clones of  MCF-7 or other non-placental tumour cell lines. This 
would not only confirm the invasive capacities of drug-resistant spheroids from non-
placental tumours, but also compare the differences between the drug-resistant spheroids 
that are produced from trophoblast (physiologically rapidly dividing cells) and tumour cells.  
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Most importantly it is essential to explore all the proteins that have been identified by 
SWATH-MS to have several fold (of either increase or reduced) changes during spheroids 
transformation. This was not possible during this study due to time restrictions. Using 
bioinformatics, the cellular functions of these proteins/peptides can be identified. Following 
this the real time status of these proteins can be investigated using qRT-PCR and western 
blotting. 
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 A. Appendix 
A.1 Clinical data of patients 
Table A 1: Clinical Data 
 
 
Serial No. Normotensive: Maternal age Gestational age Systolic BP Diastolic BP Placental Weight Mode of Delivery Gestational weight Gestational Sex BMI Protein in urine (g/L)
(Years) (Weeks) (mmHg) (mmHg) (Grams) (Kg)
N1 V6 34 38.4 122 60 855 Vaginal 4.24 male 21.6 N/D
N2 V7 32 38.9 120 90 700 Vaginal 3.3 female 24.5 N/D
N3 V8 29 40.1 140 68 520 Vaginal 3.8 male 23 N/D
N4 V9 36 39.2 128 68 579 Vaginal 3.12 male 24.2 N/D
N5 V10 39 39.2 130 70 636 Vaginal 3.03 male 23.5 N/D
N6 V11 35 38.1 120 70 654 Vaginal 3 male 23 N/D
N7 V12 34 38.3 120 72 725 Vaginal 3.33 female 23 N/D
N8 V13 40 38.4 123 70 852 Vaginal 4.24 male 24.2 N/D
N9 V15 29 39.2 122 66 625 Vaginal 3.21 male 23.5 N/D
N10 V23 36 39.1 110 70 579 Vaginal 3.01 male 24 N/D
N11 V24 35 39.2 125 71 560 Vaginal 3.01 female 24.7 N/D
N12 SITE-1 35 38.5 109 78 698 Vaginal 3.5 female 23.5 N/D
N13 ALISON 34 39.3 122 67 524 Vaginal 3.51 male 24.5 N/D
Average 34.46 38.92 122.38 70.77 654.38 3.41 23.63
STD 3.20 0.55 7.94 7.04 109.85 0.44 0.86
Serial no. Pre-eclamptic: Maternal age Gestational age Systolic BP Diastolic BP Placental Weight Mode of Delivery Gestational weight Gestational Sex BMI Protein in urine (g/L)
(Years) (Weeks) (mmHg) (mmHg) (Grams) (Kg)
P1 Kirsty 28 33 150 92 360 Vaginal 1.66 male 23.5 2.5
P2 PE3 27 36 168 95 470 Cesearean 2.3 male 22.8 1.5
P3 PE5 29 37 152 110 505 Cesearean 1.87 male 22.5 1.14
P4 V14 29 38 150 111 420 Vaginal 1.82 female 24.4 1.01
P5 V16 27 36 160 92 545 Cesearean 2.6 male 24.6 1
P6 V17 28 39 160 90 480 Cesearean 1.76 male 22.8 0.9
P7 V18 32 37 150 90 510 Cesearean 2.98 male 22.5 0.98
P8 V19 28 38 150 90 529 Cesearean 3.1 female 21 1
P9 V22 28 39.5 155 95 510 Cesearean 2.8 male 23.5 0.91
P10 V25 28 38 155 112 517 Cesearean 2.9 male 22.8 0.875
P11 V26 29 39 140 108 620 Vaginal 3.59 female 23 0.88
P12 Angela 29 39.4 156 98 610 Cesearean 3.12 male 22 1.1
Average 28.5 37.5 153.3 98.5 506.3 2.54 22.95 1.14
STD 1.31 1.86 6.99 8.98 71.79 0.64 0.98 0.46
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A.2 The extraction of RNA from NT (Panel A) and PE (panel B) placental tissues. 
  
 
 
 
Figure A 1 The purity of extracted RNA from NT and PE placental tissues. 
 [M= 1Kb Molecular marker; Panel A = RNA extracted from 13 NT samples; Panel B = 
RNA extracted from 12 PE samples] 
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A.3. Temperature optimisation for factors of interest  
 
 
Figure A 2: Confirmation of PCR products in agarose gel. 
[Amplified factor products with placental sample. M-Molecular marker (ladder) 50bp, 
lane1- ALDH3A1, lane2- AURK-A, lane3- AURK C, lane4- PDGFR-α, lane5- TWIST1, 
lane6- JAG1 and lane7- MCF-7 (used as positive control). 
 
A.4. Accession numbers for target factors used for primer designing 
Table A 2: NCBI accession numbers for factors. 
 
Factor 
 
NCBI accession number 
 
ALDH3A1 
 
 
NM_001135168.1; NM_001135167.1 
 
 
AURK- A 
 
 
NM_198433.1; NM_003600.2 
 
 
AURK-C 
 
 
NM_001015878.1;NM_001015879.1;NM_003160.2 
  
 
PDGFR-α 
 
 
NM_006206.4 
 
TWIST-1 
 
 
NM_000474.3 
 
JAG1 
 
 
NM_000214.2  
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A.5 Example of sequencing 
 
Figure A 3 : The DNA sequencing data for AURK-A PCR product. 
The bases represented by N were replaced by the specific bases identified by their coloured 
peaks (A- Green, T- Red, G- Black and C- Blue). 
 
 
Figure A 4: Example of BLAST matching data for AURK-A sequence obtained from 
sequencing. 
The red bands shows >=200 alignment score for the DNA sequence received from the 
company and the gene of interest PASD1 (with 99% maximum identity).   
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A.6 Western blot whole blot 
 
 
 
 
 
 
 
 
235 
 
                Appendix 
 
 
 
 
236 
 
                Appendix 
 
A.7 The extraction of RNA from trophoblast cell lines 
 
Figure A 5: The purity of extracted RNA from trophoblast cell lines in parental 
conditions. 
[M= 1Kb Molecular marker; lane1- HTR8/SVneo, lane2- TEV-1, lane3- JEG-3, lane4- 
BeWo, lane5- MCF-7 (used as positive control). 
A.8 Temperature optimisation for markers of interest  
 
  
Figure A 6: Example of PCR product confirmation in Agarose gel. 
[Amplified marker (OCT4) products with trophoblast cell line (parental conditions). M-
Molecular marker (ladder) 50bp, lane1- HTR8/SVneo, lane2- TEV-1, lane3- JEG-3, lane4- 
BeWo, lane5- MCF-7 (used as positive control).  
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A.9 Accession numbers for target factors used for primer designing 
Table A 3: NCBI accession numbers for markers. 
 
Marker 
 
NCBI accession number 
 
OCT4 
 
 
NM_001173531.2; NM_001285986.1; NM_001285987.1 
 
 
SOX2  
 
NM_003106.3  
 
 
NANOG1 
 
NM_001297698.1  
 
 
CDX2 
 
NM_001265.4 
 
 
NOTCH 
 
NM_017617.3  
 
238 
 
 References 
 
Aaboe, M., Offersen, B.V., Christensen, A. and Andreasen, P.A. (2003) ‘Vitronectin in human breast 
carcinomas’, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1638(1), pp. 72–
82. 
Abell, A.N., Granger, D.A., Johnson, N.L., Vincent-Jordan, N., Dibble, C.F. and Johnson, G.L. 
(2009) ‘Trophoblast stem cell maintenance by Fibroblast growth factor 4 requires MEKK4 activation 
of Jun n-terminal Kinase’, Molecular and Cellular Biology, 29(10), pp. 2748–2761. 
Achilli, T.-M., Meyer, J. and Morgan, J.R. (2012) ‘Advances in the formation, use and understanding 
of multi-cellular spheroids’, Expert Opinion on Biological Therapy, 12(10), pp. 1347–1360.  
Albelda, S., Mette, S., Elder, D., Stewart, R., Damjanovich, L., Herlyn, M. and Buck, C. (1990) 
‘Integrin distribution in malignant melanoma: Association of the beta 3 subunit with tumor 
progression’, Cancer research, 50(20), pp. 6757–64. 
Alfano, D., Franco, P., Vocca, I., Gambi, N., Pisa, V., Mancini, A., Caputi, M., Carriero, M.V., 
Iaccarino, I. and Stoppelli, M.P. (2005) ‘The urokinase plasminogen activator and its receptor. Role 
in cell growth and apoptosis’, Thrombosis and Haemostasis. 
Al-Hajj, M., Wicha, M.S., Benito-Hernandez, A., Morrison, S.J. and Clarke, M.F. (2003) 
‘Prospective identification of tumorigenic breast cancer cells’, Proceedings of the National Academy 
of Sciences, 100(7), pp. 3983–3988. 
Alnouti, Y. and Klaassen, C.D. (2007) ‘Tissue distribution, Ontogeny, and regulation of Aldehyde 
Dehydrogenase (Aldh) enzymes mRNA by prototypical microsomal enzyme Inducers in mice’, 
Toxicological Sciences, 101(1), pp. 51–64.  
Alvarez, R.H., Kantarjian, H.M. and Cortes, J.E. (2006) ‘Biology of Platelet-Derived growth factor 
and its involvement in disease’, Mayo Clinic Proceedings, 81(9), pp. 1241–1257.  
Andrae, J., Gallini, R. and Betsholtz, C. (2008) ‘Role of platelet-derived growth factors in physiology 
and medicine’, Genes & Development, 22(10), pp. 1276–1312. 
Andreasen, P.A., Egelund, R. and Petersen, H.H. (2000) ‘The plasminogen activation system in 
tumor growth, invasion, and metastasis’, Cellular and Molecular Life Sciences (CMLS), 57(1), pp. 
25–40. 
Anin, S., Vince, G. and Quenby, S. (2004) ‘Trophoblast invasion’, Human Fertility, 7(3), pp. 169–
174.  
Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B.P., Thomas, C., Fauvet, F., Puisieux, I., 
Doglioni, C., Piccinin, S., Maestro, R., Voeltzel, T., Selmi, A., Valsesia-Wittmann, S., Caron de 
Fromentel, C. and Puisieux, A. (2008) ‘Induction of EMT by twist proteins as a collateral effect of 
tumor-promoting inactivation of premature Senescence’, Cancer Cell, 14(1), pp. 79–89. 
Aplin, J. (1991) ‘Implantation, trophoblast differentiation and haemochorial placentation: 
Mechanistic evidence in vivo and in vitro’, Journal of cell science., 99, pp. 681–92. 
Aplin, J., Sattar, A. and Mould, A. (1992) ‘Variant choriocarcinoma (BeWo) cells that differ in 
adhesion and migration on fibronectin display conserved patterns of integrin expression’, Journal of 
cell science., 103, pp. 435–44. 
 
 
239 
 
 Arai, K.Y., Nishiyama, T. and kojiarai (2007) ‘Developmental changes in Extracellular matrix 
messenger RNAs in the mouse Placenta during the Second Half of pregnancy: Possible factors 
involved in the regulation of Placental Extracellular matrix expression’, Biology of Reproduction, 
77(6), pp. 923–933 
Arsenijevic, Y., Weiss, S., Schneider, B. and Aebischer, P. (2001) ‘Insulin-like growth factor-i is 
necessary for neural stem cell proliferation and demonstrates distinct actions of epidermal growth 
factor and fibroblast growth factor-2’, The Journal of neuroscience : the official journal of the Society 
for Neuroscience., 21(18), pp. 7194–7202. 
Ashton, S.V., St J Whitley, G., Dash, P.R., Wareing, M., Crocker, I.P., Baker, P.N. and Cartwright, 
J.E. (2005) ‘Uterine spiral artery remodeling involves endothelial Apoptosis induced by Extra villous 
Trophoblasts through Fas/FasL interactions’, Arteriosclerosis, Thrombosis, and Vascular Biology, 
25(1), pp. 102–108.  
Avasthi, S., Srivastava, R.N. and Singh, A. (2008) ‘Stem cell: Past, present and future- A review 
article’, Internet Journal of Medical Update - E-journal, 3(1).  
Avo Santos, M., van de Werken, C., de Vries, M., Jahr, H., Vromans, M.J.M., Laven, J.S.E., Fauser, 
B.C., Kops, G.J., Lens, S.M. and Baart, E.B. (2011) ‘A role for Aurora C in the chromosomal 
passenger complex during human preimplantation embryo development’, Human Reproduction, 
26(7), pp. 1868–1881.  
Balber, A.E. (2011) ‘Concise review: Aldehyde Dehydrogenase bright stem and Progenitor cell 
populations from normal tissues: Characteristics, activities, and emerging uses in Regenerative 
medicine’, Stem Cells, 29(4), pp. 570–575.  
Balboula, A.Z. and Schindler, K. (2014) ‘Selective disruption of Aurora C Kinase reveals distinct 
functions from Aurora B Kinase during Meiosis in mouse Oocytes’, PLOS Genetics, 10(2), pp. 
e1004194.  
Bartholoma, P. (2005) ‘A more aggressive breast cancer Spheroid model coupled to an electronic 
capillary sensor system for a high-content screening of Cytotoxic agents in cancer therapy: 3-
Dimensional in vitro tumor Spheroids as a screening model’, Journal of Biomolecular Screening, 
10(7), pp. 705–714.  
Beard, J. (1911) ‘The Enzyme Treatment of Cancer and its Scientific Basis’, New York: New Spring 
Press,2010.  (Original  work published in 1911).  
Behrens, J. (1993) ‘Loss of epithelial differentiation and gain of invasiveness correlates with tyrosine 
phosphorylation of the E-cadherin/beta-catenin complex in cells transformed with a temperature-
sensitive v-sRC gene’, The Journal of Cell Biology, 120(3), pp. 757–766.  
Benedito, R., Roca, C., Sörensen, I., Adams, S., Gossler, A., Fruttiger, M. and Adams, R.H. (2009) 
‘The notch ligands Dll4 and jagged1 have opposing effects on Angiogenesis’, 137(6), pp. 1124–
1135.  
Berdnik, D. and Knoblich, J.A. (2002) ‘Drosophila Aurora-A is required for Centrosome maturation 
and Actin-Dependent asymmetric protein localization during Mitosis’, Current Biology, 12(8), pp. 
640–647.  
Betsholtz, C., Karlsson, L. and Lindahl, P. (2001) ‘Developmental roles of platelet-derived growth 
factors’, Bioessays, 23(6), pp. 494–507. 
Bhat, M., Philp, A., Glover, D. and Bellen, H. (1996) ‘Chromatid segregation at anaphase requires 
the barren product, a novel chromosome-associated protein that interacts with Topoisomerase II’, 
Cell., 87(6), pp. 1103–1114. 
240 
 
 Bilban, M., Haslinger, P., Prast, J., Klinglmüller, F., Woelfel, T., Haider, S., Sachs, A., Otterbein, 
L.E., Desoye, G., Hiden, U., Wagner, O. and Knöfler, M. (2009) ‘Identification of novel Trophoblast 
invasion-related genes: Heme Oxygenase-1 controls Motility via Peroxisome Proliferator-Activated 
receptor γ’, Endocrinology, 150(2), pp. 1000–1013.  
Bilban, M., Tauber, S., Haslinger, P., Pollheimer, J., Saleh, L., Pehamberger, H., Wagner, O. and 
Knöfler, M. (2010) ‘Trophoblast invasion: Assessment of cellular models using gene expression 
signatures’, Placenta, 31(11), pp. 989–996.  
Boer, B., Cox, J.L., Claassen, D., Mallanna, S.K., Desler, M. and Rizzino, A. (2009) ‘Regulation of 
the Nanog gene by both positive and negative cis -regulatory elements in embryonal carcinoma cells 
and embryonic stem cells’, Molecular Reproduction and Development, 76(2), pp. 173–182.  
Bolos, V., Mira, E., Martínez-Poveda, B., Luxán, G., Cañamero, M., Martínez-A, C., Mañes, S., de 
Biotecnología, C.N., CSIC, Unit, C.P. and Program, B. (2013) ‘Breast cancer research’, Breast 
Cancer Research, 15(4), pp. 1.  
Bourassa, S., Fournier, F., Nehmé, B., Kelly, I., Tremblay, A., Lemelin, V., Lamarche, B., Couture, 
P. and Droit, A. (2015) ‘Evaluation of iTRAQ and SWATH-MS for the quantification of proteins 
associated with insulin resistance in human duodenal biopsy samples’, PLOS ONE, 10(5), pp. 
e0125934.  
Boyer, L.A., Lee, T.I., Cole, M.F., Johnstone, S.E., Levine, S.S., Zucker, J.P., Guenther, M.G., 
Kumar, R.M., Murray, H.L., Jenner, R.G., Gifford, D.K., Melton, D.A., Jaenisch, R. and Young, 
R.A. (2005) ‘Core Transcriptional regulatory circuitry in human embryonic stem cells’, Cell, 122(6), 
pp. 947–956 
Braam, S.R., Zeinstra, L., Litjens, S., Ward-van Oostwaard, D., van den Brink, S., van Laake, L., 
Lebrin, F., Kats, P., Hochstenbach, R., Passier, R., Sonnenberg, A. and Mummery, C.L. (2008) 
‘Recombinant Vitronectin is a functionally defined substrate that supports human embryonic stem 
cell self-renewal via αVβ5 Integrin’, Stem Cells, 26(9), pp. 2257–2265. 
Bravo-Cordero, J.J., Hodgson, L. and Condeelis, J. (2012) ‘Directed cell invasion and migration 
during metastasis’, Current Opinion in Cell Biology, 24(2), pp. 277–283.  
Bronzert, D.A., Pantazis, P., Antoniades, H.N., Kasid, A., Davidson, N., Dickson, R.B. and Lippman, 
M.E. (1987) ‘Synthesis and secretion of platelet-derived growth factor by human breast cancer cell 
lines’, Proceedings of the National Academy of Sciences, 84(16), pp. 5763–5767.  
Bubeník, J. (2003) ‘Tumour MHC class I downregulation and immunotherapy (review)’, Oncology 
reports., 10(6), pp. 2005–8. 
Buck, V.U., Gellersen, B., Leube, R.E. and Classen-Linke, I. (2015) ‘Interaction of human 
trophoblast cells with gland-like endometrial spheroids: A model system for trophoblast invasion’, 
Human Reproduction, 30(4), pp. 906–916.  
Burleigh, D.W., Kendziorski, C.M., Choi, Y.J., Grindle, K.M., Grendell, R.L., Magness, R.R. and 
Golos, T.G. (2007) ‘Microarray analysis of BeWo and JEG3 Trophoblast cell lines: Identification of 
Differentially expressed transcripts’, Placenta, 28(5-6), pp. 383–389.  
Burleson, K., Casey, R., Skubitz, K., Pambuccian, S., Oegema, T. and Skubitz, A. (2004) ‘Ovarian 
carcinoma ascites spheroids adhere to extracellular matrix components and mesothelial cell 
monolayers’, Gynecologic oncology., 93(1), pp. 170–81. 
Burton, G. and Jauniaux, E. (2006) ‘Placental oxidative stress: From miscarriage to preeclampsia’, 
Journal of the Society for Gynecologic Investigation, 11(6), pp. 342–352.  
Butt, A.J., Firth, S.M. and Baxter, R.C. (1999) ‘The IGF axis and programmed cell death’, 
Immunology and Cell Biology, 77(3), pp. 256–262.  
241 
 
 Cabrera Je, E. (2013) ‘The role of transcription factor TWIST in cancer cells’, Journal of Genetic 
Syndromes & Gene Therapy, 04(01).  
Carlson, B.M. and Mosby, S.L. (1994) ‘Human embryology and developmental biology 
Carvalho, I., Milanezi, F., Martins, A., Reis, R.M. and Schmitt, F. (2005) Breast Cancer Research, 
7(5), pp. R788.  
Castellucci, M., Kosanke, G., Verdenelli, F., Huppertz, B. and Kaufmann, P. (2000) ‘Villous 
sprouting: Fundamental mechanisms of human placental development’, Human reproduction 
update, 6(5), pp. 485–494. 
Chaddha, V., Viero, S., Huppertz, B. and Kingdom, J. (2004) ‘Developmental biology of the placenta 
and the origins of placental insufficiency’, Seminars in fetal & neonatal medicine, 9(5), pp. 357–69. 
Chang, C., Shieh, G., Wu, P., Lin, C., Shiau, A. and Wu, C. (2008) ‘Oct-3/4 expression reflects tumor 
progression and regulates Motility of bladder cancer cells’, Cancer Research, 68(15), pp. 6281–6291.  
Chang, S.-D., Chao, A.-S., Peng, H.-H., Chang, Y.-L., Wang, C.-N., Cheng, P.-J., Lee, Y.-S. and 
Wang, T.-H. (2011) ‘Analyses of placental gene expression in pregnancy-related hypertensive 
disorders’, Taiwanese Journal of Obstetrics and Gynecology, 50(3), pp. 283–291.  
Chen, H.-F., Huang, C.-H., Liu, C.-J., Hung, J.-J., Hsu, C.-C., Teng, S.-C. and Wu, K.-J. (2014) 
‘Twist1 induces endothelial differentiation of tumour cells through the jagged1-KLF4 axis’, Nature 
Communications, 225, pp. 4697.  
Chen, Y., Shi, L., Zhang, L., Li, R., Liang, J., Yu, W., Sun, L., Yang, X., Wang, Y., Zhang, Y. and 
Shang, Y. (2008) ‘The molecular mechanism governing the Oncogenic potential of SOX2 in breast 
cancer’, Journal of Biological Chemistry, 283(26), pp. 17969–17978.  
Chen, Z.F. and Behringer, R.R. (1995) ‘Twist is required in head mesenchyme for cranial neural tube 
morphogenesis’, Genes & Development, 9(6), pp. 686–699.  
Ciftci, K., Su, J. and Trovitch, P.B. (2003) ‘Growth factors and chemotherapeutic modulation of 
breast cancer cells’, Journal of Pharmacy and Pharmacology, 55(8), pp. 1135–1141. 
Cobb, L. (2013) ‘Cell based assays: The cell cycle, cell proliferation and cell death’, Materials and 
Methods, 3.  
Cohen, M. and Bischof, P. (2007) ‘Factors regulating Trophoblast invasion’, Gynecologic and 
Obstetric Investigation, 64(3), pp. 126–130.  
Coskun, M., Troelsen, J.T. and Nielsen, O.H. (2011) ‘The role of CDX2 in intestinal homeostasis 
and inflammation’, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1812(3), pp. 
283–289.  
Crocker, I.P., Cooper, S., Ong, S.C. and Baker, P.N. (2003) ‘Differences in Apoptotic susceptibility 
of Cytotrophoblasts and Syncytiotrophoblasts in normal pregnancy to those complicated with 
Preeclampsia and intrauterine growth restriction’, The American Journal of Pathology, 162(2), pp. 
637–643.  
Cuman, C., Menkhorst, E., Winship, A., Van Sinderen, M., Osianlis, T., Rombauts, L.J. and 
Dimitriadis, E. (2013) ‘Fetal-maternal communication: The role of notch signalling in embryo 
implantation’, Reproduction, 147(3), pp. R75–R86.  
Curran, S. and Murray, G. (2000) ‘Matrix metalloproteinases: Molecular aspects of their roles in 
tumour invasion and metastasis’, European journal of cancer (Oxford, England : 1990)., 36, pp. 
1621–1630. 
242 
 
 Czeczuga-Semeniuk, E., Lemancewicz, D. and Wołczyński, S. (2004) ‘Estradiol and tamoxifen 
differently affects the inhibitory effects of vitamin A and their metabolites on the proliferation and 
expression of α2β1 integrins in MCF-7 breast cancer cells’, Advances in Medical Sciences, 54(1).  
Dar, A.A., Goff, L.W., Majid, S., Berlin, J. and El-Rifai, W. (2010) ‘Aurora Kinase inhibitors - rising 
stars in cancer Therapeutics?’, Molecular Cancer Therapeutics, 9(2), pp. 268–278.  
Das, R., Gregory, P., Hollier, B., Tilley, W. and Selth, L. (2014) ‘Epithelial plasticity in prostate 
cancer: Principles and clinical perspectives’, Trends in molecular medicine. 20(11), pp. 643–651. 
De Falco, M., Cobellis, L., Giraldi, D., Mastrogiacomo, A., Perna, A., Colacurci, N., Miele, L. and 
De Luca, A. (2007b) ‘Expression and distribution of notch protein members in human Placenta 
throughout pregnancy’, Placenta, 28(2-3), pp. 118–126.  
DeBerardinis, R.J., Lum, J.J., Hatzivassiliou, G. and Thompson, C.B. (2008) ‘The biology of cancer: 
Metabolic Reprogramming fuels cell growth and proliferation’, Cell Metabolism, 7(1), pp. 11–20.  
Den van, der, van, Cheung, H., Buijs, J., Lippitt, J., Guzmán-Ramírez, N., Hamdy, F., Eaton, C., 
Thalmann, G., Cecchini, M. and Pelger, R. (2010) ‘High aldehyde dehydrogenase activity identifies 
tumor-initiating and metastasis-initiating cells in human prostate cancer’, Cancer research., 70(12), 
pp. 5163–5173. 
Denard, B., Lee, C. and Ye, J. (2012) ‘Doxorubicin blocks proliferation of cancer cells through 
proteolytic activation of CREB3L1’, eLife, 1. 
DeNardo, D.G., Andreu, P. and Coussens, L.M. (2010) ‘Interactions between lymphocytes and 
myeloid cells regulate pro- versus anti-tumor immunity’, Cancer and Metastasis Reviews, 29(2), pp. 
309–316.  
Deryugina, E.I., Quigley, J.P. and Corporation, H.P. (2012) ‘Cell surface remodeling by Plasmin: A 
new function for an old enzyme’, BioMed Research International, 2012.  
Dickson, B.C., Mulligan, A.M., Zhang, H., Lockwood, G., O’Malley, F.P., Egan, S.E. and Reedijk, 
M. (2007) ‘High-level JAG1 mRNA and protein predict poor outcome in breast cancer’, Modern 
Pathology, 20(6), pp. 685–693.  
Dieterich, K., Soto Rifo, R., Karen Faure, A., Hennebicq, S., Amar, B.B., Zahi, M., Perrin, J., 
Martinez, D., Sèle, B., Jouk, P.-S., Ohlmann, T., Rousseaux, S., Lunardi, J. and Ray, P.F. (2007) 
‘Homozygous mutation of AURKC yields large-headed polyploid spermatozoa and causes male 
infertility’, Nature Genetics, 39(5), pp. 661–665.  
Dimova, I., Popivanov, G. and Djonov, V. (2014) ‘Angiogenesis in cancer - general pathways and 
their therapeutic implications’, Journal of B.U.ON. : official journal of the Balkan Union of 
Oncology., 19(1), pp. 15–21. 
Djamgoz, M.B.A., Coombes, R.C. and Schwab, A. (2014) ‘Ion transport and cancer: From initiation 
to metastasis’, Philosophical Transactions of the Royal Society B: Biological Sciences, 369(1638), 
pp. 20130092–20130092.  
Doillon, C., Gagnon, E., Paradis, R. and Koutsilieris, M. (2004) ‘Three-dimensional culture system 
as a model for studying cancer cell invasion capacity and anticancer drug sensitivity’, Anticancer 
research. 24(4), pp. 2169–2177. 
Donnelly, L. and Campling, G. (2014) ‘Functions of the placenta’, Anaesthesia & Intensive Care 
Medicine, 15(3), pp. 136–139. 
Doroshow, J.H. (1986) ‘Role of hydrogen peroxide and hydroxyl radical formation in the killing of 
Ehrlich tumor cells by anticancer quinones’, Proceedings of the National Academy of Sciences, 
83(12), pp. 4514–4518.  
243 
 
 Douville, J., Beaulieu, R. and Balicki, D. (2009) ‘ALDH1 as a functional marker of cancer stem and 
Progenitor cells’, Stem Cells and Development, 18(1), pp. 17–26. 
Duong, H.S., Le, A.D., Zhang, Q. and Messadi, D.V. (2004) ‘A novel 3-dimensional culture system 
as an in vitro model for studying oral cancer cell invasion’, International Journal of Experimental 
Pathology, 86(6), pp. 365–374. 
Eckert, M.A., Lwin, T.M., Chang, A.T., Kim, J., Danis, E., Ohno-Machado, L. and Yang, J. (2011) 
‘Twist1-Induced Invadopodia formation promotes tumor Metastasis’, Cancer Cell, 19(3), pp. 372–
386.  
Edmondson, R., Broglie, J.J., Adcock, A.F. and Yang, L. (2014) ‘Three-Dimensional cell culture 
systems and their applications in drug discovery and cell-based Biosensors’, ASSAY and Drug 
Development Technologies, 12(4), pp. 207–218.  
Elmore, S. (2007) ‘Apoptosis: A review of programmed cell death’, 35(4). 
Enquobahrie, D.A., Meller, M., Rice, K., Psaty, B.M., Siscovick, D.S. and Williams, M.A. (2008) 
‘Differential placental gene expression in preeclampsia’, American Journal of Obstetrics and 
Gynecology, 199(5), pp. 566.e1–566.e11. 
Falco, D., Cobellis, L., Giraldi, D., Mastrogiacomo, A., Perna, A., Colacurci, N., Miele, L. and Luca, 
D. (2006) ‘Expression and distribution of notch protein members in human placenta throughout 
pregnancy’, Placenta., 28, pp. 118–126. 
Fang, B., Kovačević, Ž., Park, K., Kalinowski, D., Jansson, P., Lane, D., Sahni, S. and Richardson 
(2013) ‘Molecular functions of the iron-regulated metastasis suppressor, NDRG1, and its potential 
as a molecular target for cancer therapy’, Biochimica et biophysica acta., 1845(1), pp. 1–19. 
Fellmeth, J.E., Gordon, D., Robins, C.E., Scott, R.T., Treff, N.R. and Schindler, K. (2015) 
‘Expression and characterization of three Aurora kinase C splice variants found in human oocytes’, 
Molecular Human Reproduction, 21(8), pp. 633–644.  
Feng, H., Choy, M., Deng, W., Wong, H., Lau, W., Cheung, A., Ngan, H. and Tsao, S. (2005) 
‘Establishment and characterization of a human First-Trimester Extravillous Trophoblast cell line 
(TEV-1)’, Journal of the Society for Gynecologic Investigation, 12(4), pp. e21–e32.  
Ferretti, C., Bruni, L., Dangles-Marie, V., Pecking, A.P. and Bellet, D. (2007) ‘Molecular circuits 
shared by placental and cancer cells, and their implications in the proliferative, invasive and 
migratory capacities of trophoblasts’, Human Reproduction Update, 13(2), pp. 121–141.  
Findeklee, S. and Costa, S.D. (2015) ‘Placenta Accreta and total Placenta Previa in the 19th week 
of pregnancy’, Geburtshilfe Frauenheilkd, 75(8). 
Fitzgerald, J., Busch, S., Wengenmayer, T., Foerster, K., de, la, Poehlmann, T. and Markert, U. 
(2005) ‘Signal transduction in trophoblast invasion’, Chemical immunology and allergy., 88, pp. 
181–99. 
Fletcher, O., Johnson, N., Palles, C., dos Santos Silva, I., McCormack, V., Whittaker, J., Ashworth, 
A. and Peto, J. (2006) ‘Inconsistent association between the STK15 F31I genetic Polymorphism and 
breast cancer risk’, JNCI Journal of the National Cancer Institute, 98(14), pp. 1014–1018.  
Fogh, J. and Orfeo, T. (1997) ‘one hundred and twenty -seven cultured human tumor cell lines 
producing tumors in nude mice’, J.Nati.Cancer inst., 59, pp. 221–226. 
Folkman, J. (1971) ‘Tumor angiogenesis: Therapeutic implications’, The New England journal of 
medicine., 285(21), pp. 1182–1186. 
Fong, H., Hohenstein, K.A. and Donovan, P.J. (2008) ‘Regulation of self-renewal and Pluripotency 
by Sox2 in human embryonic stem cells’, Stem Cells, 26(8), pp. 1931–1938.  
244 
 
 Forbes, K. and Westwood, M. (2010) ‘Maternal growth factor regulation of human placental 
development and fetal growth’, Journal of Endocrinology, 207(1), pp. 1–16.  
Fotakis, G. and Timbrell, J.A. (2006) ‘In vitro cytotoxicity assays: Comparison of LDH, neutral red, 
MTT and protein assay in hepatoma cell lines following exposure to cadmium chloride’, Toxicology 
Letters, 160(2), pp. 171–177.  
Frank, H.-G., Funayama, H., Gaus, G. and Schmitz, U. (1999) ‘Choriocarcinoma-trophoblast hybrid 
cells: Reconstructing the pathway from normal to malignant trophoblast — concept and 
perspectives’, Placenta, 20, pp. 11–24.  
Fu, J., Bian, M., Jiang, Q. and Zhang, C. (2007) ‘Roles of Aurora Kinases in Mitosis and 
Tumorigenesis’, Molecular Cancer Research, 5(1), pp. 1–10.  
Funahashi, Y., Shawber, C.J., Sharma, A., Kanamaru, E., Choi, Y.K. and Kitajewski, J. (2011) 
‘Notch modulates VEGF action in endothelial cells by inducing matrix Metalloprotease activity’, 
Vascular Cell, 3(1), pp. 2.  
Gabrilovich, D., Chen, H., Girgis, K., Cunningham, H., Meny, G., Nadaf, S., Kavanaugh, D. and 
Carbone, D. (1996) ‘Production of vascular endothelial growth factor by human tumors inhibits the 
functional maturation of dendritic cells’, Nature medicine., 2(10), pp. 1096–1103. 
Gajewski, E., Gaur, S., Akman, S.A., Matsumoto, L., van Balgooy, J.N.A. and Doroshow, J.H. 
(2007) ‘Oxidative DNA base damage in MCF-10A breast epithelial cells at clinically achievable 
concentrations of doxorubicin’, Biochemical Pharmacology, 73(12), pp. 1947–1956.  
Gao, J.-X. (2007) ‘Stem cells review series: Cancer stem cells: The lessons from pre-cancerous stem 
cells’, Journal of Cellular and Molecular Medicine, 12(1), pp. 67–96.  
Gewirtz, D. (1999) ‘A critical evaluation of the mechanisms of action proposed for the antitumor 
effects of the anthracycline antibiotics adriamycin and daunorubicin’, Biochemical Pharmacology, 
57(7), pp. 727–741.  
Gilmore, A.P. (2005) ‘Anoikis’, Cell Death and Differentiation, 12, pp. 1473–1477.  
Ginestier, C., Hur, M.H., Charafe-Jauffret, E., Monville, F., Dutcher, J., Brown, M., Jacquemier, J., 
Viens, P., Kleer, C.G., Liu, S., Schott, A., Hayes, D., Birnbaum, D., Wicha, M.S. and Dontu, G. 
(2007) ‘ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of 
poor clinical outcome’, Cell Stem Cell, 1(5), pp. 555–567. 
Goldman-Wohl, D. and Yagel, S. (2002) ‘Regulation of trophoblast invasion: From normal 
implantation to pre-eclampsia’, Molecular and Cellular Endocrinology, 187(1-2), pp. 233–238.  
Gong, X., Lin, C., Cheng, J., Su, J., Zhao, H., Liu, T., Wen, X. and Zhao, P. (2015) ‘Generation of 
Multicellular tumor Spheroids with Microwell-Based Agarose Scaffolds for drug testing’, PLOS 
ONE, 10(6), pp. e0130348.  
Graham, C. (1993) ‘Establishment and characterization of First trimester human Trophoblast cells 
with extended Lifespan’, Experimental Cell Research, 206(2), pp. 204–211.  
Graham, C.H. and Lala, P.K. (1992) ‘Mechanisms of placental invasion of the uterus and their 
control’, Biochemistry and Cell Biology, 70(10-11), pp. 867–874.  
Grill, S., Rusterholz, C., Zanetti-Dällenbach, R., Tercanli, S., Holzgreve, W., Hahn, S. and Lapaire, 
O. (2009) ‘Potential markers of preeclampsia – a review’, Reproductive Biology and Endocrinology, 
7(1), pp. 70.  
 
245 
 
 Grizzi, F., Di Ieva, A., Russo, C., Frezza, E.E., Cobos, E., Muzzio, P. and Chiriva-Internati, M. 
(2006) Theoretical Biology and Medical Modelling, 3(1), pp. 37. Grümmer, R., Hohn, H.., Mareel, 
M.M. and Denker, H.. (1994) ‘Adhesion and invasion of three human choriocarcinoma cell lines into 
human endometrium in a three-dimensional organ culture system’, Placenta, 15(4), pp. 411–429.  
Grümmer, R., Hohn, H.. and Denker, H.. (1989) ‘Choriocarcinoma cell Spheroids: An in vitro model 
for the human Trophoblast’, Trophoblast Invasion and Endometrial Receptivity, , pp. 97–111.  
Gude, N., Roberts, C., Kalionis, B. and King, R. (2004) ‘Growth and function of the normal human 
placenta’, Thrombosis research., 114, pp. 397–407. 
Guibourdenche, J., Fournier, T., Malassinas, A. and Evain-Brion, D. (2009) ‘Development and 
hormonal functions of the human placenta’, Polish Histochemical and Cytochemical Society., 47(5).  
Guttilla, I., Phoenix, K., Hong, X., Tirnauer, J., Claffey, K. and White, B. (2011) ‘Prolonged 
mammosphere culture of MCF-7 cells induces an EMT and repression of the estrogen receptor by 
microRNAs’, Breast cancer research and treatment., 132(1), pp. 75–85. 
Guttmacher, A.E., Maddox, Y.T. and Spong, C.Y. (2014) ‘The human Placenta project: Placental 
structure, development, and function in real time’, Placenta, 35(5), pp. 303–304.  
Haider, S. and Knöfler, M. (2009) ‘Human Tumour necrosis factor: Physiological and pathological 
roles in Placenta and Endometrium’, Placenta, 30(2), pp. 111–123.  
Haider, S., Meinhardt, G., Velicky, P., Otti, G., Whitley, G., Fiala, C., Pollheimer, J. and Knöfler, 
M. (2014) ‘Notch signaling plays a critical role in motility and differentiation of human first-trimester 
cytotrophoblasts’, Endocrinology., 155(1), pp. 263–274. 
Hamilton, W.J. and Boyd, J.D. (1960) ‘Development of the human placenta in the first three months 
of gestation’, 94(Pt 3). 
Hammer, A. (2011) ‘Immunological regulation of trophoblast invasion’, Journal of reproductive 
immunology., 90(1), pp. 21–28. 
Han, G., Wang, H. and Hao, J. (2013) ‘Pluripotent stem cells’. 
Hanahan, D. and Weinberg, R.A. (2000) ‘The hallmarks of cancer’, Cell, 100(1), pp. 57–70.  
Hanahan, D. and Weinberg, R.A. (2011) ‘Hallmarks of cancer: The next generation’, Cell, 144(5), 
pp. 646–674.  
Hannan, N.J., Paiva, P., Dimitriadis, E. and Salamonsen, L.A. (2009) ‘Models for study of human 
embryo implantation: Choice of cell lines’, Biology of Reproduction, 82(2), pp. 235–245.  
Hansson, S., Chen, Y., Brodszki, J., Hernandez-Andrade, E., Inman, J., Kozhich, O., Larsson, I., 
Marsál, K., Medstrand, P., Xiang, C. and Brownstein, M. (2006) ‘Gene expression profiling of 
human placentas from preeclamptic and normotensive pregnancies’, Molecular human 
reproduction., 12(3), pp. 169–179. 
Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K., Ajose-Adeogun, A.O., Nakayama, 
T., Graham, J.A., Demur, C., Hercend, T., Diu-Hercend, A., Su, M., Golec, J.M.C. and Miller, K.M. 
(2004) ‘VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses 
tumor growth in vivo’, Nature Medicine, 10(3), pp. 262–267.  
Harris, L.K. (2010) ‘Review: Trophoblast-Vascular cell interactions in early pregnancy: How to 
Remodel a vessel’, Placenta, 31, pp. S93–S98.  
Heerboth, S., Housman, G., Leary, M., Longacre, M., Byler, S., Lapinska, K., Willbanks, A. and 
Sarkar, S. (2015) ‘EMT and tumor metastasis’, Clinical and Translational Medicine, 4(1).  
246 
 
 Hendrix, M.J.C., Seftor, E.A., Hess, A.R. and Seftor, R.E.B. (2003) ‘Angiogenesis: Vasculogenic 
mimicry and tumour-cell plasticity: Lessons from melanoma’, Nature Reviews Cancer, 3(6), pp. 
411–421.  
Herr, F., Schreiner, I., Baal, N., Pfarrer, C. and Zygmunt, M. (2011) ‘Expression patterns of notch 
receptors and their ligands jagged and delta in human placenta’, Placenta, 32(8), pp. 554–563.  
Herreros-Villanueva, M., Zhang, J.-S., Koenig, A., Abel, E.V., Smyrk, T.C., Bamlet, W.R., de 
Narvajas, A.A.-M., Gomez, T.S., Simeone, D.M., Bujanda, L. and Billadeau, D.D. (2013) ‘SOX2 
promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells’, 
Oncogenesis, 2(8), p. e61.  
Hiden, U., Wadsack, C., Prutsch, N., Gauster, M., Weiss, U., Frank, H.-G., Schmitz, U., Fast-Hirsch, 
C., Hengstschläger, M., Pötgens, A., Rüben, A., Knöfler, M., Haslinger, P., Huppertz, B., Bilban, 
M., Kaufmann, P. and Desoye, G. (2007) ‘The first trimester human trophoblast cell line ACH-3P: 
A novel tool to study autocrine/paracrine regulatory loops of human trophoblast subpopulations – 
TNF-α stimulates MMP15 expression’, BMC Developmental Biology, 7(1), p. 137.  
Hilton, M.J., Tu, X., Wu, X., Bai, S., Zhao, H., Kobayashi, T., Kronenberg, H.M., Teitelbaum, S.L., 
Ross, F.P., Kopan, R. and Long, F. (2008) ‘Notch signaling maintains bone marrow mesenchymal 
progenitors by suppressing osteoblast differentiation’, Nature Medicine, 14(3), pp. 306–314.  
Ho, K.K., Mukhopadhyay, A., Li, Y.F., Mukhopadhyay, S. and Weiner, H. (2008) ‘A point mutation 
produced a class 3 aldehyde dehydrogenase with increased protective ability against the killing effect 
of cyclophosphamide’, Biochemical Pharmacology, 76(5), pp. 690–696.  
Holmgren, L., O’Reilly, M.S. and Folkman, J. (1995) ‘Dormancy of micrometastases: Balanced 
proliferation and apoptosis in the presence of angiogenesis suppression’, Nature Medicine, 1(2), pp. 
149–153.  
Holtan, S.G., Creedon, D.J., Haluska, P. and Markovic, S.N. (2009) ‘Cancer and pregnancy: Parallels 
in growth, invasion, and immune modulation and implications for cancer therapeutic agents’, Mayo 
Clinic Proceedings, 84(11), pp. 985–1000.  
Hsu, P.P. and Sabatini, D.M. (2008) ‘Cancer cell metabolism: Warburg and beyond’, Cell, 134(5), 
pp. 703–707. 
Huang, E.H., Hynes, M.J., Zhang, T., Ginestier, C., Dontu, G., Appelman, H., Fields, J.Z., Wicha, 
M.S. and Boman, B.M. (2009) ‘Aldehyde Dehydrogenase 1 is a marker for normal and malignant 
human colonic stem cells (SC) and tracks SC overpopulation during colon Tumorigenesis’, Cancer 
Research, 69(8), pp. 3382–3389.  
Hunkapiller, N.M., Gasperowicz, M., Kapidzic, M., Plaks, V., Maltepe, E., Kitajewski, J., Cross, 
J.C. and Fisher, S.J. (2011) ‘A role for notch signaling in trophoblast endovascular invasion and in 
the pathogenesis of pre-eclampsia’, Development, 138(14), pp. 2987–2998.  
Hunter, K.W., Crawford, N.P. and Alsarraj, J. (2008) ‘Mechanisms of metastasis’, Breast Cancer 
Research, 10(Suppl 1), pp. S2.  
Huppertz, B. (2008) ‘The anatomy of the normal placenta’, Journal of Clinical Pathology, 61(12), 
pp. 1296–1302.  
Hurt, E.M., Chan, K., Serrat, M.A.D., Thomas, S.B., Veenstra, T.D. and Farrar, W.L. (2010) 
‘Identification of Vitronectin as an Extrinsic Inducer of cancer stem cell differentiation and tumor 
formation’, 28(3). 
 
247 
 
 Igakura, T., Kadomatsu, K., Kaname, T., Muramatsu, H., Fan, Q., Miyauchi, T., Toyama, Y., Kuno, 
N., Yuasa, S., Takahashi, M., Senda, T., Taguchi, O., Yamamura, K. and Arimura, K. (1998) ‘A null 
mutation in basigin, an immunoglobulin superfamily member, indicates its important roles in peri-
implantation development and spermatogenesis’, Developmental biology., 194(2), pp. 152–65. 
Igney, F.H. and Krammer, P.H. (2002) ‘Death and anti-death: Tumour resistance to apoptosis’, 
Nature Reviews Cancer, 2(4), pp. 277–288. 
Ishihara, N., Matsuo, H., Murakoshi, H., Laoag-Fernandez, J.B., Samoto, T. and Maruo, T. (2002) 
‘Increased apoptosis in the syncytiotrophoblast in human term placentas complicated by either 
preeclampsia or intrauterine growth retardation’, American Journal of Obstetrics and Gynecology, 
186(1), pp. 158–166.  
Jain, P., Worthylake, R.A. and Alahari, S.K. (2012) ‘Quantitative analysis of random migration of 
cells using time-lapse video microscopy’, Journal of Visualized Experiments, (63).  
James, J.L., Carter, A.M. and Chamley, L.W. (2012) ‘Human placentation from nidation to 5 weeks 
of gestation. Part I: What do we know about formative placental development following implantation 
Placenta, 33(5), pp. 327–334.  
Januchowski, R., Wojtowicz, K. and Zabel, M. (2013) ‘The role of aldehyde dehydrogenase (ALDH) 
in cancer drug resistance’, Biomedicine & Pharmacotherapy, 67(7), pp. 669–680.  
Jarvenpaa, J., Vuoristo, J., Savolainen, E., Ukkola, O., Vaskivuo, T. and Ryynanen, M. (2007) 
‘Altered expression of angiogenesis-related placental genes in pre-eclampsia associated with 
intrauterine growth restriction’, Gynecological endocrinology: the official journal of the 
International Society of Gynecological Endocrinology., 23(6), pp. 351–5. 
Ji, L., Brkić, J., Liu, M., Fu, G., Peng, C. and Wang, Y.-L. (2013) ‘Placental trophoblast cell 
differentiation: Physiological regulation and pathological relevance to preeclampsia’, Molecular 
Aspects of Medicine, 34(5), pp. 981–1023.  
Jia, R.-Z., Ding, G.-C., Gu, C.-M., Huang, T., Rui, C., Wang, Y.-X. and Lu, Q. (2014) ‘CDX2 
enhances HTR-8/SVneo Trophoblast cell invasion by altering the expression of matrix 
Metalloproteinases’, Cellular Physiology and Biochemistry, 34(3), pp. 628–636.  
Jiang, F., Qiu, Q., Khanna, A., Todd, N.W., Deepak, J., Xing, L., Wang, H., Liu, Z., Su, Y., Stass, 
S.A. and Katz, R.L. (2009) ‘Aldehyde Dehydrogenase 1 is a tumor stem cell-associated marker in 
lung cancer’, Molecular Cancer Research, 7(3), pp. 330–338.  
Jin, T., Branch, D.R., Zhang, X., Qi, S., Youngson, B. and Goss, P.E. (1999) ‘Examination ofPOU 
homeobox gene expression in human breast cancer cells’, International Journal of Cancer, 81(1), 
pp. 104–112.  
Jones, R.G. and Thompson, C.B. (2009) ‘Tumor suppressors and cell metabolism: A recipe for 
cancer growth’, Genes & Development, 23(5), pp. 537–548. 
Jurcovicova, J., Krueger, K.S., Nandy, I., Lewis, D.F., Brooks, G.G. and Brown, E.G. (1998) 
‘Expression of platelet-derived growth factor-a mRNA in human placenta: Effect of magnesium 
infusion in pre-eclampsia’, Placenta, 19(5-6), pp. 423–427.  
Kam, E.P.Y. (1999) ‘The role of trophoblast in the physiological change in decidual spiral arteries’, 
Human Reproduction, 14(8), pp. 2131–2138. 
Kang, Y. and Massagué, J. (2004) ‘Epithelial-Mesenchymal transitions’, Cell, 118(3), pp. 277–279.  
Karanu, F.N., Murdoch, B., Gallacher, L., Wu, D.M., Koremoto, M., Sakano, S. and Bhatia, M. 
(2000) ‘The notch ligand jagged-1 represents a novel growth factor of human Hematopoietic stem 
cells’, The Journal of Experimental Medicine, 192(9), pp. 1365–1372.  
248 
 
 Karlsson, L., Bondjers, C. and Betsholtz, C. (1999) ‘Roles for PDGF-A and sonic hedgehog in 
development of mesenchymal components of the hair follicle’, Development (Cambridge, 
England), 126(12), pp. 2611–21. 
Kaufman, H.L. and Disis, M.L. (2004) ‘Immune system versus tumor: Shifting the balance in favor 
of DCs and effective immunity’, 113(5). 
Kaur, S., Kumar, T., Uruno, A., Sugawara, A., Jayakumar, K. and Kartha, C. (2009) ‘Genetic 
engineering with endothelial nitric oxide synthase improves functional properties of endothelial 
progenitor cells from patients with coronary artery disease: An in vitro study’, Basic research in 
cardiology, 104(6), pp. 739–749. 
Kay, H., Nelson, M.D. and Wang, Y. (2011) The Placenta: From development to disease. John 
Wiley. 
Kenyon, G., DeMarini, D., Fuchs, E., Galas, D., Kirsch, J., Leyh, T., Moos, W., Petsko, G., Ringe, 
D., Rubin, G., Sheahan, L. and Research, N. (2002) ‘Defining the mandate of proteomics in the post-
genomics era: Workshop report’, Molecular & cellular proteomics: MCP, 1(10), pp. 763–780. 
Khan, J., Ezan, F., Crémet, J.-Y., Fautrel, A., Gilot, D., Lambert, M., Benaud, C., Troadec, M.-B. 
and Prigent, C. (2011) ‘Overexpression of active Aurora-C Kinase results in cell transformation and 
Tumour formation’, PLoS ONE, 6(10), p. e26512.  
Kim, N., Piatyszek, M., Prowse, K., Harley, C., West, M., Ho, P., Coviello, G., Wright, W., Weinrich, 
S. and Shay, J. (1994) ‘Specific association of human telomerase activity with immortal cells and 
cancer’, Science (New York, N.Y.), 266(5193), pp. 2011–2015. 
Kim, S.W., Lee, J., Lee, B. and Rhim, T. (2014) ‘Proteomic analysis in pterygium; upregulated 
protein expression of ALDH3A1, PDIA3, and PRDX2’, 20. 
Kimura, M., Matsuda, Y., Yoshioka, T. and Okano, Y. (1999) ‘Cell cycle-dependent expression and 
Centrosome localization of a Third human Aurora/Ipl1-related protein Kinase, AIK3’, Journal of 
Biological Chemistry, 274(11), pp. 7334–7340.  
King, A., Thomas, L. and Bischof, P. (2000) ‘Cell culture models of Trophoblast II: Trophoblast cell 
Lines— A workshop report’, Placenta, 21, pp. S113–S119.  
Kinder JM, Jiang TT, Ertelt JM, Xin L, Strong BS, Shaaban AF, Way SS. Cross-Generational 
Reproductive Fitness Enforced by Microchimeric Maternal Cells. Cell. 2015; 162(3):505-15. 
Kita, N., Mitsushita, J., Ohira, S., Takagi, Y., Ashida, T., Kanai, M., Nikaido, T. and Konishi, I. 
(2003) ‘Expression and activation of MAP Kinases, ERK1/2, in the human Villous Trophoblasts’, 
Placenta, 24(2-3), pp. 164–172.  
Kleinrouweler, E.C., van Uitert, M., Moerland, P.D., Ris-Stalpers, C. and Afink, G.B. (2013) 
‘Differentially expressed genes in the Pre-Eclamptic Placenta: A systematic review and Meta-
Analysis’, PLoS ONE, 8(7).  
Knöfler, M. and Pollheimer, J. (2005) ‘Human placental trophoblast invasion and differentiation: A 
particular focus on Wnt signaling’, Frontiers in Genetics, 4.  
Kollareddy, M., Dzubak, P., Zheleva, D. and Hajduch, M. (2008) ‘Aurora kinases: Structure, 
functions and their association with cancer’, Biomedical papers of the Medical Faculty of the 
University Palacký, Olomouc, Czechoslovakia., 152(1), pp. 27–33. 
Kondo, T., Setoguchi, T. and Taga, T. (2004) ‘Persistence of a small subpopulation of cancer stem-
like cells in the C6 glioma cell line’, Proceedings of the National Academy of Sciences, 101(3), pp. 
781–786.  
249 
 
 Kong, D., Li, Y., Wang, Z. and Sarkar, F. (2011) ‘Cancer stem cells and Epithelial-to-Mesenchymal 
transition (EMT)-Phenotypic cells: Are they cousins or twins?’, Cancers, 3(4), pp. 716–729.  
Kramer, N., Walzl, A., Unger, C., Rosner, M., Krupitza, G., Hengstschläger, M. and Dolznig, H. 
(2013) ‘In vitro cell migration and invasion assays’, Mutation Research/Reviews in Mutation 
Research, 752(1), pp. 10–24.  
Krebs, L.T., Xue, Y., Norton, C.R., Shutter, J.R., Maguire, M., Sundberg, J.P., Gallahan, D., Closson, 
V., Kitajewski, J., Callahan, R., Smith, G.H., Stark, K.L. and Gridley, T. (2000) ‘Notch signaling is 
essential for vascular morphogenesis in mice’, 14(11). 
Laga, A.C., Lai, C.-Y., Zhan, Q., Huang, S.J., Velazquez, E.F., Yang, Q., Hsu, M.-Y. and Murphy, 
G.F. (2010) ‘Expression of the embryonic stem cell transcription factor SOX2 in human skin’, The 
American Journal of Pathology, 176(2), pp. 903–913.  
Lala, P., Lee, B., Xu, G. and Chakraborty, C. (2002) ‘Human placental trophoblast as an in vitro 
model for tumor progression’, Canadian journal of physiology and pharmacology., 80(2), pp. 142–
149. 
Lam, C., Lim, K.. and Karumanchi, S.A. (2005) ‘Circulating Angiogenic factors in the pathogenesis 
and prediction of Preeclampsia’, Hypertension, 46(5), pp. 1077–1085.  
Landskron, G., De la fuente, M., Thuwajit, Peti, Thuwajit, Chanitra and Hermoso, M.A. (2014b) 
‘Chronic inflammation and Cytokines in the tumor Microenvironment’, Journal of Immunology 
Research, 2014, pp. 1–19.  
Lash, G.E., Hornbuckle, J., Brunt, A., Kirkley, M., Searle, R.F., Robson, S.C. and Bulmer, J.N. 
(2007) ‘Effect of low oxygen concentrations on Trophoblast-Like cell line invasion’, Placenta, 28(5-
6), pp. 390–398.  
Lengner, C.J., Camargo, F.D., Hochedlinger, K., Welstead, G.G., Zaidi, S., Gokhale, S., Scholer, 
H.R., Tomilin, A. and Jaenisch, R. (2007) ‘Oct4 expression is not required for mouse somatic stem 
cell self-renewal’, Cell Stem Cell, 1(4), pp. 403–415. 
Leptin, M. (1991) ‘Twist and snail as positive and negative regulators during Drosophila mesoderm 
development’, Genes & Development, 5(9), pp. 1568–1576.  
Li, S., Du, L., Zhang, L., Hu, Y., Xia, W., Wu, J., Zhu, J., Chen, L. and Yang, S. (2013) ‘Cathepsin 
B contributes to autophagy-related 7 (Atg7)-induced nod-like receptor 3 (NLRP3)-dependent 
proinflammatory response and aggravates lipotoxicity in rat insulinoma cell line’, The Journal of 
biological chemistry., 288(42), pp. 30094–104. 
Li, X., Wang, J., Xu, Z., Ahmad, A., Li, E., Wang, Y., Qin, S. and Wang, Q. (2012) ‘Expression of 
Sox2 and Oct4 and their clinical significance in human non-small-cell lung cancer’, International 
Journal of Molecular Sciences, 13(12), pp. 7663–7675.  
Liang, C., Park, A. and Guan, J. (2007) ‘In vitro scratch assay: A convenient and inexpensive method 
for analysis of cell migration in vitro’, Nature Protocols, 2(2), pp. 329–333.  
Librach, C.L. (1991) ‘92-kD type IV collagenase mediates invasion of human cytotrophoblasts’, The 
Journal of Cell Biology, 113(2), pp. 437–449.  
Ling, G.-Q. (2012) ‘Expression of the pluripotency markers Oct3/4, Nanog and Sox2 in human breast 
cancer cell lines’, Oncology Letters, .  
Liotta, L.A., Nageswara Rao, C. and Wewer, U.M. (1986) ‘Biochemical interactions of tumor cells 
with the basement membrane’, Annual Review of Biochemistry, 55(1).  
 
250 
 
 Liu, K., Lin, B., Zhao, M., Yang, X., Chen, M., Gao, A., Liu, F., Que, J. and Lan, X. (2013) ‘The 
multiple roles for Sox2 in stem cell maintenance and tumorigenesis’, Cellular Signalling, 25(5), pp. 
1264–1271.  
Liu, Y., Peterson, DA, Kimura, H. and Schubert, D. (1997) ‘Mechanism of cellular 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) reduction’, Journal of 
Neurochemistry., 69(2), pp. 581–593. 
Livak, K. and Schmittgen, T. (2001) ‘Analysis of relative gene expression data using real-time 
quantitative PCR and the 2(-delta delta C(T)) method’, Methods (San Diego, Calif.)., 25(4), pp. 402–
408. 
Looman, C., Sun, T., Yu, Y., Zieba, A., Ahgren, A., Feinstein, R., Forsberg, H., Hellberg, C., Heldin, 
C., Zhang, X., Forsberg-Nilsson, K., Khoo, N., Fundele, R. and Heuchel, R. (2007) ‘An activating 
mutation in the PDGF receptor-beta causes abnormal morphology in the mouse placenta’, The 
International journal of developmental biology., 51(5), pp. 361–70. 
López-Lázaro, M. (2007) ‘Why do tumors metastasize’, Cancer Biology & Therapy, 6(2), pp. 141–
144.  
Louwen, F., Muschol-Steinmetz, C., Reinhard, J., Reitter, A. and Yuan, J. (2012) ‘A lesson for cancer 
research: Placental microarray gene analysis in preeclampsia’, Oncotarget, 3(8), p. 759. 
Lu, J., Ye, X., Fan, F., Xia, L., Bhattacharya, R., Bellister, S., Tozzi, F., Sceusi, E., Zhou, Y., 
Tachibana, I., Maru, D.M., Hawke, D.H., Rak, J., Mani, S.A., Zweidler-McKay, P. and Ellis, L.M. 
(2013) ‘Endothelial cells promote the Colorectal cancer stem cell Phenotype through a soluble form 
of jagged-1’, Cancer Cell, 23(2), pp. 171–185.  
Lund, L., Romer, J., Bugge, T., Nielsen, B., Frandsen, T., Degen, J., Stephens, R. and Danø, K. 
(1999) ‘Functional overlap between two classes of matrix-degrading proteases in wound healing’, 
The EMBO Journal., 18(17), pp. 4645–56. 
Lunghi, L., Ferretti, M.E., Medici, S., Biondi, C. and Vesce, F. (2007b) Reproductive Biology and 
Endocrinology, 5(1), p. 6.  
Lyall, F. (2006) ‘Mechanisms regulating cytotrophoblast invasion in normal pregnancy and pre-
eclampsia’, The Australian & New Zealand journal of obstetrics & gynaecology., 46(4), pp. 266–73. 
Ma, C., Cummings, C. and Liu, X.J. (2003) ‘Biphasic activation of Aurora-A Kinase during the 
Meiosis I- Meiosis II transition in Xenopus Oocytes’, Molecular and Cellular Biology, 23(5), pp. 
1703–1716.  
Maestro, R., Tos, D., Hamamori, Y., Krasnokutsky, S., Sartorelli, V., Kedes, L., Doglioni, C., Beach, 
D. and Hannon, G. (1999) ‘Twist is a potential oncogene that inhibits apoptosis’, Genes & 
development., 13(17), pp. 2207–17. 
Majumdar, K., Radotra, B.D., Vasishta, R.K. and Pathak, A. (2009) ‘Platelet-derived growth factor 
expression correlates with tumor grade and proliferative activity in human oligodendrogliomas’, 
Surgical Neurology, 72(1), pp. 54–60.  
Mani, S., Guo, W., Liao, M., Eaton, E., Ayyanan, A., Zhou, A., Brooks, M., Reinhard, F., Zhang, C., 
Shipitsin, M., Campbell, L., Polyak, K., Brisken, C., Yang, J. and Weinberg, R. (2008) ‘The 
epithelial-mesenchymal transition generates cells with properties of stem cells’, Cell., 133(4), pp. 
704–15. 
Manuel Iglesias, J., Beloqui, I., Garcia-Garcia, F., Leis, O., Vazquez-Martin, A., Eguiara, A., Cufi, 
S., Pavon, A., Menendez, J.A., Dopazo, J. and Martin, A.G. (2013) ‘Mammosphere formation in 
breast carcinoma cell lines depends upon expression of E-cadherin’, PLoS ONE, 8(10), pp. e77281.  
251 
 
 Marchand, M., Horcajadas, J.A., Esteban, F.J., McElroy, S.L., Fisher, S.J. and Giudice, L.C. (2011) 
‘Transcriptomic signature of Trophoblast differentiation in a human embryonic stem cell model’, 
Biology of Reproduction, 84(6), pp. 1258–1271. 
Marchitti, S.A., Brocker, C., Stagos, D. and Vasiliou, V. (2008) ‘Non-p450 aldehyde oxidizing 
enzymes: The aldehyde dehydrogenase superfamily’, Expert Opinion on Drug Metabolism & 
Toxicology, 4(6), pp. 697–720.  
Marzusch, K. (1995) ‘Expression of the p53 tumour suppressor gene in human placenta: An 
immunohistochemical study’, Placenta, 16(1), pp. 101–104.  
Matsuo, H., Strauss, J.F. and Mochizuki, M. (1994) ‘Peroxisome proliferator and retinoid regulate 
JEG-3 choriocarcinoma cell function’, Placenta, 15(7), p. A47.  
Mehta, G., Hsiao, A.Y., Ingram, M., Luker, G.D. and Takayama, S. (2013) ‘Opportunities and 
challenges for use of tumor spheroids as models to test drug delivery and efficacy’, Journal of 
Controlled Release, 164(2), pp. 192–204. 
Miki, T. and Strom, S.C. (2006) ‘Amnion-derived pluripotent/multipotent stem cells’, Stem Cell 
Reviews, 2(2), pp. 133–141.  
Min, S., Lee, S., Bak, S. and Kim, K. (2015) ‘Ideal sphere-forming culture conditions to maintain 
pluripotency in a hepatocellular carcinoma cell lines’, Cancer cell international, 15. 
 
Mironchik, Y. (2005) ‘Twist Overexpression induces in vivo Angiogenesis and Correlates with 
Chromosomal instability in breast cancer’, Cancer Research, 65(23), pp. 10801–10809. 
Miyazawa, K., Tanaka, T., Nakai, D., Morita, N. and Suzuki, K. (2014) ‘Immunohistochemical 
expression of four different stem cell markers in prostate cancer: High expression of NANOG in 
conjunction with hypoxia-inducible factor‑ 1α expression is involved in prostate epithelial 
malignancy’, Oncology Letters. 
Moreb, J.S., Baker, H.V., Chang, L.-J., Amaya, M., Lopez, M.C., Ostmark, B. and Chou, W. (2008) 
‘ALDH isozymes downregulation affects cell growth, cell motility and gene expression in lung 
cancer cells’, Molecular Cancer, 7(1), pp. 87. 
Morey, J.S., Ryan, J.C. and Dolah, F.M. (2006) ‘Microarray validation: Factors influencing 
correlation between oligonucleotide microarrays and real-time PCR’, Biological Procedures Online, 
8(1), pp. 175–193. 
Mortlock, A., Foote, K., Heron, N., Jung, F., Pasquet, G., Lohmann, J., Warin, N., Renaud, F., Savi, 
D., Roberts, N., Johnson, T., Dousson, C., Hill, G., Perkins, D., Hatter, G., Wilkinson, R., Wedge, 
S., Heaton, S., Odedra, R., Keen, N., Crafter, C., Brown, E., Thompson, K., Brightwell, S., Khatri, 
L., Brady, M., Kearney, S., McKillop, D., Rhead, S., Parry, T. and Green, S. (2007) ‘Discovery, 
synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora 
B kinase’, Journal of medicinal chemistry., 50(9), pp. 2213–2224. 
Moser, G., Gauster, M., Orendi, K., Glasner, A., Theuerkauf, R. and Huppertz, B. (2010) 
‘Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel 
confrontation co-culture models’, Human reproduction (Oxford, England)., 25(5), pp. 1127–1136. 
Mousa, N.A., Bedaiwy, M.A. and Casper, R.F. (2006) ‘Bioline international official site (site up-
dated regularly)’, Middle East Fertility Society Journal, 11(3), pp. 152–168. 
Murre, C., McCaw, P. and Baltimore, D. (1989) ‘A new DNA binding and dimerization motif in 
immunoglobulin enhancer binding, daughterless, MyoD, and myc proteins’, Cell., 56(5), pp. 777–
783. 
252 
 
 Murthi, P., Rajaraman, G., Brennecke, S.P. and Kalionis, B. (2011) ‘The role of Placental Homeobox 
genes in human fetal growth restriction’, Journal of Pregnancy, 2011, pp. 1–11.  
Muzio, G., Maggiora, M., Paiuzzi, E., Oraldi, M. and Canuto, R.A. (2012) ‘Aldehyde 
dehydrogenases and cell proliferation’, Free Radical Biology and Medicine, 52(4), pp. 735–746.  
Nagaraja, G.M., Othman, M., Fox, B.P., Alsaber, R., Pellegrino, C.M., Zeng, Y., Khanna, R., 
Tamburini, P., Swaroop, A. and Kandpal, R.P. (2006) ‘Gene expression signatures and biomarkers 
of noninvasive and invasive breast cancer cells: Comprehensive profiles by representational 
difference analysis, microarrays and proteomics’, Oncogene, 25(16), pp. 2328–2338.  
Negi, R., Pande, D., Karki, K., Khanna, R.S., Khanna, H.D., Scientific and Publishing, A. (2011) 
‘Oxidative stress and Preeclampsia’, Advances in Life Sciences, 1(1), pp. 20–23. 
Negrini, S., Gorgoulis, V.G. and Halazonetis, T.D. (2010) ‘Genomic instability [mdash] an evolving 
hallmark of cancer: Abstract: Nature reviews molecular cell biology’, Nature Reviews Molecular 
Cell Biology, 11(3), pp. 220–228. 
Ng, Y.H., Zhu, H. and Leung, P.C.K. (2012) ‘Twist Modulates human Trophoblastic cell invasion 
via regulation of N-Cadherin’, Endocrinology, 153(2), pp. 925–936. 
Nishida, N., Yano, H., Nishida, T., Kamura, T. and Kojiro, M. (2006) ‘Angiogenesis in cancer’, 
Vascular Health and Risk Management, 2(3), pp. 213–219. 
Norwitz, E.R., Schust, D.J. and Fisher, S.J. (2001) ‘Implantation and the survival of early pregnancy’, 
New England Journal of Medicine, 345(19), pp. 1400–1408. 
Novakovic, B., Gordon, L., Wong, N.C., Moffett, A., Manuelpillai, U., Craig, J.M., Sharkey, A. and 
Saffery, R. (2011) ‘Wide-ranging DNA methylation differences of primary trophoblast cell 
populations and derived cell lines: Implications and opportunities for understanding trophoblast 
function’, Molecular Human Reproduction, 17(6), pp. 344–353. 
O’Rourke, M. and Tam, P. (2002) ‘Twist functions in mouse development’, The International 
journal of developmental biology., 46(4), pp. 401–13. 
Ochsenbein, A., Sierro, S., Odermatt, B., Pericin, M., Karrer, U., Hermans, J., Hemmi, S., 
Hengartner, H. and Zinkernagel, R. (2001) ‘Roles of tumour localization, second signals and cross 
priming in cytotoxic t-cell induction’, Nature., 411(6841), pp. 1058–1064. 
Oka, H., Shiozaki, H., Kobayashi, K., Tahara, H., Tamura, S., Miyata, M., Doki, Y., Iihara, K., 
Matsuyoshi, N., Hirano, S., Takeichi, M. and Mori, T. (1993) ‘Immunohistochemical evaluation of 
E-cadherin adhesion molecule expression in human gastric cancer’, Virchows Archiv A Pathological 
Anatomy and Histopathology, 421(2), pp. 149–156. 
Oklu, R., Walker, T.G., Wicky, S. and Hesketh, R. (2010) ‘Angiogenesis and current Antiangiogenic 
strategies for the treatment of cancer’, Journal of Vascular and Interventional Radiology, 21(12), pp. 
1791–1805. 
Orendi, K., Kivity, V., Sammar, M., Grimpel, Y., Gonen, R., Meiri, H., Lubzens, E. and Huppertz, 
B. (2011) ‘Placental and trophoblastic in vitro models to study preventive and therapeutic agents for 
preeclampsia’, Placenta, 32, pp. S49–S54. 
Osborne, C., Hobbs, K. and Trent, J. (1987) ‘Biological differences among MCF-7 human breast 
cancer cell lines from different laboratories’, Breast cancer research and treatment., 9(2), pp. 111–
121. 
Osterlund, C., Wramsby, H. and Pousette, A. (1996) ‘Temporal expression of platelet-derived growth 
factor (PDGF)-A and its receptor in human preimplantation embryos’, Molecular human 
reproduction, 2(7), pp. 507–512. 
253 
 
 Oudar, O. (2000) ‘Spheroids: Relation between tumour and endothelial cells’, Critical Reviews in 
Oncology/Hematology, 36(2-3), pp. 99–106. 
Pan, G.J., Chang, Z.Y., Scholer, H.R. and Pei, D. (2002) ‘Cell research - abstract of article: Stem cell 
pluripotency and transcription factor Oct4’, Cell Research, 12(5), pp. 321–329.  
Pattillo, R.A. and Gey, G.O. (1968) ‘The establishment of a cell line of human Hormone-synthesizing 
Trophoblastic cells in vitro’, Cancer Research, 28(7), pp. 1231–1236. 
Peng, C. (2003) ‘The TGF-beta superfamily and its roles in the human ovary and placenta’, Journal 
of obstetrics and gynaecology Canada: JOGC, 25(10), pp. 834–844. 
Pennington, K.A., Schlitt, J.M., Jackson, D.L., Schulz, L.C. and Schust, D.J. (2011) ‘Preeclampsia: 
Multiple approaches for a multifactorial disease’, Disease Models & Mechanisms, 5(1), pp. 9–18.  
Phung, Y., Barbone, D., Broaddus, V. and Ho, M. (2011) ‘Rapid generation of in vitro 
multicellular spheroids for the study of monoclonal antibody therapy’, Journal of Cancer, 2, pp. 
507–14. 
 
Pichot, C.S., Hartig, S.M., Xia, L., Arvanitis, C., Monisvais, D., Lee, F.Y., Frost, J.A. and Corey, 
S.J. (2009) ‘Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast 
cancer cells’, British Journal of Cancer, 101(1), pp. 38–47. 
Pollheimer, J., Husslein, P. and Knöfler, M. (2005) ‘Invasive trophoblasts generate regulatory 
collagen XVIII cleavage products’, Placenta, 26, pp. S42–S45.  
Prasad, S.M., Czepiel, M., Cetinkaya, C., Smigielska, K., Weli, S.C., Lysdahl, H., Gabrielsen, A., 
Petersen, K., Ehlers, N., Fink, T., Minger, S.L. and Zachar, V. (2009) ‘Continuous hypoxic culturing 
maintains activation of notch and allows long-term propagation of human embryonic stem cells 
without spontaneous differentiation’, Cell Proliferation, 42(1), pp. 63–74.  
Preissner, K. and Reuning, U. (2011) ‘Vitronectin in vascular context: Facets of a multitalented 
matricellular protein’, Seminars in thrombosis and hemostasis, 37(4), pp. 408–24. 
Purow, B., Haque, R., Noel, M., Su, Q., Burdick, M., Lee, J., Sundaresan, T., Pastorino, S., Park, J., 
Mikolaenko, I., Maric, D., Eberhart, C. and Fine, H. (2005) ‘Expression of notch-1 and its ligands, 
delta-like-1 and jagged-1, is critical for glioma cell survival and proliferation’, Cancer research, 
65(6), pp. 2353–63. 
Purow, B.W. (2013) ‘Expression of notch-1 and its ligands, delta-like-1 and jagged-1, is critical for 
Glioma cell survival and proliferation’, Cancer Research, 65(6), pp. 2353–2363.  
Qin, Q., Xu, Y., He, T., Qin, C. and Xu, J. (2012) ‘Cell research - normal and disease-related 
biological functions of twist1 and underlying molecular mechanisms’, Cell Research, 22(1), pp. 106–
190. 
Quartuccio, S.M. and Schindler, K. (2015) ‘Functions of Aurora kinase C in meiosis and cancer’, 
Frontiers in Cell and Developmental Biology, 3. 
Raica, M. and Cimpean, A.M. (2010) ‘Platelet-Derived growth factor (PDGF)/PDGF receptors 
(PDGFR) axis as target for Antitumor and Antiangiogenic therapy’, Pharmaceuticals, 3(3), pp. 572–
599.  
Red-Horse, K., Zhou, Y., Genbacev, O., Prakobphol, A., Foulk, R., McMaster, M. and Fisher, S.J. 
(2004) ‘Trophoblast differentiation during embryo implantation and formation of the maternal-fetal 
interface’, Journal of Clinical Investigation, 114(6), pp. 744–754. 
Redman, C.W. (2005) ‘Latest advances in understanding Preeclampsia’, Science, 308(5728), pp. 
1592–1594.  
254 
 
 Reya, T., Morrison, S., Clarke, M. and Weissman, I. (2001) ‘Stem cells, cancer, and cancer stem 
cells’, Nature, 414(6859), pp. 105–111. 
Rizzino, A. (2013) ‘Concise review: The Sox2-Oct4 connection: Critical players in a much larger 
interdependent network integrated at multiple levels’, Stem Cells, 31(6), pp. 1033–1039.  
Roberts, J. and Cooper, D. (2001) ‘Pathogenesis and genetics of pre-eclampsia’, Lancet (London, 
England), 357(9249), pp. 53–56. 
Roberts, J.M. and Hubel, C.A. (2009) ‘The Two stage model of Preeclampsia: Variations on the 
theme’, Placenta, 30, pp. 32–37. 
Rodrigues, M., Griffith, L.G. and Wells, A. (2010) ‘Growth factor regulation of proliferation and 
survival of multipotential stromal cells’, Stem Cell Research & Therapy, 1(4), p. 32.  
Rosario, F.J., Sadovsky, Y. and Jansson, T. (2012) ‘Gene targeting in primary human trophoblasts’, 
Placenta, 33(10), pp. 754–762.  
Rudbeck, L. (2016) ‘Adding quality to your qualitative IHC’, MLO: medical laboratory observer., 
47(12), pp. 18–9. 
Ryan, K.M., Phillips, A.C. and Vousden, K.H. (2001) ‘Regulation and function of the p53 tumor 
suppressor protein’, Current Opinion in Cell Biology, 13(3), pp. 332–337.  
Saad, R.S. (2011) ‘CDX2 as a marker for intestinal differentiation: Its utility and limitations’, World 
Journal of Gastrointestinal Surgery, 3(11), pp. 159. 
Saftlas AF, Levine RJ, Klebanoff MA, Martz KL, Ewell MG, Morris CD, Sibai BM. Abortion, 
changed paternity, and risk of preeclampsia in nulliparous women. Am J Epidemiol. 2003; 
157(12):1108-14. 
Sahin, Z., Acar, N., Ozbey, O., Ustunel, I. and Demir, R. (2011) ‘Distribution of notch family 
proteins in intrauterine growth restriction and hypertension complicated human term placentas’, Acta 
Histochemica, 113(3), pp. 270–276. 
Salk, J.J., Fox, E.J. and Loeb, L.A. (2010) ‘Mutational heterogeneity in human cancers: Origin and 
consequences’, Annual Review of Pathology: Mechanisms of Disease, 5(1), pp. 51–75.  
Samatov, T.R., Tonevitsky, A.G. and Schumacher, U. (2013) ‘Epithelial-mesenchymal transition: 
Focus on metastatic cascade, alternative splicing, non-coding RNAs and modulating compounds’, 
Molecular Cancer, 12, pp. 107. 
Sankaralingam, S., Arenas, I.A., Lalu, M.M. and Davidge, S.T. (2006) ‘Preeclampsia: Current 
understanding of the molecular basis of vascular dysfunction’, Expert Reviews in Molecular 
Medicine, 8(03). 
Sarikaya, D.P. and Jerome‑Majewska LA (2011) ‘Notch1 and the activated NOTCH1 intracellular 
domain are expressed in differentiated trophoblast cells’, Cell Biology International, 35(5), pp. 443–
447. 
Schindler, K., Davydenko, O., Fram, B., Lampson, M.A. and Schultz, R.M. (2012) ‘Maternally 
recruited Aurora C kinase is more stable than Aurora B to support mouse oocyte maturation and early 
development’, Proceedings of the National Academy of Sciences, 109(33), pp. E2215–E2222.  
Scholer, H., Ruppert, S., Suzuki, N., Chowdhury, K. and Gruss, P. (1990) ‘New type of POU domain 
in germ line-specific protein Oct-4’, Nature, 344(6265), pp. 435–439. 
255 
 
 Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W. and Selbach, 
M. (2013) ‘Corrigendum: Global quantification of mammalian gene expression control’, Nature, 
495(7439), pp. 126–127. 
Seiffert, D., Crain, K., Wagner, N.V. and Loskutoff, D.J. (1994) ‘Vitronectin gene expression in 
vivo: Evidence for extrahepatic synthesis and acute phase regulation’, Fibrinolysis, 8, pp. 121.  
Sethi, N., Dai, X., Winter, C.G. and Kang, Y. (2011) ‘Tumor-derived jagged1 promotes Osteolytic 
bone Metastasis of breast cancer by engaging notch signaling in bone cells’, Cancer Cell, 19(2), pp. 
192–205. 
Shao, S., Zhao, X., Zhang, X., Luo, M., Zuo, X., Huang, S., Wang, Y. and Gu, S. (2015) ‘Notch1 
signaling regulates the epithelial–mesenchymal transition and invasion of breast cancer in a slug-
dependent manner’, Molecular Cancer, 14(1), pp. 28.  
Sharma, G., Tyagi, A., Singh, R., Chan, D. and Agarwal, R. (2004) ‘Synergistic anti-cancer effects 
of grape seed extract and conventional cytotoxic agent doxorubicin against human breast carcinoma 
cells’, Breast cancer research and treatment., 85(1), pp. 1–12. 
Shen, J., X, Yi, F., Rasul, A. and Cui, M. (2012) ‘Increased expression levels of vitronectin in the 
maternal‑ fetal interface of placenta in early-onset severe preeclampsia’, Molecular medicine 
reports, 7(1), pp. 53–58. 
Shen, L.-C., Chen, Y.-K., Lin, L.-M. and Shaw, S.-Y. (2010) ‘Anti-invasion and anti-tumor growth 
effect of doxycycline treatment for human oral squamous-cell carcinoma – in vitro and in vivo 
studies’, Oral Oncology, 46(3), pp. 178–184. 
Shi, G. and Jin, Y. (2010) ‘Role of Oct4 in maintaining and regaining stem cell pluripotency’, Stem 
cell research & therapy, 1(5). 
Shuda, K., Schindler, K., Ma, J., Schultz, R.M. and Donovan, P.J. (2009) ‘Aurora kinase B modulates 
chromosome alignment in mouse oocytes’, Molecular Reproduction and Development, 76(11), pp. 
1094–1105. 
Siggelkow, W., Boehm, D., Gebhard, S., Battista, M., Sicking, I., Lebrecht, A., Solbach, C., Hellwig, 
B., Rahnenführer, J., Koelbl, H., Gehrmann, M., Marchan, R., Cadenas, C., Hengstler, J.G. and 
Schmidt, M. (2012) ‘Expression of aurora kinase A is associated with metastasis-free survival in 
node-negative breast cancer patients’, BMC Cancer, 12(1), p. 562. 
Singh, S., Brocker, C., Koppaka, V., Chen, Y., Jackson, B.C., Matsumoto, A., Thompson, D.C. and 
Vasiliou, V. (2013) ‘Aldehyde dehydrogenases in cellular responses to oxidative/electrophilicstress’, 
Free Radical Biology and Medicine, 56, pp. 89–101.  
Siu, M.K.Y., Wong, E.S.Y., Chan, H.Y., Ngan, H.Y.S., Chan, K.Y.K. and Cheung, A.N.Y. (2008) 
‘Overexpression of NANOG in gestational Trophoblastic diseases’, The American Journal of 
Pathology, 173(4), pp. 1165–1172. 
Sivasubramaiyan, K., Totey, S., Bhat, V. and Deb, K. (2009) ‘Y-27632 enhances differentiation of 
blastocyst like cystic human embryoid bodies to endocrinologically active trophoblast cells on a 
biomimetic platform’, Journal of Biomedical Science, 16(1), pp. 88. 
Soeda, A., Inagaki, A., Oka, N., Ikegame, Y., Aoki, H., Yoshimura, S., Nakashima, S., Kunisada, T. 
and Iwama, T. (2008) ‘Epidermal growth factor plays a crucial role in mitogenic regulation of human 
brain tumor stem cells’, The Journal of biological chemistry., 283(16), pp. 10958–66. 
Sood, R., Zehnder, J.L., Druzin, M.L. and Brown, P.O. (2006) ‘Gene expression patterns in human 
placenta’, Proceedings of the National Academy of Sciences, 103(14), pp. 5478–5483. 
256 
 
 Soundararajan, R. and Rao, A.J. (2004) ‘Trophoblast 'pseudo-tumorigenesis': Significance and 
contributory factors’ Reproductive Biology and Endocrinology, 2(1), pp. 15.  
Staff, S., Isola, J., Jumppanen, M. and Tanner, M. (2010) ‘Aurora-A gene is frequently amplified in 
basal-like breast cancer’, Oncology Reports., 23(2), pp. 307–12. 
Staun-Ram, E. and Shalev, E. (2005) Reproductive Biology and Endocrinology, 3(1), pp. 56.  
Stoppelli, P.M. (2013) ‘The Plasminogen activation system in cell invasion’, Madame Curie 
Bioscience Database. 
Sun, H., Wang, Y., Wang, Z., Meng, J., Qi, Z. and Yang, G. (2014) ‘Corrigendum to “Aurora-A 
controls cancer cell radio- and chemoresistance via ATM/Chk2-mediated DNA repair networks” 
[Biochim. Biophys. Acta 1843 (2014) 934–944]’, Biochimica et Biophysica Acta (BBA) - Molecular 
Cell Research, 1843(7), pp. 1308. 
Suzuki, F., Hashimoto, K., Kikuchi, H., Nishikawa, H., Matsumoto, H., Shimada, J., Kawase, M., 
Sunaga, K., Tsuda, T., Satoh, K. and Sakagami, H. (2005) ‘Induction of tumor-specific cytotoxicity 
and apoptosis by doxorubicin’, Anticancer research., 25, pp. 887 
Tallquist, M. and Soriano, P. (2002) ‘Cell autonomous requirement for PDGFRalpha in populations 
of cranial and cardiac neural crest cells’, Development (Cambridge, England)., 130(3), pp. 507–18. 
Tanei, T., Morimoto, K., Shimazu, K., Kim, S.J., Tanji, Y., Taguchi, T., Tamaki, Y. and Noguchi, S. 
(2009) ‘Association of breast cancer stem cells identified by Aldehyde Dehydrogenase 1 expression 
with resistance to Sequential Paclitaxel and Epirubicin-Based chemotherapy for breast cancers’, 
Clinical Cancer Research, 15(12), pp. 4234–4241. 
Thijssen, V.L.J.L., Poirier, F., Baum, L.G. and Griffioen, A.W. (2007) ‘Galectins in the tumor 
endothelium: Opportunities for combined cancer therapy’, Blood, 110(8), pp. 2819–2827.  
Tolkunova, E., Cavaleri, F., Eckardt, S., Reinbold, R., Christenson, L.K., Schöler, H.R. and Tomilin, 
A. (2006) ‘The Caudal -related protein Cdx2 promotes Trophoblast differentiation of mouse 
embryonic stem cells’, Stem Cells, 24(1), pp. 139–144. 
Töpfer, K., Kempe, S., Müller, N., Schmitz, M., Bachmann, M., Cartellieri, M., Schackert, G. and 
Temme, A. (2011) ‘Tumor evasion from T cell surveillance’, Journal of Biomedicine and 
Biotechnology, 2011, pp. 1–19. 
Tuch, B. (2006) ‘Stem cells--a clinical update’, Australian family physician, 35(9), pp. 719–21. 
Uzan, J., Carbonnel, M., Piconne, O., Asmar, R. and Ayoubi, J. (2011) ‘Pre-eclampsia: 
Pathophysiology, diagnosis, and management’, Vascular health and risk management. 7, pp. 467–
474. 
Vader, G. and Lens, S.M.A. (2008) ‘The Aurora kinase family in cell division and cancer’, 
Biochimica Biophysica Acta (BBA) - Reviews on Cancer, 1786(1), pp. 60–72. 
Van Mourik, M.S.M., Macklon, N.S. and Heijnen, C.J. (2008) ‘Embryonic implantation: Cytokines, 
adhesion molecules, and immune cells in establishing an implantation environment’, Journal of 
Leukocyte Biology, 85(1), pp. 4–19.  
Van Zijl, F., Krupitza, G. and Mikulits, W. (2011) ‘Initial steps of metastasis: Cell invasion and 
endothelial transmigration’, Mutation Research/Reviews in Mutation Research, 728(1-2), pp. 23–34.  
Villalobos, M., Aranda, M., Nunez, M.I., Becerra, D., Olea, N., de Almodovar, M.R. and Pedraza, 
V. (1995) ‘Interaction between ionizing radiation, Estrogens and Antiestrogens in the modification 
of tumor Microenvironment in estrogen dependent Multicellular Spheroids’, Acta Oncologica, 34(3), 
pp. 413–417. 
257 
 
 Wang, B., David, M.D. and Schrader, J.W. (2005) ‘Absence of Caprin-1 results in defects in cellular 
proliferation’, The Journal of Immunology, 175(7), pp. 4274–4282. 
Wang, J., Sheng, Q. and Shyr, Y. (2015) ‘SWATH-MS in proteomics: Current status’, International 
Journal of Computational Biology and Drug Design, 8(3), pp. 192. 
Wang, M., Chiou, S., and Wu, C. (2013) ‘Targeting cancer stem cells: Emerging role of Nanog 
transcription factor’, OncoTargets and therapy, 6, pp. 1207. 
Wang, S., Konorev, E.A., Kotamraju, S., Joseph, J., Kalivendi, S. and Kalyanaraman, B. (2004) 
‘Doxorubicin induces Apoptosis in normal and tumor cells via distinctly different mechanisms: 
intermediacy of H2O2 and p53-dependent pathways’, Journal of Biological Chemistry, 279(24), pp. 
25535–25543.  
 
Weber, M., Knoefler, I., Schleußner, E., Markert, U. and Fitzgerald, J. (2013) ‘HTR8/SVneo, but not 
JEG3, cells display trophoblast progenitor cell-like characteristics indicative of self-renewal, 
repopulation activity and expression of “stemness”- associated transcription factors’, Zeitschrift für 
Geburtshilfe und Neonatologie, 217(S 01). 
Whiteside, T.L. (2008) ‘The tumor microenvironment and its role in promoting tumor growth’, 
Oncogene, 27(45), pp. 5904–5912. 
Wong, R.S. (2011) ‘Apoptosis in cancer: From pathogenesis to treatment’, Journal of Experimental 
and Clinical Cancer Research, 30(1), pp. 87. 
Wu, F., Ye, X., Wang, P., Jung, K., Wu, C., Douglas, D., Kneteman, N., Bigras, G., Ma, Y. and Lai, 
R. (2013) ‘Sox2 suppresses the invasiveness of breast cancer cells via a mechanism that is dependent 
on twist1 and the status of Sox2 transcription activity’, BMC Cancer, 13(1), pp. 317.  
Xiang, R., Liao, D., Cheng, T., Zhou, H., Shi, Q., Chuang, T.S., Markowitz, D., Reisfeld, R.A. and 
Luo, Y. (2011) ‘Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth 
and metastasis of lung cancer’, British Journal of Cancer, 104(9), pp. 1410–1417.  
Yagel, S., Casper, R.F., Powell, W., Parhar, R.S. and Lala, P.K. (1989) ‘Characterization of pure 
human first-trimester cytotrophoblast cells in long-term culture: Growth pattern, markers, and 
hormone production’, American Journal of Obstetrics and Gynecology, 160(4), pp. 938–945.  
Yang, J.I., Kong, T.W. and Kim, H.S. (2015) ‘The Proteomic analysis of human Placenta with Pre-
eclampsia and normal pregnancy’, Journal of Korean Medical Science, 30(6), pp. 770.  
Yang, M.-H., Wu, M.-Z., Chiou, S.-H., Chen, P.-M., Chang, S.-Y., Liu, C.-J., Teng, S.-C. and Wu, 
K.-J. (2008) ‘Direct regulation of TWIST by HIF-1α promotes metastasis’, Nature Cell Biology, 
10(3), pp. 295–305. 
Yoon, Y., Cowley, D.O., Gallant, J., Jones, S.N., Van Dyke, T. and Rivera-Perez, J.A. (2012) 
‘Conditional Aurora A deficiency differentially affects early mouse embryo patterning’, 
Developmental Biology, 371(1), pp. 77–85. 
Zawacka-Pankau, J., Kostecka, A., Sznarkowska, A., Hedström, E. and Kawiak, A. (2010) ‘P73 
tumor suppressor protein: A close relative of p53 not only in structure but also in anti-cancer 
approach’, Cell Cycle, 9(4), pp. 720–728. 
Zhang, S. (2015) ‘Sox2, a key factor in the regulation of pluripotency and neural differentiation’, 
World Journal of Stem Cells, 6(3), pp. 305. 
Zhang, X., Zhang, F., Guo, L., Wang, Y., Zhang, P., Wang, R., Zhang, N. and Chen, R. (2013) 
‘Interactome analysis reveals that C1QBP (complement component 1, q subcomponent binding 
protein) is associated with cancer cell Chemotaxis and Metastasis’, Molecular & Cellular 
Proteomics, 12(11), pp. 3199–3209.  
258 
 
 Zhang, Z., Wang, H., Ikeda, S., Fahey, F., Bielenberg, D., Smits, P. and Hauschka, P.V. (2010) 
‘Notch3 in human breast cancer cell lines regulates Osteoblast-Cancer cell interactions and 
Osteolytic bone Metastasis’, The American Journal of Pathology, 177(3), pp. 1459–1469. 
Zhao, W., Ji, X., Zhang, F., Li, L. and Ma, L. (2012) ‘Embryonic stem cell markers’, Molecules, 
17(12), pp. 6196–6236. 
Zhou, Y., Fisher, S.J., Janatpour, M., Genbacev, O., Dejana, E., Wheelock, M. and Damsky, C.H. 
(1997) ‘Human cytotrophoblasts adopt a vascular phenotype as they differentiate. A strategy for 
successful endovascular invasion’, Journal of Clinical Investigation, 99(9), pp. 2139–2151.  
Ziegler, A.N., Chidambaram, S., Forbes, B.E., Wood, T.L. and Levison, S.W. (2014) ‘Insulin-like 
growth Factor-II (IGF-II) and IGF-II Analogs with enhanced insulin receptor-a binding affinity 
promote neural stem cell expansion’, Journal of Biological Chemistry, 289(8), pp. 4626–4633.  
Zuo, Y., Fu, Z., Hu, Y., Li, Y., Xu, Q., Sun, D. and Tan, Y. (2014) ‘Effects of transforming growth 
factor-β1 on the proliferation and invasion of the HTR-8/SVneo cell line’, Oncology Letters,  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
259 
 
  
Website links: 
www1: http://www.etymonline.com/index.php?term=placenta 
www2: Quizlet.com 
www3: http://www.pathologyoutlines.com/topic/placentanormalanatomy.html 
www4: http://www.mhhe.com 
www5: http://www.embryology.ch/anglais/gnidation/etape02.html 
www6:https://www.researchgate.net/publication/6515520_Control_of_human_trophoblast_function
/figures 
www7:  http://womensandinfantshealth.ca/fetal-medicine/placenta/placental-complications-of-
pregnancy/ 
www8:  http://www.who.int/en/ 
www9: http://www.ncbi.nlm.nih.gov/gene/182 
www10: http://www.google.co.uk/patents/US8551775 
www11: http://stemcells.nih.gov/info/basics/pages/basics1.aspx 
www12: http://www.ncbi.nlm.nih.gov/gene/6657 
www13: http://www.ncbi.nlm.nih.gov/gene/1045 
www14: http://www.ncbi.nlm.nih.gov/ 
www15: http://primer3.ut.ee/ 
www16: https://www.idtdna.com/calc/analyzer 
www17: http://www.ebi.ac.uk/Tools/msa/clustalw2/ 
www18: http://blast.ncbi.nlm.nih.gov/Blast.cgi 
www19: http://www.wimasis.com 
www20: http://stemcells.nih.gov/info/basics/pages/basics4.aspx 
www21:http://www.genengnews.com/gen-articles/advertorial-3-d-tumor-spheroids-in- 
extracellular-matrix-old-hat-new-trick/4812/ 
www22: http://www.pubfacts.com/detail/25602070/The-placenta-a-multifaceted-transient-organ 
www23: https://minerva-access.unimelb.edu.au/handle/11343/5250 
260 
 
